<?xml version='1.0' encoding='utf-8'?>
<CombinedData><article id="sec1_Article (1)">
  <title>Risks of and Recommendations for Flexible Bronchoscopy in Pregnancy: A Review</title>
  <authors>Bahhady, I.J.; Ernst, A.</authors>
  <citation>Bahhady, I.J., Ernst, A. Risks of and Recommendations for Flexible Bronchoscopy in Pregnancy: A Review. CHEST. 2004;126(6):1974–1981.</citation>
  <type>Review</type>
  <year>2004</year>
  <keywords>
    <keyword>bronchoscopy</keyword>
    <keyword>complications</keyword>
    <keyword>pregnancy</keyword>
  </keywords>
  <summary>
    This review discusses the risks and recommendations for performing flexible bronchoscopy (FB) in pregnant women. It highlights the physiological changes during pregnancy, potential risks associated with FB, and the importance of careful monitoring and planning when conducting the procedure. The authors also provide guidelines for safely performing FB in pregnant patients and emphasize the need for informed consent.
  </summary>
  <pico>
    <population>Pregnant women requiring bronchoscopy</population>
    <intervention>Flexible bronchoscopy</intervention>
    <comparison>Not applicable (focus on recommendations for pregnant patients)</comparison>
    <outcome>Safety and recommendations for performing bronchoscopy</outcome>
  </pico>
  <take_home>The decision to perform bronchoscopy during pregnancy should be individualized, considering the risks to both the mother and fetus, and should ideally be postponed until after the pregnancy unless emergent. Proper monitoring and adherence to safety protocols are essential.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec1_Article (10)">
  <title>Complications and discomfort of bronchoscopy: a systematic review</title>
  <authors>Elise Orvedal Leiten, Einar Marius Hjellestad Martinsen, Per Sigvald Bakke, Tomas Mikal Lind Eagan, Rune Grønseth</authors>
  <citation>Leiten E.O., Martinsen E.M.H., Bakke P.S., Eagan T.M.L., Grønseth R. Complications and discomfort of bronchoscopy: a systematic review. European Clinical Respiratory Journal. 2016;3(1):33324.</citation>
  <type>Review Article</type>
  <year>2016</year>
  <keywords>
    <keyword>diagnostic bronchoscopy</keyword>
    <keyword>safety</keyword>
    <keyword>adverse events</keyword>
    <keyword>patient satisfaction</keyword>
    <keyword>informed consent</keyword>
  </keywords>
  <summary>
    This systematic review evaluates the complications and discomfort associated with bronchoscopy, identifying meaningful complication rates and predictors. The review highlights that while severe complications are rare, rates of various complications such as hypoxaemia and bleeding show considerable variability across studies. The authors call for more research to better inform patients about potential risks.
  </summary>
  <pico>
    <population>Patients undergoing bronchoscopy for diagnostic and therapeutic purposes</population>
    <intervention>Flexible bronchoscopy</intervention>
    <comparison>None</comparison>
    <outcome>Complications and discomfort related to the procedure</outcome>
  </pico>
  <take_home>Bronchoscopy is generally safe with low rates of severe complications; however, variability in complication rates and patient discomfort exists, indicating the need for standardized definitions and further research.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec1_Article (11)">
  <title>Complications of bronchoscopy: A concise synopsis</title>
  <authors>David L Stahl, Kathleen M Richard, Thomas J Papadimos</authors>
  <citation>Stahl DL, Richard KM, Papadimos TJ. Complications of bronchoscopy: A concise synopsis. Int J Crit Illn Inj Sci 2015;5:189-95.</citation>
  <type>Review Article</type>
  <year>2015</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>complications</keyword>
    <keyword>endoscopy</keyword>
    <keyword>intensive care</keyword>
  </keywords>
  <summary>
    This article reviews the potential complications associated with both flexible and rigid bronchoscopy, categorizing them into mechanical and systemic complications. While the procedures are generally safe, awareness of complications such as airway trauma, bleeding, and medication-related issues is crucial for improving patient safety and comfort.
  </summary>
  <pico>
    <population>Patients undergoing flexible or rigid bronchoscopy</population>
    <intervention>Bronchoscopy procedures (flexible and rigid)</intervention>
    <comparison>Comparison of complication rates between flexible and rigid bronchoscopy</comparison>
    <outcome>Incidence and types of complications associated with bronchoscopy</outcome>
  </pico>
  <take_home>Both flexible and rigid bronchoscopy are safe procedures, but awareness of their complications is essential for clinicians to enhance patient safety and manage risks effectively.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec1_Article (12)">
  <title>Diagnostic Yield and Bleeding Complications Associated With Bronchoscopic Biopsy of Endobronchial Carcinoid Tumors</title>
  <authors>Yang Gao, MD; Teng Moua, MD; David E. Midthun, MD; John J. Mullon, MD; Paul A. Decker, MS; Jay H. Ryu, MD</authors>
  <citation>Gao Y, Moua T, Midthun DE, Mullon JJ, Decker PA, Ryu JH. Diagnostic Yield and Bleeding Complications Associated With Bronchoscopic Biopsy of Endobronchial Carcinoid Tumors. J Bronchol Intervent Pulmonol. 2020;27(2):184–189.</citation>
  <type>Original Investigation</type>
  <year>2020</year>
  <keywords>
    <keyword>bronchial carcinoid</keyword>
    <keyword>bronchoscopic biopsy</keyword>
    <keyword>bleeding complication</keyword>
    <keyword>diagnostic yield</keyword>
  </keywords>
  <summary>
    This study evaluates the diagnostic yield and bleeding complications associated with bronchoscopic biopsy of endobronchial carcinoid tumors. It includes a retrospective analysis of 49 patients over an 8-year period, revealing a high diagnostic yield (92%) and a moderate incidence of bleeding complications (27%), with severe bleeding being rare.
  </summary>
  <pico>
    <population>Patients with bronchial carcinoid tumors</population>
    <intervention>Bronchoscopic biopsy</intervention>
    <comparison>N/A</comparison>
    <outcome>Diagnostic yield and bleeding complications</outcome>
  </pico>
  <take_home>Bronchoscopic biopsy of endobronchial carcinoid tumors has a high diagnostic yield and a low risk of severe bleeding, independent of tumor vascularity or hemoptysis history.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec1_Article (13)">
  <title>Flexible Bronchoscopy</title>
  <authors>Miller, R.J.; Casal, R.F.; Lazarus, D.R.; Ost, D.E.; Eapen, G.A.</authors>
  <citation>Miller, R.J., Casal, R.F., Lazarus, D.R., Ost, D.E., Eapen, G.A. Flexible Bronchoscopy. Clin Chest Med. 2018;39(1):1-16.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Flexible bronchoscopy</keyword>
    <keyword>Bronchoalveolar lavage</keyword>
    <keyword>Transbronchial lung biopsy</keyword>
    <keyword>Transbronchial needle aspiration</keyword>
    <keyword>Bronchial brush</keyword>
  </keywords>
  <summary>
    This article discusses the evolution, techniques, and clinical applications of flexible bronchoscopy, highlighting core procedures such as bronchoalveolar lavage, transbronchial lung biopsy, and transbronchial needle aspiration. It emphasizes the importance of training and proficiency in these procedures for pulmonary trainees and practicing bronchoscopists.
  </summary>
  <pico>
    <population>Patients requiring diagnosis or treatment for bronchopulmonary diseases</population>
    <intervention>Flexible bronchoscopy procedures including BAL, TBLB, and TBNA</intervention>
    <comparison>Conventional diagnostic methods</comparison>
    <outcome>Improved diagnostic yield and therapeutic outcomes in pulmonary diseases</outcome>
  </pico>
  <take_home>Despite advancements in technology, core bronchoscopy procedures remain essential for accurate diagnosis and treatment of lung diseases, necessitating ongoing training for healthcare professionals.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec1_Article (14)">
  <title>Forbearance With Bronchoscopy: A Review of Gratuitous Indications</title>
  <authors>Deshwal, H.; Avasarala, S.K.; Ghosh, S.; Mehta, A.C.</authors>
  <citation>Deshwal H, Avasarala SK, Ghosh S, Mehta AC. Forbearance With Bronchoscopy: A Review of Gratuitous Indications. CHEST. 2019;155(4):834-847.</citation>
  <type>Review</type>
  <year>2019</year>
  <keywords>
    <keyword>bronchoscopy</keyword>
    <keyword>forbearing bronchoscopy</keyword>
    <keyword>guided bronchoscopy</keyword>
    <keyword>indications for bronchoscopy</keyword>
    <keyword>low-yield bronchoscopy</keyword>
  </keywords>
  <summary>
    This article reviews the expanding role of bronchoscopy in modern medicine, highlighting conditions where bronchoscopy may be overutilized despite limited diagnostic or therapeutic value. It emphasizes the need for caution and a careful assessment of the risk-benefit ratio when considering bronchoscopy in certain clinical scenarios.
  </summary>
  <pico>
    <population>Patients with respiratory conditions where bronchoscopy is frequently performed</population>
    <intervention>Bronchoscopy</intervention>
    <comparison>Alternative diagnostic methods</comparison>
    <outcome>Assessment of the appropriateness and effectiveness of bronchoscopy in various conditions</outcome>
  </pico>
  <take_home>Bronchoscopy should be reserved for cases where it has a clear diagnostic or therapeutic advantage, as its overuse can lead to unnecessary procedures and complications.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec1_Article (15)">
  <title>Iatrogenic bleeding during flexible bronchoscopy: risk factors, prophylactic measures and management</title>
  <authors>Bernasconi, M.; Koegelenberg, C.F.N.; Koutsokera, A.; Ogna, A.; Casutt, A.; Nicod, L.; Lovis, A.</authors>
  <citation>Bernasconi M, Koegelenberg CFN, Koutsokera A, et al. Iatrogenic bleeding during flexible bronchoscopy: risk factors, prophylactic measures and management. ERJ Open Res. 2017;3:00084-2016.</citation>
  <type>Review</type>
  <year>2017</year>
  <keywords>
    <keyword>Flexible bronchoscopy</keyword>
    <keyword>Iatrogenic bleeding</keyword>
    <keyword>Risk factors</keyword>
    <keyword>Management</keyword>
    <keyword>Prophylactic measures</keyword>
  </keywords>
  <summary>
    This review addresses the incidence, severity, risk factors, and management strategies for iatrogenic bleeding during flexible bronchoscopy. It aims to provide pulmonologists with practical guidance on prevention and intervention for this rare but potentially life-threatening complication.
  </summary>
  <pico>
    <population>Patients undergoing flexible bronchoscopy</population>
    <intervention>Flexible bronchoscopy procedures</intervention>
    <comparison>Standard management versus standardized protocols for bleeding</comparison>
    <outcome>Incidence and management of iatrogenic bleeding</outcome>
  </pico>
  <take_home>Significant iatrogenic bleeding during flexible bronchoscopy is rare and usually self-limiting, but a standardized approach for management is crucial, especially in cases of life-threatening hemorrhage.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec1_Article (2)">
  <title>Sedation in Bronchoscopy: A Review</title>
  <authors>McCambridge, A.J.; Boesch, R.P.; Mullon, J.J.</authors>
  <citation>McCambridge, A.J., Boesch, R.P., Mullon, J.J. Sedation in Bronchoscopy: A Review. Clin Chest Med. 2018;39(1):65–77.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Sedation</keyword>
    <keyword>Anesthesia</keyword>
    <keyword>Review</keyword>
  </keywords>
  <summary>
    This article provides a comprehensive review of sedation practices during bronchoscopy, discussing different sedative agents, their effects, and the importance of sedation in enhancing patient tolerance and comfort during the procedure. The review highlights the trend towards using moderate sedation and the emerging use of agents like propofol, ketamine, and dexmedetomidine.
  </summary>
  <pico>
    <population>Patients undergoing bronchoscopy</population>
    <intervention>Various sedation techniques including topical anesthesia, benzodiazepines, opioids, propofol, ketamine, and dexmedetomidine</intervention>
    <comparison>Moderate sedation versus no sedation or different sedation combinations</comparison>
    <outcome>Patient comfort, tolerance, reduction in cough, and procedural success</outcome>
  </pico>
  <take_home>Sedation is generally recommended for all patients undergoing bronchoscopic procedures to enhance comfort and procedural success, with a variety of sedative agents available to optimize patient outcomes.</take_home>
  <embedding_file>sec1_Article (2)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec1_Article (3)">
  <title>The role of bronchoscopy in the diagnosis of airway disease</title>
  <authors>Paradis T.J.; Dixon J.; Tieu B.H.</authors>
  <citation>Paradis T.J., Dixon J., Tieu B.H. The role of bronchoscopy in the diagnosis of airway disease. J Thorac Dis. 2016;8(12):3826-3837.</citation>
  <type>Review</type>
  <year>2016</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Lung disease</keyword>
    <keyword>Diagnosis</keyword>
    <keyword>Endosonography</keyword>
    <keyword>Electromagnetic fields</keyword>
  </keywords>
  <summary>
    This review discusses the evolution and significance of bronchoscopy in diagnosing various airway diseases, including the use of flexible and rigid bronchoscopy, endobronchial ultrasound (EBUS), and electromagnetic navigational bronchoscopy (ENB). It highlights advancements in technology that have improved diagnostic yields and the essential anesthetic considerations for performing these procedures.
  </summary>
  <pico>
    <population>Patients with suspected bronchopulmonary diseases</population>
    <intervention>Bronchoscopy (flexible, rigid, EBUS, ENB)</intervention>
    <comparison>Traditional diagnostic methods</comparison>
    <outcome>Improved diagnostic yield and management of airway diseases</outcome>
  </pico>
  <take_home>Bronchoscopy remains a critical tool for evaluating bronchopulmonary diseases, with advancements in technology enhancing its diagnostic capabilities and safety.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec1_Article (4)">
  <title>The utility of bronchoscopy in immunocompromised patients: a review</title>
  <authors>Morton, C.; Puchalski, J.</authors>
  <citation>MORTON, C., PUCHALSKI, J. The utility of bronchoscopy in immunocompromised patients: a review. J Thorac Dis. 2019;11(12):5603-5612.</citation>
  <type>Review</type>
  <year>2019</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Immunocompromised</keyword>
    <keyword>Next generation sequencing</keyword>
    <keyword>Metagenomics</keyword>
    <keyword>Opportunistic infections</keyword>
    <keyword>Bronchoalveolar lavage</keyword>
  </keywords>
  <summary>
    This review discusses the role of bronchoscopy in diagnosing pulmonary disorders in immunocompromised patients. It highlights the importance of bronchoscopy for both infectious and non-infectious pulmonary conditions, the diagnostic yield, potential complications, and the influence of timing on outcomes. The review emphasizes the need for individualized approaches in managing these patients due to their varied responses to bronchoscopy and the complexities of their underlying conditions.
  </summary>
  <pico>
    <population>Immunocompromised patients, including those with hematologic malignancies, organ transplants, and those on immunosuppressive therapies.</population>
    <intervention>Bronchoscopy, including bronchoalveolar lavage (BAL) and transbronchial biopsies (TBB).</intervention>
    <comparison>Non-invasive testing methods and timing of bronchoscopy.</comparison>
    <outcome>Diagnostic yield, impact on medical management, complications, and mortality rates.</outcome>
  </pico>
  <take_home>Timely bronchoscopy can significantly improve diagnostic yield in immunocompromised patients, but careful consideration is needed regarding the timing and potential complications.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec1_Article (5)">
  <title>Update on tracheobronchial anatomy and flexible fiberoptic bronchoscopy in thoracic anesthesia</title>
  <authors>Campos, J.H.</authors>
  <citation>Campos, J.H. Update on tracheobronchial anatomy and flexible fiberoptic bronchoscopy in thoracic anesthesia. Current Opinion in Anaesthesiology. 2009;22(1):4–10.</citation>
  <type>Review</type>
  <year>2009</year>
  <keywords>
    <keyword>bronchial blockers</keyword>
    <keyword>double-lumen endotracheal tubes</keyword>
    <keyword>flexible fiberoptic bronchoscopy</keyword>
    <keyword>tracheobronchial anatomy</keyword>
  </keywords>
  <summary>
    This review discusses the importance of understanding tracheobronchial anatomy and the role of flexible fiberoptic bronchoscopy in thoracic anesthesia. It highlights the anatomical changes that occur with age and the implications for lung isolation techniques, emphasizing the need for anesthesiologists to be proficient in these areas to ensure successful patient management during thoracic surgery.
  </summary>
  <pico>
    <population>Patients undergoing thoracic surgery</population>
    <intervention>Flexible fiberoptic bronchoscopy for lung isolation device placement</intervention>
    <comparison>Traditional methods of lung isolation device placement</comparison>
    <outcome>Improved accuracy and safety in the placement of lung isolation devices</outcome>
  </pico>
  <take_home>Mastery of tracheobronchial anatomy and fiberoptic bronchoscopy techniques is essential for anesthesiologists to ensure safe and effective management of patients during thoracic anesthesia.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec1_Article (6)">
  <title>Bronchoscopy Education: An Experiential Learning Theory Perspective</title>
  <authors>Septimiu D. Murgu, MD; Jonathan S. Kurman, MD; Omar Hasan, DO</authors>
  <citation>Murgu SD, Kurman JS, Hasan O. Bronchoscopy Education: An Experiential Learning Theory Perspective. Clin Chest Med. 2018;39(1):99–110.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Education</keyword>
    <keyword>Experiential learning theory</keyword>
    <keyword>Flipped classroom model</keyword>
    <keyword>Problem-based learning</keyword>
    <keyword>Checklists</keyword>
    <keyword>Simulation</keyword>
  </keywords>
  <summary>
    This article discusses the integration of experiential learning theory (ELM) into bronchoscopy education, emphasizing the need for active learning strategies that accommodate various learning styles. The authors advocate for problem-based learning (PBL), flipped classroom models, and the use of checklists and simulation to enhance knowledge retention and improve clinical practice among physicians.
  </summary>
  <pico>
    <population>Physicians undergoing bronchoscopy training</population>
    <intervention>Implementation of experiential learning theory in bronchoscopy education</intervention>
    <comparison>Traditional lecture-based education</comparison>
    <outcome>Improved knowledge retention, clinical skills, and practice changes</outcome>
  </pico>
  <take_home>The application of experiential learning theory in bronchoscopy education enhances active learning, leading to better retention and practical application of skills among physicians.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec1_Article (7)">
  <title>Bronchoscopes of the Twenty-First Century</title>
  <authors>Yarmus, L.; Feller-Kopman, D.</authors>
  <citation>Yarmus, L., Feller-Kopman, D. Bronchoscopes of the Twenty-First Century. Clin Chest Med. 2010;31(1):19–27.</citation>
  <type>Review</type>
  <year>2010</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Autofluorescence bronchoscopy</keyword>
    <keyword>Electromagnetic navigation</keyword>
    <keyword>Narrow-band imaging</keyword>
    <keyword>Confocal fluorescence microendoscopy</keyword>
    <keyword>Endobronchial ultrasound</keyword>
  </keywords>
  <summary>
    The article reviews the historical evolution and recent technological advancements in bronchoscopy, highlighting innovations in both rigid and flexible bronchoscopes. It discusses the implications of these advancements for diagnostic and therapeutic procedures in pulmonology, including the use of endobronchial ultrasound (EBUS), electromagnetic navigation, and imaging technologies such as autofluorescence and narrow-band imaging.
  </summary>
  <pico>
    <population>Patients undergoing bronchoscopy for diagnostic and therapeutic purposes</population>
    <intervention>Use of advanced bronchoscopy techniques and technologies</intervention>
    <comparison>Traditional bronchoscopy methods</comparison>
    <outcome>Improved diagnostic accuracy and therapeutic options</outcome>
  </pico>
  <take_home>Bronchoscopy technology has significantly advanced, enhancing the ability to diagnose and treat pulmonary conditions with greater precision and minimal invasiveness.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec1_Article (8)">
  <title>British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults</title>
  <authors>Du Rand IA, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, Mandal S, Martin J, Mills J, Navani N, Rahman NM, Wrightson JM, Munavvar M</authors>
  <citation>Du Rand IA, Blaikley J, Booton R, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults. Thorax. 2013;68:i1–i44.</citation>
  <type>Guideline</type>
  <year>2013</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Guideline</keyword>
    <keyword>Respiratory Medicine</keyword>
    <keyword>Diagnostic Procedures</keyword>
    <keyword>Patient Safety</keyword>
  </keywords>
  <summary>
    This article presents the British Thoracic Society's updated guidelines on the safe and effective use of flexible bronchoscopy in adults, covering monitoring, sedation, complications, and specific recommendations for various patient populations. It emphasizes the importance of patient safety and the need for continuous monitoring during the procedure.
  </summary>
  <pico>
    <population>Adults undergoing flexible bronchoscopy</population>
    <intervention>Diagnostic flexible bronchoscopy</intervention>
    <comparison>N/A</comparison>
    <outcome>Guidelines for monitoring, sedation, and management of complications</outcome>
  </pico>
  <take_home>Flexible bronchoscopy is a safe and essential diagnostic tool in respiratory medicine, but requires careful monitoring, appropriate sedation, and management of potential complications to ensure patient safety.</take_home>
  <embedding_file>https://doi.org/10.1136/thoraxjnl-2013-203618</embedding_file>
</article>
```
```xml
<article id="sec1_Article (8)">
  <title>Guidelines for Diagnostic Flexible Bronchoscopy in Adults</title>
  <authors>Du Rand, I.A.; Blaikley, J.; Booton, R.; Chaudhuri, N.; Gupta, V.; Khalid, S.; Mandal, S.; Martin, J.; Mills, J.; Navani, N.; Rahman, N.M.; Wrightson, J.; Munavvar, M.</authors>
  <citation>Du Rand, I.A., Blaikley, J., Booton, R., et al. Guidelines for Diagnostic Flexible Bronchoscopy in Adults. Thorax. 2023;78(Suppl 1):i1–i21.</citation>
  <type>Guideline</type>
  <year>2023</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>ICU</keyword>
    <keyword>Patient Safety</keyword>
    <keyword>Sedation</keyword>
    <keyword>Infection Control</keyword>
  </keywords>
  <summary>
    This guideline provides a comprehensive overview of best practices for diagnostic flexible bronchoscopy in adults, focusing on safety, efficacy, and optimal procedural techniques. It emphasizes the importance of patient monitoring, the selection of appropriate sedation, and the management of complications, while also addressing infection control measures and staff safety protocols.
  </summary>
  <pico>
    <population>Adults undergoing diagnostic flexible bronchoscopy</population>
    <intervention>Flexible bronchoscopy procedures</intervention>
    <comparison>Standard care vs. bronchoscopy for various indications</comparison>
    <outcome>Diagnostic yield, safety, patient satisfaction</outcome>
  </pico>
  <take_home>Flexible bronchoscopy is a critical tool in respiratory medicine, and its practice must prioritize patient safety, effective sedation, and infection control to ensure optimal outcomes.</take_home>
  <embedding_file>guidelines_bronchoscopy_2023.pdf</embedding_file>
</article>
```
```xml
<article id="sec1_Article (8)">
  <title>Bronchoscopy: Procedure and Patient Information</title>
  <authors>British Thoracic Society</authors>
  <citation>British Thoracic Society. Bronchoscopy: Procedure and Patient Information. Journal of Thoracic Medicine. 2023;6(1):1-15.</citation>
  <type>Guideline</type>
  <year>2023</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Patient Information</keyword>
    <keyword>Procedure</keyword>
    <keyword>Safety</keyword>
    <keyword>Preparation</keyword>
  </keywords>
  <summary>
    This article provides a comprehensive overview of the bronchoscopy procedure, including its purpose, preparation, execution, and post-procedure care. It addresses common reasons for performing bronchoscopy, alternative tests, and outlines necessary precautions to ensure patient safety and comfort during the procedure.
  </summary>
  <pico>
    <population>Patients requiring examination of the respiratory system</population>
    <intervention>Bronchoscopy procedure</intervention>
    <comparison>Alternative tests (e.g., X-rays, CT scans)</comparison>
    <outcome>Diagnosis of respiratory conditions, patient safety, and comfort</outcome>
  </pico>
  <take_home>Bronchoscopy is a safe and effective procedure for diagnosing respiratory issues, requiring careful patient preparation and post-procedure monitoring.</take_home>
  <embedding_file>bronchoscopy_patient_info.pdf</embedding_file>
</article>
```
```xml
<article id="sec1_Article (9)">
  <title>Basic Bronchoscopy Technology, Techniques, and Professional Fees</title>
  <authors>Ninan, N.; Wahidi, M.M.</authors>
  <citation>Ninan, N., Wahidi, M.M. Basic Bronchoscopy Technology, Techniques, and Professional Fees. CHEST. 2019;155(5):1067-1074.</citation>
  <type>Review</type>
  <year>2019</year>
  <keywords>
    <keyword>bronchoscopy</keyword>
    <keyword>lung biopsy</keyword>
    <keyword>practice management</keyword>
  </keywords>
  <summary>
    The article discusses the evolution of flexible bronchoscopy, its techniques, and the complexities of coding and billing associated with bronchoscopic procedures. It highlights the importance of understanding the Current Procedural Terminology (CPT) codes and the reimbursement landscape for these procedures, as well as the basic bronchoscopic techniques such as bronchoalveolar lavage (BAL), transbronchial lung biopsy (TBLB), and transbronchial needle aspiration (TBNA).
  </summary>
  <pico>
    <population>Patients requiring bronchoscopic evaluation</population>
    <intervention>Flexible bronchoscopy procedures</intervention>
    <comparison>Not applicable</comparison>
    <outcome>Improved understanding of coding, billing, and procedural techniques in bronchoscopy</outcome>
  </pico>
  <take_home>Understanding the coding and billing complexities of bronchoscopy is essential for optimizing reimbursement and ensuring effective practice management.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec2_Article (1)">
  <title>Moderate Sedation Changes for Bronchoscopy in 2017</title>
  <authors>NELSON, M.E.</authors>
  <citation>NELSON, M.E. Moderate Sedation Changes for Bronchoscopy in 2017. CHEST. 2017;152(4):893-897.</citation>
  <type>Review</type>
  <year>2017</year>
  <keywords>
    <keyword>billing</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>coding</keyword>
    <keyword>management</keyword>
    <keyword>sedation</keyword>
  </keywords>
  <summary>
    This article discusses significant changes in the reimbursement and coding for moderate sedation during bronchoscopy procedures effective January 1, 2017. It highlights the historical context of sedation practices, the evolution of coding for moderate sedation, and the implications of recent regulatory changes by the Centers for Medicare and Medicaid Services (CMS). The article emphasizes the importance of understanding these changes for appropriate reimbursement.
  </summary>
  <pico>
    <population>Patients undergoing bronchoscopy</population>
    <intervention>Moderate sedation provided by bronchoscopists</intervention>
    <comparison>Moderate sedation provided by anesthesia services</comparison>
    <outcome>Changes in coding and reimbursement rates for bronchoscopy procedures</outcome>
  </pico>
  <take_home>Healthcare providers performing bronchoscopy should be aware of the new coding requirements for moderate sedation to ensure proper reimbursement.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec2_Article (2)">
  <title>Performance, Long-term Management, and Coding for Percutaneous Dilational Tracheostomy</title>
  <authors>Jaspal Singh, MD, MHS, MHA, FCCP; Ronald F. Sing, DO, FCCP</authors>
  <citation>SINGH, J., SING, R.F. Performance, Long-term Management, and Coding for Percutaneous Dilational Tracheostomy. CHEST. 2019;155(3):639-644.</citation>
  <type>Review Article</type>
  <year>2019</year>
  <keywords>
    <keyword>interventional pulmonary</keyword>
    <keyword>respiratory failure</keyword>
    <keyword>tracheostomy</keyword>
    <keyword>tracheotomy</keyword>
  </keywords>
  <summary>
    This article discusses the evolution, safety, and clinical outcomes of percutaneous dilatational tracheostomy (PDT), emphasizing its growing acceptance in ICU settings. The authors outline procedural logistics, contraindications, and the importance of training for both surgeons and nonsurgeons. They advocate for PDT as the preferred method for tracheostomy in patients requiring prolonged mechanical ventilation.
  </summary>
  <pico>
    <population>Patients in the ICU requiring prolonged mechanical ventilation</population>
    <intervention>Percutaneous dilatational tracheostomy (PDT)</intervention>
    <comparison>Open surgical tracheostomy</comparison>
    <outcome>Safety, efficacy, complication rates, and resource utilization</outcome>
  </pico>
  <take_home>Percutaneous dilatational tracheostomy is a safe and effective procedure for tracheostomy in ICU patients, with proven benefits in terms of clinical outcomes and resource savings.</take_home>
  <embedding_file>https://doi.org/10.1016/j.chest.2018.10.049</embedding_file>
</article>
```
```xml
<article id="sec2_Article (3)">
  <title>Advanced Diagnostic and Therapeutic Bronchoscopy Technology and Reimbursement</title>
  <authors>Neeraj R. Desai, MD, FCCP; Thomas R. Gildea, MD, FCCP; Edward Kessler, MD, FCCP; Neil Ninan, MD, FCCP; Kim D. French, MHSA, FCCP; Denise A. Merlino, MBA, CNMT, CPC; Momen M. Wahidi, MD, FCCP; Kevin L. Kovitz, MD, FCCP</authors>
  <citation>Desai NR, Gildea TR, Kessler E, Ninan N, French KD, Merlino DA, Wahidi MM, Kovitz KL. Advanced Diagnostic and Therapeutic Bronchoscopy Technology and Reimbursement. CHEST. 2021;160(1):259-267.</citation>
  <type>Review</type>
  <year>2021</year>
  <keywords>
    <keyword>bronchoscopy</keyword>
    <keyword>coding</keyword>
    <keyword>Current Procedural Terminology</keyword>
    <keyword>interventional pulmonology</keyword>
    <keyword>therapeutic bronchoscopy</keyword>
  </keywords>
  <summary>
    This article discusses the evolution and complexity of advanced diagnostic and therapeutic bronchoscopy procedures, focusing on coding and reimbursement challenges. It highlights the importance of collaboration among healthcare professionals to ensure effective implementation and reimbursement for these advanced techniques.
  </summary>
  <pico>
    <population>Patients requiring advanced bronchoscopy for diagnosis and treatment of pulmonary conditions</population>
    <intervention>Advanced diagnostic and therapeutic bronchoscopy procedures</intervention>
    <comparison>Standard bronchoscopy procedures</comparison>
    <outcome>Improved diagnostic yield, therapeutic outcomes, and understanding of coding complexities</outcome>
  </pico>
  <take_home>Effective collaboration among clinical, financial, and coding professionals is essential to optimize the use and reimbursement of advanced bronchoscopy procedures.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec2_Article (4)">
  <title>Advanced Diagnostic and Therapeutic Bronchoscopy Technology and Reimbursement</title>
  <authors>Desai, N.R.; Gildea, T.R.; Kessler, E.; Ninan, N.; French, K.D.; Merlino, D.A.; Wahidi, M.M.; Kovitz, K.L.</authors>
  <citation>Desai N.R., Gildea T.R., Kessler E., Ninan N., French K.D., Merlino D.A., Wahidi M.M., Kovitz K.L. Advanced Diagnostic and Therapeutic Bronchoscopy Technology and Reimbursement. CHEST. 2021;160(1):259-267.</citation>
  <type>Review</type>
  <year>2021</year>
  <keywords>
    <keyword>airway stent</keyword>
    <keyword>argon plasma coagulation</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>coding</keyword>
    <keyword>Current Procedural Terminology</keyword>
    <keyword>endobronchial ultrasound</keyword>
    <keyword>laser</keyword>
    <keyword>navigational bronchoscopy</keyword>
  </keywords>
  <summary>
    The article discusses the evolution and refinement of advanced interventional pulmonary procedures, specifically focusing on the complexities of coding and reimbursement associated with these procedures. It highlights the importance of collaboration among healthcare professionals to navigate the challenges posed by advanced bronchoscopic techniques, including the description of procedures and their corresponding Current Procedural Terminology (CPT) codes.
  </summary>
  <pico>
    <population>Patients undergoing advanced bronchoscopic procedures for various lung conditions</population>
    <intervention>Advanced diagnostic and therapeutic bronchoscopy techniques</intervention>
    <comparison>Basic bronchoscopy procedures</comparison>
    <outcome>Improved diagnostic yield, procedural efficiency, and accurate reimbursement coding</outcome>
  </pico>
  <take_home>Understanding the complexities of coding and reimbursement for advanced bronchoscopy is crucial for optimizing clinical practice and financial outcomes in interventional pulmonology.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec3_Article (1)">
  <title>A Prospective, Randomized Trial for the Comparison of 19-G and 22-G Endobronchial Ultrasound-Guided Transbronchial Aspiration Needles; Introducing a Novel End Point of Sample Weight Corrected for Blood Content</title>
  <authors>Celina Wolters, Kaid Darwiche, Daniel Franzen, Thomas Hager, Beata Bode-Lesnievska, Peter J. Kneuertz, Kai He, Michael Koenig, Lutz Freitag, Lai Wei, Stephan Eisenmann, Christian Taube, Gerhard Weinreich, Filiz Oezkan</authors>
  <citation>Wolters C, Darwiche K, Franzen D, et al. A Prospective, Randomized Trial for the Comparison of 19-G and 22-G Endobronchial Ultrasound-Guided Transbronchial Aspiration Needles; Introducing a Novel End Point of Sample Weight Corrected for Blood Content. Clinical Lung Cancer. 2019;20(3):e265-73.</citation>
  <type>Original Study</type>
  <year>2019</year>
  <keywords>
    <keyword>EBUS-TBNA</keyword>
    <keyword>19-G</keyword>
    <keyword>22-G</keyword>
    <keyword>NSCLC</keyword>
    <keyword>Tissue quality</keyword>
  </keywords>
  <summary>
    This study compares the efficacy of 19-G and 22-G endobronchial ultrasound-guided transbronchial aspiration needles in terms of tissue quality, diagnostic yield, safety, and performance. Results show that the 19-G needle provides significantly more tissue and tumor cells compared to the 22-G needle, with similar safety profiles.
  </summary>
  <pico>
    <population>Patients with computed tomography scan indicative of lung cancer with mediastinal or hilar lymph node metastases</population>
    <intervention>Use of 19-G EBUS needle for transbronchial needle aspiration</intervention>
    <comparison>Use of 22-G EBUS needle for transbronchial needle aspiration</comparison>
    <outcome>Higher tissue quality and tumor cell count with the 19-G needle</outcome>
  </pico>
  <take_home>The 19-G EBUS needle yields significantly more tissue and tumor cells than the 22-G needle, with a similar safety profile, highlighting its potential for better molecular analyses in lung cancer diagnostics.</take_home>
  <embedding_file>Clinical_Lung_Cancer_2019_Article_Comparison_of_19-G_and_22-G_EBUS_TBNA_Needles.xml</embedding_file>
</article>
```
```xml
<article id="sec3_Article (10)">
  <title>Evaluation of a Novel Endobronchial Ultrasound-Guided Lymph Node Forceps in Enlarged Mediastinal Lymph Nodes</title>
  <authors>Darwiche, K.; Freitag, L.; Nair, A.; Neumann, C.; Karpf-Wissel, R.; Welter, S.; Wohlschlaeger, J.; Theegarten, D.</authors>
  <citation>Darwiche, K., Freitag, L., Nair, A., Neumann, C., Karpf-Wissel, R., Welter, S., Wohlschlaeger, J., Theegarten, D. Evaluation of a Novel Endobronchial Ultrasound-Guided Lymph Node Forceps in Enlarged Mediastinal Lymph Nodes. Respiration. 2013;86:229–236.</citation>
  <type>Research Article</type>
  <year>2013</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Endobronchial ultrasound</keyword>
    <keyword>Lung cancer</keyword>
    <keyword>Mediastinal lymph node</keyword>
    <keyword>Sarcoidosis</keyword>
    <keyword>Ultrasound-guided biopsy</keyword>
    <keyword>Transbronchial needle aspiration</keyword>
  </keywords>
  <summary>
    This study evaluates a novel endobronchial ultrasound-guided lymph node forceps (EBUS-TBFB) for biopsy of enlarged mediastinal lymph nodes, assessing its safety, feasibility, and diagnostic yield compared to traditional EBUS-TBNA. The results show that EBUS-TBFB significantly increases diagnostic yield, particularly in benign conditions, and allows for adequate histological specimens without complications.
  </summary>
  <pico>
    <population>Patients with enlarged mediastinal or hilar lymph nodes</population>
    <intervention>EBUS-guided transbronchial forceps biopsy (EBUS-TBFB)</intervention>
    <comparison>EBUS-transbronchial needle aspiration (EBUS-TBNA)</comparison>
    <outcome>Diagnostic yield, safety, and feasibility of the biopsy techniques</outcome>
  </pico>
  <take_home>EBUS-TBFB is a safe and effective technique that enhances the diagnostic yield for both benign and malignant conditions in patients with enlarged mediastinal lymph nodes.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec3_Article (11)">
  <title>Randomized Clinical Trial of Endobronchial Ultrasound Needle Biopsy With and Without Aspiration</title>
  <authors>Roberto F. Casal, MD; Gregg A. Staerkel, MD; David Ost, MD, FCCP; Francisco A. Almeida, MD, FCCP; Mateen H. Uzbeck, MD; George A. Eapen, MD, FCCP; Carlos A. Jimenez, MD, FCCP; Graciela M. Nogueras-Gonzalez, MPH; Mona Sarkiss, MD, PhD; Rodolfo C. Morice, MD, FCCP</authors>
  <citation>Casal RF, Staerkel GA, Ost D, et al. Randomized Clinical Trial of Endobronchial Ultrasound Needle Biopsy With and Without Aspiration. CHEST. 2012;142(3):568–573.</citation>
  <type>Original Research</type>
  <year>2012</year>
  <keywords>
    <keyword>Endobronchial ultrasound</keyword>
    <keyword>Needle biopsy</keyword>
    <keyword>Aspiration</keyword>
    <keyword>Transbronchial</keyword>
    <keyword>Randomized clinical trial</keyword>
  </keywords>
  <summary>
    This study compares the efficacy of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) with suction against endobronchial ultrasound-guided transbronchial needle capillary sampling (EBUS-TBNCS) without suction in patients with suspicious mediastinal lymph nodes. The results indicate high concordance rates in sample adequacy, diagnosis, and quality between the two techniques, suggesting that suction may not be necessary for effective sampling.
  </summary>
  <pico>
    <population>Adults with suspicious hilar or mediastinal lymph nodes</population>
    <intervention>Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)</intervention>
    <comparison>Endobronchial ultrasound-guided transbronchial needle capillary sampling (EBUS-TBNCS)</comparison>
    <outcome>Concordance in sample adequacy, diagnosis, and quality</outcome>
  </pico>
  <take_home>EBUS-TBNCS is a simpler and equally effective technique for obtaining biopsies of mediastinal and hilar lymph nodes compared to EBUS-TBNA with suction.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec3_Article (12)">
  <title>Rapid On-Site Cytologic Evaluation during Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Diagnosing Lung Cancer: A Randomized Study</title>
  <authors>Masahide Oki; Hideo Saka; Chiyoe Kitagawa; Yoshihito Kogure; Naohiko Murata; Takashi Adachi; Masahiko Ando</authors>
  <citation>Oki M, Saka H, Kitagawa C, Kogure Y, Murata N, Adachi T, Ando M. Rapid On-Site Cytologic Evaluation during Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Diagnosing Lung Cancer: A Randomized Study. Respiration. 2013;85(6):486–492.</citation>
  <type>Research Article</type>
  <year>2013</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Diagnosis</keyword>
    <keyword>Mediastinal lymph nodes</keyword>
    <keyword>Staging</keyword>
  </keywords>
  <summary>
    This study evaluates the efficacy of rapid on-site cytologic evaluation (ROSE) during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for diagnosing lung cancer. It found that ROSE significantly reduced the need for additional procedures and the number of needle punctures, although it did not affect overall diagnostic accuracy or complication rates.
  </summary>
  <pico>
    <population>Patients suspected of having lung cancer with hilar/mediastinal lymphadenopathy or a tumor adjacent to the central airway</population>
    <intervention>Endobronchial ultrasound-guided transbronchial needle aspiration with rapid on-site cytologic evaluation (ROSE)</intervention>
    <comparison>Endobronchial ultrasound-guided transbronchial needle aspiration without rapid on-site cytologic evaluation (non-ROSE)</comparison>
    <outcome>Diagnostic accuracy, number of punctures, need for additional procedures</outcome>
  </pico>
  <take_home>ROSE during EBUS-TBNA reduces the number of punctures and the need for additional procedures without compromising diagnostic accuracy.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
```xml
<article id="sec3_Article (13)">
  <title>Rapid On-Site Cytologic Evaluation During Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Nodal Staging in Patients With Lung Cancer</title>
  <authors>Nakajima, T.; Yasufuku, K.; Saegusa, F.; Fujiwara, T.; Sakairi, Y.; Hiroshima, K.; Nakatani, Y.; Yoshino, I.</authors>
  <citation>Nakajima, T., Yasufuku, K., Saegusa, F., Fujiwara, T., Sakairi, Y., Hiroshima, K., Nakatani, Y., Yoshino, I. Rapid On-Site Cytologic Evaluation During Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Nodal Staging in Patients With Lung Cancer. Ann Thorac Surg. 2013;95:1695–9.</citation>
  <type>Research Article</type>
  <year>2013</year>
  <keywords>
    <keyword>Endobronchial ultrasound</keyword>
    <keyword>Transbronchial needle aspiration</keyword>
    <keyword>Lung cancer</keyword>
    <keyword>Rapid on-site evaluation</keyword>
    <keyword>Cytology</keyword>
  </keywords>
  <summary>
    This study evaluates the effectiveness of rapid on-site evaluation (ROSE) during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for lymph node staging in lung cancer patients. It analyzes the correlation between ROSE results and final pathologic diagnosis, highlighting the accuracy and limitations of ROSE in clinical practice.
  </summary>
  <pico>
    <population>Patients with suspected or diagnosed lung cancer undergoing EBUS-TBNA for lymph node staging.</population>
    <intervention>Rapid on-site evaluation (ROSE) during EBUS-TBNA.</intervention>
    <comparison>Final pathologic diagnosis based on Papanicolaou and HandE staining.</comparison>
    <outcome>Concordance rate for staging, sensitivity, specificity, and diagnostic accuracy of EBUS-TBNA.</outcome>
  </pico>
  <take_home>ROSE during EBUS-TBNA demonstrates a low rate of non-diagnostic sampling and high agreement with final pathologic evaluations, but caution is advised due to a notable false-negative rate.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec3_Article (14)">
  <title>Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration CHEST Guideline and Expert Panel Report</title>
  <authors>Wahidi M.M., Herth F., Yasufuku K., Shepherd R.W., Yarmus L., Chawla M., Lamb C., Casey K.R., Patel S., Silvestri G.A., Feller-Kopman D.J.</authors>
  <citation>Wahidi M.M., Herth F., Yasufuku K., Shepherd R.W., Yarmus L., Chawla M., Lamb C., Casey K.R., Patel S., Silvestri G.A., Feller-Kopman D.J. Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration CHEST Guideline and Expert Panel Report. CHEST. 2016;149(3):816-835.</citation>
  <type>Guideline</type>
  <year>2016</year>
  <keywords>
    <keyword>endobronchial ultrasound</keyword>
    <keyword>transbronchial needle aspiration</keyword>
    <keyword>lung cancer</keyword>
    <keyword>guidelines</keyword>
    <keyword>evidence-based medicine</keyword>
  </keywords>
  <summary>
    This guideline provides an evidence-based review of the technical aspects of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). It synthesizes findings from literature to guide clinicians on best practices regarding sedation, needle size, number of passes, and other procedural factors to optimize diagnostic yield in various conditions including lung cancer, sarcoidosis, tuberculosis, and lymphoma.
  </summary>
  <pico>
    <population>Patients undergoing EBUS-TBNA for diagnostic evaluation</population>
    <intervention>Endobronchial ultrasound-guided transbronchial needle aspiration</intervention>
    <comparison>Various procedural techniques and sedation methods</comparison>
    <outcome>Diagnostic yield and procedural safety</outcome>
  </pico>
  <take_home>EBUS-TBNA is a valuable and minimally invasive diagnostic tool that requires careful consideration of procedural techniques to maximize diagnostic yield, particularly in lung cancer and other mediastinal diseases.</take_home>
  <embedding_file>embedding_file_path</embedding_file>
</article>
```
```xml
<article id="sec3_Article (2)">
  <title>Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy</title>
  <authors>Erin Faber, Horiana Grosu, Sharjeel Sabir, Francis Anthony San Lucas, Bedia A Barkoh, Roland L Bassett, Rajyalakshmi Luthra, John Stewart, Sinchita Roy-Chowdhuri</authors>
  <citation>Faber E, Grosu H, Sabir S, et al. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy. J Clin Pathol. 2022;75:612–619.</citation>
  <type>Research Article</type>
  <year>2022</year>
  <keywords>
    <keyword>Non-small-cell lung cancer</keyword>
    <keyword>Genomic profiling</keyword>
    <keyword>Biomarker testing</keyword>
    <keyword>Immune checkpoint inhibitors</keyword>
    <keyword>Targeted therapy</keyword>
  </keywords>
  <summary>
    This study evaluates the adequacy of small biopsy and cytology specimens for comprehensive genomic profiling in patients with advanced-stage non-small-cell lung cancer (NSCLC). It assesses the success rates of biomarker testing, correlating factors such as DNA concentration and specimen type with testing outcomes.
  </summary>
  <pico>
    <population>Patients with advanced-stage non-small-cell lung cancer</population>
    <intervention>Comprehensive genomic profiling using small biopsy and cytology specimens</intervention>
    <comparison>Comparison of adequacy rates between core needle biopsy (CNB) and fine-needle aspiration (FNA) specimens</comparison>
    <outcome>Success rates of biomarker testing for guideline-recommended biomarkers (EGFR, BRAF, ALK, ROS1, RET, MET, PD-L1)</outcome>
  </pico>
  <take_home>Thoracic small tissue specimens can be adequately used for genomic profiling in most cases, and success rates improve when CNB and FNA specimens are used in combination.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec3_Article (3)">
  <title>A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer</title>
  <authors>Yasufuku, K.; Pierre, A.; Darling, G.; de Perrot, M.; Waddell, T.; Johnston, M.; da Cunha Santos, G.; Geddie, W.; Boerner, S.; Le, L.W.; Keshavjee, S.</authors>
  <citation>Yasufuku, K., Pierre, A., Darling, G., de Perrot, M., Waddell, T., Johnston, M., da Cunha Santos, G., Geddie, W., Boerner, S., Le, L.W., Keshavjee, S. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg. 2011;142:1393-400.</citation>
  <type>Research Article</type>
  <year>2011</year>
  <keywords>
    <keyword>Endobronchial ultrasound</keyword>
    <keyword>Mediastinoscopy</keyword>
    <keyword>Lung cancer</keyword>
    <keyword>Staging</keyword>
    <keyword>Transbronchial needle aspiration</keyword>
  </keywords>
  <summary>
    This study compares the effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) with mediastinoscopy for the mediastinal lymph node staging of potentially resectable non-small cell lung cancer (NSCLC). The results indicate that both methods achieve similar staging accuracy, with EBUS-TBNA offering a less invasive alternative to mediastinoscopy.
  </summary>
  <pico>
    <population>Patients with confirmed or suspected non-small cell lung cancer requiring mediastinoscopy for staging</population>
    <intervention>Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)</intervention>
    <comparison>Mediastinoscopy</comparison>
    <outcome>Accuracy of mediastinal lymph node staging</outcome>
  </pico>
  <take_home>EBUS-TBNA can effectively replace mediastinoscopy for mediastinal staging in potentially resectable lung cancer, providing similar accuracy with fewer complications.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec3_Article (4)">
  <title>Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS)</title>
  <authors>Peter Vilmann; Paul Frost Clementsen; Sara Colella; Mette Siemsen; Paul De Leyn; Jean-Marc Dumonceau; Felix J. Herth; Alberto Larghi; Enrique Vazquez-Sequeiros; Cesare Hassan; Laurence Crombag; Daniël A. Korevaar; Lars Konge; Jouke T. Annema</authors>
  <citation>Vilmann P, Clementsen PF, Colella S, Siemsen M, De Leyn P, Dumonceau JM, Herth FJ, Larghi A, Vazquez-Sequeiros E, Hassan C, Crombag L, Korevaar DA, Konge L, Annema JT. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy. 2015;47:545–559.</citation>
  <type>Guideline</type>
  <year>2015</year>
  <keywords>
    <keyword>lung cancer</keyword>
    <keyword>endobronchial ultrasound</keyword>
    <keyword>endoscopic ultrasound</keyword>
    <keyword>mediastinal staging</keyword>
    <keyword>non-small-cell lung cancer</keyword>
  </keywords>
  <summary>
    This guideline outlines the use of combined endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS) for the diagnosis and staging of lung cancer. It emphasizes the advantages of these minimally invasive techniques over traditional surgical staging, particularly in patients with suspected non-small-cell lung cancer (NSCLC). The guideline provides recommendations based on the strength of evidence and aims to improve diagnostic accuracy and patient outcomes.
  </summary>
  <pico>
    <population>Patients with suspected or proven non-small-cell lung cancer (NSCLC)</population>
    <intervention>Combined endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS) for mediastinal nodal staging</intervention>
    <comparison>Surgical staging</comparison>
    <outcome>Improved diagnostic accuracy and reduced unnecessary thoracotomies</outcome>
  </pico>
  <take_home>Combined endobronchial and esophageal endosonography is recommended as the initial procedure for mediastinal nodal staging in lung cancer, offering superior diagnostic accuracy compared to surgical staging.</take_home>
  <embedding_file>http://dx.doi.org/10.1055/s-0034-1392040</embedding_file>
</article>
```
```xml
<article id="sec3_Article (5)">
  <title>Complications, Consequences, and Practice Patterns of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Results of the AQuIRE Registry</title>
  <authors>Eapen, G.A.; Shah, A.M.; Lei, X.; Jimenez, C.A.; Morice, R.C.; Yarmus, L.; Filner, J.; Ray, C.; Michaud, G.; Greenhill, S.R.; Sarkiss, M.; Casal, R.; Rice, D.; Ost, D.E.</authors>
  <citation>Eapen, G.A., Shah, A.M., Lei, X., Jimenez, C.A., Morice, R.C., Yarmus, L., Filner, J., Ray, C., Michaud, G., Greenhill, S.R., Sarkiss, M., Casal, R., Rice, D., Ost, D.E. Complications, Consequences, and Practice Patterns of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Results of the AQuIRE Registry. CHEST. 2013;143(4):1044–1053.</citation>
  <type>Original Research</type>
  <year>2013</year>
  <keywords>
    <keyword>Endobronchial Ultrasound</keyword>
    <keyword>Transbronchial Needle Aspiration</keyword>
    <keyword>Complications</keyword>
    <keyword>AQuIRE Registry</keyword>
    <keyword>Practice Patterns</keyword>
  </keywords>
  <summary>
    This study evaluates the incidence and risk factors for complications associated with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) using data from the AQuIRE registry. It identifies transbronchial lung biopsy (TBBx) as the only significant risk factor for complications and discusses variations in practice patterns and outcomes across hospitals.
  </summary>
  <pico>
    <population>Patients undergoing EBUS-TBNA across six hospitals</population>
    <intervention>Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)</intervention>
    <comparison>Patients undergoing EBUS-TBNA with and without transbronchial lung biopsy (TBBx)</comparison>
    <outcome>Incidence of complications, need for escalation of care, and interhospital variations in practice</outcome>
  </pico>
  <take_home>EBUS-TBNA is a safe procedure with a low complication rate of 1.44%, primarily associated with concurrent TBBx. The use of rapid onsite cytologic evaluation (ROSE) significantly reduces the need for TBBx.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec3_Article (6)">
  <title>Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration vs Conventional Transbronchial Needle Aspiration in the Diagnosis of Sarcoidosis</title>
  <authors>Gupta, Dheeraj; Dadhwal, Devendra S.; Agarwal, Ritesh; Gupta, Nalini; Bal, Amanjit; Aggarwal, Ashutosh N.</authors>
  <citation>Gupta, D., Dadhwal, D.S., Agarwal, R., Gupta, N., Bal, A., Aggarwal, A.N. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration vs Conventional Transbronchial Needle Aspiration in the Diagnosis of Sarcoidosis. CHEST. 2014;146(3):547-556.</citation>
  <type>Original Research</type>
  <year>2014</year>
  <keywords>
    <keyword>Sarcoidosis</keyword>
    <keyword>Endobronchial ultrasound</keyword>
    <keyword>Transbronchial needle aspiration</keyword>
    <keyword>Bronchoscopy</keyword>
    <keyword>Granulomas</keyword>
  </keywords>
  <summary>
    This study compares the diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and conventional transbronchial needle aspiration (cTBNA) in patients with sarcoidosis. The trial found that EBUS-TBNA has a higher individual yield compared to cTBNA, but when combined with transbronchial lung biopsy (TBLB) and endobronchial biopsy (EBB), the overall diagnostic yields become similar.
  </summary>
  <pico>
    <population>Patients with clinical diagnosis of sarcoidosis</population>
    <intervention>Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)</intervention>
    <comparison>Conventional transbronchial needle aspiration (cTBNA)</comparison>
    <outcome>Detection of granulomas and diagnostic yield</outcome>
  </pico>
  <take_home>EBUS-TBNA is the most effective procedure for diagnosing sarcoidosis, especially when combined with TBLB. However, cTBNA with additional biopsies can achieve similar diagnostic yields.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec3_Article (7)">
  <title>Endobronchial Ultrasound–Guided Transbronchial Needle Aspiration for the Diagnosis and Subtyping of Lymphoma</title>
  <authors>Horiana B. Grosu, Mihai Iliesiu, Nancy P. Caraway, L. Jeffrey Medeiros, Xiudong Lei, Carlos A. Jimenez, Rodolfo C. Morice, Roberto F. Casal, David Ost, George A. Eapen</authors>
  <citation>Grosu H.B., Iliesiu M., Caraway N.P., Medeiros L.J., Lei X., Jimenez C.A., Morice R.C., Casal R.F., Ost D., Eapen G.A. Endobronchial Ultrasound–Guided Transbronchial Needle Aspiration for the Diagnosis and Subtyping of Lymphoma. Ann Am Thorac Soc. 2015;12(9):1336–1344.</citation>
  <type>Research Article</type>
  <year>2015</year>
  <keywords>
    <keyword>endobronchial ultrasound-guided fine needle aspiration</keyword>
    <keyword>lymphoma</keyword>
    <keyword>mediastinal lymphadenopathy</keyword>
  </keywords>
  <summary>
    This study investigates the effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in diagnosing and subtyping lymphoma. The authors conducted a retrospective review of patients who underwent EBUS-TBNA for suspected lymphoma, analyzing diagnostic outcomes based on likelihood ratios, sensitivity, and specificity.
  </summary>
  <pico>
    <population>Patients with suspected lymphoma undergoing EBUS-TBNA</population>
    <intervention>Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)</intervention>
    <comparison>Excisional biopsy</comparison>
    <outcome>Diagnostic accuracy and ability to subtype lymphoma</outcome>
  </pico>
  <take_home>EBUS-TBNA is an effective, minimally invasive diagnostic tool for suspected lymphoma, offering high sensitivity and specificity, particularly in identifying and subtyping lymphoma.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec3_Article (8)">
  <title>EBUS-TBNA and EUS-FNA Risk Assessment for Patients Receiving Clopidogrel</title>
  <authors>Meena, N.; Abouzgheib, W.; Patolia, S.; Rosenheck, J.; Boujaoude, Z.; Bartter, T.</authors>
  <citation>Meena N, Abouzgheib W, Patolia S, et al. EBUS-TBNA and EUS-FNA Risk Assessment for Patients Receiving Clopidogrel. J Bronchol Intervent Pulmonol. 2016;23:303–307.</citation>
  <type>Original Investigation</type>
  <year>2016</year>
  <keywords>
    <keyword>clopidogrel</keyword>
    <keyword>endobronchial ultrasound</keyword>
    <keyword>esophageal ultrasound</keyword>
    <keyword>bleeding</keyword>
  </keywords>
  <summary>
    This study evaluates the bleeding risk associated with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and esophageal ultrasound fine needle aspiration (EUS-FNA) in patients taking clopidogrel. A retrospective review of 395 procedures indicated no significant bleeding complications in patients who continued clopidogrel during the procedures, suggesting that these procedures can be safely performed when necessary.
  </summary>
  <pico>
    <population>Patients undergoing EBUS-TBNA and EUS-FNA while on clopidogrel</population>
    <intervention>EBUS-TBNA and EUS-FNA procedures</intervention>
    <comparison>Control group of patients who had stopped clopidogrel for more than 4 days</comparison>
    <outcome>Incidence of significant bleeding complications</outcome>
  </pico>
  <take_home>It is reasonable to proceed with EBUS-TBNA or EUS-FNA in patients who cannot stop clopidogrel if an important diagnostic question is at stake, as no significant bleeding complications were observed in this study.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec3_Article (9)">
  <title>Endosonography for mediastinal disease: esophageal ultrasound vs. endobronchial ultrasound</title>
  <authors>Meena, N.; Bartter, T.</authors>
  <citation>Meena, N., Bartter, T. Endosonography for mediastinal disease: esophageal ultrasound vs. endobronchial ultrasound. Endosc Int Open. 2015; 03: E302–E306.</citation>
  <type>Original article</type>
  <year>2015</year>
  <keywords>
    <keyword>endosonography</keyword>
    <keyword>esophageal ultrasound</keyword>
    <keyword>endobronchial ultrasound</keyword>
    <keyword>mediastinal disease</keyword>
    <keyword>fine needle aspiration</keyword>
  </keywords>
  <summary>
    This study compares the procedural characteristics of esophageal ultrasound (EUS) and endobronchial ultrasound (EBUS) for diagnosing mediastinal disease. It highlights that EUS is better tolerated, requires less sedation, and is faster than EBUS, making it the preferred method when applicable. The study involved a retrospective analysis of 155 procedures and found significant differences in time, sedation, and recovery between EUS and EBUS.
  </summary>
  <pico>
    <population>Patients undergoing endosonography for mediastinal disease</population>
    <intervention>Esophageal ultrasound (EUS)</intervention>
    <comparison>Endobronchial ultrasound (EBUS)</comparison>
    <outcome>Procedure time, sedation requirements, and recovery</outcome>
  </pico>
  <take_home>Esophageal ultrasound (EUS) is a faster and better-tolerated procedure compared to endobronchial ultrasound (EBUS) for assessing mediastinal disease, suggesting it should be the first choice when feasible.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec4_Article (1)">
  <title>Biopsy of peripheral lung nodules utilizing cone beam computer tomography with and without trans bronchial access tool: a retrospective analysis</title>
  <authors>Sobieszczyk, M.J.; Yuan, Z.; Li, W.; Krimsky, W.</authors>
  <citation>Sobieszczyk, M.J., Yuan, Z., Li, W., Krimsky, W. Biopsy of peripheral lung nodules utilizing cone beam computer tomography with and without trans bronchial access tool: a retrospective analysis. J Thorac Dis. 2018;10(10):5953-5959.</citation>
  <type>Original Article</type>
  <year>2018</year>
  <keywords>
    <keyword>Lung nodule</keyword>
    <keyword>Lung cancer</keyword>
    <keyword>Bronchoscopy</keyword>
    <keyword>Endobronchial ultrasound</keyword>
    <keyword>Radial ultrasound</keyword>
    <keyword>Electromagnetic ultrasound</keyword>
    <keyword>Cone beam computer tomography (CBCT)</keyword>
    <keyword>Trans bronchial access tool</keyword>
  </keywords>
  <summary>
    This study evaluates the feasibility and safety of using a combination of cone beam computed tomography (CBCT), electromagnetic navigation bronchoscopy (ENB), and the Transbronchial Access Tool (TBAT) for diagnosing peripheral lung nodules. A retrospective analysis of 22 patients revealed a diagnostic yield of 77.2%, with TBAT achieving a 100% yield in the cases it was used. No complications were reported, indicating that the combined modalities may enhance diagnostic accuracy for challenging lung lesions.
  </summary>
  <pico>
    <population>Patients with peripheral pulmonary nodules on chest computed tomography</population>
    <intervention>Navigation bronchoscopy using CBCT, ENB, and TBAT</intervention>
    <comparison>Diagnostic yields with and without TBAT</comparison>
    <outcome>Diagnostic yield and safety of the combined techniques</outcome>
  </pico>
  <take_home>The combination of CBCT, ENB, and TBAT is a safe and effective approach for diagnosing peripheral lung nodules, improving diagnostic yield, especially in challenging cases.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec4_Article (10)">
  <title>Fiducial marker placement with electromagnetic navigation bronchoscopy: a subgroup analysis of the prospective, multicenter NAVIGATE study</title>
  <authors>Mark R. Bowling, Erik E. Folch, Sandeep J. Khandhar, Jordan Kazakov, William S. Krimsky, Gregory P. LeMense, Philip A. Linden, Boris A. Murillo, Michael A. Nead, Michael A. Pritchett, Catalina V. Teba, Christopher W. Towe, Terence Williams, Carlos J. Anciano</authors>
  <citation>Bowling M.R., Folch E.E., Khandhar S.J., et al. Fiducial marker placement with electromagnetic navigation bronchoscopy: a subgroup analysis of the prospective, multicenter NAVIGATE study. Ther Adv Respir Dis. 2019;13:1–11.</citation>
  <type>Research Article</type>
  <year>2019</year>
  <keywords>
    <keyword>electromagnetic navigation bronchoscopy</keyword>
    <keyword>fiducial markers</keyword>
    <keyword>lung cancer</keyword>
    <keyword>prospective clinical study</keyword>
    <keyword>stereotactic body radiation therapy</keyword>
  </keywords>
  <summary>
    This study evaluates the safety, accuracy, and practice patterns of fiducial marker (FM) placement using electromagnetic navigation bronchoscopy (ENB) in lung cancer patients. The NAVIGATE study is the largest prospective, multicenter study on this topic, involving 258 patients across 21 centers. Results indicate high accuracy in FM placement with low complication rates, highlighting ENB's versatility in facilitating concurrent procedures.
  </summary>
  <pico>
    <population>Patients undergoing ENB-guided fiducial marker placement for lung cancer management</population>
    <intervention>Electromagnetic navigation bronchoscopy for fiducial marker placement</intervention>
    <comparison>Not applicable (observational study)</comparison>
    <outcome>Safety, accuracy, and procedural characteristics of fiducial marker placement</outcome>
  </pico>
  <take_home>ENB-guided fiducial marker placement is safe and accurate, with low complication rates, making it an efficient option for lung cancer management.</take_home>
  <embedding_file>https://doi.org/10.1177/1753466619841234</embedding_file>
</article>
```
```xml
<article id="sec4_Article (11)">
  <title>First Human Use of a New Robotic-Assisted Fiber Optic Sensing Navigation System for Small Peripheral Pulmonary Nodules</title>
  <authors>David I.K. Fielding, Farzad Bashirzadeh, Jung Hwa Son, Maryann Todman, Adrian Chin, Lionel Tan, Karin Steinke, Morgan N. Windsor, Arthur Wai Sung</authors>
  <citation>Fielding DIK, Bashirzadeh F, Son JH, Todman M, Chin A, Tan L, Steinke K, Windsor MN, Sung AW. First Human Use of a New Robotic-Assisted Fiber Optic Sensing Navigation System for Small Peripheral Pulmonary Nodules. Respiration. 2019;98:142–150.</citation>
  <type>Research Article</type>
  <year>2019</year>
  <keywords>
    <keyword>Lung biopsy</keyword>
    <keyword>Solitary pulmonary nodule</keyword>
    <keyword>Robotic bronchoscopy</keyword>
    <keyword>Lung cancer</keyword>
  </keywords>
  <summary>
    This study evaluated the safety and feasibility of a novel robotic-assisted bronchoscope system designed to biopsy small peripheral pulmonary nodules. The system demonstrated high success rates in reaching targets and obtaining samples, with no device-related adverse events reported.
  </summary>
  <pico>
    <population>Patients with small peripheral pulmonary nodules (1–3 cm)</population>
    <intervention>Robotic-assisted bronchoscope system for biopsy</intervention>
    <comparison>Conventional bronchoscopy techniques</comparison>
    <outcome>Safety, feasibility, and diagnostic yield of biopsy</outcome>
  </pico>
  <take_home>This robotic-assisted bronchoscope system shows promise for safely and effectively sampling small peripheral pulmonary nodules, achieving a high diagnostic yield without significant complications.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec4_Article (12)">
  <title>Improved diagnostic yield for lung nodules with digital tomosynthesis-corrected navigational bronchoscopy: Initial experience with a novel adjunct</title>
  <authors>ABOUDARA, M.; ROLLER, L.; RICKMAN, O.; LENTZ, R.J.; PANNU, J.; CHEN, H.; MALDONADO, F.</authors>
  <citation>ABOUDARA, M., ROLLER, L., RICKMAN, O., LENTZ, R.J., PANNU, J., CHEN, H., MALDONADO, F. Improved diagnostic yield for lung nodules with digital tomosynthesis-corrected navigational bronchoscopy: Initial experience with a novel adjunct. Journal Name. 2019;VOLUME(ISSUE):PAGES.</citation>
  <type>Original Article</type>
  <year>2019</year>
  <keywords>
    <keyword>fluoroscopy</keyword>
    <keyword>lung nodule</keyword>
    <keyword>navigational bronchoscopy</keyword>
    <keyword>tomosynthesis</keyword>
  </keywords>
  <summary>
    This study evaluates the impact of fluoroscopic electromagnetic navigation bronchoscopy (F-ENB) on the diagnostic yield for lung nodules compared to standard electromagnetic navigation bronchoscopy (S-ENB). A retrospective review demonstrated a significant increase in diagnostic yield from 54% with S-ENB to 79% with F-ENB, indicating that F-ENB effectively corrects for nodule divergence and improves biopsy accuracy.
  </summary>
  <pico>
    <population>Patients with lung nodules undergoing electromagnetic navigation bronchoscopy</population>
    <intervention>Fluoroscopic electromagnetic navigation bronchoscopy (F-ENB)</intervention>
    <comparison>Standard electromagnetic navigation bronchoscopy (S-ENB)</comparison>
    <outcome>Diagnostic yield of lung biopsies</outcome>
  </pico>
  <take_home>Fluoroscopic electromagnetic navigation bronchoscopy significantly improves the diagnostic yield for lung nodules compared to standard techniques, with a low complication rate.</take_home>
  <embedding_file>sec4_Article (12)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec4_Article (13)">
  <title>Interventional Bronchoscopy</title>
  <authors>Gerard J. Criner, Ralf Eberhardt, Sebastian Fernandez-Bussy, Daniela Gompelmann, Fabien Maldonado, Neal Patel, Pallav L. Shah, Dirk-Jan Slebos, Arschang Valipour, Momen M. Wahidi, Mark Weir, Felix J. Herth</authors>
  <citation>Criner G.J., Eberhardt R., Fernandez-Bussy S., Gompelmann D., Maldonado F., Patel N., Shah P.L., Slebos D.J., Valipour A., Wahidi M.M., Weir M., Herth F.J. Interventional Bronchoscopy. Am J Respir Crit Care Med. 2020;202(1):29–50.</citation>
  <type>Review</type>
  <year>2020</year>
  <keywords>
    <keyword>bronchoscopy</keyword>
    <keyword>lung cancer</keyword>
    <keyword>emphysema</keyword>
    <keyword>chronic bronchitis</keyword>
    <keyword>interventional pulmonology</keyword>
  </keywords>
  <summary>
    This article reviews the evolution and advancements in interventional bronchoscopy, highlighting its diagnostic and therapeutic applications for various lung diseases. It discusses recent technological innovations, imaging techniques, and navigational tools that enhance the efficacy of bronchoscopy in diagnosing and treating conditions such as lung cancer, emphysema, and chronic bronchitis. The review emphasizes the expanding role of flexible bronchoscopy in providing minimally invasive interventions and improving patient outcomes.
  </summary>
  <pico>
    <population>Patients with lung diseases requiring diagnostic and therapeutic interventions</population>
    <intervention>Flexible bronchoscopy with advanced imaging and navigational techniques</intervention>
    <comparison>Standard bronchoscopy techniques</comparison>
    <outcome>Improved diagnostic yield and therapeutic efficacy for lung conditions</outcome>
  </pico>
  <take_home>Interventional bronchoscopy has significantly advanced in the past decade, providing new diagnostic and therapeutic options for a variety of lung diseases, thereby improving patient care.</take_home>
  <embedding_file>interventional_bronchoscopy_summary.pdf</embedding_file>
</article>
```
```xml
<article id="sec4_Article (14)">
  <title>Management of Significant Airway Bleeding during Robotic Assisted Bronchoscopy: A Tailored Approach</title>
  <authors>Sebastian Fernandez-Buss, David Abia-Trujillo, Adnan Majid, Erik E. Folch, Neal M. Patel, Felix J.F. Herth, Janani S. Reisenauer</authors>
  <citation>Fernandez-Buss, S., Abia-Trujillo, D., Majid, A., Folch, E.E., Patel, N.M., Herth, F.J.F., Reisenauer, J.S. Management of Significant Airway Bleeding during Robotic Assisted Bronchoscopy: A Tailored Approach. Respiration. 2021;100:547–550.</citation>
  <type>Case Report</type>
  <year>2021</year>
  <keywords>
    <keyword>Robotic assisted bronchoscopy</keyword>
    <keyword>Significant airway bleeding</keyword>
    <keyword>Lung nodule management</keyword>
  </keywords>
  <summary>
    This article discusses the challenges and management strategies for significant airway bleeding during robotic assisted bronchoscopy (RAB). It presents a standardized approach that utilizes a combined flexible and robotic bronchoscopic technique, illustrated through a case report of a 71-year-old woman with lung nodules.
  </summary>
  <pico>
    <population>Patients undergoing robotic assisted bronchoscopy with significant airway bleeding</population>
    <intervention>Combined flexible and robotic bronchoscopic approach for managing airway bleeding</intervention>
    <comparison>Standard management techniques for airway bleeding during traditional bronchoscopy</comparison>
    <outcome>Successful control of significant airway bleeding and continuation of the procedure without complications</outcome>
  </pico>
  <take_home>The proposed combined approach of using flexible bronchoscopy alongside robotic bronchoscopy is effective in managing significant airway bleeding during RAB, providing a clear treatment algorithm for such complications.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec4_Article (15)">
  <title>A Prospective Randomized Comparative Study of Three Guided Bronchoscopic Approaches for Investigating Pulmonary Nodules: The PRECISION-1 Study</title>
  <authors>Lonny Yarmus, DO; Jason Akulian, MD, MPH; Momen Wahidi, MD; Alex Chen, MD; Jennifer P. Steltz, BS; Sam L. Solomon, BS; Diana Yu, MD; Fabien Maldonado, MD; Jose Cardenas-Garcia, MD; Daniela Molena, MD; Hans Lee, MD; Anil Vachani, MD</authors>
  <citation>Yarmus L, Akulian J, Wahidi M, et al. A Prospective Randomized Comparative Study of Three Guided Bronchoscopic Approaches for Investigating Pulmonary Nodules: The PRECISION-1 Study. CHEST. 2020;157(3):694-701.</citation>
  <type>Original Research</type>
  <year>2020</year>
  <keywords>
    <keyword>interventional bronchoscopy</keyword>
    <keyword>lung cancer</keyword>
    <keyword>lung nodule</keyword>
    <keyword>navigational bronchoscopy</keyword>
    <keyword>robotic bronchoscopy</keyword>
  </keywords>
  <summary>
    This study investigates the efficacy of robotic bronchoscopy (RB), electromagnetic navigation (EMN), and ultrathin bronchoscopy with radial endobronchial ultrasound (UTB-rEBUS) for localizing and puncturing small peripheral pulmonary nodules (PPNs) in a cadaver model. The results show that RB significantly outperforms EMN and UTB-rEBUS in successful localization and puncture of PPNs.
  </summary>
  <pico>
    <population>Patients with small peripheral pulmonary nodules (PPNs) measuring less than 2 cm</population>
    <intervention>Robotic bronchoscopy (RB)</intervention>
    <comparison>Electromagnetic navigation (EMN) and ultrathin bronchoscopy with radial endobronchial ultrasound (UTB-rEBUS)</comparison>
    <outcome>Success rates in localization and puncture of PPNs</outcome>
  </pico>
  <take_home>Robotic bronchoscopy significantly improves the ability to localize and puncture small peripheral pulmonary nodules compared to existing technologies.</take_home>
  <embedding_file>https://doi.org/10.1016/j.chest.2019.10.016</embedding_file>
</article>
```
```xml
<article id="sec4_Article (16)">
  <title>Robot-assisted bronchoscopy for pulmonary lesion diagnosis: results from the initial multicenter experience</title>
  <authors>Udit Chaddha, Stephen P. Kovacs, Christopher Manley, D. Kyle Hogarth, Gustavo Cumbo-Nacheli, Sivasubramanium V. Bhavani, Rohit Kumar, Manisha Shende, John P. Egan III, Septimiu Murgu</authors>
  <citation>Chaddha U, Kovacs SP, Manley C, Hogarth DK, Cumbo-Nacheli G, Bhavani SV, Kumar R, Shende M, Egan JP III, Murgu S. Robot-assisted bronchoscopy for pulmonary lesion diagnosis: results from the initial multicenter experience. BMC Pulm Med. 2019;19(1):89.</citation>
  <type>Research Article</type>
  <year>2019</year>
  <keywords>
    <keyword>Robotic bronchoscopy</keyword>
    <keyword>Biopsy</keyword>
    <keyword>Electromagnetic navigation</keyword>
    <keyword>Lung cancer</keyword>
    <keyword>Lung lesion</keyword>
  </keywords>
  <summary>
    This study evaluates the feasibility, safety, and diagnostic yield of robot-assisted bronchoscopy (RAB) for lung lesion diagnosis in a multicenter setting. The initial results indicate that RAB is a safe and effective method, achieving a diagnostic yield of 69.1-77% with manageable complication rates.
  </summary>
  <pico>
    <population>Patients with suspected lung lesions requiring biopsy</population>
    <intervention>Robot-assisted bronchoscopy (RAB)</intervention>
    <comparison>Conventional guided bronchoscopy techniques</comparison>
    <outcome>Diagnostic yield and safety outcomes</outcome>
  </pico>
  <take_home>Robot-assisted bronchoscopy is a safe and feasible method for diagnosing lung lesions, with a promising initial diagnostic yield. Further comparative studies are needed to assess its cost-effectiveness against existing technologies.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec4_Article (17)">
  <title>Robotic bronchoscopy for pulmonary lesions: a review of existing technologies and clinical data</title>
  <authors>Abhinav Agrawal, D. Kyle Hogarth, Septimiu Murgu</authors>
  <citation>Agrawal A, Hogarth DK, Murgu S. Robotic bronchoscopy for pulmonary lesions: a review of existing technologies and clinical data. J Thorac Dis. 2020;12(6):3279-3286.</citation>
  <type>Review Article</type>
  <year>2020</year>
  <keywords>
    <keyword>Robotic bronchoscopy</keyword>
    <keyword>peripheral lung lesion</keyword>
    <keyword>lung cancer</keyword>
    <keyword>biopsy</keyword>
    <keyword>navigational bronchoscopy</keyword>
  </keywords>
  <summary>
    This article reviews the advancements in robotic bronchoscopy technologies aimed at improving the diagnostic yield for peripheral lung lesions, particularly in the context of lung cancer. It discusses the limitations of existing bronchoscopy platforms and how robotic systems can enhance precision in sampling and potentially aid in the treatment of non-operable tumors through ablative therapies.
  </summary>
  <pico>
    <population>Patients with suspicious pulmonary lesions</population>
    <intervention>Robotic-assisted bronchoscopy</intervention>
    <comparison>Conventional bronchoscopy techniques</comparison>
    <outcome>Improved diagnostic yield and safety in sampling peripheral lung lesions</outcome>
  </pico>
  <take_home>Robotic bronchoscopy platforms may significantly enhance the diagnostic yield for peripheral lung lesions and could play a role in the treatment of certain lung cancers.</take_home>
  <embedding_file>sec4_Article (17)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec4_Article (18)">
  <title>Robotic Bronchoscopy for Diagnosing Peripheral Lung Lesions: Are We There Yet?</title>
  <authors>Kramer, T.; Manley, C.J.; Annema, J.T.</authors>
  <citation>Kramer T, Manley CJ, Annema JT. Robotic bronchoscopy for diagnosing peripheral lung lesions: Are we there yet? Chest. 2021;159(2):845-852.</citation>
  <type>Research Commentary</type>
  <year>2021</year>
  <keywords>
    <keyword>Robotic bronchoscopy</keyword>
    <keyword>Peripheral lung lesions</keyword>
    <keyword>Diagnostic yield</keyword>
    <keyword>Radial endobronchial ultrasound</keyword>
  </keywords>
  <summary>
    This commentary discusses the findings of a pilot study on robotic bronchoscopy for peripheral lung lesions, highlighting the high navigational success rate but a lower diagnostic yield. The authors propose that combining robotic bronchoscopy with real-time feedback tools could improve diagnostic outcomes.
  </summary>
  <pico>
    <population>Patients undergoing robotic bronchoscopy for peripheral lung lesions</population>
    <intervention>Robotic bronchoscopy with radial endobronchial ultrasound</intervention>
    <comparison>Conventional bronchoscopic techniques</comparison>
    <outcome>Lesion localization success and diagnostic yield</outcome>
  </pico>
  <take_home>While robotic bronchoscopy shows promise in lesion localization, further studies are needed to improve the diagnostic yield and establish best practices.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec4_Article (19)">
  <title>Sensitivity and Safety of Electromagnetic Navigation Bronchoscopy for Lung Cancer Diagnosis: Systematic Review and Meta-analysis</title>
  <authors>Erik E. Folch, MD; Gonzalo Labarca, MD; Daniel Ospina-Delgado, MD; Fayez Kheir, MD; Adnan Majid, MD; Sandeep J. Khandhar, MD; Hiren J. Mehta, MD; Michael A. Jantz, MD; Sebastian Fernandez-Bussy, MD</authors>
  <citation>Folch EE, Labarca G, Ospina-Delgado D, et al. Sensitivity and Safety of Electromagnetic Navigation Bronchoscopy for Lung Cancer Diagnosis: Systematic Review and Meta-analysis. CHEST. 2020;158(4):1753-1769.</citation>
  <type>Original Research</type>
  <year>2020</year>
  <keywords>
    <keyword>electromagnetic navigation</keyword>
    <keyword>image-guided biopsy</keyword>
    <keyword>lung cancer</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>peripheral pulmonary lesions</keyword>
  </keywords>
  <summary>
    This systematic review and meta-analysis evaluated the sensitivity and safety of electromagnetic navigation bronchoscopy (ENB) in diagnosing lung cancer in patients with peripheral pulmonary lesions (PPLs). The analysis included 40 studies with a total of 3,342 participants, reporting a pooled sensitivity of 77% and a specificity of 100% for malignancy. The risk of complications, such as pneumothorax, was found to be low, at 2.0%. The findings suggest that ENB is a safe and effective diagnostic tool for lung cancer.
  </summary>
  <pico>
    <population>Patients with peripheral pulmonary lesions suspected of lung cancer</population>
    <intervention>Electromagnetic navigation bronchoscopy (ENB)</intervention>
    <comparison>Surgery or longitudinal follow-up</comparison>
    <outcome>Sensitivity and safety of ENB for diagnosing malignancy</outcome>
  </pico>
  <take_home>ENB is a safe and effective procedure for diagnosing lung cancer in patients with peripheral pulmonary lesions, with a high sensitivity and low complication rate.</take_home>
  <embedding_file>https://www.crd.york.ac.uk/prospero/CRD42019109449</embedding_file>
</article>
```
```xml
<article id="sec4_Article (2)">
  <title>Bronchoscopic transparenchymal nodule access (BTPNA): first in human trial of a novel procedure for sampling solitary pulmonary nodules</title>
  <authors>Felix JF Herth, Ralf Eberhardt, Daniel Sterman, Gerard A Silvestri, Hans Hoffmann, Pallav L Shah</authors>
  <citation>Herth FJF, Eberhardt R, Sterman D, et al. Bronchoscopic transparenchymal nodule access (BTPNA): first in human trial of a novel procedure for sampling solitary pulmonary nodules. Thorax. 2015;70:326–332.</citation>
  <type>Original Article</type>
  <year>2015</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Lung cancer</keyword>
    <keyword>Solitary pulmonary nodules</keyword>
    <keyword>Interventional pulmonology</keyword>
  </keywords>
  <summary>
    This study presents the first human trial of a novel bronchoscopic procedure, Bronchoscopic Trans-Parenchymal Nodule Access (BTPNA), designed for sampling solitary pulmonary nodules (SPNs) through a transparenchymal approach. The results indicate that the procedure is feasible and safe, with a high success rate in obtaining adequate biopsy samples.
  </summary>
  <pico>
    <population>Patients with solitary pulmonary nodules detected on CT imaging suspicious for lung cancer</population>
    <intervention>Bronchoscopic transparenchymal nodule access (BTPNA)</intervention>
    <comparison>Not applicable (single-arm interventional study)</comparison>
    <outcome>Feasibility and safety of the BTPNA procedure</outcome>
  </pico>
  <take_home>Bronchoscopic transparenchymal nodule access is a novel and feasible technique for sampling peripheral lung nodules that demonstrates a high success rate and minimal complications.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec4_Article (20)">
  <title>Shape-Sensing Robotic-Assisted Bronchoscopy vs Digital Tomosynthesis-Corrected Electromagnetic Navigation Bronchoscopy: A Comparative Cohort Study of Diagnostic Performance</title>
  <authors>See-Wei Low, MD; Robert J. Lentz, MD; Heidi Chen, PhD; James Katsis, MD; Matthew C. Aboudara, MD; Samuel Whatley; Rafael Paez, MD; Otis B. Rickman, DO; Fabien Maldonado, MD</authors>
  <citation>Low SW, Lentz RJ, Chen H, et al. Shape-Sensing Robotic-Assisted Bronchoscopy vs Digital Tomosynthesis-Corrected Electromagnetic Navigation Bronchoscopy: A Comparative Cohort Study of Diagnostic Performance. CHEST. 2023;163(4):977-984.</citation>
  <type>Original Research</type>
  <year>2023</year>
  <keywords>
    <keyword>digital tomosynthesis</keyword>
    <keyword>electromagnetic navigational bronchoscopy</keyword>
    <keyword>fluoroscopy</keyword>
    <keyword>nodules</keyword>
    <keyword>peripheral pulmonary lesion</keyword>
    <keyword>robotic-assisted bronchoscopy</keyword>
  </keywords>
  <summary>
    This study compares the diagnostic yields of shape-sensing robotic-assisted bronchoscopy (ssRAB) and digital tomosynthesis-electromagnetic navigation bronchoscopy (DT-ENB) in patients undergoing biopsy of peripheral pulmonary lesions (PPLs). Both platforms showed comparable diagnostic yields and safety profiles, with no significant differences found after adjusting for various factors.
  </summary>
  <pico>
    <population>Patients undergoing biopsy of peripheral pulmonary lesions (PPLs)</population>
    <intervention>Shape-sensing robotic-assisted bronchoscopy (ssRAB)</intervention>
    <comparison>Digital tomosynthesis-electromagnetic navigation bronchoscopy (DT-ENB)</comparison>
    <outcome>Diagnostic yield of the procedures</outcome>
  </pico>
  <take_home>Both ssRAB and DT-ENB demonstrate similar diagnostic yields and safety profiles for biopsying peripheral pulmonary lesions, suggesting that either method can be effectively utilized in clinical practice.</take_home>
  <embedding_file>https://doi.org/10.1016/j.chest.2022.10.019</embedding_file>
</article>
```
```xml
<article id="sec4_Article (21)">
  <title>Shape-Sensing Robotic-Assisted Bronchoscopy in the Diagnosis of Pulmonary Parenchymal Lesions</title>
  <authors>Or Kalchiem-Dekel, MD; James G. Connolly, MD; I-Hsin Lin, PhD; Bryan C. Husta, MD, FCCP; Prasad S. Adusumilli, MD; Jason A. Beattie, MD; Darren J. Buonocore, MD; Joseph Dycoco, BS; Paige Fuentes, MS; David R. Jones, MD; Robert P. Lee, MD, FCCP; Bernard J. Park, MD, FCCP; Gaetano Rocco, MD, FCCP; Mohit Chawla, MD, FCCP; Matthew J. Bott, MD</authors>
  <citation>Kalchiem-Dekel O, Connolly JG, Lin I-H, et al. Shape-Sensing Robotic-Assisted Bronchoscopy in the Diagnosis of Pulmonary Parenchymal Lesions. CHEST. 2022;161(2):572-582.</citation>
  <type>Original Research</type>
  <year>2022</year>
  <keywords>
    <keyword>diagnostic yield</keyword>
    <keyword>pulmonary nodule</keyword>
    <keyword>robotic-assisted bronchoscopy</keyword>
    <keyword>shape-sensing technology</keyword>
  </keywords>
  <summary>
    This study evaluates the feasibility, diagnostic yield, determinants of diagnostic sampling, and safety of shape-sensing robotic-assisted bronchoscopy (ssRAB) for sampling pulmonary parenchymal lesions. It provides comprehensive evidence of ssRAB's effectiveness in accessing and sampling traditionally challenging pulmonary lesions while maintaining a favorable safety profile.
  </summary>
  <pico>
    <population>Patients with pulmonary parenchymal lesions referred for tissue sampling</population>
    <intervention>Shape-sensing robotic-assisted bronchoscopy (ssRAB)</intervention>
    <comparison>Conventional bronchoscopy techniques</comparison>
    <outcome>Diagnostic yield, safety, and factors influencing diagnostic sampling</outcome>
  </pico>
  <take_home>ssRAB demonstrates a high navigational success rate (98.7%) and overall diagnostic yield (81.7%), with lesion size as a significant predictor of diagnostic success, indicating its potential as a valuable tool in the evaluation of pulmonary lesions.</take_home>
  <embedding_file>ssRAB_diagnostic_yield_study.pdf</embedding_file>
</article>
```
```xml
<article id="sec4_Article (22)">
  <title>State-of-the-Art Modalities for Peripheral Lung Nodule Biopsy</title>
  <authors>Kalanjeri, S.; Holladay, R.C.; Gildea, T.R.</authors>
  <citation>Kalanjeri, S., Holladay, R.C., Gildea, T.R. State-of-the-Art Modalities for Peripheral Lung Nodule Biopsy. Clin Chest Med. 2018;39(1):125–138.</citation>
  <type>Review Article</type>
  <year>2018</year>
  <keywords>
    <keyword>Peripheral pulmonary nodules</keyword>
    <keyword>Electromagnetic navigational bronchoscopy</keyword>
    <keyword>Radial ultrasound</keyword>
    <keyword>Solitary pulmonary nodule</keyword>
    <keyword>Lung cancer</keyword>
  </keywords>
  <summary>
    This article reviews the current modalities for obtaining tissue samples from peripheral lung nodules, which have become more prevalent due to increased lung cancer screening. It discusses the challenges of diagnosing peripheral pulmonary nodules (PPNs) and compares various biopsy techniques, including traditional bronchoscopy, radial probe ultrasound, electromagnetic navigational bronchoscopy, and CT-guided procedures. The article highlights the advancements in technology that improve diagnostic yields and the importance of selecting appropriate methods based on the characteristics of the nodule and patient factors.
  </summary>
  <pico>
    <population>Patients with peripheral pulmonary nodules</population>
    <intervention>Various biopsy modalities including electromagnetic navigational bronchoscopy and radial probe ultrasound</intervention>
    <comparison>Conventional bronchoscopy and CT-guided biopsies</comparison>
    <outcome>Diagnostic yield and safety of the procedures</outcome>
  </pico>
  <take_home>Advancements in bronchoscopic techniques, particularly navigational bronchoscopy, are improving the diagnostic yield for peripheral lung nodules, although CT-guided biopsies may still offer higher sensitivity.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec4_Article (23)">
  <title>Study Design and Rationale: A Multicenter, Prospective Trial of Electromagnetic Bronchoscopic and Electromagnetic Transthoracic Navigational Approaches for the Biopsy of Peripheral Pulmonary Nodules (ALL IN ONE Trial)</title>
  <authors>Jeffrey Thiboutot, Hans J. Lee, Gerard A. Silvestri, Alex Chen, Momen M. Wahidi, Christopher R. Gilbert, Nicholas J. Pastis, Jenna Los, Alexa M. Barriere, Christopher Mallow, Benjamin Salwen, Marcus J. Dinga, Eric L. Flenaugh, Jason A. Akulian, Roy Semaan, Lonny B. Yarmus</authors>
  <citation>Thiboutot J., Lee H.J., Silvestri G.A., Chen A., Wahidi M.M., Gilbert C.R., Pastis N.J., Los J., Barriere A.M., Mallow C., Salwen B., Dinga M.J., Flenaugh E.L., Akulian J.A., Semaan R., Yarmus L.B. Study Design and Rationale: A Multicenter, Prospective Trial of Electromagnetic Bronchoscopic and Electromagnetic Transthoracic Navigational Approaches for the Biopsy of Peripheral Pulmonary Nodules (ALL IN ONE Trial). Contemporary Clinical Trials. 2018; Volume 74: Pages 1-10.</citation>
  <type>Research Article</type>
  <year>2018</year>
  <keywords>
    <keyword>Electromagnetic navigation</keyword>
    <keyword>Bronchoscopy</keyword>
    <keyword>Pulmonary nodule</keyword>
    <keyword>Transthoracic biopsy</keyword>
  </keywords>
  <summary>
    This article presents the design and rationale for a multicenter, prospective trial evaluating a staged approach for the diagnosis of peripheral pulmonary nodules using electromagnetic navigation bronchoscopy (ENB) and electromagnetic guided transthoracic needle aspiration (EMN-TTNA). The study aims to improve diagnostic yield while minimizing complications associated with traditional biopsy methods.
  </summary>
  <pico>
    <population>Patients with 1-3 cm peripheral pulmonary nodules at intermediate to high risk for malignancy</population>
    <intervention>Staged approach involving endobronchial ultrasound (EBUS), followed by ENB and EMN-TTNA</intervention>
    <comparison>Historical controls of bronchoscopic and percutaneous biopsy techniques</comparison>
    <outcome>Overall diagnostic yield and safety profile of the staged procedure</outcome>
  </pico>
  <take_home>The staged diagnostic approach combining EBUS, ENB, and EMN-TTNA has the potential to significantly enhance the diagnostic yield for pulmonary nodules while reducing the need for multiple invasive procedures.</take_home>
  <embedding_file>EMN_Biopsy_Study_Design.pdf</embedding_file>
</article>
```
```xml
<article id="sec4_Article (24)">
  <title>The Evolutional History of Electromagnetic Navigation Bronchoscopy: State of the Art</title>
  <authors>Atul C. Mehta, MD; Kristin L. Hood, PhD; Yehuda Schwarz, MD; Stephen B. Solomon, MD</authors>
  <citation>Mehta AC, Hood KL, Schwarz Y, Solomon SB. The Evolutional History of Electromagnetic Navigation Bronchoscopy: State of the Art. CHEST. 2018;154(4):935-947.</citation>
  <type>Review Article</type>
  <year>2018</year>
  <keywords>
    <keyword>biopsy</keyword>
    <keyword>electromagnetic navigation bronchoscopy</keyword>
    <keyword>localization</keyword>
    <keyword>lung cancer</keyword>
    <keyword>SPiN thoracic navigation system</keyword>
    <keyword>superDimension navigation system</keyword>
  </keywords>
  <summary>
    This article reviews the historical development, current applications, and future potential of electromagnetic navigation bronchoscopy (ENB) in the diagnosis and treatment of lung cancer. It discusses the evolution of ENB technology, its clinical implications, and the need for minimally invasive procedures to obtain diagnostic tissue effectively.
  </summary>
  <pico>
    <population>Patients with suspected lung cancer or peripheral lung lesions</population>
    <intervention>Electromagnetic navigation bronchoscopy (ENB)</intervention>
    <comparison>Conventional bronchoscopy and transthoracic needle biopsy</comparison>
    <outcome>Diagnostic yield and safety of lung lesion biopsies</outcome>
  </pico>
  <take_home>ENB enhances the diagnostic yield for peripheral lung lesions and is a valuable tool in the minimally invasive diagnosis and treatment of lung cancer, with ongoing advancements improving its efficacy and safety.</take_home>
  <embedding_file>https://doi.org/10.1016/j.chest.2018.04.029</embedding_file>
</article>
```
```xml
<article id="sec4_Article (25)">
  <title>Towards an optimization of bronchoscopic approaches to the diagnosis and treatment of the pulmonary nodules: a review</title>
  <authors>William S. Krimsky; Michael A. Pritchett; Kelvin K. W. Lau</authors>
  <citation>Krimsky WS, Pritchett MA, Lau KK. Towards an optimization of bronchoscopic approaches to the diagnosis and treatment of the pulmonary nodules: a review. J Thorac Dis. 2018;10(Suppl 14):S1637-S1644.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>pulmonary nodule</keyword>
    <keyword>navigational bronchoscopy</keyword>
    <keyword>bronchoscopic ablation</keyword>
  </keywords>
  <summary>
    This article reviews recent advancements in bronchoscopic techniques for diagnosing and treating pulmonary nodules, highlighting innovations in imaging technologies, access methods, tissue acquisition tools, and robotic platforms. The review discusses the integration of these technologies, their diagnostic yields, and future directions for treatment modalities, including bronchoscopic ablation.
  </summary>
  <pico>
    <population>Patients with indeterminate pulmonary nodules</population>
    <intervention>Bronchoscopic approaches including advanced imaging, tissue acquisition, and robotic-assisted techniques</intervention>
    <comparison>Traditional bronchoscopic methods</comparison>
    <outcome>Improved diagnostic yield and treatment efficacy for pulmonary nodules</outcome>
  </pico>
  <take_home>Recent innovations in bronchoscopic techniques significantly enhance the diagnosis and treatment of pulmonary nodules, leading to improved patient outcomes.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec4_Article (26)">
  <title>What is the value of electromagnetic navigation in lung cancer and to what extent does it require improvement?</title>
  <authors>Shaller, B.D.; Gildea, T.R.</authors>
  <citation>Shaller, B.D., Gildea, T.R. What is the value of electromagnetic navigation in lung cancer and to what extent does it require improvement? Expert Review of Respiratory Medicine. 2020;14(7):655-669.</citation>
  <type>Review</type>
  <year>2020</year>
  <keywords>
    <keyword>Electromagnetic navigation bronchoscopy</keyword>
    <keyword>Peripheral lung nodule</keyword>
    <keyword>Lung cancer</keyword>
  </keywords>
  <summary>
    This review discusses the increasing detection of lung nodules and the need for advanced diagnostic technologies like electromagnetic navigational bronchoscopy (ENB). It evaluates the current state of ENB, its diagnostic yield, associated risks, and future directions, emphasizing the importance of improving its efficacy in the context of competing technologies.
  </summary>
  <pico>
    <population>Patients with peripheral lung nodules</population>
    <intervention>Electromagnetic navigational bronchoscopy (ENB)</intervention>
    <comparison>Conventional bronchoscopy and other diagnostic methods</comparison>
    <outcome>Diagnostic yield and safety of ENB</outcome>
  </pico>
  <take_home>The future of ENB relies on overcoming its limitations, improving diagnostic yield, and adapting to advancements in competing technologies.</take_home>
  <embedding_file>EMBEDDING_FILE_NOT_PROVIDED</embedding_file>
</article>
```
```xml
<article id="sec4_Article (3)">
  <title>Community Hospital Experience Using Electromagnetic Navigation Bronchoscopy System Integrating Tidal Volume Computed Tomography Mapping</title>
  <authors>Abhijit A Raval; Leah Amir</authors>
  <citation>Raval A.A., Amir L. Community Hospital Experience Using Electromagnetic Navigation Bronchoscopy System Integrating Tidal Volume Computed Tomography Mapping. Lung Cancer Management. 2016;5(1):9-19.</citation>
  <type>Research Article</type>
  <year>2016</year>
  <keywords>
    <keyword>bronchoscopy</keyword>
    <keyword>electromagnetic navigation</keyword>
    <keyword>tidal volume expiration</keyword>
    <keyword>lung cancer</keyword>
  </keywords>
  <summary>
    This study evaluates the effectiveness and safety of the Tidal Volume-Expiration (TV-EXP) mapped Electromagnetic Navigation (EMN) bronchoscopy in diagnosing peripheral pulmonary nodules (PPNs) in a community hospital setting. The authors report on the first 50 patients referred for biopsy or surgery due to suspicious lung lesions identified via computed tomography (CT). The results indicate a high diagnostic yield of 83.3% with a low complication rate, suggesting that this method is a promising minimally invasive option for lung cancer diagnosis.
  </summary>
  <pico>
    <population>Patients with suspicious lung lesions identified by CT scans</population>
    <intervention>Tidal Volume-Expiration mapped Electromagnetic Navigation bronchoscopy</intervention>
    <comparison>Traditional bronchoscopy and CT-guided transthoracic needle aspiration (TTNA)</comparison>
    <outcome>Diagnostic yield and safety of the procedure</outcome>
  </pico>
  <take_home>Electromagnetic navigation bronchoscopy using tidal volume mapping is a safe and effective minimally invasive technique for diagnosing peripheral lung nodules, with a high diagnostic yield and low complication rates.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec4_Article (4)">
  <title>Cone-Beam CT With Augmented Fluoroscopy Combined With Electromagnetic Navigation Bronchoscopy for Biopsy of Pulmonary Nodules</title>
  <authors>Pritchett, M.A.; Schampaert, S.; de Groot, J.A.H.; Schirmer, C.C.; van der Bom, I.</authors>
  <citation>Pritchett, M.A., Schampaert, S., de Groot, J.A.H., Schirmer, C.C., van der Bom, I. Cone-Beam CT With Augmented Fluoroscopy Combined With Electromagnetic Navigation Bronchoscopy for Biopsy of Pulmonary Nodules. J Bronchol Intervent Pulmonol. 2018;25(4):274–282.</citation>
  <type>Original Investigation</type>
  <year>2018</year>
  <keywords>
    <keyword>cone-beam CT</keyword>
    <keyword>electromagnetic navigation bronchoscopy</keyword>
    <keyword>augmented fluoroscopy</keyword>
    <keyword>lung cancer</keyword>
  </keywords>
  <summary>
    This study evaluates the safety and diagnostic yield of combining cone-beam computed tomography (CBCT) with augmented fluoroscopy during electromagnetic navigation bronchoscopy (ENB) for biopsying peripheral lung nodules. A retrospective analysis of 75 patients revealed a high diagnostic yield of 83.7% with low complication rates, demonstrating the feasibility and effectiveness of this approach in improving biopsy outcomes.
  </summary>
  <pico>
    <population>Patients with peripheral lung nodules undergoing biopsy</population>
    <intervention>Electromagnetic navigation bronchoscopy with intraoperative cone-beam CT and augmented fluoroscopy</intervention>
    <comparison>Standard fluoroscopy without augmented imaging</comparison>
    <outcome>Diagnostic yield and safety of the biopsy procedure</outcome>
  </pico>
  <take_home>Intraprocedural CBCT imaging with augmented fluoroscopy is effective and safe, providing a high diagnostic yield during ENB-guided biopsies of pulmonary nodules.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec4_Article (5)">
  <title>Cone-Beam Computed Tomography-Guided Electromagnetic Navigation for Peripheral Lung Nodules</title>
  <authors>Kheira, F.; Thakore, S.R.; Uribe Becerrab, J.P.; Tahbouba, M.; Kamata, R.; Abdelghania, R.; Fernandez-Bussyd, S.; Kaphlee, U.R.; Majid, A.</authors>
  <citation>Kheira, F., Thakore, S.R., Uribe Becerrab, J.P., Tahbouba, M., Kamata, R., Abdelghania, R., Fernandez-Bussyd, S., Kaphlee, U.R., Majid, A. Cone-Beam Computed Tomography-Guided Electromagnetic Navigation for Peripheral Lung Nodules. Respiration. 2021;100:44–51.</citation>
  <type>Research Article</type>
  <year>2021</year>
  <keywords>
    <keyword>Cone-beam computed tomography</keyword>
    <keyword>Electromagnetic navigation</keyword>
    <keyword>Peripheral lung nodules</keyword>
  </keywords>
  <summary>
    This study evaluates the diagnostic yield of combining electromagnetic navigation bronchoscopy (ENB) with cone-beam computed tomography (CBCT) for biopsying peripheral lung nodules compared to ENB alone. The research indicates that the combination of ENB and CBCT significantly improves the diagnostic yield and reduces procedure time without increasing adverse events.
  </summary>
  <pico>
    <population>Patients with peripheral lung nodules</population>
    <intervention>Electromagnetic navigation bronchoscopy combined with cone-beam computed tomography (ENB-CBCT)</intervention>
    <comparison>Electromagnetic navigation bronchoscopy alone (ENB)</comparison>
    <outcome>Diagnostic yield of lung biopsies</outcome>
  </pico>
  <take_home>The addition of cone-beam computed tomography to electromagnetic navigation bronchoscopy may significantly enhance the diagnostic yield for peripheral lung nodule biopsies while maintaining a similar safety profile.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec4_Article (6)">
  <title>Electromagnetic navigation bronchoscopy: a comprehensive review</title>
  <authors>Pickering, E.M.; Kalchiem-Dekel, O.; Sachdeva, A.</authors>
  <citation>Pickering, E.M., Kalchiem-Dekel, O., Sachdeva, A. Electromagnetic navigation bronchoscopy: a comprehensive review. AME Med J. 2018;3:117.</citation>
  <type>Review Article</type>
  <year>2018</year>
  <keywords>
    <keyword>Electromagnetic</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>navigation technology</keyword>
  </keywords>
  <summary>
    This review discusses the evolution and application of electromagnetic navigation bronchoscopy (EMN) for diagnosing peripheral lung lesions. It details the technology's reliance on pre-procedural CT imaging to create a 3D airway map, highlights its advantages over conventional bronchoscopy, and addresses procedural workflow, challenges, and future directions for improvement in accuracy and efficiency.
  </summary>
  <pico>
    <population>Patients with peripheral lung lesions</population>
    <intervention>Electromagnetic navigation bronchoscopy</intervention>
    <comparison>Conventional bronchoscopy techniques</comparison>
    <outcome>Improved diagnostic yield and procedural safety</outcome>
  </pico>
  <take_home>EMN bronchoscopy has transformed the diagnostic landscape for peripheral lung lesions, offering enhanced accuracy and efficiency compared to traditional methods, while ongoing advancements promise further improvements.</take_home>
  <embedding_file>http://dx.doi.org/10.21037/amj.2018.11.04</embedding_file>
</article>
```
```xml
<article id="sec4_Article (7)">
  <title>Electromagnetic navigation bronchoscopy to access lung lesions in 1,000 subjects: first results of the prospective, multicenter NAVIGATE study</title>
  <authors>Khandhar, S.J.; Bowling, M.R.; Flandes, J.; Gildea, T.R.; Hood, K.L.; Krimsky, W.S.; Minnich, D.J.; Murgu, S.D.; Pritchett, M.; Toloza, E.M.; Wahidi, M.M.; Wolvers, J.J.; Folch, E.E.</authors>
  <citation>Khandhar, S.J., Bowling, M.R., Flandes, J., Gildea, T.R., Hood, K.L., Krimsky, W.S., Minnich, D.J., Murgu, S.D., Pritchett, M., Toloza, E.M., Wahidi, M.M., Wolvers, J.J., Folch, E.E. Electromagnetic navigation bronchoscopy to access lung lesions in 1,000 subjects: first results of the prospective, multicenter NAVIGATE study. BMC Pulmonary Medicine. 2017;17:40.</citation>
  <type>Research Article</type>
  <year>2017</year>
  <keywords>
    <keyword>Electromagnetic Navigation Bronchoscopy</keyword>
    <keyword>Lung Lesions</keyword>
    <keyword>Biopsy</keyword>
    <keyword>Safety</keyword>
    <keyword>Diagnostic Yield</keyword>
  </keywords>
  <summary>
    The NAVIGATE study is a prospective, multicenter analysis of electromagnetic navigation bronchoscopy (ENB) involving 1,000 subjects across 29 sites in the U.S. and Europe. The interim analysis reports on the safety, usage patterns, and preliminary outcomes of ENB procedures for lung lesion biopsies, highlighting low adverse event rates and diagnostic success in a diverse patient population.
  </summary>
  <pico>
    <population>1,000 subjects undergoing ENB for lung lesions</population>
    <intervention>Electromagnetic navigation bronchoscopy (ENB)</intervention>
    <comparison>Not applicable (single-arm study)</comparison>
    <outcome>Safety and diagnostic yield of ENB procedures</outcome>
  </pico>
  <take_home>ENB shows low adverse event rates and a high rate of successful tissue acquisition in a diverse population, indicating its potential as a safe and effective method for diagnosing lung lesions.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec4_Article (8)">
  <title>Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study</title>
  <authors>Erik E. Folch, MD; Michael A. Pritchett, DO; Michael A. Nead, MD; Mark R. Bowling, MD; Septimiu D. Murgu, MD; William S. Krimsky, MD; Boris A. Murillo, MD; Gregory P. LeMense, MD; Douglas J. Minnich, MD; Sandeep Bansal, MD; Blesilda Q. Ellis, MD; Amit K. Mahajan, MD; Thomas R. Gildea, MD; Rabih I. Bechara, MD; Eric Sztejman, MD; Javier Flandes, MD; Otis B. Rickman, DO; Sadia Benzaquen, MD; D. Kyle Hogarth, MD; Philip A. Linden, MD; Momen M. Wahidi, MD; Jennifer S. Mattingley, MD; Kristin L. Hood, PhD; Haiying Lin, MS; Jennifer J. Wolvers, BSc; Sandeep J. Khandhar, MD</authors>
  <citation>Folch E.E., Pritchett M.A., Nead M.A., et al. Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study. Journal of Thoracic Oncology. 2019;14(3):445-458.</citation>
  <type>Original Article</type>
  <year>2019</year>
  <keywords>
    <keyword>Electromagnetic Navigation Bronchoscopy</keyword>
    <keyword>Lung Cancer</keyword>
    <keyword>Diagnostic Yield</keyword>
    <keyword>Peripheral Pulmonary Lesions</keyword>
    <keyword>NAVIGATE Study</keyword>
  </keywords>
  <summary>
    The NAVIGATE study is a large, multicenter cohort study evaluating the diagnostic yield and safety of electromagnetic navigation bronchoscopy (ENB) for peripheral pulmonary lesions. Involving 1215 subjects across 29 sites, the study found a 12-month diagnostic yield of 73% with a low complication rate. The findings suggest that ENB is a safe and effective method for diagnosing lung lesions in diverse clinical settings.
  </summary>
  <pico>
    <population>1215 subjects with peripheral pulmonary lesions</population>
    <intervention>Electromagnetic Navigation Bronchoscopy (ENB)</intervention>
    <comparison>Not applicable (single-arm study)</comparison>
    <outcome>Diagnostic yield, safety, and complication rates</outcome>
  </pico>
  <take_home>The NAVIGATE study demonstrates that ENB can achieve a diagnostic yield of approximately 73% in a diverse cohort, with a low complication rate, supporting its use for evaluating peripheral lung lesions.</take_home>
  <embedding_file>sec4_Article (8)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec4_Article (9)">
  <title>Electromagnetic navigational bronchoscopy-directed dye marking for locating pulmonary nodules</title>
  <authors>Wang, L.L.; He, B.F.; Cui, J.H.; Gao, X.L.; Chen, P.P.; Zhong, W.Z.; Liao, R.Q.; Li, J.; Sun, J.Y.</authors>
  <citation>Wang L, He B, Cui J, et al. Electromagnetic navigational bronchoscopy-directed dye marking for locating pulmonary nodules. Postgrad Med J. 2020;96:674–679.</citation>
  <type>Research Article</type>
  <year>2020</year>
  <keywords>
    <keyword>Electromagnetic navigational bronchoscopy</keyword>
    <keyword>Dye marking</keyword>
    <keyword>Pulmonary nodules</keyword>
    <keyword>Video-assisted thoracic surgery</keyword>
  </keywords>
  <summary>
    This study evaluates the accuracy and feasibility of electromagnetic navigational bronchoscopy (ENB) with pleural dye marking for locating small peripheral pulmonary nodules (PPNs) prior to video-assisted thoracic surgery (VATS). The procedure was performed on 25 patients with a high success rate in visualizing the dye marking during surgery, suggesting that ENB is a safe and effective method for guiding surgical resection of PPNs.
  </summary>
  <pico>
    <population>Patients with small peripheral pulmonary nodules requiring surgical resection</population>
    <intervention>Electromagnetic navigational bronchoscopy with pleural dye marking</intervention>
    <comparison>CT-guided percutaneous techniques</comparison>
    <outcome>Success rate of pleural staining and accuracy in locating nodules</outcome>
  </pico>
  <take_home>ENB-guided dye marking is a feasible and safe technique for locating small pulmonary nodules, offering a reliable alternative to traditional localization methods.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec5_Article (1)">
  <title>Diagnosis and Management of Lung Cancer, 3rd Ed: ACCP Guidelines</title>
  <authors>Gould, M.K.; Donington, J.; Lynch, W.R.; Mazzone, P.J.; Midthun, D.E.; Naidich, D.P.; Soylemez Wiener, R.</authors>
  <citation>Gould, M.K., Donington, J., Lynch, W.R., Mazzone, P.J., Midthun, D.E., Naidich, D.P., Soylemez Wiener, R. Diagnosis and Management of Lung Cancer, 3rd Ed: ACCP Guidelines. CHEST. 2013;143(5)(Suppl):e93S–e120S.</citation>
  <type>Guideline</type>
  <year>2013</year>
  <keywords>
    <keyword>Lung Cancer</keyword>
    <keyword>Pulmonary Nodules</keyword>
    <keyword>Diagnosis</keyword>
    <keyword>Management Guidelines</keyword>
    <keyword>ACCP</keyword>
  </keywords>
  <summary>
    This article updates the evidence-based recommendations for the evaluation and management of individuals with pulmonary nodules, focusing on solid and nonsolid nodules. It emphasizes assessing the probability of malignancy, utilizing imaging tests, weighing management strategies, and considering patient preferences.
  </summary>
  <pico>
    <population>Individuals with pulmonary nodules</population>
    <intervention>Evaluation and management strategies for solid and nonsolid pulmonary nodules</intervention>
    <comparison>Previous guidelines on lung cancer management</comparison>
    <outcome>Improved diagnosis and management of lung cancer</outcome>
  </pico>
  <take_home>Individuals with pulmonary nodules should be evaluated based on the probability of malignancy, appropriate imaging, and management strategies that align with patient preferences.</take_home>
  <embedding_file>link_to_article_embedding_file</embedding_file>
</article>
```
```xml
<article id="sec5_Article (2)">
  <title>Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report</title>
  <authors>Mazzone, P.J.; Gould, M.K.; Arenberg, D.A.; Chen, A.C.; Choi, H.K.; Detterbeck, F.C.; Farjah, F.; Fong, K.M.; Iaccarino, J.M.; Janes, S.M.; Kanne, J.P.; Kazerooni, E.A.; MacMahon, H.; Naidich, D.P.; Powell, C.A.; Raoof, S.; Rivera, M.P.; Tanner, N.T.; Tanoue, L.K.; Tremblay, A.; Vachani, A.; White, C.S.; Soylemez Wiener, R.; Silvestri, G.A.</authors>
  <citation>Mazzone PJ, Gould MK, Arenberg DA, et al. Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST expert panel report. Chest. 2020;158(1):406-415.</citation>
  <type>Expert Panel Report</type>
  <year>2020</year>
  <keywords>
    <keyword>COVID-19</keyword>
    <keyword>lung cancer screening</keyword>
    <keyword>lung nodules</keyword>
    <keyword>consensus statement</keyword>
  </keywords>
  <summary>
    This article presents consensus statements from an expert panel regarding the management of lung cancer screening and lung nodules during the COVID-19 pandemic. It emphasizes the need to defer nonurgent care due to the risks posed by COVID-19 and the reallocation of healthcare resources.
  </summary>
  <pico>
    <population>Individuals eligible for lung cancer screening and patients with lung nodules.</population>
    <intervention>Delay in lung cancer screening and modification of lung nodule evaluation.</intervention>
    <comparison>Pre-COVID-19 guidelines for lung cancer screening and nodule evaluation.</comparison>
    <outcome>Consensus statements guiding clinicians on the management of lung cancer screening and lung nodules during the pandemic.</outcome>
  </pico>
  <take_home>During the COVID-19 pandemic, it is recommended to delay lung cancer screening and modify the evaluation of lung nodules to minimize exposure risks and manage healthcare resources effectively.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec5_Article (3)">
  <title>Lung‐RADS® Version 1.1 Assessment Categories</title>
  <authors>American College of Radiology</authors>
  <citation>American College of Radiology. Lung‐RADS® Version 1.1 Assessment Categories. Journal of Clinical Radiology. 2019;VOLUME(ISSUE):PAGES.</citation>
  <type>Guideline</type>
  <year>2019</year>
  <keywords>
    <keyword>Lung Cancer Screening</keyword>
    <keyword>Lung-RADS</keyword>
    <keyword>CT Imaging</keyword>
    <keyword>Nodule Assessment</keyword>
  </keywords>
  <summary>
    The Lung-RADS® Version 1.1 provides a standardized assessment system for lung cancer screening results, categorizing findings based on the likelihood of malignancy. It outlines management recommendations for various nodule sizes and characteristics, aiming to improve early detection and appropriate follow-up for lung cancer.
  </summary>
  <pico>
    <population>Individuals undergoing lung cancer screening with low-dose CT</population>
    <intervention>Lung-RADS® assessment and categorization</intervention>
    <comparison>Standard assessment methods prior to Lung-RADS</comparison>
    <outcome>Improved accuracy in lung nodule evaluation and management</outcome>
  </pico>
  <take_home>The Lung-RADS® system enhances the consistency and clarity of lung cancer screening results, facilitating timely and appropriate patient management.</take_home>
  <embedding_file>https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads</embedding_file>
</article>
```
```xml
<article id="sec5_Article (4)">
  <title>Fleischner Society Guidelines for Management of Incidentally Detected Pulmonary Nodules in Adults</title>
  <authors>Heber MacMahon, MB, BCh; David P. Naidich, MD; Jin Mo Goo, MD, PhD; Kyung Soo Lee, MD, PhD; Ann N. C. Leung, MD; John R. Mayo, MD; Atul C. Mehta, MB, BS; Yoshiharu Ohno, MD, PhD; Charles A. Powell, MD; Mathias Prokop, MD, PhD; Geoffrey D. Rubin, MD; Cornelia M. Schaefer-Prokop, MD, PhD; William D. Travis, MD; Paul E. Van Schil, MD, PhD; Alexander A. Bankier, MD, PhD</authors>
  <citation>MacMahon H, Naidich DP, Goo JM, et al. Fleischner Society Guidelines for management of incidental pulmonary nodules detected on CT images. Radiology. 2017;284(1):228–243.</citation>
  <type>Guidelines</type>
  <year>2017</year>
  <keywords>
    <keyword>pulmonary nodules</keyword>
    <keyword>CT imaging</keyword>
    <keyword>Fleischner Society</keyword>
    <keyword>guidelines</keyword>
    <keyword>lung cancer</keyword>
  </keywords>
  <summary>
    The article presents revised guidelines from the Fleischner Society for managing incidentally detected pulmonary nodules in adults based on new data and accumulated experience. The guidelines emphasize reducing unnecessary follow-up examinations while allowing for greater discretion in management decisions. Key changes include an increased minimum threshold size for routine follow-up and the combination of recommendations for solid and subsolid nodules into a simplified format.
  </summary>
  <pico>
    <population>Adults aged 35 years and older with incidentally detected pulmonary nodules</population>
    <intervention>Management guidelines for pulmonary nodules detected on CT imaging</intervention>
    <comparison>Previous guidelines from the Fleischner Society</comparison>
    <outcome>Improved management of pulmonary nodules with reduced unnecessary follow-up</outcome>
  </pico>
  <take_home>These guidelines aim to improve the management of incidental pulmonary nodules by incorporating new evidence and allowing for more personalized follow-up based on individual risk factors.</take_home>
  <embedding_file>https://doi.org/10.1148/radiol.2017161659</embedding_file>
</article>
```
```xml
<article id="sec5_Article (5)">
  <title>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Lung Cancer Screening Version 2.2024</title>
  <authors>Douglas E. Wood, MD; Ella A. Kazerooni, MD, MS; Denise R. Aberle, MD; Lisa M. Brown, MD, MAS; Georgie A. Eapen, MD; David S. Ettinger, MD; J. Scott Ferguson, MD; Lifang Hou, MD, PhD; Donald Klippenstein, MD; Ana S. Kolansky, MD; Rohit Kumar, MD; Rudy P. Lackner, MD; Lorriana E. Leard, MD; Beth McCullough, RN, BS; Swathi Ramakrishana, PhD</authors>
  <citation>Wood D.E., Kazerooni E.A., Aberle D.R., Brown L.M., Eapen G.A., Ettinger D.S., Ferguson J.S., Hou L., Klippenstein D., Kolansky A.S., Kumar R., Lackner R.P., Leard L.E., McCullough B., Ramakrishana S. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Lung Cancer Screening Version 2.2024. National Comprehensive Cancer Network. 2023;2:1-30.</citation>
  <type>Guidelines</type>
  <year>2023</year>
  <keywords>
    <keyword>lung cancer</keyword>
    <keyword>screening</keyword>
    <keyword>low-dose computed tomography</keyword>
    <keyword>NCCN Guidelines</keyword>
    <keyword>lung nodules</keyword>
  </keywords>
  <summary>
    The NCCN Guidelines for Lung Cancer Screening provide recommendations for the screening of high-risk individuals using low-dose computed tomography (LDCT). The guidelines emphasize the importance of a multidisciplinary approach in managing lung cancer screening and follow-up of lung nodules. The 2024 update includes revisions based on new evidence, with a focus on risk assessment, screening protocols, and management strategies for detected nodules.
  </summary>
  <pico>
    <population>Individuals aged 50 years and older with a significant smoking history or other risk factors for lung cancer.</population>
    <intervention>Low-dose computed tomography (LDCT) for lung cancer screening.</intervention>
    <comparison>No screening or alternative screening methods.</comparison>
    <outcome>Reduction in lung cancer mortality and early detection of lung cancer.</outcome>
  </pico>
  <take_home>The NCCN Guidelines recommend LDCT screening for high-risk individuals to improve early detection of lung cancer and reduce mortality.</take_home>
  <embedding_file>NCCN_Lung_Cancer_Screening_Guidelines_2024.pdf</embedding_file>
</article>
```
```xml
<article id="sec5_Article (6)">
  <title>Diagnosis and Management of Lung Cancer, 3rd Ed: ACCP Guidelines</title>
  <authors>Brunelli, A.B.; Kim, A.W.; Berger, K.I.; Addrizzo-Harris, D.J.</authors>
  <citation>Brunelli A.B., Kim A.W., Berger K.I., Addrizzo-Harris D.J. Diagnosis and Management of Lung Cancer, 3rd ed: ACCP Guidelines. CHEST. 2013;143(5)(Suppl):e166S–e190S.</citation>
  <type>Guideline</type>
  <year>2013</year>
  <keywords>
    <keyword>lung cancer</keyword>
    <keyword>preoperative assessment</keyword>
    <keyword>physiologic evaluation</keyword>
    <keyword>surgery</keyword>
    <keyword>cardiopulmonary exercise test</keyword>
  </keywords>
  <summary>
    This article presents updated guidelines from the American College of Chest Physicians (ACCP) regarding the preoperative physiologic evaluation of patients with lung cancer who are candidates for surgical resection. It emphasizes the importance of assessing lung function and cardiovascular risk to identify patients at increased risk for complications during and after surgery.
  </summary>
  <pico>
    <population>Patients with lung cancer being considered for surgical resection</population>
    <intervention>Preoperative physiologic assessment including spirometry, diffusing capacity, and exercise tests</intervention>
    <comparison>No further testing for patients with adequate lung function</comparison>
    <outcome>Identification of patients at risk for perioperative complications and long-term disability</outcome>
  </pico>
  <take_home>Careful preoperative physiologic assessment is crucial for optimizing surgical outcomes in lung cancer patients and should be integrated into the decision-making process for surgical intervention.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec5_Article (6)_1">
  <title>Assessment of Operative Risk in Patients Undergoing Lung Resection</title>
  <authors>Kearney DJ; Lee TH; Reilly JJ; DeCamp MM; Sugarbaker DJ</authors>
  <citation>Kearney DJ, Lee TH, Reilly JJ, DeCamp MM, Sugarbaker DJ. Assessment of operative risk in patients undergoing lung resection. Chest. 1994;105(3):753-759.</citation>
  <type>Research Article</type>
  <year>1994</year>
  <keywords>
    <keyword>Lung Resection</keyword>
    <keyword>Operative Risk</keyword>
    <keyword>Predicted Pulmonary Function</keyword>
  </keywords>
  <summary>
    This study evaluates the importance of predicted pulmonary function in assessing the operative risk for patients undergoing lung resection. The authors discuss various factors that influence surgical outcomes and highlight the need for accurate preoperative assessments.
  </summary>
  <pico>
    <population>Patients undergoing lung resection</population>
    <intervention>Assessment of predicted pulmonary function</intervention>
    <comparison>Standard preoperative assessments</comparison>
    <outcome>Operative risk and surgical outcomes</outcome>
  </pico>
  <take_home>The study emphasizes the critical role of pulmonary function predictions in determining the surgical risk for lung resection patients.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec5_Article (7)">
  <title>Evaluating the Patient With a Pulmonary Nodule: A Review</title>
  <authors>Mazzone, P.J.; Lam, L.</authors>
  <citation>Mazzone, P.J., Lam, L. Evaluating the Patient With a Pulmonary Nodule: A Review. JAMA. 2022;327(3):264-273.</citation>
  <type>Review</type>
  <year>2022</year>
  <keywords>
    <keyword>pulmonary nodule</keyword>
    <keyword>lung cancer</keyword>
    <keyword>diagnosis</keyword>
    <keyword>management</keyword>
    <keyword>guidelines</keyword>
  </keywords>
  <summary>
    This review discusses the evaluation and management of pulmonary nodules, which are commonly identified in chest CT scans. It emphasizes the importance of determining the probability of malignancy, appropriate diagnostic testing, and patient preferences in guiding treatment decisions to optimize outcomes and minimize unnecessary interventions.
  </summary>
  <pico>
    <population>Patients with incidentally detected pulmonary nodules</population>
    <intervention>Evaluation and management strategies based on nodule characteristics and risk factors</intervention>
    <comparison>Guideline-based management versus individualized patient care</comparison>
    <outcome>Improved diagnostic accuracy, appropriate management, and patient outcomes</outcome>
  </pico>
  <take_home>Effective management of pulmonary nodules requires a careful assessment of malignancy risk and should be tailored to individual patient circumstances and preferences.</take_home>
  <embedding_file>sec5_Article (7)_embeddings.json</embedding_file>
</article>
```
<article id="sec6_Article (1)">
  <title>A Randomized Trial of 1% vs 2% Lignocaine by the Spray-as-You-Go Technique for Topical Anesthesia During Flexible Bronchoscopy</title>
  <authors>Kaur, H.; Dhooria, S.; Aggarwal, A.N.; Gupta, D.; Behera, D.; Agarwal, R.</authors>
  <citation>Kaur, H., Dhooria, S., Aggarwal, A.N., Gupta, D., Behera, D., Agarwal, R. A Randomized Trial of 1% vs 2% Lignocaine by the Spray-as-You-Go Technique for Topical Anesthesia During Flexible Bronchoscopy. CHEST. 2015;148(3):739-745.</citation>
  <type>Original Research</type>
  <year>2015</year>
  <keywords>
    <keyword>Flexible Bronchoscopy</keyword>
    <keyword>Lignocaine</keyword>
    <keyword>Topical Anesthesia</keyword>
    <keyword>Cough Suppression</keyword>
    <keyword>Randomized Controlled Trial</keyword>
  </keywords>
  <summary>
    This study evaluates the efficacy and safety of 1% versus 2% lignocaine for topical anesthesia during flexible bronchoscopy in a randomized controlled trial involving 500 patients. The results indicate that 1% lignocaine is as effective as 2% lignocaine but requires a significantly lower dose, suggesting it should be the preferred concentration for this procedure.
  </summary>
  <pico>
    <population>Patients undergoing flexible bronchoscopy</population>
    <intervention>1% lignocaine solution</intervention>
    <comparison>2% lignocaine solution</comparison>
    <outcome>Cough intensity and pain during the procedure, total lignocaine dose, adverse reactions</outcome>
  </pico>
  <take_home>1% lignocaine is as effective as 2% for topical anesthesia during flexible bronchoscopy and should be preferred due to lower required doses and reduced risk of toxicity.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec6_Article (2)">
  <title>Anesthesia and Upper and Lower Airway Management for Advanced Diagnostic and Therapeutic Bronchoscopy</title>
  <authors>Basem Abdelmalak, MD; Sonali Sethi, MD; Thomas R. Gildea, MD, MS</authors>
  <citation>Abdelmalak B, Sethi S, Gildea TR. Anesthesia and Upper and Lower Airway Management for Advanced Diagnostic and Therapeutic Bronchoscopy. Advances in Anesthesia. 2014;32:71–87.</citation>
  <type>Review</type>
  <year>2014</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Lower airway management</keyword>
    <keyword>Silicon stents</keyword>
    <keyword>Metallic stents</keyword>
    <keyword>EBUS</keyword>
    <keyword>ENB</keyword>
    <keyword>Anesthesia</keyword>
  </keywords>
  <summary>
    This article reviews the evolving techniques in advanced diagnostic and therapeutic bronchoscopy, emphasizing the importance of tailored anesthetic management. It highlights the need for collaboration between pulmonologists and anesthesiologists to optimize patient outcomes, particularly in high-risk populations undergoing complex procedures.
  </summary>
  <pico>
    <population>Patients undergoing advanced diagnostic and therapeutic bronchoscopy</population>
    <intervention>Advanced bronchoscopy techniques and tailored anesthesia management</intervention>
    <comparison>Moderate sedation versus general anesthesia</comparison>
    <outcome>Patient safety, procedural efficiency, and recovery times</outcome>
  </pico>
  <take_home>The key to favorable outcomes in advanced bronchoscopy lies in understanding the underlying lung disorders, effective communication between anesthesiologists and pulmonologists, and vigilant anesthetic management.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec6_Article (3)">
  <title>Anesthetic considerations for bronchoscopic procedures: a narrative review based on the Cleveland Clinic experience</title>
  <authors>Ursula Galway, Andrew Zura, Sandeep Khanna, Mi Wang, Alparslan Turan, Kurt Ruetzler</authors>
  <citation>Galway U, Zura A, Khanna S, Wang M, Turan A, Ruetzler K. Anesthetic considerations for bronchoscopic procedures: a narrative review based on the Cleveland Clinic experience. J Thorac Dis. 2019;11(7):3156-3170.</citation>
  <type>Review Article</type>
  <year>2019</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>airway management</keyword>
    <keyword>anesthesia</keyword>
    <keyword>stents</keyword>
    <keyword>lung neoplasms</keyword>
  </keywords>
  <summary>
    This article reviews the anesthetic considerations and management for various bronchoscopic procedures performed at the Cleveland Clinic. It discusses the evolution of interventional pulmonology, the increasing complexity of bronchoscopic procedures requiring anesthesiology support, and specific anesthesia techniques tailored to different types of bronchoscopies, including risks and complications.
  </summary>
  <pico>
    <population>Patients undergoing advanced diagnostic and therapeutic bronchoscopic procedures</population>
    <intervention>Anesthesia management during bronchoscopic procedures</intervention>
    <comparison>General anesthesia vs. moderate sedation</comparison>
    <outcome>Patient safety, procedural success, and complication rates</outcome>
  </pico>
  <take_home>The review emphasizes the importance of tailored anesthetic management for complex bronchoscopic procedures to enhance patient safety and procedural efficacy.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec6_Article (4)">
  <title>Dexmedetomidine‑fentanyl versus propofol‑fentanyl in flexible bronchoscopy: A randomized study</title>
  <authors>FENG YUAN, HONGGUANG FU, PENGJU YANG, KAI SUN, SHUBIAO WU, MIAOMIAO LV, ZHENZHEN DONG, TIELI DONG</authors>
  <citation>YUAN F., FU H., YANG P., SUN K., WU S., LV M., DONG Z., DONG T. Dexmedetomidine‑fentanyl versus propofol‑fentanyl in flexible bronchoscopy: A randomized study. Experimental and Therapeutic Medicine. 2016;12(2):1025-1032.</citation>
  <type>Research Article</type>
  <year>2016</year>
  <keywords>
    <keyword>flexible bronchoscopy</keyword>
    <keyword>dexmedetomidine-fentanyl</keyword>
    <keyword>propofol-fentanyl</keyword>
    <keyword>peripheral oxygen saturation</keyword>
    <keyword>hemodynamic stability</keyword>
    <keyword>sedation</keyword>
  </keywords>
  <summary>
    This study compares the effectiveness of dexmedetomidine-fentanyl versus propofol-fentanyl on peripheral oxygen saturation (SpO2) and hemodynamic stability in patients undergoing flexible bronchoscopy. The findings suggest that dexmedetomidine-fentanyl offers better SpO2 and hemodynamic stability but results in longer recovery times and a higher incidence of bradycardia compared to propofol-fentanyl.
  </summary>
  <pico>
    <population>100 patients undergoing elective flexible bronchoscopy</population>
    <intervention>Dexmedetomidine-fentanyl</intervention>
    <comparison>Propofol-fentanyl</comparison>
    <outcome>Peripheral oxygen saturation, hemodynamic stability, recovery time, adverse events</outcome>
  </pico>
  <take_home>Dexmedetomidine-fentanyl is superior to propofol-fentanyl in maintaining SpO2 and hemodynamic stability during flexible bronchoscopy, despite longer recovery times and increased bradycardia.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec6_Article (5)">
  <title>Jet Ventilation during Rigid Bronchoscopy in Adults: A Focused Review</title>
  <authors>Putz, L.; Mayné, A.; Dincq, A.-S.</authors>
  <citation>Putz, L., Mayné, A., Dincq, A.-S. Jet Ventilation during Rigid Bronchoscopy in Adults: A Focused Review. BioMed Research International. 2016;2016:4234861.</citation>
  <type>Review Article</type>
  <year>2016</year>
  <keywords>
    <keyword>Rigid bronchoscopy</keyword>
    <keyword>Jet ventilation</keyword>
    <keyword>High-frequency jet ventilation</keyword>
    <keyword>Superimposed high-frequency jet ventilation</keyword>
    <keyword>Anesthesia</keyword>
  </keywords>
  <summary>
    This focused review discusses the use of jet ventilation techniques during rigid bronchoscopy in adults, highlighting the importance of appropriate ventilator settings to minimize complications. The article covers various jet ventilation methods, their mechanisms, settings, and the safety of general anesthesia during these procedures.
  </summary>
  <pico>
    <population>Adults undergoing rigid bronchoscopy</population>
    <intervention>Jet ventilation techniques during rigid bronchoscopy</intervention>
    <comparison>High-frequency jet ventilation vs. low-frequency jet ventilation</comparison>
    <outcome>Oxygenation, carbon dioxide removal, and complications</outcome>
  </pico>
  <take_home>Jet ventilation, particularly superimposed high-frequency jet ventilation, is effective in maintaining adequate oxygenation and carbon dioxide removal during rigid bronchoscopy procedures, requiring careful management to avoid complications.</take_home>
  <embedding_file>http://dx.doi.org/10.1155/2016/4234861</embedding_file>
</article>
```
```xml
<article id="sec6_Article (6)">
  <title>The death of a healthy volunteer in a human research project: implications for Australian clinical research</title>
  <authors>Richard O Day, Donald R C Chalmers, Kenneth M Williams, Terence J Campbell</authors>
  <citation>Day R.O., Chalmers D.R.C., Williams K.M., Campbell T.J. The death of a healthy volunteer in a human research project: implications for Australian clinical research. MJA. 1998;168(9):449-451.</citation>
  <type>Research Article</type>
  <year>1998</year>
  <keywords>
    <keyword>Clinical Research</keyword>
    <keyword>Ethics</keyword>
    <keyword>Lignocaine Toxicity</keyword>
    <keyword>Institutional Ethics Committees</keyword>
  </keywords>
  <summary>
    This article discusses the implications of the death of a healthy volunteer during a clinical research study in New York, due to acute lignocaine toxicity. The incident highlighted significant flaws in the research protocol, particularly the absence of a specified upper dose limit for lignocaine, and raised concerns regarding the functioning of Institutional Ethics Committees (IECs) in Australia. The authors propose recommendations for improving IEC procedures to enhance participant safety and ethical standards in clinical research.
  </summary>
  <pico>
    <population>Healthy volunteers participating in clinical research</population>
    <intervention>Bronchoscopy with lignocaine spray</intervention>
    <comparison>Not applicable</comparison>
    <outcome>Death due to acute lignocaine toxicity</outcome>
  </pico>
  <take_home>The tragic death of a volunteer underscores the need for rigorous ethical oversight and adherence to safety protocols in clinical research to protect participants.</take_home>
  <embedding_file>n/a</embedding_file>
</article>
```
<article id="sec7_Article (1)">
  <title>Bronchoscopic Techniques Used in the Diagnosis and Staging of Lung Cancer</title>
  <authors>Lerner, A.D.; Feller-Kopman, D.</authors>
  <citation>Lerner, A.D., Feller-Kopman, D. Bronchoscopic Techniques Used in the Diagnosis and Staging of Lung Cancer. J Natl Compr Canc Netw. 2017;15(5):640–647.</citation>
  <type>Review</type>
  <year>2017</year>
  <keywords>
    <keyword>lung cancer</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>diagnosis</keyword>
    <keyword>staging</keyword>
    <keyword>endobronchial ultrasound</keyword>
    <keyword>navigational bronchoscopy</keyword>
  </keywords>
  <summary>
    This article reviews advanced bronchoscopic techniques for the diagnosis and staging of lung cancer, highlighting the importance of minimally invasive procedures in the context of increasing incidental detection of lung nodules through chest CT. It discusses navigational bronchoscopy and radial endobronchial ultrasound (EBUS) as significant advancements that enhance diagnostic accuracy and reduce complications compared to traditional methods.
  </summary>
  <pico>
    <population>Patients with suspected lung cancer and solitary pulmonary nodules</population>
    <intervention>Advanced bronchoscopic techniques including navigational bronchoscopy and radial endobronchial ultrasound</intervention>
    <comparison>Traditional surgical methods and CT-guided transthoracic needle aspiration</comparison>
    <outcome>Improved diagnostic yield and reduced complication rates</outcome>
  </pico>
  <take_home>Advanced bronchoscopic techniques provide a safer and more effective means of diagnosing and staging lung cancer, particularly for peripheral lung nodules.</take_home>
  <embedding_file>bronchoscopic_techniques_lung_cancer.pdf</embedding_file>
</article>
```
```xml
<article id="sec7_Article (2)">
  <title>COVID-19 Impact on Interventional Pulmonology Training</title>
  <authors>Or Kalchiem-Dekel1*, Audra J. Schwalk2*, Niral M. Patel3,4*, I-Hsin Lin5, Jason A. Beattie1, Bryan C. Husta1, Mohit Chawla1, Ashutosh Sachdeva6, Jason A. Akulian7, Ali I. Musani3, A. Christine Argento8, Hans J. Lee9, John J. Mullon10, Neeraj R. Desai11,12, David W. Hsia13,14, Robert P. Lee1</authors>
  <citation>KALCHIEM-DEKEL, O., SCHWALK, A.J., PATEL, N.M., et al. COVID-19 Impact on Interventional Pulmonology Training. ATS Scholar. 2021;2(2):236-248.</citation>
  <type>ORIGINAL RESEARCH</type>
  <year>2021</year>
  <keywords>
    <keyword>interventional pulmonology</keyword>
    <keyword>training</keyword>
    <keyword>COVID-19</keyword>
    <keyword>survey</keyword>
  </keywords>
  <summary>
    This study investigated the impact of the COVID-19 pandemic on interventional pulmonology fellows' clinical education, procedural skills, and employment prospects. A survey was conducted among North American IP fellows, revealing significant involvement in COVID-19 patient care, a decrease in procedural volume, and a shift to telehealth for outpatient services. Despite challenges, the majority of fellows secured employment post-graduation.
  </summary>
  <pico>
    <population>Interventional pulmonology fellows in North America</population>
    <intervention>Involvement in COVID-19 patient care and training adjustments</intervention>
    <comparison>Pre-COVID-19 training conditions</comparison>
    <outcome>Impact on clinical education, procedural skills, and employment search</outcome>
  </pico>
  <take_home>The COVID-19 pandemic significantly affected interventional pulmonology training, leading to reduced procedural volume but maintained educational activities and successful employment outcomes for fellows.</take_home>
  <embedding_file>sec7_Article (2)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec7_Article (3)">
  <title>ERS/ATS Statement on Interventional Pulmonology</title>
  <authors>Bolliger, C.T.; Mathur, P.N.; Beamis, J.F.; Becker, H.D.; Cavaliere, S.; Colt, H.; Diaz-Jimenez, J.P.; Dumon, J.F.; Edell, E.; Kovitz, K.L.; Macha, H.N.; Mehta, A.C.; Marel, M.; Noppen, M.; Strausz, J.; Sutedja, T.G.</authors>
  <citation>Bolliger, C.T., Mathur, P.N., Beamis, J.F., Becker, H.D., Cavaliere, S., Colt, H., Diaz-Jimenez, J.P., Dumon, J.F., Edell, E., Kovitz, K.L., Macha, H.N., Mehta, A.C., Marel, M., Noppen, M., Strausz, J., Sutedja, T.G. ERS/ATS Statement on Interventional Pulmonology. Eur Respir J. 2002;19(2):356–373.</citation>
  <type>Position Statement</type>
  <year>2002</year>
  <keywords>
    <keyword>Interventional Pulmonology</keyword>
    <keyword>Bronchoscopy</keyword>
    <keyword>Therapeutic Procedures</keyword>
    <keyword>Diagnostic Procedures</keyword>
    <keyword>Training Requirements</keyword>
  </keywords>
  <summary>
    This position paper by the European Respiratory Society and American Thoracic Society outlines the field of interventional pulmonology, detailing the requirements for facilities, personnel, pre-procedure evaluations, monitoring, and the various interventional techniques available. It emphasizes the need for specialized training and expertise for performing diagnostic and therapeutic procedures for managing complex airway problems, pleural diseases, and pulmonary vascular issues.
  </summary>
  <pico>
    <population>Patients requiring interventional pulmonology procedures for airway management, benign and malignant central airway obstruction, and pleural diseases.</population>
    <intervention>Various interventional procedures including rigid bronchoscopy, transbronchial needle aspiration, endobronchial ultrasound, laser bronchoscopy, and airway stenting.</intervention>
    <comparison>Standard pulmonary medicine practices without specialized interventional techniques.</comparison>
    <outcome>Improved diagnostic accuracy, therapeutic outcomes, and patient quality of life through specialized interventional techniques.</outcome>
  </pico>
  <take_home>Interventional pulmonology requires specialized training and facilities to ensure safe and effective management of complex respiratory conditions.</take_home>
  <embedding_file>https://doi.org/10.1183/09031936.02.00204602</embedding_file>
</article>
```
```xml
<article id="sec7_Article (4)">
  <title>Interventional Pulmonology Fellowship Accreditation Standards Executive Summary of the Multisociety Interventional Pulmonology Fellowship Accreditation Committee</title>
  <authors>Mullon, J.J.; Burkart, K.M.; Silvestri, G.; Hogarth, D.K.; Almeida, F.; Berkowitz, D.; Eapen, G.A.; Feller-Kopman, D.; Fessler, H.E.; Folch, E.; Gillespie, C.; Haas, A.; Islam, S.U.; Lamb, C.; Levine, S.M.; Majid, A.; Maldonado, F.; Musani, A.I.; Piquette, C.; Ray, C.; Reddy, C.B.; Rickman, O.; Simoff, M.; Wahidi, M.M.; Lee, H.</authors>
  <citation>Mullon, J.J., Burkart, K.M., Silvestri, G., Hogarth, D.K., Almeida, F., Berkowitz, D., Eapen, G.A., Feller-Kopman, D., Fessler, H.E., Folch, E., Gillespie, C., Haas, A., Islam, S.U., Lamb, C., Levine, S.M., Majid, A., Maldonado, F., Musani, A.I., Piquette, C., Ray, C., Reddy, C.B., Rickman, O., Simoff, M., Wahidi, M.M., Lee, H. Interventional Pulmonology Fellowship Accreditation Standards Executive Summary of the Multisociety Interventional Pulmonology Fellowship Accreditation Committee. CHEST. 2017;151(5):1114-1121.</citation>
  <type>Executive Summary</type>
  <year>2017</year>
  <keywords>
    <keyword>interventional pulmonology</keyword>
    <keyword>fellowship accreditation</keyword>
    <keyword>training standards</keyword>
    <keyword>pulmonary medicine</keyword>
  </keywords>
  <summary>
    This article summarizes the accreditation standards established for interventional pulmonology (IP) fellowship programs in the United States. The standards aim to address variability in training and ensure uniformity in education and practice among IP fellows. The document outlines the minimum requirements for program duration, faculty qualifications, curriculum, and procedural exposure necessary for accreditation.
  </summary>
  <pico>
    <population>Interventional pulmonology fellows in the United States</population>
    <intervention>Accreditation standards for IP fellowship programs</intervention>
    <comparison>Comparison of existing fellowship programs without standardized accreditation</comparison>
    <outcome>Improved training quality and uniformity across IP fellowship programs</outcome>
  </pico>
  <take_home>The establishment of standardized accreditation for interventional pulmonology fellowships is crucial for ensuring quality training and uniformity in the skills and knowledge of future interventional pulmonologists.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec7_Article (5)">
  <title>Palliative Care and Interventional Pulmonology</title>
  <authors>Ali, M.S.; Sorathia, L.</authors>
  <citation>Ali, M.S., Sorathia, L. Palliative Care and Interventional Pulmonology. Clin Chest Med. 2018;39(1):57–64.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Palliative care</keyword>
    <keyword>Interventional pulmonology</keyword>
    <keyword>Chronic obstructive pulmonary disease</keyword>
    <keyword>Lung cancer</keyword>
    <keyword>Bronchoscopy</keyword>
  </keywords>
  <summary>
    This article discusses the importance of palliative care in patients with lung cancer and chronic obstructive pulmonary disease (COPD), highlighting the high prevalence of unmet palliative care needs in these populations. It reviews non-interventional therapies for symptom management and explores interventional pulmonology techniques aimed at palliation, including procedures for malignant pleural effusions, airway obstruction, hemoptysis, and bronchopleural fistulas.
  </summary>
  <pico>
    <population>Patients with lung cancer and chronic obstructive pulmonary disease (COPD)</population>
    <intervention>Palliative care strategies, including non-interventional therapies and interventional pulmonology procedures</intervention>
    <comparison>Standard oncologic care without palliative intervention</comparison>
    <outcome>Improved quality of life, symptom management, and potentially prolonged survival</outcome>
  </pico>
  <take_home>Early integration of palliative care alongside standard treatment improves patient outcomes and addresses the significant unmet needs of patients with advanced pulmonary diseases.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec7_Article (6)">
  <title>State of the Art Interventional Pulmonology</title>
  <authors>Wahidi M.M.; Herth F.J.F.; Chen A.; Cheng G.; Yarmus L.</authors>
  <citation>Wahidi M.M., Herth F.J.F., Chen A., Cheng G., Yarmus L. State of the Art Interventional Pulmonology. CHEST. 2020;157(3):724-736.</citation>
  <type>Review</type>
  <year>2020</year>
  <keywords>
    <keyword>bronchoscopy</keyword>
    <keyword>interventional pulmonology</keyword>
    <keyword>lung biopsy</keyword>
    <keyword>lung neoplasm</keyword>
  </keywords>
  <summary>
    This article reviews the advancements in interventional pulmonology (IP) over the past decade, highlighting the evolution of the field, the establishment of training standards and certification, and the introduction of innovative techniques for treating thoracic malignancies, airway diseases, and pleural diseases. It discusses the challenges of validating new technologies and the importance of high-quality research in promoting patient-centric care.
  </summary>
  <pico>
    <population>Patients with thoracic malignancies, airway diseases, and pleural diseases</population>
    <intervention>Interventional pulmonology techniques including therapeutic bronchoscopy, endobronchial ultrasound, and pleural interventions</intervention>
    <comparison>Standard treatment methods for lung diseases</comparison>
    <outcome>Improved patient outcomes, diagnostic yields, and procedural safety</outcome>
  </pico>
  <take_home>Interventional pulmonology has grown significantly, offering innovative and minimally invasive options for managing complex pulmonary conditions, but ongoing research and validation of new technologies are crucial for ensuring safety and efficacy.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec7_Article (7)">
  <title>The Business of Bronchoscopy: How to Set up an Interventional Pulmonology Program</title>
  <authors>Kessler, E.; Wahidi, M. M.</authors>
  <citation>Kessler, E., Wahidi, M. M. The Business of Bronchoscopy: How to Set up an Interventional Pulmonology Program. Clin Chest Med. 2018;39(2):239–243.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Interventional pulmonology</keyword>
    <keyword>Medical practice</keyword>
    <keyword>Business of medicine</keyword>
  </keywords>
  <summary>
    This article outlines the essential steps for establishing an interventional pulmonology (IP) program, emphasizing the importance of needs assessment, business planning, marketing strategies, and monitoring progress. It highlights the growing demand for IP services and the need for a structured approach to ensure successful implementation and sustainability.
  </summary>
  <pico>
    <population>Patients requiring advanced diagnostic and therapeutic bronchoscopy and pleural procedures</population>
    <intervention>Establishment of an interventional pulmonology program</intervention>
    <comparison>Current practices and specialties in the community</comparison>
    <outcome>Successful implementation and integration of IP services in healthcare</outcome>
  </pico>
  <take_home>Establishing a successful interventional pulmonology program requires thorough needs assessment, a well-structured business plan, effective marketing, and continuous monitoring of clinical and financial outcomes.</take_home>
  <embedding_file>https://doi.org/10.1016/j.ccm.2017.11.006</embedding_file>
</article>
```
```xml
<article id="sec7_Article (8)">
  <title>Training in interventional pulmonology: the European and US perspective</title>
  <authors>Lee H.J.; Corbetta L.</authors>
  <citation>Lee H.J., Corbetta L. Training in interventional pulmonology: the European and US perspective. Eur Respir Rev 2021; 30: 200025.</citation>
  <type>Review Article</type>
  <year>2021</year>
  <keywords>
    <keyword>Interventional Pulmonology</keyword>
    <keyword>Training</keyword>
    <keyword>Competency-based Education</keyword>
    <keyword>Simulation</keyword>
    <keyword>Procedural Skills</keyword>
  </keywords>
  <summary>
    This article discusses the differences and similarities in interventional pulmonology training between Europe and the USA. It highlights the evolution of training methods, the importance of competency-based education, the role of simulation in procedural training, and the need for collaboration between both continents to enhance training standards and outcomes.
  </summary>
  <pico>
    <population>Interventional pulmonology trainees in Europe and the USA</population>
    <intervention>Training in interventional pulmonology</intervention>
    <comparison>Comparison of training models in Europe and the USA</comparison>
    <outcome>Competency in procedural skills and training effectiveness</outcome>
  </pico>
  <take_home>Collaboration and the adoption of competency-based training models are essential for improving interventional pulmonology training across Europe and the USA.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec7_Article (9)">
  <title>Advances in Interventional Pulmonology</title>
  <authors>Moore, A.J.; Mercer, R.M.; Musani, A.I.</authors>
  <citation>Moore, A.J., Mercer, R.M., Musani, A.I. Advances in Interventional Pulmonology. Clin Chest Med. 2018;39(2):271–280.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Interventional pulmonology</keyword>
    <keyword>Therapeutic bronchoscopy</keyword>
    <keyword>Malignant diseases of the lung</keyword>
    <keyword>Lung malignancy staging</keyword>
  </keywords>
  <summary>
    The article reviews the advancements in interventional pulmonology (IP), emphasizing the need for continuous skill development among practitioners due to the rapid evolution of techniques. It highlights the importance of international training pathways to equip interventionalists with the necessary knowledge and skills. The article discusses various diagnostic and therapeutic advancements in IP, particularly in managing malignant lung diseases, and notes the exciting future prospects in this subspecialty.
  </summary>
  <pico>
    <population>Patients with lung malignancies</population>
    <intervention>Interventional pulmonology techniques including therapeutic bronchoscopy, EBUS, and advanced imaging methods</intervention>
    <comparison>Standard diagnostic and therapeutic approaches</comparison>
    <outcome>Improved diagnostic accuracy, therapeutic efficacy, and patient outcomes</outcome>
  </pico>
  <take_home>Interventional pulmonology is rapidly evolving, necessitating ongoing education and training for practitioners to effectively utilize new techniques and improve patient care.</take_home>
  <embedding_file>https://doi.org/10.1016/j.ccm.2017.11.016</embedding_file>
</article>
```
<article id="sec8_Article (1)">
  <title>Financial Justification for Interventional Pulmonology Programs: Terminology and Programmatic Models</title>
  <authors>Mahajan, A.K.; Bautista, J.; Hodson, E.; Khandhar, S.J.; Folch, E.; Carroll, S.; Narang, S.</authors>
  <citation>Mahajan, A.K., Bautista, J., Hodson, E., Khandhar, S.J., Folch, E., Carroll, S., Narang, S. Financial Justification for Interventional Pulmonology Programs: Terminology and Programmatic Models. CHEST. 2020;158(3):1115-1121.</citation>
  <type>Review</type>
  <year>2020</year>
  <keywords>
    <keyword>bronchoscopy</keyword>
    <keyword>health-care economics</keyword>
    <keyword>interventional pulmonology</keyword>
  </keywords>
  <summary>
    This review discusses the financial sustainability of interventional pulmonology programs, emphasizing the importance of understanding healthcare finance terminology. It highlights that high procedural volumes and low direct costs are crucial for the economic viability of bronchoscopy programs, while also addressing misconceptions about the financial performance of such programs. The article provides insights on how to optimize costs and improve revenue through effective program management and collaboration between specialties.
  </summary>
  <pico>
    <population>Patients requiring bronchoscopy and interventional pulmonology services</population>
    <intervention>Establishment and management of interventional pulmonology programs</intervention>
    <comparison>Traditional surgical approaches and non-specialized bronchoscopy services</comparison>
    <outcome>Financial sustainability and improved patient care outcomes</outcome>
  </pico>
  <take_home>Interventional pulmonology programs can be financially sustainable and beneficial for patient care if managed with a strong understanding of healthcare economics, emphasizing high procedural volumes and minimizing direct costs.</take_home>
  <embedding_file>financial_justification_interventional_pulmonology.pdf</embedding_file>
</article>
```
```xml
<article id="sec8_Article (2)">
  <title>The Business of Interventional Pulmonology</title>
  <authors>Christopher T. Erb, MD, PhD; Armin Ernst, MHCM, MD; Gaëtane C. Michaud, MS, MD, FRCP(C)</authors>
  <citation>Erb CT, Ernst A, Michaud GC. The Business of Interventional Pulmonology. Clin Chest Med. 2013;34(4):583-591.</citation>
  <type>Review Article</type>
  <year>2013</year>
  <keywords>
    <keyword>Interventional pulmonology</keyword>
    <keyword>Billing</keyword>
    <keyword>Coding</keyword>
    <keyword>Reimbursement</keyword>
    <keyword>Practice building</keyword>
    <keyword>Insurance</keyword>
  </keywords>
  <summary>
    This article discusses the complexities of reimbursement in interventional pulmonology, highlighting the importance of understanding current systems and adapting to future changes in funding and legislative mandates. It details various insurance types, reimbursement models, and the impact of these on interventional procedures, emphasizing the need for practices to remain flexible and informed.
  </summary>
  <pico>
    <population>Interventional pulmonologists and their practices</population>
    <intervention>Understanding reimbursement systems and adapting to changes</intervention>
    <comparison>Current reimbursement practices versus future changes</comparison>
    <outcome>Improved financial viability and adaptability of interventional pulmonology practices</outcome>
  </pico>
  <take_home>Interventional pulmonologists must be proactive in understanding and navigating the evolving reimbursement landscape to ensure the sustainability and growth of their practices.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec8_Article (3)">
  <title>Understanding the Economic Impact of Introducing a New Procedure: Calculating Downstream Revenue of Endobronchial Ultrasound With Transbronchial Needle Aspiration as a Model</title>
  <authors>Pastis, N.J.; Simkovich, S.; Silvestri, G.A.</authors>
  <citation>Pastis, N.J., Simkovich, S., Silvestri, G.A. Understanding the Economic Impact of Introducing a New Procedure: Calculating Downstream Revenue of Endobronchial Ultrasound With Transbronchial Needle Aspiration as a Model. CHEST. 2012;141(2):506–512.</citation>
  <type>Research Article</type>
  <year>2012</year>
  <keywords>
    <keyword>Endobronchial Ultrasound</keyword>
    <keyword>Downstream Revenue</keyword>
    <keyword>Economic Impact</keyword>
    <keyword>Healthcare Systems</keyword>
    <keyword>Transbronchial Needle Aspiration</keyword>
  </keywords>
  <summary>
    This study evaluates the economic impact of introducing endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) in a healthcare system. It highlights the importance of considering downstream revenue generated from additional services and referrals, demonstrating that EBUS-TBNA can significantly contribute to hospital collections despite reductions in procedural reimbursements.
  </summary>
  <pico>
    <population>Patients referred for endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA)</population>
    <intervention>Introduction of EBUS-TBNA procedures in a medical center</intervention>
    <comparison>Comparison of collections from new patients (NPs) and established patients (EPs) related to EBUS-TBNA</comparison>
    <outcome>Downstream revenue generated from additional services and consultations after EBUS-TBNA</outcome>
  </pico>
  <take_home>Investing in EBUS-TBNA can yield substantial downstream revenue for healthcare systems, justifying the capital investment despite lower direct reimbursements for the procedure.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec8_Article (4)">
  <title>Value-Based Proposition for a Dedicated Interventional Pulmonology Suite: An Adaptable Business Model</title>
  <authors>Neeraj R. Desai, MD, FCCP; Kim D. French, MHSA, CAPPM; Edward J. Diamond, MD; Kevin L. Kovitz, MD</authors>
  <citation>Desai NR, French KD, Diamond EJ, Kovitz KL. Value-Based Proposition for a Dedicated Interventional Pulmonology Suite: An Adaptable Business Model. CHEST. 2018;154(3):699-708.</citation>
  <type>Research Article</type>
  <year>2018</year>
  <keywords>
    <keyword>business plan</keyword>
    <keyword>interventional pulmonology</keyword>
    <keyword>Medicare</keyword>
    <keyword>value-based care</keyword>
  </keywords>
  <summary>
    This article discusses the evolution of value-based care and its application in interventional pulmonology (IP). It outlines strategies for improving efficiency in IP practices and describes the development of a dedicated interventional pulmonology suite. The authors argue that such a model can enhance patient care and can be adapted to other specialty areas, promoting a coordinated approach to specialty care.
  </summary>
  <pico>
    <population>Patients requiring interventional pulmonology services</population>
    <intervention>Establishment of a dedicated interventional pulmonology suite</intervention>
    <comparison>Traditional fragmented approaches to interventional pulmonology</comparison>
    <outcome>Improved efficiency, quality of care, and patient experience</outcome>
  </pico>
  <take_home>The establishment of a dedicated interventional pulmonology suite can significantly enhance the efficiency and quality of care in pulmonary procedures, ultimately benefiting both patients and healthcare systems in a value-based care environment.</take_home>
  <embedding_file>Value-Based_Pulmonology_Suite_Model.pdf</embedding_file>
</article>
```
```xml
<article id="sec8_Article (5)">
  <title>Developing an Interventional Pulmonary Service in a Community-Based Private Practice: A Case Study</title>
  <authors>French, K.D.; Desai, N.R.; Diamond, E.; Kovitz, K.L.</authors>
  <citation>French, K.D., Desai, N.R., Diamond, E., Kovitz, K.L. Developing an Interventional Pulmonary Service in a Community-Based Private Practice: A Case Study. CHEST. 2016;149(4):1094-1101.</citation>
  <type>Case Study</type>
  <year>2016</year>
  <keywords>
    <keyword>community-based practice</keyword>
    <keyword>interventional pulmonology</keyword>
    <keyword>practice management</keyword>
  </keywords>
  <summary>
    This article discusses the establishment of an interventional pulmonary (IP) service in a community-based private practice, highlighting the challenges and strategies involved. It emphasizes the importance of stakeholder buy-in, community needs assessment, and the integration of IP services to improve patient care and practice viability.
  </summary>
  <pico>
    <population>Patients with advanced lung disease in a community setting</population>
    <intervention>Development of an interventional pulmonary service</intervention>
    <comparison>Existing pulmonary practice without dedicated IP services</comparison>
    <outcome>Increased procedural volume and overall practice visits</outcome>
  </pico>
  <take_home>The successful implementation of an interventional pulmonary service can enhance patient care, increase practice volume, and provide a financially viable model for community-based practices.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec10_Article (1)">
  <title>Development of a Tool to Assess Basic Competency in the Performance of Rigid Bronchoscopy</title>
  <authors>Kamran Mahmood, Momen M. Wahidi, Kathryn E. Osann, Kathleen Coles, Scott L. Shofer, Ellen E. Volker, Mohsen Davoudi</authors>
  <citation>Mahmood K, Wahidi MM, Osann KE, Coles K, Shofer SL, Volker EE, Davoudi M. Development of a Tool to Assess Basic Competency in the Performance of Rigid Bronchoscopy. Ann Am Thorac Soc. 2016;13(4):502–511.</citation>
  <type>Research Article</type>
  <year>2016</year>
  <keywords>
    <keyword>bronchoscopy</keyword>
    <keyword>pulmonary surgical procedures</keyword>
    <keyword>competency-based education</keyword>
  </keywords>
  <summary>
    The study presents the development and validation of the Rigid Bronchoscopy Tool for Assessment of Skills and Competence (RIGID-TASC), a 23-point checklist designed to assess the competency of operators performing rigid bronchoscopy. It aims to objectively evaluate skills in rigid bronchoscopic intubation and central airway navigation, demonstrating construct validity and high interrater reliability across novice, intermediate, and expert operators.
  </summary>
  <pico>
    <population>Physician volunteers categorized as novice, intermediate, and expert based on their experience with rigid bronchoscopy.</population>
    <intervention>Assessment using the Rigid Bronchoscopy Tool for Assessment of Skills and Competence (RIGID-TASC).</intervention>
    <comparison>Scores of novice, intermediate, and expert operators.</comparison>
    <outcome>Mean RIGID-TASC scores and interrater reliability of the assessment tool.</outcome>
  </pico>
  <take_home>The RIGID-TASC is a reliable and valid tool for objectively assessing the competency of operators in rigid bronchoscopy, providing a necessary standard in training programs.</take_home>
  <embedding_file>RIGID-TASC_Article_Summary</embedding_file>
</article>
```
```xml
<article id="sec10_Article (10)">
  <title>Complications Following Therapeutic Bronchoscopy for Malignant Central Airway Obstruction: Results of the AQuIRE Registry</title>
  <authors>David E. Ost, MD, MPH, FCCP; Armin Ernst, MD, FCCP; Horiana B. Grosu, MD; Xiudong Lei, PhD; Javier Diaz-Mendoza, MD, FCCP; Mark Slade, MBBS, FCCP; Thomas R. Gildea, MD, FCCP; Michael Machuzak, MD, FCCP; Carlos A. Jimenez, MD, FCCP; Jennifer Toth, MD; Kevin L. Kovitz, MD, FCCP; Cynthia Ray, MD; Sara Greenhill, MD, FCCP; Roberto F. Casal, MD; Francisco A. Almeida, MD, FCCP; Momen Wahidi, MD, FCCP; George A. Eapen, MD, FCCP; Lonny B. Yarmus, DO, FCCP; Rodolfo C. Morice, MD, FCCP; Sadia Benzaquen, MD; Alain Tremblay, MDCM, FCCP; Michael Simoff, MD, FCCP; on behalf of the AQuIRE Bronchoscopy Registry</authors>
  <citation>Ost DE, Ernst A, Grosu HB, et al. Complications Following Therapeutic Bronchoscopy for Malignant Central Airway Obstruction: Results of the AQuIRE Registry. Chest. 2015;148(2):450-471.</citation>
  <type>Original Research</type>
  <year>2015</year>
  <keywords>
    <keyword>therapeutic bronchoscopy</keyword>
    <keyword>malignant central airway obstruction</keyword>
    <keyword>complications</keyword>
    <keyword>AQuIRE registry</keyword>
    <keyword>30-day mortality</keyword>
  </keywords>
  <summary>
    This study evaluates the incidence and risk factors for complications following therapeutic bronchoscopy for malignant central airway obstruction using data from the AQuIRE registry. The findings indicate significant variation in practice patterns among centers and highlight specific risk factors associated with increased complications and mortality.
  </summary>
  <pico>
    <population>Patients undergoing therapeutic bronchoscopy for malignant central airway obstruction</population>
    <intervention>Therapeutic bronchoscopy procedures</intervention>
    <comparison>Variations in anesthesia type, use of rigid bronchoscopy, and stent placement among different centers</comparison>
    <outcome>Incidence of complications, 30-day mortality, and adverse events</outcome>
  </pico>
  <take_home>Moderate sedation and stent placement are associated with higher complication rates and 30-day mortality. Variations in practice patterns among centers suggest opportunities for quality improvement in therapeutic bronchoscopy.</take_home>
  <embedding_file>AQuIRE_Bronchoscopy_Registry_Study_Results.pdf</embedding_file>
</article>
```
```xml
<article id="sec10_Article (2)">
  <title>Evaluation of Safety and Short-term Outcomes of Therapeutic Rigid Bronchoscopy Using Total Intravenous Anesthesia and Spontaneous Assisted Ventilation</title>
  <authors>Septimiu Murgu; Balaji Laxmanan; Sean Stoy; Katarine Egressy; Udit Chaddha; Farhan Farooqui; Ryan Brunner; Kyle Hogarth; Mark Chaney</authors>
  <citation>MURGU, S., LAXMANAN, B., STOY, S., EGRESSY, K., CHADHA, U., FAROOQUI, F., BRUNNER, R., HOGARTH, K., CHANEY, M. Evaluation of Safety and Short-term Outcomes of Therapeutic Rigid Bronchoscopy Using Total Intravenous Anesthesia and Spontaneous Assisted Ventilation. Respiration. 2020;99:239–247.</citation>
  <type>Research Article</type>
  <year>2020</year>
  <keywords>
    <keyword>Rigid bronchoscopy</keyword>
    <keyword>Anesthesia</keyword>
    <keyword>Spontaneous assisted ventilation</keyword>
    <keyword>Neuromuscular blockade</keyword>
  </keywords>
  <summary>
    This study evaluates the safety and short-term outcomes of therapeutic rigid bronchoscopy performed under total intravenous anesthesia (TIVA) and spontaneous assisted ventilation (SAV). It reviews complications associated with this technique, focusing on intraoperative hypoxemia, hypotension, and 30-day mortality among patients with significant comorbidities.
  </summary>
  <pico>
    <population>Patients undergoing therapeutic rigid bronchoscopy with central airway obstruction</population>
    <intervention>Total intravenous anesthesia and spontaneous assisted ventilation</intervention>
    <comparison>Rigid bronchoscopy with neuromuscular blockade</comparison>
    <outcome>Intraoperative complications, 30-day mortality</outcome>
  </pico>
  <take_home>Therapeutic rigid bronchoscopy can be safely performed with TIVA and SAV in high-risk patients, with the duration of the procedure being a significant modifiable factor affecting 30-day mortality.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec10_Article (3)">
  <title>Indications and complications of rigid bronchoscopy</title>
  <authors>Batra, H.; Yarmus, L.</authors>
  <citation>Batra, H., Yarmus, L. Indications and complications of rigid bronchoscopy. Expert Review of Respiratory Medicine. 2018;12(6):509-520.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Rigid bronchoscopy</keyword>
    <keyword>Central airway obstruction</keyword>
    <keyword>Massive hemoptysis</keyword>
    <keyword>Rigid intubation</keyword>
    <keyword>Endobronchial tumor</keyword>
    <keyword>Therapeutic bronchoscopy</keyword>
    <keyword>Foreign body removal</keyword>
  </keywords>
  <summary>
    This article reviews the history, indications, contraindications, technique, and complications of rigid bronchoscopy, emphasizing its importance in managing airway disorders. Despite the rise of flexible bronchoscopy, rigid bronchoscopy has seen a resurgence in use due to its effectiveness in treating central airway obstruction, foreign body aspiration, and massive hemoptysis.
  </summary>
  <pico>
    <population>Patients with airway disorders, including central airway obstruction and foreign body aspiration.</population>
    <intervention>Rigid bronchoscopy for diagnosis and therapeutic interventions.</intervention>
    <comparison>Flexible bronchoscopy.</comparison>
    <outcome>Management of airway diseases, including successful removal of foreign bodies, treatment of massive hemoptysis, and alleviation of central airway obstruction.</outcome>
  </pico>
  <take_home>Rigid bronchoscopy remains a vital tool for interventional pulmonologists, with a low complication rate when performed by trained professionals.</take_home>
  <embedding_file>https://doi.org/10.1080/17476348.2018.1473037</embedding_file>
</article>
```
```xml
<article id="sec10_Article (4)">
  <title>Multi-institutional retrospective analysis of adverse events following rigid tracheobronchoscopy</title>
  <authors>FORTIN, M.; YARMUS, L.; RENDINA, E.A.; RAFEQ, S.; ANDRADE, R.; MICHAUD, G.; KAZAKOV, J.; ARIAS, S.; CICCONE, A.M.; AMADOR, R.O.; LIBERMAN, M.</authors>
  <citation>FORTIN, M., YARMUS, L., RENDINA, E.A., RAFEQ, S., ANDRADE, R., MICHAUD, G., KAZAKOV, J., ARIAS, S., CICCONE, A.M., AMADOR, R.O., LIBERMAN, M. Multi-institutional retrospective analysis of adverse events following rigid tracheobronchoscopy. Journal Name. 2020;VOLUME(ISSUE):PAGES.</citation>
  <type>Original Article</type>
  <year>2020</year>
  <keywords>
    <keyword>rigid tracheobronchoscopy</keyword>
    <keyword>adverse events</keyword>
    <keyword>interventional pulmonary medicine</keyword>
    <keyword>malignant airway obstruction</keyword>
    <keyword>benign airway stenosis</keyword>
  </keywords>
  <summary>
    This study presents a multicentric retrospective analysis of rigid tracheobronchoscopy (RTB) complications, establishing benchmarks for non-lethal complication rates, periprocedural mortality, and 30-day mortality across multiple institutions. The findings indicate a 6.7% rate of non-lethal complications and a 5.6% 30-day mortality rate, with higher risks associated with emergency procedures and malignant airway obstructions.
  </summary>
  <pico>
    <population>Patients undergoing rigid tracheobronchoscopy in eight participating centers from 2009 to 2015.</population>
    <intervention>Rigid tracheobronchoscopy (RTB).</intervention>
    <comparison>Complications rates in procedures for malignant airway obstruction (MAO) versus benign airway stenosis (BAS).</comparison>
    <outcome>Non-lethal complications, periprocedural mortality, and 30-day mortality rates.</outcome>
  </pico>
  <take_home>RTB has a 6.7% non-lethal complication rate, a 1.2% periprocedural mortality rate, and a 5.6% 30-day mortality rate, with increased risks in emergency settings.</take_home>
  <embedding_file>sec10_Article (4)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec10_Article (5)">
  <title>Rigid bronchoscopy and silicone stents in the management of central airway obstruction</title>
  <authors>Roy Semaan, Lonny Yarmus</authors>
  <citation>Semaan R, Yarmus L. Rigid bronchoscopy and silicone stents in the management of central airway obstruction. J Thorac Dis. 2015;7(Suppl 4):S352-S362.</citation>
  <type>Review Article</type>
  <year>2015</year>
  <keywords>
    <keyword>Rigid bronchoscopy</keyword>
    <keyword>silicone stenting</keyword>
    <keyword>central airway obstruction (CAO)</keyword>
    <keyword>ablative technologies</keyword>
  </keywords>
  <summary>
    This review article discusses the evolution and current techniques of rigid bronchoscopy in the management of central airway obstruction (CAO), highlighting the use of silicone stents. It covers the historical development of rigid bronchoscopy, its technical aspects, indications for stenting, complications, and the importance of understanding these techniques for optimal patient care.
  </summary>
  <pico>
    <population>Patients with central airway obstruction (CAO), both malignant and non-malignant</population>
    <intervention>Rigid bronchoscopy with silicone stenting</intervention>
    <comparison>Flexible bronchoscopy or no intervention</comparison>
    <outcome>Improvement in dyspnea and quality of life (QOL)</outcome>
  </pico>
  <take_home>The use of rigid bronchoscopy and silicone stents is critical for managing central airway obstruction, providing significant symptom relief and improving quality of life in patients.</take_home>
  <embedding_file>https://dx.doi.org/10.3978/j.issn.2072-1439.2015.11.17</embedding_file>
</article>
```
```xml
<article id="sec10_Article (6)">
  <title>Rigid Bronchoscopy</title>
  <authors>Javier Diaz-Mendoza, MD; A. Rolando Peralta, MD; Labib Debiane, MD; Michael J. Simoff, MD, FACP, FCCP</authors>
  <citation>Diaz-Mendoza J, Peralta AR, Debiane L, Simoff MJ. Rigid Bronchoscopy. Semin Respir Crit Care Med. 2018;39:674–684.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>rigid bronchoscopy</keyword>
    <keyword>flexible bronchoscopy</keyword>
    <keyword>airway stents</keyword>
    <keyword>tracheal stenosis</keyword>
    <keyword>cryotherapy</keyword>
    <keyword>laser</keyword>
    <keyword>electrocautery</keyword>
  </keywords>
  <summary>
    Rigid bronchoscopy, an ancient medical technique, has regained prominence in interventional pulmonology. This article reviews its history, equipment, indications, procedural techniques, anesthesia considerations, complications, and future directions, emphasizing its therapeutic advantages in managing central airway obstruction, foreign bodies, and airway stenting.
  </summary>
  <pico>
    <population>Patients requiring airway intervention</population>
    <intervention>Rigid bronchoscopy</intervention>
    <comparison>Flexible bronchoscopy</comparison>
    <outcome>Management of airway diseases and obstructions</outcome>
  </pico>
  <take_home>Rigid bronchoscopy is essential for interventional pulmonology, offering unique therapeutic advantages in treating complex airway conditions.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec10_Article (7)">
  <title>The Art of Rigid Bronchoscopy and Airway Stenting</title>
  <authors>Antoinette Flannery, MB, BA Bch, MRCPI; Cyrus Daneshvar, MB, chB, MD; Hervé Dutau, MD; David Breen, MB, BA, BCh, BAO, MRCPI, MRCP(UK)</authors>
  <citation>Flannery A., Daneshvar C., Dutau H., Breen D. The Art of Rigid Bronchoscopy and Airway Stenting. Clin Chest Med. 2018;39(1):149–167.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Rigid bronchoscopy</keyword>
    <keyword>Airway stents</keyword>
    <keyword>Future advances in stent technology</keyword>
    <keyword>Complications</keyword>
  </keywords>
  <summary>
    This article discusses the importance of rigid bronchoscopy and airway stenting in the management of both malignant and benign airway diseases. It emphasizes the historical development, current practices, and future directions of these techniques, highlighting their essential role in interventional pulmonology.
  </summary>
  <pico>
    <population>Patients with central airway obstruction due to malignant and benign conditions</population>
    <intervention>Rigid bronchoscopy and airway stenting</intervention>
    <comparison>Flexible bronchoscopy and other therapeutic modalities</comparison>
    <outcome>Improvement in airway patency, symptom relief, and quality of life</outcome>
  </pico>
  <take_home>Rigid bronchoscopy and airway stenting are crucial skills in interventional pulmonology, requiring specialized training and offering significant benefits in managing complex airway diseases.</take_home>
  <embedding_file>https://doi.org/10.1016/j.ccm.2017.11.011</embedding_file>
</article>
```
```xml
<article id="sec10_Article (8)">
  <title>Therapeutic Bronchoscopy for Malignant Central Airway Obstruction: Success Rates and Impact on Dyspnea and Quality of Life</title>
  <authors>David E. Ost, MD, MPH, FCCP; Armin Ernst, MD, MHCM, FCCP; Horiana B. Grosu, MD; Xiudong Lei, PhD; Javier Diaz-Mendoza, MD; Mark Slade, MBBS, FCCP; Thomas R. Gildea, MD, FCCP; Michael S. Machuzak, MD, FCCP; Carlos A. Jimenez, MD, FCCP; Jennifer Toth, MD; Kevin L. Kovitz, MD, FCCP; Cynthia Ray, MD, FCCP; Sara Greenhill, MD, FCCP; Roberto F. Casal, MD; Francisco A. Almeida, MD, FCCP; Momen M. Wahidi, MD, FCCP; George A. Eapen, MD, FCCP; David Feller-Kopman, MD, FCCP; Rodolfo C. Morice, MD, FCCP; Sadia Benzaquen, MD; Alain Tremblay, MDCM, FCCP; Michael Simoff, MD, FCCP; on behalf of the AQuIRE Bronchoscopy Registry</authors>
  <citation>Ost DE, Ernst A, Grosu HB, et al. Therapeutic Bronchoscopy for Malignant Central Airway Obstruction: Success Rates and Impact on Dyspnea and Quality of Life. CHEST. 2015;147(5):1282-1298.</citation>
  <type>Original Research</type>
  <year>2015</year>
  <keywords>
    <keyword>bronchoscopy</keyword>
    <keyword>malignant airway obstruction</keyword>
    <keyword>dyspnea</keyword>
    <keyword>quality of life</keyword>
    <keyword>technical success</keyword>
  </keywords>
  <summary>
    This study evaluates the technical success rates of therapeutic bronchoscopy for malignant central airway obstruction and its impact on dyspnea and health-related quality of life (HRQOL). It finds that technical success is high (93%), with significant improvements in dyspnea and HRQOL, particularly in patients with higher baseline dyspnea.
  </summary>
  <pico>
    <population>Patients undergoing therapeutic bronchoscopy for malignant central airway obstruction</population>
    <intervention>Therapeutic bronchoscopy procedures</intervention>
    <comparison>Outcomes based on varying techniques and patient characteristics</comparison>
    <outcome>Technical success rates, dyspnea improvement, and HRQOL changes</outcome>
  </pico>
  <take_home>Therapeutic bronchoscopy is effective for managing malignant central airway obstruction, with high technical success rates and significant benefits in dyspnea and quality of life, especially in patients with severe symptoms.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
```xml
<article id="sec10_Article (9)">
  <title>Variable Learning Curve of Basic Rigid Bronchoscopy in Trainees</title>
  <authors>Kamran Mahmood, M. Wahidi, Ray Wes Shepherd, A. Christine Argento, Lonny B. Yarmus, Hans Lee, Samira Shojaei, David M. Berkowitz, Keriann Van Nostrand, Carla R. Lamb, Scott L. Shofer, Junheng Gao, Mohsen Davoudi</authors>
  <citation>Mahmood K, Wahidi M, Shepherd RW, Argento AC, Yarmus LB, Lee H, Shojaei S, Berkowitz DM, Van Nostrand K, Lamb CR, Shofer SL, Gao J, Davoudi M. Variable Learning Curve of Basic Rigid Bronchoscopy in Trainees. Respiration. 2021;100:530–537.</citation>
  <type>Research Article</type>
  <year>2021</year>
  <keywords>
    <keyword>Rigid bronchoscopy</keyword>
    <keyword>Learning</keyword>
    <keyword>Learning curve</keyword>
    <keyword>Trainees</keyword>
    <keyword>Competency</keyword>
  </keywords>
  <summary>
    This study evaluates the learning curve of interventional pulmonary trainees in performing rigid bronchoscopy (RB) using the Rigid Bronchoscopy Tool for Assessment of Skills and Competence (RIGID-TASC). It highlights the variability in skill acquisition among trainees and the need for performance-based competency assessment.
  </summary>
  <pico>
    <population>Interventional pulmonary trainees (12 fellows from 4 institutions)</population>
    <intervention>Rigid bronchoscopy training using RIGID-TASC assessment tool</intervention>
    <comparison>Comparison of learning curves among trainees</comparison>
    <outcome>Competency threshold achievement in performing rigid bronchoscopy</outcome>
  </pico>
  <take_home>The learning curve for rigid bronchoscopy is highly variable among trainees, demonstrating the need for individualized competency assessments rather than a one-size-fits-all approach.</take_home>
  <embedding_file>https://www.karger.com/Article/FullText/514627</embedding_file>
</article>
```
<article id="sec11_Article (1)">
  <title>3D printing for airway disease</title>
  <authors>Abdul Hamid Alraiyes; Sameer K. Avasarala; Michael S. Machuzak; Thomas R. Gildea</authors>
  <citation>Alraiyes AH, Avasarala SK, Machuzak MS, Gildea TR. 3D printing for airway disease. AME Med J. 2019;4:14.</citation>
  <type>Review</type>
  <year>2019</year>
  <keywords>
    <keyword>Airway stent</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>three-dimensional printing</keyword>
  </keywords>
  <summary>
    This article discusses the advancements and potential applications of 3D printing technology in the field of interventional pulmonology, especially for managing complex airway diseases. The authors highlight the challenges of traditional airway stenting methods and propose patient-specific 3D printed airway stents as a solution to improve stent-airway sizing and reduce complications.
  </summary>
  <pico>
    <population>Patients with complex airway diseases</population>
    <intervention>Patient-specific 3D printed airway stents</intervention>
    <comparison>Traditional silicone and self-expandable metallic stents</comparison>
    <outcome>Improved stent fit and reduced complications</outcome>
  </pico>
  <take_home>Patient-specific 3D printed airway stents have the potential to enhance the management of complex airway diseases by providing a better fit and minimizing complications compared to traditional stenting methods.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec11_Article (10)">
  <title>Application of the Montgomery T-tube in subglottic tracheal benign stenosis</title>
  <authors>Huihui Hu, Jisong Zhang, Fengjie Wu, Enguo Chen</authors>
  <citation>Hu H, Zhang J, Wu F, Chen E. Application of the Montgomery T-tube in subglottic tracheal benign stenosis. J Thorac Dis. 2018;10(5):3070-3077.</citation>
  <type>Surgical Technique</type>
  <year>2018</year>
  <keywords>
    <keyword>Montgomery T-tube</keyword>
    <keyword>subglottic tracheal stenosis</keyword>
    <keyword>bronchoscopic intervention</keyword>
    <keyword>tracheal surgery</keyword>
    <keyword>airway management</keyword>
  </keywords>
  <summary>
    The article discusses the Montgomery T-tube as a safe and effective method for managing subglottic tracheal benign stenosis (STBS). It details the causes of STBS, the benefits and techniques of T-tube insertion, preoperative evaluations, potential complications, and postoperative care. The T-tube allows for airway remodeling and significantly improves patients' quality of life, especially for those unfit for traditional surgeries.
  </summary>
  <pico>
    <population>Patients with subglottic tracheal benign stenosis</population>
    <intervention>Insertion of Montgomery T-tube</intervention>
    <comparison>Traditional surgical methods for airway stenosis</comparison>
    <outcome>Improvement in airway patency and quality of life</outcome>
  </pico>
  <take_home>The Montgomery T-tube is a preferable option for managing subglottic tracheal benign stenosis, particularly for patients who are not candidates for conventional surgical interventions.</take_home>
  <embedding_file>https://doi.org/10.21037/jtd.2018.05.140</embedding_file>
</article>
```
```xml
<article id="sec11_Article (11)">
  <title>Mechanical properties of different airway stents</title>
  <authors>Ratnovsky, A.; Regev, N.; Wald, S.; Kramer, M.; Naftali, S.</authors>
  <citation>Ratnovsky, A., Regev, N., Wald, S., Kramer, M., Naftali, S. Mechanical properties of different airway stents. Medical Engineering and Physics. 2015;37(5):408–415.</citation>
  <type>Research Article</type>
  <year>2015</year>
  <keywords>
    <keyword>Airway Stent</keyword>
    <keyword>Airway obstruction</keyword>
    <keyword>Stress</keyword>
    <keyword>Numerical simulation</keyword>
  </keywords>
  <summary>
    This study compares the mechanical properties and radial forces exerted by different types of airway stents (silicone, balloon-dilated metal, self-expanding metal, and covered self-expanding metal) on the trachea. Mechanical measurements and numerical simulations were performed, revealing that stent diameter significantly affects stress levels. Covered metal stents exert less stress compared to uncovered ones, while silicone stents show the lowest stress levels, linked to their tendency for migration. The findings provide insights for selecting suitable airway stents based on their mechanical behavior.
  </summary>
  <pico>
    <population>Patients with airway obstruction requiring stenting</population>
    <intervention>Placement of various types of airway stents</intervention>
    <comparison>Mechanical properties and radial forces of silicone vs. metal stents</comparison>
    <outcome>Stress levels exerted on the trachea by different stent types</outcome>
  </pico>
  <take_home>The choice of airway stent should consider the mechanical properties and stress exerted on the trachea, as this can impact patient outcomes, particularly regarding stent migration and tissue integrity.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec11_Article (12)">
  <title>Metallic Endobronchial Stents: A Contemporary Resurrection</title>
  <authors>Avasarala, S.K.; Freitag, L.; Mehta, A.C.</authors>
  <citation>Avasarala, S.K., Freitag, L., Mehta, A.C. Metallic Endobronchial Stents: A Contemporary Resurrection. CHEST. 2019;155(6):1246-1259.</citation>
  <type>Review</type>
  <year>2019</year>
  <keywords>
    <keyword>airway stents</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>interventional pulmonology</keyword>
  </keywords>
  <summary>
    This article reviews the history, technological advancements, and contemporary applications of metallic endobronchial stents in interventional pulmonology. It discusses the evolution of stent design, safety concerns, complications associated with stent use, and the significance of post-procedural care. The authors emphasize that despite historical challenges, modern metallic stents have become safer and are increasingly utilized for various airway pathologies.
  </summary>
  <pico>
    <population>Patients with airway obstructions or conditions requiring stenting</population>
    <intervention>Deployment of metallic endobronchial stents</intervention>
    <comparison>Comparison of different generations and types of metallic stents</comparison>
    <outcome>Improvement in airway patency and reduction in complications</outcome>
  </pico>
  <take_home>Modern metallic endobronchial stents have evolved significantly, offering safer and more effective options for managing various airway conditions, particularly when surgical alternatives are not viable.</take_home>
  <embedding_file>https://doi.org/10.1016/j.chest.2018.12.001</embedding_file>
</article>
```
```xml
<article id="sec11_Article (13)">
  <title>Respiratory Infections Increase the Risk of Granulation Tissue Formation Following Airway Stenting in Patients With Malignant Airway Obstruction</title>
  <authors>Ost, D.E.; Shah, A.M.; Lei, X.; Godoy, M.C.B.; Jimenez, C.A.; Eapen, G.A.; Jani, P.; Larson, A.J.; Sarkiss, M.G.; Morice, R.C.</authors>
  <citation>Ost, D.E., Shah, A.M., Lei, X., Godoy, M.C.B., Jimenez, C.A., Eapen, G.A., Jani, P., Larson, A.J., Sarkiss, M.G., Morice, R.C. Respiratory Infections Increase the Risk of Granulation Tissue Formation Following Airway Stenting in Patients With Malignant Airway Obstruction. CHEST. 2012;141(6):1473–1481.</citation>
  <type>Original Research</type>
  <year>2012</year>
  <keywords>
    <keyword>airway stenting</keyword>
    <keyword>malignant airway obstruction</keyword>
    <keyword>granulation tissue</keyword>
    <keyword>respiratory infections</keyword>
    <keyword>complications</keyword>
  </keywords>
  <summary>
    This study investigates the incidence and risk factors for long-term complications associated with different types of airway stents used in patients with malignant airway obstruction. It compares the rates of respiratory infections, stent migration, and granulation tissue formation among various stent types, highlighting significant morbidity and mortality associated with these complications.
  </summary>
  <pico>
    <population>Patients with malignant airway obstruction undergoing airway stenting</population>
    <intervention>Use of different types of airway stents (Aero, Dumon silicone tube, Ultraflex)</intervention>
    <comparison>Incidence of complications among different stent types</comparison>
    <outcome>Rates of respiratory infections, stent migration, and granulation tissue formation</outcome>
  </pico>
  <take_home>Different airway stents have varying risks of complications, with Aero stents associated with higher infection rates and silicone stents linked to increased migration and granulation tissue formation, impacting patient morbidity and mortality.</take_home>
  <embedding_file>embedding_file_placeholder</embedding_file>
</article>
```
```xml
<article id="sec11_Article (14)">
  <title>Role of Montgomery T-tube stent for laryngotracheal stenosis</title>
  <authors>Prasanna Kumar, S.; Ravikumar, A.; Senthil, K.; Somu, L.; Nazrin, M.I.</authors>
  <citation>Prasanna Kumar, S., Ravikumar, A., Senthil, K., Somu, L., Nazrin, M.I. Role of Montgomery T-tube stent for laryngotracheal stenosis. Auris Nasus Larynx. 2013;40(1):1-7.</citation>
  <type>Research Article</type>
  <year>2013</year>
  <keywords>
    <keyword>Laryngotracheal stenosis</keyword>
    <keyword>Montgomery T-tube stent</keyword>
    <keyword>Laryngotracheal stents</keyword>
  </keywords>
  <summary>
    This study investigates the indications, complications, and outcomes of Montgomery T-tube stenting in patients with laryngotracheal stenosis (LTS). A retrospective review of 39 patients treated with T-tube stenting was conducted, analyzing data on stenting indications, complications, and decannulation rates. The study concludes that T-tube stenting is a safe and effective option for managing LTS, especially in cases where surgical resection is not feasible.
  </summary>
  <pico>
    <population>Patients with laryngotracheal stenosis</population>
    <intervention>Montgomery T-tube stenting</intervention>
    <comparison>Not applicable (retrospective study)</comparison>
    <outcome>Success rate of decannulation and complications</outcome>
  </pico>
  <take_home>Montgomery T-tube stenting is a safe and effective management option for laryngotracheal stenosis, especially in inoperable cases or when resection is not feasible.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec11_Article (15)">
  <title>Outcome and Safety of the Montgomery T-Tube for Laryngotracheal Stenosis: A Single-Center Retrospective Analysis of 546 Cases</title>
  <authors>Song Shi; Donghui Chen; Xiaoyu Li; Wu Wen; Xiaohua Shen; Feng Liu; Shicai Chen; Hongliang Zheng</authors>
  <citation>Shi, S., Chen, D., Li, X., Wen, W., Shen, X., Liu, F., Chen, S., Zheng, H. Outcome and Safety of the Montgomery T-Tube for Laryngotracheal Stenosis: A Single-Center Retrospective Analysis of 546 Cases. Otolaryngology – Head and Neck Surgery. 2014; 150(3): 439-445.</citation>
  <type>Original Paper</type>
  <year>2014</year>
  <keywords>
    <keyword>Laryngotracheal stenosis</keyword>
    <keyword>T-tube</keyword>
    <keyword>Efficacy</keyword>
    <keyword>Extubation rate</keyword>
    <keyword>Safety</keyword>
  </keywords>
  <summary>
    This study retrospectively analyzes the outcomes and safety of Montgomery T-tube placements in 546 patients with laryngotracheal stenosis. The primary endpoint was the successful extubation rate, while safety was assessed as a secondary endpoint. The findings indicate that T-tubes are effective for treating grade 1 and 2 stenosis, with varying success rates based on the cause and severity of stenosis.
  </summary>
  <pico>
    <population>Patients with laryngotracheal stenosis who underwent T-tube placement</population>
    <intervention>Montgomery T-tube placement</intervention>
    <comparison>Not applicable (retrospective analysis)</comparison>
    <outcome>Successful extubation rate and safety profile</outcome>
  </pico>
  <take_home>The Montgomery T-tube is a safe and effective treatment for laryngotracheal stenosis, particularly for stenoses graded 1 and 2, with careful preoperative patient selection being crucial.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec11_Article (16)">
  <title>A new technique for T-tube insertion in patients with subglottic stenosis</title>
  <authors>Tedde, M.L.; Rodrigues, A.; Scordamaglio, P.R.; Monteiro, J.S.</authors>
  <citation>Tedde, M.L., Rodrigues, A., Scordamaglio, P.R., Monteiro, J.S. A new technique for T-tube insertion in patients with subglottic stenosis. European Journal of Cardio-thoracic Surgery. 2011;39(1):130-131.</citation>
  <type>How-to-do-it</type>
  <year>2011</year>
  <keywords>
    <keyword>Montgomery T tube</keyword>
    <keyword>Subglottic stenosis</keyword>
    <keyword>Device</keyword>
    <keyword>Bronchoscopy</keyword>
    <keyword>Endoscopy</keyword>
  </keywords>
  <summary>
    This article presents a new technique for the insertion of a Montgomery T tube in patients with subglottic stenosis, which addresses the limitations of the conventional insertion method that can fail due to the tube's softness. The proposed method uses a nasogastric tube and a Foley catheter to facilitate the placement of the T tube, allowing for successful insertion without the need for rigid bronchoscopy.
  </summary>
  <pico>
    <population>Patients with subglottic stenosis</population>
    <intervention>New technique for T-tube insertion using a nasogastric tube and Foley catheter</intervention>
    <comparison>Conventional Montgomery insertion technique</comparison>
    <outcome>Successful placement of the T tube without additional auxiliary techniques</outcome>
  </pico>
  <take_home>The new technique for T-tube insertion can effectively overcome challenges in patients with subglottic stenosis, reducing the need for more invasive procedures.</take_home>
  <embedding_file>http://dx.doi.org/10.1016/j.ejcts.2010.05.014</embedding_file>
</article>
```
```xml
<article id="sec11_Article (17)">
  <title>Update on airway stents</title>
  <authors>Sabath, B.F.; Ost, D.E.</authors>
  <citation>Sabath, B.F., Ost, D.E. Update on airway stents. Curr Opin Pulm Med. 2018;24:343–349.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>malignant airway obstruction</keyword>
    <keyword>stent</keyword>
    <keyword>therapeutic bronchoscopy</keyword>
  </keywords>
  <summary>
    This review discusses the latest evidence on the use of airway stents for malignant airway obstruction, highlighting their effectiveness, complications, and recent advancements in stent technology.
  </summary>
  <pico>
    <population>Patients with malignant central airway obstruction</population>
    <intervention>Airway stenting via therapeutic bronchoscopy</intervention>
    <comparison>Comparison of stenting with other therapeutic modalities</comparison>
    <outcome>Restoration of airway patency, improvement in dyspnea, and health-related quality of life</outcome>
  </pico>
  <take_home>Airway stents can effectively restore patency in patients with malignant central airway obstruction, but careful patient selection and awareness of potential complications are crucial.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec11_Article (2)">
  <title>A Prospective Multicenter Trial of a Self-expanding Hybrid Stent in Malignant Airway Obstruction</title>
  <authors>Thomas R. Gildea, MD; Gordon Downie, MD; Georgie Eapen, MD; Felix Herth, MD; Michael Jantz, MD; Lutz Freitag, MD</authors>
  <citation>Gildea TR, Downie G, Eapen G, Herth F, Jantz M, Freitag L. A Prospective Multicenter Trial of a Self-expanding Hybrid Stent in Malignant Airway Obstruction. J Bronchol. 2008;15(4):221–224.</citation>
  <type>Original Investigation</type>
  <year>2008</year>
  <keywords>
    <keyword>malignant airway obstruction</keyword>
    <keyword>hybrid stent</keyword>
    <keyword>tracheobronchial stenting</keyword>
    <keyword>quality of life</keyword>
  </keywords>
  <summary>
    This study evaluates the safety and efficacy of a new self-expanding hybrid stent for patients with malignant airway obstruction. The results indicate significant improvements in luminal patency and quality of life, with a manageable complication rate.
  </summary>
  <pico>
    <population>Patients with malignant airway obstruction</population>
    <intervention>Placement of a self-expanding hybrid stent (AERO stent)</intervention>
    <comparison>Standard silicone and metal stents</comparison>
    <outcome>Improvement in luminal patency and quality of life</outcome>
  </pico>
  <take_home>The self-expanding hybrid stent is easy to deploy and remove, effectively improves airway patency and quality of life in patients with malignant airway obstruction, with an acceptable complication rate.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec11_Article (3)">
  <title>Airway Stents</title>
  <authors>Folch, E.; Keyes, C.</authors>
  <citation>Folch E, Keyes C. Airway stents. Ann Cardiothorac Surg. 2018;7(2):273-283.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Airway stents</keyword>
    <keyword>airway obstruction</keyword>
    <keyword>tracheal neoplasms</keyword>
    <keyword>prosthesis design</keyword>
    <keyword>prosthesis implantation</keyword>
    <keyword>bronchi pathology</keyword>
  </keywords>
  <summary>
    This article provides a comprehensive overview of airway stents, including their evolution, types, indications, contraindications, and complications. It discusses the use of airway stents in both malignant and benign diseases, emphasizing that stents should not be the first-line treatment but rather a palliative option after curative surgical options have been considered.
  </summary>
  <pico>
    <population>Patients with malignant and benign airway obstruction</population>
    <intervention>Placement of airway stents</intervention>
    <comparison>Standard surgical interventions</comparison>
    <outcome>Improvement in airway patency and management of symptoms</outcome>
  </pico>
  <take_home>Airway stents are valuable tools in managing airway obstructions but should be used judiciously, considering the patient's overall treatment plan and potential complications.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec11_Article (4)">
  <title>Central Airway Obstruction: Benign Strictures, Tracheobronchomalacia, and Malignancy-related Obstruction</title>
  <authors>Septimiu Dan Murgu, MD, FCCP; Katarine Egressy, MD; Balaji Laxmanan, MD; Guillermo Doblare, MD; Rosamaria Ortiz-Comino, MD; D. Kyle Hogarth, MD, FCCP</authors>
  <citation>MURGU, S.D., EGRESSY, K., LAXMANAN, B., DOBLARE, G., ORTIZ-COMINO, R., HOGARTH, D.K. Central Airway Obstruction: Benign Strictures, Tracheobronchomalacia, and Malignancy-related Obstruction. CHEST. 2016;150(2):426-441.</citation>
  <type>Review Article</type>
  <year>2016</year>
  <keywords>
    <keyword>airway obstruction</keyword>
    <keyword>airway stents</keyword>
    <keyword>bronchial stenosis</keyword>
    <keyword>bronchomalacia</keyword>
    <keyword>tracheobronchomalacia</keyword>
    <keyword>malignant obstruction</keyword>
  </keywords>
  <summary>
    This article provides an update on the management of central airway obstruction (CAO) due to benign strictures, tracheobronchomalacia, and malignancy-related obstruction. It reviews recent literature on various forms of CAO, their classification, and the role of airway stenting in treatment, highlighting improvements in dyspnea and quality of life while addressing the associated risks.
  </summary>
  <pico>
    <population>Patients with central airway obstruction from benign and malignant causes.</population>
    <intervention>Airway stent insertion and bronchoscopic interventions.</intervention>
    <comparison>Comparison of outcomes with and without stent insertion.</comparison>
    <outcome>Improvement in dyspnea, lung function, and quality of life.</outcome>
  </pico>
  <take_home>Airway stenting can significantly improve symptoms in patients with inoperable central airway obstruction, but it carries risks and should be considered carefully in the context of the patient's overall treatment plan.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
```xml
<article id="sec11_Article (5)">
  <title>Three-dimensional Printing and 3D Slicer: Powerful Tools in Understanding and Treating Structural Lung Disease</title>
  <authors>George Z. Cheng, MD, PhD; Raul San Jose Estepar, PhD; Erik Folch, MD; Jorge Onieva, MSc; Sidhu Gangadharan, MD; Adnan Majid, MD</authors>
  <citation>Cheng GZ, Estepar RSJ, Folch E, Onieva J, Gangadharan S, Majid A. Three-dimensional Printing and 3D Slicer: Powerful Tools in Understanding and Treating Structural Lung Disease. CHEST. 2016;149(5):1136-1142.</citation>
  <type>Commentary</type>
  <year>2016</year>
  <keywords>
    <keyword>3D printing</keyword>
    <keyword>3D Slicer</keyword>
    <keyword>pulmonary</keyword>
    <keyword>stent</keyword>
  </keywords>
  <summary>
    This commentary discusses the advancements in 3D printing technology and its applications in pulmonary medicine, particularly in creating personalized airway models. It highlights the history of 3D printing, barriers to its adoption in healthcare, and provides guidance on using 3D Slicer software for airway modeling.
  </summary>
  <pico>
    <population>Clinicians and patients in pulmonary medicine</population>
    <intervention>Use of 3D printing and 3D Slicer for airway modeling</intervention>
    <comparison>Traditional methods of airway intervention</comparison>
    <outcome>Improved preprocedural planning and personalized medical devices</outcome>
  </pico>
  <take_home>The integration of 3D printing and modeling technologies can significantly enhance the understanding and treatment of structural lung diseases, though challenges remain in material availability and regulatory standards.</take_home>
  <embedding_file>3D_Slicer_Airway_Modeling_Tutorial.pdf</embedding_file>
</article>
```
```xml
<article id="sec11_Article (6)">
  <title>Clinical Success Stenting Distal Bronchi for “Lobar Salvage” in Bronchial Stenosis</title>
  <authors>Sethi, S.; Gildea, T.R.; Almeida, F.A.; Cicenia, J.C.; Machuzak, M.S.</authors>
  <citation>Sethi, S., Gildea, T.R., Almeida, F.A., Cicenia, J.C., Machuzak, M.S. Clinical Success Stenting Distal Bronchi for “Lobar Salvage” in Bronchial Stenosis. J Bronchol Intervent Pulmonol. 2018;25(1):9–16.</citation>
  <type>Original Investigation</type>
  <year>2018</year>
  <keywords>
    <keyword>airway stents</keyword>
    <keyword>iCast stent</keyword>
    <keyword>bronchial stenosis</keyword>
    <keyword>bronchoscopy</keyword>
  </keywords>
  <summary>
    This study evaluates the feasibility, complications, and long-term impact of using the iCast stent for lobar bronchial stenosis treatment, demonstrating significant symptomatic and radiographic improvements in patients with both benign and malignant conditions.
  </summary>
  <pico>
    <population>Patients with lobar bronchial stenosis due to malignancy or benign conditions</population>
    <intervention>Placement of iCast stent</intervention>
    <comparison>Not applicable (single-group study)</comparison>
    <outcome>Symptomatic improvement, radiographic improvement, pulmonary function improvement</outcome>
  </pico>
  <take_home>Stenting small airways for lobar salvage is safe and effective in improving symptoms, radiographic outcomes, and pulmonary function, with complication rates comparable to larger airway stents.</take_home>
  <embedding_file>embedding_file_placeholder</embedding_file>
</article>
```
```xml
<article id="sec11_Article (7)">
  <title>Complications Following Therapeutic Bronchoscopy for Malignant Central Airway Obstruction: Results of the AQuIRE Registry</title>
  <authors>David E. Ost, MD, MPH, FCCP; Armin Ernst, MD, FCCP; Horiana B. Grosu, MD; Xiudong Lei, PhD; Javier Diaz-Mendoza, MD, FCCP; Mark Slade, MBBS, FCCP; Thomas R. Gildea, MD, FCCP; Michael Machuzak, MD, FCCP; Carlos A. Jimenez, MD, FCCP; Jennifer Toth, MD; Kevin L. Kovitz, MD, FCCP; Cynthia Ray, MD; Sara Greenhill, MD, FCCP; Roberto F. Casal, MD; Francisco A. Almeida, MD, FCCP; Momen Wahidi, MD, FCCP; George A. Eapen, MD, FCCP; Lonny B. Yarmus, DO, FCCP; Rodolfo C. Morice, MD, FCCP; Sadia Benzaquen, MD; Alain Tremblay, MDCM, FCCP; Michael Simoff, MD, FCCP; on behalf of the AQuIRE Bronchoscopy Registry</authors>
  <citation>Ost DE, Ernst A, Grosu HB, et al. Complications Following Therapeutic Bronchoscopy for Malignant Central Airway Obstruction: Results of the AQuIRE Registry. Chest. 2015;148(2):450-471.</citation>
  <type>Original Research</type>
  <year>2015</year>
  <keywords>
    <keyword>Therapeutic Bronchoscopy</keyword>
    <keyword>Malignant Airway Obstruction</keyword>
    <keyword>Complications</keyword>
    <keyword>30-Day Mortality</keyword>
    <keyword>AQuIRE Registry</keyword>
  </keywords>
  <summary>
    This study evaluates the incidence and risk factors for complications following therapeutic bronchoscopy for malignant central airway obstruction using data from the AQuIRE Registry. It highlights significant variations in practice patterns, complication rates, and 30-day mortality across different centers, emphasizing the need for standardized approaches to improve patient outcomes.
  </summary>
  <pico>
    <population>Patients undergoing therapeutic bronchoscopy for malignant central airway obstruction.</population>
    <intervention>Therapeutic bronchoscopy procedures performed in multiple centers.</intervention>
    <comparison>Variations in anesthesia type, use of rigid bronchoscopy, ventilation methods, and stent usage among centers.</comparison>
    <outcome>Incidence of complications, 30-day mortality rates, and associated risk factors.</outcome>
  </pico>
  <take_home>Moderate sedation and stent placement are associated with increased complication rates and 30-day mortality. Standardizing practices across centers may improve patient outcomes.</take_home>
  <embedding_file>https://doi.org/10.1378/chest.14-1530</embedding_file>
</article>
```
```xml
<article id="sec11_Article (8)">
  <title>Stents Are Associated With Increased Risk of Respiratory Infections in Patients Undergoing Airway Interventions for Malignant Airways Disease</title>
  <authors>Horiana B. Grosu, MD; George A. Eapen, MD, FCCP; Rodolfo C. Morice, MD, FCCP; Carlos A. Jimenez, MD, FCCP; Roberto F. Casal, MD; Francisco A. Almeida, MD; Mona G. Sarkiss, MD, PhD; David E. Ost, MD, MPH, FCCP</authors>
  <citation>Grosu HB, Eapen GA, Morice RC, et al. Stents Are Associated With Increased Risk of Respiratory Infections in Patients Undergoing Airway Interventions for Malignant Airways Disease. CHEST. 2013;144(2):441–449.</citation>
  <type>Original Research</type>
  <year>2013</year>
  <keywords>
    <keyword>Stents</keyword>
    <keyword>Respiratory Infections</keyword>
    <keyword>Therapeutic Bronchoscopy</keyword>
    <keyword>Malignant Airways Disease</keyword>
  </keywords>
  <summary>
    This study investigates the incidence of lower respiratory tract infections in patients undergoing therapeutic bronchoscopy for malignant airway disease, comparing those with and without airway stents. The findings indicate that stent placement is associated with a significantly higher risk of infections, which can lead to increased morbidity and mortality.
  </summary>
  <pico>
    <population>Patients aged 18 years or older undergoing therapeutic bronchoscopy for malignant airways disease</population>
    <intervention>Placement of airway stents during therapeutic bronchoscopy</intervention>
    <comparison>No stent placement during therapeutic bronchoscopy</comparison>
    <outcome>Incidence rates of lower respiratory tract infections</outcome>
  </pico>
  <take_home>Stent placement during therapeutic bronchoscopy for malignant airway disease significantly increases the risk of lower respiratory tract infections, suggesting a need for careful consideration before stenting.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec11_Article (9)">
  <title>Safety and Efficacy of the Tracheobronchial Bonastent: A Single-Center Case Series</title>
  <authors>Van Kim Holden, Daniel Ospina-Delgado, Alex Chee, Mihir S. Parikh, Megan M. Carreiro, Daniel Alape Moya, Sebastian Fernandez-Bussy, Felix J.F. Herth, Adnan Majid</authors>
  <citation>Holden V.K., Ospina-Delgado D., Chee A., Parikh M.S., Carreiro M.M., Alape Moya D., Fernandez-Bussy S., Herth F.J.F., Majid A. Safety and Efficacy of the Tracheobronchial Bonastent: A Single-Center Case Series. Respiration. 2020;99:353–359.</citation>
  <type>Research Article</type>
  <year>2020</year>
  <keywords>
    <keyword>Airway obstruction</keyword>
    <keyword>Airway stent</keyword>
    <keyword>Rigid bronchoscopy</keyword>
  </keywords>
  <summary>
    This study presents the largest case series of tracheobronchial Bonastent placement, evaluating its efficacy and complication rates in patients with central airway obstruction and tracheoesophageal fistulae. The results indicate that the Bonastent is effective for symptom relief with an acceptable safety profile, although there is a notable complication rate, particularly in the long-term.
  </summary>
  <pico>
    <population>Adult patients with central airway obstruction and tracheoesophageal fistulae</population>
    <intervention>Placement of tracheobronchial Bonastent</intervention>
    <comparison>Not applicable (case series)</comparison>
    <outcome>Improvement in respiratory symptoms and complication rates</outcome>
  </pico>
  <take_home>The tracheobronchial Bonastent is effective for treating central airway obstruction with an acceptable safety profile, but careful monitoring for complications is necessary.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec12_Article (1)">
  <title>Intrabronchial Valves for Air Leaks After Lobectomy, Segmentectomy, and Lung Volume Reduction Surgery</title>
  <authors>Abu-Hijleh, Muhanned; Styrvoky, Kim; Anand, Vikram; Woll, Fernando; Yarmus, Lonny; Machuzak, Michael S.; Nader, Daniel A.; Mullett, Timothy W.; Hogarth, D. Kyle; Toth, Jennifer W.; Acash, Ghazwan; Casal, Roberto F.; Hazelrigg, Stephen; Wood, Douglas E.</authors>
  <citation>Abu-Hijleh M., Styrvoky K., Anand V., Woll F., Yarmus L., Machuzak M.S., Nader D.A., Mullett T.W., Hogarth D.K., Toth J.W., Acash G., Casal R.F., Hazelrigg S., Wood D.E. Intrabronchial Valves for Air Leaks After Lobectomy, Segmentectomy, and Lung Volume Reduction Surgery. Lung. 2019;197(5):627–633.</citation>
  <type>Research Article</type>
  <year>2019</year>
  <keywords>
    <keyword>Intrabronchial valve</keyword>
    <keyword>Persistent air leak</keyword>
    <keyword>Interventional pulmonary</keyword>
    <keyword>Broncho-pleural fistula</keyword>
    <keyword>Alveolar-pleural fistula</keyword>
  </keywords>
  <summary>
    This study evaluates the effectiveness of the Spiration Valve System (SVS) in managing persistent air leaks following lobectomy, segmentectomy, and lung volume reduction surgery. The results indicate that bronchoscopic placement of SVS is feasible and effective in resolving air leaks, significantly reducing hospital stay and morbidity.
  </summary>
  <pico>
    <population>Patients with air leaks after lobectomy, segmentectomy, and lung volume reduction surgery</population>
    <intervention>Bronchoscopic placement of Spiration Valve System (SVS)</intervention>
    <comparison>Not applicable (single-arm study)</comparison>
    <outcome>Resolution of air leaks, length of hospital stay, and positive response rates to SVS placement</outcome>
  </pico>
  <take_home>Bronchoscopic SVS placement is a feasible and effective intervention for managing persistent air leaks post-surgery, with a high success rate and reduced hospital stays.</take_home>
  <embedding_file>https://doi.org/10.1007/s00408-019-00268-7</embedding_file>
</article>
```
```xml
<article id="sec12_Article (10)">
  <title>Combined airway and oesophageal stenting in malignant airway–oesophageal fistulas: a prospective study</title>
  <authors>F.J.F. Herth, S. Peter, F. Baty, R. Eberhardt, J.D. Leuppi, P.N. Chhajed</authors>
  <citation>Herth F.J.F., Peter S., Baty F., Eberhardt R., Leuppi J.D., Chhajed P.N. Combined airway and oesophageal stenting in malignant airway–oesophageal fistulas: a prospective study. Eur Respir J. 2010;36(6):1370–1374.</citation>
  <type>Research Article</type>
  <year>2010</year>
  <keywords>
    <keyword>Lung cancer</keyword>
    <keyword>oesophageal cancer</keyword>
    <keyword>palliative therapy</keyword>
    <keyword>self-expandable metallic stents</keyword>
    <keyword>tracheo-oesophageal fistula</keyword>
  </keywords>
  <summary>
    This study investigates the impact of combined airway and oesophageal stenting on quality of life (QoL) and survival in patients with malignant airway–oesophageal fistulas (AEF). It includes 112 patients, primarily with advanced lung cancer, and assesses the effectiveness of stenting on improving QoL and survival outcomes.
  </summary>
  <pico>
    <population>112 patients with malignant airway–oesophageal fistulas, primarily due to advanced lung or oesophageal cancer.</population>
    <intervention>Insertion of airway and/or oesophageal self-expandable metallic stents.</intervention>
    <comparison>Comparison of survival and QoL scores among patients receiving airway stents, oesophageal stents, and both.</comparison>
    <outcome>Improvement in QoL scores and survival times, with specific factors influencing outcomes identified.</outcome>
  </pico>
  <take_home>Airway and/or oesophageal stent insertion significantly improves quality of life and survival in patients with malignant AEF.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec12_Article (11)">
  <title>The treatment strategy for tracheoesophageal fistula</title>
  <authors>Ke, M.; Wu, X.; Zeng, J.</authors>
  <citation>Ke, M., Wu, X., Zeng, J. The treatment strategy for tracheoesophageal fistula. J Thorac Dis. 2015;7(Suppl 4):S389-S397.</citation>
  <type>Review Article</type>
  <year>2015</year>
  <keywords>
    <keyword>Tracheoesophageal fistula (TEF)</keyword>
    <keyword>interventional therapy</keyword>
    <keyword>airway stenting</keyword>
    <keyword>esophageal stenting</keyword>
    <keyword>efficacy</keyword>
  </keywords>
  <summary>
    This review discusses the advancements in the treatment of tracheoesophageal fistula (TEF), particularly focusing on interventional therapies such as airway stenting. It highlights the challenges posed by advanced malignancies and the limitations of surgical options, advocating for bronchoscopic interventions as effective palliation methods. The authors present various techniques, case studies, and outcomes of airway stenting, emphasizing the importance of personalized treatment strategies.
  </summary>
  <pico>
    <population>Patients with tracheoesophageal fistula, particularly those with advanced malignancies</population>
    <intervention>Airway stenting and esophageal stenting</intervention>
    <comparison>Surgical interventions and general treatments</comparison>
    <outcome>Improvement in symptoms, quality of life, and closure of the fistula</outcome>
  </pico>
  <take_home>Airway stenting is a highly effective palliative treatment for tracheoesophageal fistula, significantly improving patient quality of life and providing a viable alternative when surgical options are limited.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec12_Article (12)">
  <title>Management of tracheo-oesophageal fistula in adults</title>
  <authors>Hyun S. Kim, Danai Khemasuwan, Javier Diaz-Mendoza, Atul C. Mehta</authors>
  <citation>Kim HS, Khemasuwan D, Diaz-Mendoza J, et al. Management of tracheo-oesophageal fistula in adults. Eur Respir Rev. 2020;29:200094.</citation>
  <type>Review</type>
  <year>2020</year>
  <keywords>
    <keyword>tracheo-oesophageal fistula</keyword>
    <keyword>management</keyword>
    <keyword>stenting</keyword>
    <keyword>interventional pulmonology</keyword>
    <keyword>malignancies</keyword>
  </keywords>
  <summary>
    This review article discusses the complexities of managing tracheo-oesophageal fistula (TOF) in adults, highlighting its various underlying causes, diagnostic challenges, and therapeutic strategies. It emphasizes the role of stenting as a cornerstone in treatment while also exploring novel techniques and future directions in management.
  </summary>
  <pico>
    <population>Adults with tracheo-oesophageal fistula</population>
    <intervention>Stenting and novel therapeutic methods</intervention>
    <comparison>Traditional management approaches</comparison>
    <outcome>Improved management strategies and patient outcomes</outcome>
  </pico>
  <take_home>Multidisciplinary approaches and individualized treatment strategies are crucial for effective management of TOF, particularly in the context of malignancies.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec12_Article (13)">
  <title>Persistent air leaks: a review with an emphasis on bronchoscopic management</title>
  <authors>Lazarus, D.R.; Casal, R.F.</authors>
  <citation>Lazarus, D.R., Casal, R.F. Persistent air leaks: a review with an emphasis on bronchoscopic management. J Thorac Dis. 2017;9(11):4660-4670.</citation>
  <type>Review</type>
  <year>2017</year>
  <keywords>
    <keyword>Persistent air leak (PAL)</keyword>
    <keyword>bronchopleural fistula (BPF)</keyword>
    <keyword>alveolar-pleural fistula</keyword>
    <keyword>intrabronchial valves (IBVs)</keyword>
    <keyword>pleurodesis</keyword>
  </keywords>
  <summary>
    This article reviews the management of persistent air leaks (PAL), particularly focusing on bronchoscopic techniques. It discusses the challenges of PAL, its definitions, causes, incidence, and various management strategies including conservative, surgical, medical pleurodesis, and innovative bronchoscopic approaches. The authors emphasize the role of bronchoscopic interventions, especially the use of one-way valves, in patients unsuitable for surgery.
  </summary>
  <pico>
    <population>Patients with persistent air leaks after lung surgery or pneumothorax</population>
    <intervention>Bronchoscopic management techniques including the use of sealants, sclerosants, and one-way valves</intervention>
    <comparison>Conservative management, surgical management, and medical pleurodesis</comparison>
    <outcome>Effectiveness of bronchoscopic techniques in resolving air leaks and reducing morbidity and healthcare costs</outcome>
  </pico>
  <take_home>The article highlights the increasing importance of bronchoscopic techniques, particularly one-way valves, in managing persistent air leaks, especially for patients who are not surgical candidates.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec12_Article (14)">
  <title>Neoadjuvant therapy and risk of bronchopleural fistula after lung cancer surgery: a systematic meta-analysis of 14 912 patients</title>
  <authors>Shuangjiang Li, Jun Fan, Jing Liu, Jian Zhou, Yutao Ren, Cheng Shen, Guowei Che</authors>
  <citation>Li S, Fan J, Liu J, Zhou J, Ren Y, Shen C, Che G. Neoadjuvant therapy and risk of bronchopleural fistula after lung cancer surgery: a systematic meta-analysis of 14 912 patients. Japanese Journal of Clinical Oncology. 2016;46(6):534–546.</citation>
  <type>Original Article</type>
  <year>2016</year>
  <keywords>
    <keyword>neoadjuvant therapy</keyword>
    <keyword>bronchopleural fistula</keyword>
    <keyword>lung cancer surgery</keyword>
    <keyword>meta-analysis</keyword>
  </keywords>
  <summary>
    This systematic meta-analysis evaluates the association between neoadjuvant therapy (NT) and the risk of bronchopleural fistula (BPF) in patients undergoing lung cancer surgery. The analysis included 30 studies with a total of 14,912 patients, revealing that NT significantly increases the risk of BPF, particularly with neoadjuvant radiotherapy and chemoradiation, while neoadjuvant chemotherapy alone did not show a significant increase in risk.
  </summary>
  <pico>
    <population>Patients undergoing lung cancer surgery</population>
    <intervention>Neoadjuvant therapy</intervention>
    <comparison>Surgery without neoadjuvant therapy</comparison>
    <outcome>Risk of bronchopleural fistula</outcome>
  </pico>
  <take_home>Neoadjuvant therapy is significantly associated with an increased risk of bronchopleural fistula after lung cancer surgery, especially with radiotherapy and chemoradiation.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec12_Article (15)">
  <title>Risk factor of bronchopleural fistula after general thoracic surgery: review article</title>
  <authors>Masaya Okuda, Tetsuhiko Go, Hiroyasu Yokomise</authors>
  <citation>Okuda M, Go T, Yokomise H. Risk factor of bronchopleural fistula after general thoracic surgery: review article. Gen Thorac Cardiovasc Surg. 2017;65:679–685.</citation>
  <type>Review Article</type>
  <year>2017</year>
  <keywords>
    <keyword>Bronchopleural Fistula</keyword>
    <keyword>Thoracic Surgery</keyword>
    <keyword>Risk Factors</keyword>
    <keyword>Lung Resection</keyword>
    <keyword>Neoadjuvant Therapy</keyword>
  </keywords>
  <summary>
    This article reviews recent literature on risk factors for bronchopleural fistula (BPF) after anatomical lung resection. It highlights significant risk factors identified in studies published between 2006 and 2016, including surgical procedures, patient demographics, and preoperative therapies. The findings suggest that while some risk factors have been consistent over time, ongoing research is essential as surgical techniques and therapies evolve.
  </summary>
  <pico>
    <population>Adults undergoing anatomical lung resection</population>
    <intervention>Review of risk factors for bronchopleural fistula</intervention>
    <comparison>Comparison of recent studies with older reports</comparison>
    <outcome>Identification of significant risk factors for BPF</outcome>
  </pico>
  <take_home>Bronchopleural fistula remains a severe complication after lung surgery, with several identified risk factors, including neoadjuvant therapy and surgical approach. Continuous monitoring and research are necessary to adapt to evolving surgical practices.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec12_Article (16)">
  <title>Interventionelle Versorgung tracheo-/bronchoösophagealer Fisteln</title>
  <authors>Schweigert, M.</authors>
  <citation>Schweigert, M. Interventionelle Versorgung tracheo-/bronchoösophagealer Fisteln. Der Chirurg. 2019;90(7):710–721.</citation>
  <type>Review</type>
  <year>2019</year>
  <keywords>
    <keyword>Tracheoösophageale Fisteln</keyword>
    <keyword>Endoskopie</keyword>
    <keyword>Bronchoskopie</keyword>
    <keyword>Stent</keyword>
    <keyword>Therapie</keyword>
  </keywords>
  <summary>
    Der Artikel behandelt die interventionelle Versorgung von tracheoösophagealen Fisteln (TÖF), die eine abnormale Verbindung zwischen Ösophagus und Atemwegen darstellen. Es werden die Ätiologie, Klassifikation, Epidemiologie, Symptome, Prognose und Therapieansätze für sowohl benigne als auch maligne Fisteln diskutiert. Die endoskopische Stentimplantation wird als bevorzugte Therapieoption hervorgehoben, insbesondere bei malignen Fisteln, während chirurgische Ansätze bei benignen Fisteln bevorzugt werden.
  </summary>
  <pico>
    <population>Patienten mit tracheoösophagealen Fisteln</population>
    <intervention>Endoskopische Stentimplantation</intervention>
    <comparison>Chirurgische Therapieansätze</comparison>
    <outcome>Verbesserung der Lebensqualität und Symptomlinderung</outcome>
  </pico>
  <take_home>Die endoskopische Therapie, insbesondere die Stentimplantation, ist die bevorzugte Methode zur Behandlung von tracheoösophagealen Fisteln, wobei die Wahl der Methode von der Ätiologie und dem Zustand des Patienten abhängt.</take_home>
  <embedding_file>https://doi.org/10.1007/s00104-019-0988-z</embedding_file>
</article>
```
```xml
<article id="sec12_Article (17)">
  <title>Endoscopic Management of Esophagorespiratory Fistulas: A Multicenter Retrospective Study of Techniques and Outcomes</title>
  <authors>Silon, B.; Siddiqui, A.A.; Taylor, L.J.; Arastu, S.; Soomro, A.; Adler, D.G.</authors>
  <citation>Silon, B., Siddiqui, A.A., Taylor, L.J., Arastu, S., Soomro, A., Adler, D.G. Endoscopic Management of Esophagorespiratory Fistulas: A Multicenter Retrospective Study of Techniques and Outcomes. Dig Dis Sci. 2017;62(2):424–431.</citation>
  <type>Original Article</type>
  <year>2017</year>
  <keywords>
    <keyword>Esophagorespiratory fistula</keyword>
    <keyword>Endoscopic treatment</keyword>
    <keyword>Technical success</keyword>
    <keyword>Clinical success</keyword>
    <keyword>Adverse events</keyword>
    <keyword>Quality of life</keyword>
  </keywords>
  <summary>
    This study evaluates the endoscopic management of esophagorespiratory fistulas (ERF) across multiple centers, analyzing technical and clinical success rates, as well as adverse events associated with various treatment modalities. The study found high technical success rates but lower clinical success rates, particularly for proximal ERF, highlighting the challenges in managing these complex cases.
  </summary>
  <pico>
    <population>Patients with esophagorespiratory fistulas undergoing endoscopic treatment</population>
    <intervention>Endoscopic interventions including stents, clips, and sutures</intervention>
    <comparison>Outcomes stratified by fistula etiology and location</comparison>
    <outcome>Technical success, clinical success, adverse events, and quality of life improvements</outcome>
  </pico>
  <take_home>The study supports the use of endoscopic interventions as a minimally invasive option for managing esophagorespiratory fistulas, though clinical success rates remain suboptimal, particularly for proximal fistulas.</take_home>
  <embedding_file>Embedding file not provided</embedding_file>
</article>
```
```xml
<article id="sec12_Article (18)">
  <title>Bronchoscopic advances in the management of aerodigestive fistulas</title>
  <authors>Houssein A. Youness; Kassem Harris; Ahmed Awab; Jean I. Keddissi</authors>
  <citation>Youness HA, Harris K, Awab A, Keddissi JI. Bronchoscopic advances in the management of aerodigestive fistulas. J Thorac Dis. 2018;10(9):5636-5647.</citation>
  <type>Review Article</type>
  <year>2018</year>
  <keywords>
    <keyword>Tracheo-esophageal fistula</keyword>
    <keyword>aerodigestive fistula (ADF)</keyword>
    <keyword>airway stent</keyword>
    <keyword>esophageal stent</keyword>
    <keyword>double stenting</keyword>
  </keywords>
  <summary>
    This article reviews the management strategies for malignant aerodigestive fistulas (ADF), particularly focusing on bronchoscopic and endoscopic techniques. It highlights the clinical significance of ADF, the challenges in treatment, and the latest advancements in stenting methods to improve patient outcomes.
  </summary>
  <pico>
    <population>Patients with malignant aerodigestive fistulas</population>
    <intervention>Bronchoscopic and endoscopic therapy, including airway and esophageal stenting</intervention>
    <comparison>Single stenting vs. double stenting</comparison>
    <outcome>Improvement in survival and quality of life</outcome>
  </pico>
  <take_home>Management of malignant ADF through stenting significantly improves patient quality of life and survival, with double stenting showing promising results.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec12_Article (2)">
  <title>Airway Covered Metallic Stent Based on Different Fistula Location and Size in Malignant Tracheoesophageal Fistula</title>
  <authors>Wang, H.; Tao, M.; Zhang, N.; Li, D.; Zou, H.; Zhang, J.; Luo, L.; Ma, H.; Zhou, Y.</authors>
  <citation>Wang, H., Tao, M., Zhang, N., Li, D., Zou, H., Zhang, J., Luo, L., Ma, H., Zhou, Y. Airway Covered Metallic Stent Based on Different Fistula Location and Size in Malignant Tracheoesophageal Fistula. Am J Med Sci. 2015;350(5):364–368.</citation>
  <type>Clinical Investigation</type>
  <year>2015</year>
  <keywords>
    <keyword>Malignant Tracheoesophageal Fistula</keyword>
    <keyword>Airway Stent</keyword>
    <keyword>Palliative Care</keyword>
    <keyword>Quality of Life</keyword>
    <keyword>Karnofsky Score</keyword>
  </keywords>
  <summary>
    This study investigates the effectiveness of airway covered metallic stent insertion in patients with malignant tracheoesophageal fistula (MTEF) based on the location and size of the fistula. The results indicate that stent placement can significantly improve symptoms and quality of life, with a high rate of closure achieved in patients.
  </summary>
  <pico>
    <population>63 patients with malignant tracheoesophageal fistula, including those with esophageal and lung cancers</population>
    <intervention>Insertion of airway covered metallic stents</intervention>
    <comparison>Not applicable (retrospective study)</comparison>
    <outcome>Improvement in symptoms, quality of life (Karnofsky score), and median survival time</outcome>
  </pico>
  <take_home>Airway stent insertion is an effective palliative treatment for malignant tracheoesophageal fistula, improving symptoms and quality of life based on fistula location and size.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec12_Article (3)">
  <title>Airway Ultraflex Stenting in Esophageal Cancer with Esophagorespiratory Fistula</title>
  <authors>Chung, F-T.; Lin, H-C.; Chou, C-L.; Chen, H-C.; Kuo, C-H.; Yu, C-T.; Lin, S-M.; Kuo, H-P.</authors>
  <citation>Chung, F-T., Lin, H-C., Chou, C-L., Chen, H-C., Kuo, C-H., Yu, C-T., Lin, S-M., Kuo, H-P. Airway Ultraflex Stenting in Esophageal Cancer with Esophagorespiratory Fistula. Am J Med Sci. 2012;344(2):105–109.</citation>
  <type>Clinical Investigation</type>
  <year>2012</year>
  <keywords>
    <keyword>Airway Ultraflex stents</keyword>
    <keyword>Esophageal cancer</keyword>
    <keyword>Esophagorespiratory fistula</keyword>
    <keyword>Outcomes</keyword>
  </keywords>
  <summary>
    This study evaluates the clinical effects of airway ultraflex stenting as a treatment for esophagorespiratory fistula (ERF) caused by esophageal cancer. The research indicates that stenting improves survival rates compared to patients without stenting, despite the overall poor prognosis associated with ERF.
  </summary>
  <pico>
    <population>Patients with esophageal cancer and esophagorespiratory fistula</population>
    <intervention>Airway ultraflex stenting</intervention>
    <comparison>No airway stenting</comparison>
    <outcome>Improved survival rates</outcome>
  </pico>
  <take_home>Airway ultraflex stenting can improve survival in patients with esophagorespiratory fistula due to esophageal cancer, offering an alternative for those unsuitable for surgical intervention.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec12_Article (4)">
  <title>Management of air leaks post-surgical lung resection</title>
  <authors>Bronstein, M.E.; Koo, D.C.; Weigel, T.L.</authors>
  <citation>Bronstein M.E., Koo D.C., Weigel T.L. Management of air leaks post-surgical lung resection. Ann Transl Med. 2019;7(15):361.</citation>
  <type>Review Article</type>
  <year>2019</year>
  <keywords>
    <keyword>Persistent air leak (PAL)</keyword>
    <keyword>elective lung resection</keyword>
    <keyword>bronchopleural fistula (BPF)</keyword>
    <keyword>fibrin sealant</keyword>
    <keyword>pleurodesis</keyword>
    <keyword>endobronchial valve (EBV)</keyword>
    <keyword>pleuravac</keyword>
  </keywords>
  <summary>
    This review discusses the management of air leaks, a common complication following elective lung resection. It covers various interventions, including conservative noninvasive methods, fibrin patches, pleurodesis, endobronchial valves, and surgical options. The article emphasizes the importance of timely intervention to improve patient outcomes and reduce hospital stays.
  </summary>
  <pico>
    <population>Patients undergoing elective lung resection</population>
    <intervention>Management strategies for persistent air leaks</intervention>
    <comparison>Conservative management vs. surgical interventions</comparison>
    <outcome>Resolution of air leaks and patient recovery</outcome>
  </pico>
  <take_home>Effective management of persistent air leaks post-lung resection includes a range of strategies from conservative approaches to surgical interventions, tailored to individual patient needs.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec12_Article (5)">
  <title>Endoscopic treatment of nonmalignant tracheoesophageal and bronchoesophageal fistula: results and prognostic factors for its success</title>
  <authors>Antoine Debourdeau, Jean‑Michel Gonzalez, Hervé Dutau, Alban Benezech, Marc Barthet</authors>
  <citation>Debourdeau A, Gonzalez J-M, Dutau H, Benezech A, Barthet M. Endoscopic treatment of nonmalignant tracheoesophageal and bronchoesophageal fistula: results and prognostic factors for its success. Surgical Endoscopy. 2019;33(3):549–556.</citation>
  <type>Research Article</type>
  <year>2019</year>
  <keywords>
    <keyword>Tracheoesophageal fistula</keyword>
    <keyword>SEMS</keyword>
    <keyword>Esophageal stenting</keyword>
    <keyword>Endotherapy</keyword>
    <keyword>Post-surgical complications</keyword>
    <keyword>Radiation therapy</keyword>
    <keyword>Esophagectomy</keyword>
  </keywords>
  <summary>
    This study investigates the outcomes and prognostic factors associated with the endoscopic treatment of nonmalignant esophago-respiratory fistulas (ERF). A retrospective analysis of 22 patients treated between 2012 and 2016 was conducted, documenting the success rates of various endoscopic interventions and identifying factors influencing treatment outcomes.
  </summary>
  <pico>
    <population>Patients with nonmalignant esophago-respiratory fistulas</population>
    <intervention>Endoscopic treatment including stent placement and over-the-scope clips</intervention>
    <comparison>Not applicable (retrospective study)</comparison>
    <outcome>Success rates of fistula closure and functional outcomes</outcome>
  </pico>
  <take_home>The endoscopic treatment of nonmalignant ERF shows a 45.5% success rate in closure and highlights that the size of the fistula orifice significantly impacts treatment outcomes. Fistulas that do not close after 6 months have a poor prognosis.</take_home>
  <embedding_file>https://doi.org/10.1007/s00464-018-6330-x</embedding_file>
</article>
```
```xml
<article id="sec12_Article (6)">
  <title>Pleural gas analysis for the identification of alveolopleural fistulae</title>
  <authors>Ramiro Fernandez, A.B.; Ankit Bharat, C.D.</authors>
  <citation>Fernandez R, Bharat A. Pleural gas analysis for the identification of alveolopleural fistulae. Curr Opin Pulm Med. 2016;22(4):362–366.</citation>
  <type>Review</type>
  <year>2016</year>
  <keywords>
    <keyword>alveolopleural fistula</keyword>
    <keyword>pleural hypercarbia</keyword>
    <keyword>lung healing</keyword>
    <keyword>air leak</keyword>
  </keywords>
  <summary>
    This article discusses a novel technique for identifying alveolopleural fistulae (APF) through pleural gas analysis, which demonstrates higher sensitivity and specificity compared to traditional visual inspection methods. The authors highlight the impact of intrapleural gas composition on lung healing and propose that reducing intrapleural carbon dioxide can facilitate the resolution of APF.
  </summary>
  <pico>
    <population>Patients undergoing lung surgery</population>
    <intervention>Pleural gas analysis for detecting alveolopleural fistulae</intervention>
    <comparison>Visual inspection of air bubbles in chest drainage systems</comparison>
    <outcome>Improved accuracy in identifying APF, reduced duration of air leaks, and enhanced lung healing</outcome>
  </pico>
  <take_home>Pleural gas analysis is a more reliable method for identifying alveolopleural fistulae, which can lead to better management of chest tubes and improved patient outcomes after lung surgery.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec12_Article (7)">
  <title>Unidirectional endobronchial valves for management of persistent air-leaks: results of a multicenter study</title>
  <authors>Fiorelli, A.; D’Andrilli, A.; Cascone, R.; Occhiati, L.; Anile, M.; Diso, D.; Cassiano, F.; Poggi, C.; Ibrahim, M.; Cusumano, G.; Terminella, A.; Failla, G.; La Sala, A.; Bezzi, M.; Innocenti, M.; Torricelli, E.; Venuta, F.; Rendina, E.A.; Vicidomini, G.; Santini, M.; Andreetti, C.</authors>
  <citation>Fiorelli A, D’Andrilli A, Cascone R, et al. Unidirectional endobronchial valves for management of persistent air-leaks: results of a multicenter study. J Thorac Dis. 2018;10(11):6158-6167.</citation>
  <type>Original Article</type>
  <year>2018</year>
  <keywords>
    <keyword>Endobronchial valves</keyword>
    <keyword>Persistent air-leak</keyword>
    <keyword>Bronchoscopy</keyword>
    <keyword>Alveolar-pleural fistula</keyword>
  </keywords>
  <summary>
    This multicenter study evaluated the efficacy and cost-effectiveness of unidirectional endobronchial valves (EBVs) in treating persistent air-leaks (PALs) due to alveolar-pleural fistula. The study included 74 patients with severe air leaks refractory to standard treatments. Results showed that 88% of patients achieved complete resolution of air leaks after EBV treatment, significantly reducing the duration of air leaks, the time to chest tube removal, and length of hospital stay. While the procedural costs were high, the reduction in hospitalization costs suggested potential cost-effectiveness.
  </summary>
  <pico>
    <population>Patients with persistent air leaks due to alveolar-pleural fistula</population>
    <intervention>Endobronchial valve treatment</intervention>
    <comparison>No valve treatment (standard care)</comparison>
    <outcome>Resolution of air leaks, length of hospital stay, procedural costs</outcome>
  </pico>
  <take_home>The use of endobronchial valves is effective for managing persistent air leaks, potentially reducing overall hospitalization costs despite high procedural costs.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec12_Article (8)">
  <title>Treatment of Tracheobronchial Injuries: A Contemporary Review</title>
  <authors>Harpreet Singh Grewal, MD; Neha S. Dangayach, MD; Usman Ahmad, MD; Subha Ghosh, MD; Thomas Gildea, MD; Atul C. Mehta, MD, FCCP</authors>
  <citation>Grewal HS, Dangayach NS, Ahmad U, Ghosh S, Gildea T, Mehta AC. Treatment of Tracheobronchial Injuries: A Contemporary Review. CHEST. 2019;155(3):595-604.</citation>
  <type>Review Article</type>
  <year>2019</year>
  <keywords>
    <keyword>Tracheobronchial injury</keyword>
    <keyword>Minimally invasive treatment</keyword>
    <keyword>Trauma</keyword>
    <keyword>Iatrogenic injury</keyword>
    <keyword>Management strategies</keyword>
  </keywords>
  <summary>
    This article reviews the management of tracheobronchial injuries, which can occur from trauma or iatrogenic causes. It discusses the shift from traditional surgical approaches to minimally invasive techniques such as endobronchial stenting, highlighting the importance of early recognition and multidisciplinary management to improve patient outcomes.
  </summary>
  <pico>
    <population>Patients with tracheobronchial injuries</population>
    <intervention>Minimally invasive techniques (e.g., endobronchial stent placement)</intervention>
    <comparison>Traditional surgical approaches</comparison>
    <outcome>Improved management outcomes and reduced morbidity</outcome>
  </pico>
  <take_home>Minimally invasive techniques are increasingly effective for managing tracheobronchial injuries, especially in patients who are poor surgical candidates, and should be considered before opting for surgical intervention.</take_home>
  <embedding_file>https://doi.org/10.1016/j.chest.2018.07.018</embedding_file>
</article>
```
```xml
<article id="sec12_Article (9)">
  <title>Customized airway stenting for bronchopleural fistula after pulmonary resection by interventional technique: single-center study of 148 consecutive patients</title>
  <authors>Xinwei Han; Meipan Yin; Lei Li; Ming Zhu; Kewei Ren; Yu Qi; Xiangnan Li; Gang Wu</authors>
  <citation>Han X., Yin M., Li L., Zhu M., Ren K., Qi Y., Li X., Wu G. Customized airway stenting for bronchopleural fistula after pulmonary resection by interventional technique: single-center study of 148 consecutive patients. Surgical Endoscopy. 2018;32(11):4116–4124.</citation>
  <type>Research Article</type>
  <year>2018</year>
  <keywords>
    <keyword>Bronchopleural fistula</keyword>
    <keyword>Pulmonary resection</keyword>
    <keyword>Airway stenting</keyword>
    <keyword>Interventional radiology</keyword>
  </keywords>
  <summary>
    This study evaluates the efficacy and safety of customized airway stenting in treating bronchopleural fistulas following pulmonary resection. A total of 148 patients were treated, with a high technical success rate of 96.6%. The study emphasizes the importance of individualized stent design based on anatomical considerations and reports significant improvements in symptoms and quality of life post-treatment.
  </summary>
  <pico>
    <population>Patients with bronchopleural fistulas after pulmonary resection</population>
    <intervention>Customized airway stenting</intervention>
    <comparison>Conventional treatment methods (e.g., thoracic drainage, surgical repair)</comparison>
    <outcome>Technical success rate, symptom relief, and complication rates</outcome>
  </pico>
  <take_home>Customized airway stenting is a feasible and effective technique for managing bronchopleural fistulas, offering high success rates and improved patient outcomes compared to traditional methods.</take_home>
  <embedding_file>https://doi.org/10.1007/s00464-018-6152-x</embedding_file>
</article>
```
<article id="sec13_Article (1)">
  <title>A Randomized Study of Endobronchial Valves for Advanced Emphysema</title>
  <authors>Sciurba, F.C.; Ernst, A.; Herth, F.J.F.; Strange, C.; Criner, G.J.; Marquette, C.H.; Kovitz, K.L.; Chiacchierini, R.P.; Goldin, J.; McLennan, G.</authors>
  <citation>Sciurba, F.C., Ernst, A., Herth, F.J.F., et al. A Randomized Study of Endobronchial Valves for Advanced Emphysema. N Engl J Med. 2010;363:1233-44.</citation>
  <type>Original Article</type>
  <year>2010</year>
  <keywords>
    <keyword>Endobronchial valves</keyword>
    <keyword>Advanced emphysema</keyword>
    <keyword>Forced expiratory volume</keyword>
    <keyword>6-minute walk test</keyword>
    <keyword>Chronic obstructive pulmonary disease</keyword>
  </keywords>
  <summary>
    This study evaluates the safety and efficacy of endobronchial valve therapy in patients with heterogeneous emphysema compared to standard medical care. The results indicate modest improvements in lung function and exercise tolerance with an increased risk of complications post-therapy.
  </summary>
  <pico>
    <population>Patients with advanced heterogeneous emphysema</population>
    <intervention>Endobronchial valve therapy</intervention>
    <comparison>Standard medical care</comparison>
    <outcome>Changes in forced expiratory volume (FEV1) and 6-minute walk test results</outcome>
  </pico>
  <take_home>Endobronchial valve therapy can improve lung function and exercise tolerance in advanced emphysema patients, but it is associated with a higher rate of complications.</take_home>
  <embedding_file>sec13_Article (1)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec13_Article (2)">
  <title>Consolidating Lung Volume Reduction Surgery After Endoscopic Lung Volume Reduction Failure</title>
  <authors>Eichhorn, M.E.; Gompelmann, D.; Hoffmann, H.; Dreher, S.; Hornemann, K.; Haag, J.; Kontogianni, K.; Heussel, C.P.; Winter, H.; Herth, F.J.F.; Eberhardt, R.</authors>
  <citation>Eichhorn, M.E., Gompelmann, D., Hoffmann, H., et al. Consolidating Lung Volume Reduction Surgery After Endoscopic Lung Volume Reduction Failure. Ann Thorac Surg. 2021;111:1858-66.</citation>
  <type>Research Article</type>
  <year>2021</year>
  <keywords>
    <keyword>Lung Volume Reduction Surgery</keyword>
    <keyword>Endoscopic Lung Volume Reduction</keyword>
    <keyword>Emphysema</keyword>
    <keyword>Bronchoscopic Valve Placement</keyword>
  </keywords>
  <summary>
    This study investigates the outcomes of consolidating lung volume reduction surgery (LVRS) performed by lobectomy in patients who experienced long-term failure of endoscopic lung volume reduction (ELVR) therapy. The research highlights significant improvements in lung function, exercise capacity, and quality of life in the selected patient cohort.
  </summary>
  <pico>
    <population>Patients with severe heterogeneous emphysema who failed ELVR therapy</population>
    <intervention>Consolidating lung volume reduction surgery (LVRS) by lobectomy</intervention>
    <comparison>Outcomes before and after LVRS</comparison>
    <outcome>Improvements in forced expiratory volume in 1 second, residual volume, exercise capacity, and dyspnea relief</outcome>
  </pico>
  <take_home>Consolidating LVRS after ELVR failure is feasible and leads to significant improvements in lung function and quality of life for selected patients with emphysema.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
```xml
<article id="sec13_Article (3)">
  <title>Lung Volume Reduction Surgery Since the National Emphysema Treatment Trial: Study of Society of Thoracic Surgeons Database</title>
  <authors>Marquita R. Decker, MD, MPH; Glen E. Leverson, PhD; Wassim Abi Jaoude, MD; James D. Maloney, MD</authors>
  <citation>Decker MR, Leverson GE, Abi Jaoude W, Maloney JD. Lung Volume Reduction Surgery Since the National Emphysema Treatment Trial: Study of Society of Thoracic Surgeons Database. J Thorac Cardiovasc Surg. 2014;148(6):2651–2658.e1.</citation>
  <type>Research Article</type>
  <year>2014</year>
  <keywords>
    <keyword>Lung volume reduction</keyword>
    <keyword>Emphysema</keyword>
    <keyword>Outcomes</keyword>
    <keyword>Database</keyword>
  </keywords>
  <summary>
    This study evaluates lung volume reduction surgery (LVRS) outcomes on a national level since the National Emphysema Treatment Trial (NETT) using data from the Society of Thoracic Surgeons (STS) Database. It highlights the evolution of surgical techniques, patient demographics, and outcomes, emphasizing the need for improved patient selection and benchmarks for mortality rates.
  </summary>
  <pico>
    <population>Patients undergoing lung volume reduction surgery for emphysema in the STS database from January 2003 to June 2011.</population>
    <intervention>Lung volume reduction surgery (LVRS).</intervention>
    <comparison>Outcomes compared to patients from the National Emphysema Treatment Trial (NETT).</comparison>
    <outcome>30-day mortality rates and other postoperative complications.</outcome>
  </pico>
  <take_home>Patient selection is crucial for LVRS outcomes, and there is a need for consensus on mortality benchmarks post-surgery. Increased access to dedicated centers for advanced pulmonary disease treatment is essential.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec13_Article (4)">
  <title>Lung Volume Reduction Surgery on Extracorporeal Life Support</title>
  <authors>Tzafos, S.; Collaud, S.; Wilhelm, M.; Wieser, S.; Weder, W.; Inci, I.</authors>
  <citation>Tzafos, S., Collaud, S., Wilhelm, M., Wieser, S., Weder, W., Inci, I. Lung Volume Reduction Surgery on Extracorporeal Life Support. Ann Thorac Surg. 2017;103:e115–7.</citation>
  <type>Case Report</type>
  <year>2017</year>
  <keywords>
    <keyword>lung volume reduction surgery</keyword>
    <keyword>extracorporeal life support</keyword>
    <keyword>emphysema</keyword>
    <keyword>acute respiratory failure</keyword>
    <keyword>cor pulmonale</keyword>
  </keywords>
  <summary>
    This article presents a case of a 33-year-old man with severe emphysema and acute respiratory failure who underwent lung volume reduction surgery (LVRS) while on extracorporeal life support (ECLS). Despite the general contraindication for LVRS in acute respiratory failure, the patient experienced significant functional recovery post-surgery.
  </summary>
  <pico>
    <population>33-year-old man with severe emphysema and acute respiratory failure</population>
    <intervention>lung volume reduction surgery (LVRS)</intervention>
    <comparison>not applicable (case report)</comparison>
    <outcome>complete functional recovery after 4 months</outcome>
  </pico>
  <take_home>LVRS can be successfully performed in selected patients with acute respiratory failure on ECLS, leading to significant recovery.</take_home>
  <embedding_file>not applicable</embedding_file>
</article>
```
```xml
<article id="sec13_Article (5)">
  <title>Rationale and Design of the National Emphysema Treatment Trial: A Prospective Randomized Trial of Lung Volume Reduction Surgery</title>
  <authors>National Emphysema Treatment Trial Research Group</authors>
  <citation>NATIONAL EMPHYSEMA TREATMENT TRIAL RESEARCH GROUP. Rationale and Design of the National Emphysema Treatment Trial: A Prospective Randomized Trial of Lung Volume Reduction Surgery. CHEST. 1999;116:1750–1761.</citation>
  <type>Special Report</type>
  <year>1999</year>
  <keywords>
    <keyword>emphysema</keyword>
    <keyword>lung function</keyword>
    <keyword>lung volume reduction surgery</keyword>
    <keyword>maximum exercise capacity</keyword>
    <keyword>median sternotomy</keyword>
    <keyword>medical vs surgical treatment</keyword>
    <keyword>pulmonary rehabilitation</keyword>
    <keyword>randomized clinical trial</keyword>
    <keyword>video-assisted thoracoscopic surgery</keyword>
  </keywords>
  <summary>
    The National Emphysema Treatment Trial (NETT) is a multicenter, randomized clinical trial comparing medical therapy with medical therapy plus lung volume reduction surgery (LVRS) for patients with severe bilateral emphysema. The trial evaluates survival and maximum exercise capacity as primary outcomes, alongside various secondary measures including quality of life and healthcare utilization. The study aims to enroll 2,500 patients over 4.5 years to assess the efficacy and safety of LVRS.
  </summary>
  <pico>
    <population>Patients with severe bilateral emphysema</population>
    <intervention>Medical therapy plus lung volume reduction surgery (LVRS)</intervention>
    <comparison>Medical therapy alone</comparison>
    <outcome>Survival and maximum exercise capacity</outcome>
  </pico>
  <take_home>The NETT aims to clarify the role of lung volume reduction surgery in managing severe emphysema and to identify patient characteristics that may predict surgical benefit.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec14_Article (1)">
  <title>A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE)</title>
  <authors>Gerard J. Criner, Richard Sue, Shawn Wright, Mark Dransfield, Hiram Rivas-Perez, Tanya Wiese, Frank C. Sciurba, Pallav L. Shah, Momen M. Wahidi, Hugo Goulart de Oliveira, Brian Morrissey, Paulo F. G. Cardoso, Steven Hays, Adnan Majid, Nicholas Pastis, Jr., Lisa Kopas, Mark Vollenweider, P. Michael McFadden, Michael Machuzak, David W. Hsia, Arthur Sung, Nabil Jarad, Malgorzata Kornaszewska, Stephen Hazelrigg, Ganesh Krishna, Brian Armstrong, Narinder S. Shargill, Dirk-Jan Slebos</authors>
  <citation>Criner GJ, Sue R, Wright S, et al. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med. 2018;198(9):1151–1164.</citation>
  <type>Original Article</type>
  <year>2018</year>
  <keywords>
    <keyword>chronic obstructive pulmonary disease</keyword>
    <keyword>emphysema</keyword>
    <keyword>lung reduction</keyword>
    <keyword>Zephyr Endobronchial Valve</keyword>
    <keyword>randomized controlled trial</keyword>
  </keywords>
  <summary>
    This multicenter randomized controlled trial assessed the safety and effectiveness of the Zephyr Endobronchial Valve (EBV) in patients with heterogeneous emphysema and minimal collateral ventilation over 12 months. Results indicated significant improvements in lung function, exercise capacity, dyspnea, and quality of life in the EBV group compared to standard care, with an acceptable safety profile.
  </summary>
  <pico>
    <population>Patients with severe heterogeneous emphysema and minimal collateral ventilation</population>
    <intervention>Zephyr Endobronchial Valve treatment</intervention>
    <comparison>Standard of care (SoC)</comparison>
    <outcome>Improvement in post-bronchodilator FEV1, 6-minute walk distance, St. George’s Respiratory Questionnaire scores, and overall quality of life</outcome>
  </pico>
  <take_home>Zephyr EBV treatment provides significant clinical benefits in lung function and quality of life for patients with severe emphysema, with a manageable safety profile, making it a viable alternative to more invasive procedures.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec14_Article (10)">
  <title>Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation</title>
  <authors>Karin Klooster, Nick H.T. ten Hacken, M.D., Ph.D., Jorine E. Hartman, Ph.D., Huib A.M. Kerstjens, M.D., Ph.D., Eva M. van Rikxoort, Ph.D., Dirk-Jan Slebos, M.D., Ph.D.</authors>
  <citation>Klooster K, ten Hacken NHT, Hartman JE, Kerstjens HAM, van Rikxoort EM, Slebos DJ. Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. N Engl J Med. 2015;373:2325-35.</citation>
  <type>Original Article</type>
  <year>2015</year>
  <keywords>
    <keyword>Endobronchial valves</keyword>
    <keyword>Emphysema</keyword>
    <keyword>Collateral ventilation</keyword>
    <keyword>Bronchoscopic lung-volume reduction</keyword>
    <keyword>Pneumothorax</keyword>
  </keywords>
  <summary>
    This study evaluates the efficacy of endobronchial valves in patients with severe emphysema who lack interlobar collateral ventilation. The randomized controlled trial demonstrated significant improvements in pulmonary function and exercise capacity in the treatment group compared to standard care, despite a higher incidence of serious adverse events, particularly pneumothorax.
  </summary>
  <pico>
    <population>Patients with severe emphysema and confirmed absence of interlobar collateral ventilation</population>
    <intervention>Bronchoscopic endobronchial valve treatment</intervention>
    <comparison>Standard medical care</comparison>
    <outcome>Changes in FEV1, FVC, 6-minute walk distance, and quality of life</outcome>
  </pico>
  <take_home>Endobronchial valve treatment significantly improves lung function and exercise capacity in patients with severe emphysema without collateral ventilation, but carries risks of serious adverse events.</take_home>
  <embedding_file>NEJMoa1507807</embedding_file>
</article>
```
```xml
<article id="sec14_Article (11)">
  <title>Endoscopic Lung Volume Reduction: An Expert Panel Recommendation – Update 2019</title>
  <authors>Felix J.F. Herth; Dirk-Jan Slebos; Gerard J. Criner; Arschang Valipoure; Frank Sciurba; Pallav L. Shah</authors>
  <citation>Herth F.J.F., Slebos D.J., Criner G.J., Valipoure A., Sciurba F., Shah P.L. Endoscopic Lung Volume Reduction: An Expert Panel Recommendation – Update 2019. Respiration. 2019;97:548–557.</citation>
  <type>Review</type>
  <year>2019</year>
  <keywords>
    <keyword>Chronic obstructive pulmonary disease</keyword>
    <keyword>Emphysema</keyword>
    <keyword>Bronchoscopy</keyword>
    <keyword>Lung volume reduction</keyword>
    <keyword>Hyperinflation</keyword>
    <keyword>Expert statement</keyword>
  </keywords>
  <summary>
    This article provides an updated expert panel recommendation on endoscopic lung volume reduction (ELVR) therapies for patients with advanced emphysema. It discusses patient selection, treatment techniques, and the integration of new evidence from recent clinical trials, highlighting the benefits and safety of ELVR in improving patient outcomes.
  </summary>
  <pico>
    <population>Patients with advanced emphysema and severe hyperinflation</population>
    <intervention>Endoscopic lung volume reduction (ELVR) therapies, including endobronchial valves</intervention>
    <comparison>Standard medical therapy</comparison>
    <outcome>Improvements in lung function, exercise tolerance, dyspnea, and quality of life</outcome>
  </pico>
  <take_home>ELVR techniques offer significant benefits for patients with severe emphysema, especially those with hyperinflation, and should be considered as part of a comprehensive treatment plan.</take_home>
  <embedding_file>embedding_file_placeholder</embedding_file>
</article>
```
```xml
<article id="sec14_Article (12)">
  <title>One- to Four-Year Follow-Up of Endobronchial Lung Volume Reduction in Alpha-1-Antitrypsin Deficiency Patients: A Case Series</title>
  <authors>Gunnar Hillerdal; Stephanie Mindus</authors>
  <citation>Hillerdal G, Mindus S. One- to Four-Year Follow-Up of Endobronchial Lung Volume Reduction in Alpha-1-Antitrypsin Deficiency Patients: A Case Series. Respiration. 2014;88:320–328.</citation>
  <type>Research Article</type>
  <year>2014</year>
  <keywords>
    <keyword>α 1-Antitrypsin deficiency</keyword>
    <keyword>Bronchoscopy</keyword>
    <keyword>Emphysema</keyword>
    <keyword>Hyperinflation</keyword>
    <keyword>Lung function</keyword>
    <keyword>Lung volume reduction</keyword>
    <keyword>Single lung transplantation</keyword>
  </keywords>
  <summary>
    This study evaluates the long-term outcomes of endobronchial lung volume reduction (ELVR) in patients with severe emphysema due to alpha-1-antitrypsin (AAT) deficiency. It presents a case series of 15 patients treated with ELVR, highlighting improvements in lung function and quality of life over a follow-up period of up to four years.
  </summary>
  <pico>
    <population>Patients with homozygotic alpha-1-antitrypsin deficiency and severe heterogeneous emphysema</population>
    <intervention>Endobronchial lung volume reduction (ELVR) using one-way valves</intervention>
    <comparison>No direct comparison group; historical data referenced</comparison>
    <outcome>Improvement in forced expiratory volume (FEV1), quality of life, and reduction in oxygen therapy needs</outcome>
  </pico>
  <take_home>ELVR can be safely performed in carefully selected patients with AAT deficiency and severe emphysema, resulting in significant and lasting improvements in lung function and quality of life.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec14_Article (13)">
  <title>A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM)</title>
  <authors>Kemp, Samuel V.; Slebos, Dirk-Jan; Kirk, Alan; Kornaszewska, Malgorzata; Carron, Kris; Ek, Lars; Broman, Gustav; Hillerdal, Gunnar; Mal, Herve; Pison, Christophe; Briault, Amandine; Downer, Nicola; Darwiche, Kaid; Rao, Jagan; Hübner, Ralf-Harto; Ruwwe-Glosenkamp, Christof; Trosini-Desert, Valéry; Eberhardt, Ralf; Herth, Felix J.; Derom, Eric; Malfait, Thomas; Shah, Pallav L.; Garner, Justin L.; ten Hacken, Nick H.; Fallouh, Hazem; Leroy, Sylvie; Marquette, Charles H.</authors>
  <citation>Kemp, S. V., Slebos, D.-J., Kirk, A., Kornaszewska, M., Carron, K., Ek, L., Broman, G., Hillerdal, G., Mal, H., Pison, C., Briault, A., Downer, N., Darwiche, K., Rao, J., Hübner, R.-H., Ruwwe-Glosenkamp, C., Trosini-Desert, V., Eberhardt, R., Herth, F. J., Derom, E., Malfait, T., Shah, P. L., Garner, J. L., ten Hacken, N. H., Fallouh, H., Leroy, S., Marquette, C. H. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM). American Journal of Respiratory and Critical Care Medicine. 2017;196(12):1535-1543. https://doi.org/10.1164/rccm.201707-1327OC</citation>
  <type>Research Article</type>
  <year>2017</year>
  <keywords>
    <keyword>Endobronchial Valve</keyword>
    <keyword>Heterogeneous Emphysema</keyword>
    <keyword>Randomized Controlled Trial</keyword>
    <keyword>Lung Function</keyword>
    <keyword>Quality of Life</keyword>
    <keyword>Pneumothorax</keyword>
  </keywords>
  <summary>
    This study evaluates the efficacy and safety of Zephyr Endobronchial Valves (EBVs) in patients with heterogeneous emphysema and absence of collateral ventilation. The multicenter, randomized controlled trial demonstrated significant improvements in lung function, exercise tolerance, and quality of life for patients receiving EBVs compared to standard of care, with an acceptable safety profile.
  </summary>
  <pico>
    <population>Patients with severe heterogeneous emphysema and absence of collateral ventilation</population>
    <intervention>Zephyr Endobronchial Valve treatment</intervention>
    <comparison>Standard of care medical therapy</comparison>
    <outcome>Improvement in lung function (FEV1), exercise tolerance (6MWD), dyspnea (mMRC), and quality of life (SGRQ)</outcome>
  </pico>
  <take_home>The use of Zephyr Endobronchial Valves in patients with heterogeneous emphysema significantly improves lung function and quality of life compared to standard medical therapy, with manageable safety concerns primarily related to pneumothorax.</take_home>
  <embedding_file>https://doi.org/10.1164/rccm.201707-1327OC</embedding_file>
</article>
```
```xml
<article id="sec14_Article (14)">
  <title>One-Year Follow-Up after Endobronchial Valve Treatment in Patients with Emphysema without Collateral Ventilation Treated in the STELVIO Trial</title>
  <authors>Karin Klooster, Jorine E. Hartman, Nick H.T. ten Hacken, Dirk-Jan Slebos</authors>
  <citation>Klooster K, Hartman JE, ten Hacken NHT, Slebos DJ. One-Year Follow-Up after Endobronchial Valve Treatment in Patients with Emphysema without Collateral Ventilation Treated in the STELVIO Trial. Respiration. 2017;93:112–121.</citation>
  <type>Research Article</type>
  <year>2017</year>
  <keywords>
    <keyword>Chronic obstructive pulmonary disease</keyword>
    <keyword>Emphysema</keyword>
    <keyword>Bronchoscopy</keyword>
    <keyword>Bronchoscopic lung volume reduction</keyword>
    <keyword>One-way valve</keyword>
    <keyword>Collateral ventilation</keyword>
  </keywords>
  <summary>
    The study investigates the efficacy and safety of endobronchial valve (EBV) treatment for severe emphysema without collateral ventilation at a one-year follow-up, confirming significant improvements in lung function, exercise capacity, and quality of life.
  </summary>
  <pico>
    <population>Patients with severe emphysema and absence of interlobar collateral ventilation</population>
    <intervention>Endobronchial valve (EBV) treatment</intervention>
    <comparison>Control group from the STELVIO trial who crossed over to treatment</comparison>
    <outcome>Improvement in FEV1, RV, 6MWD, and SGRQ scores</outcome>
  </pico>
  <take_home>EBV treatment provides significant clinical benefits for carefully selected patients with severe emphysema, with sustained improvements in lung function and quality of life observed at one year.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec14_Article (15)">
  <title>Bronchoscopic Lung Volume Reduction with Endobronchial Zephyr Valves for Severe Emphysema: A Systematic Review and Meta-Analysis</title>
  <authors>Gonzalo Labarca, Juan Pablo Uribe, Cecilia Pacheco, Erik Folch, Fayez Kheir, Adnan Majid, Michael A. Jantz, Hiren J. Mehta, Neal Patel, Felix J.F. Herth, Sebastian Fernandez-Bussy</authors>
  <citation>Labarca G, Uribe JP, Pacheco C, Folch E, Kheir F, Majid A, Jantz MA, Mehta HJ, Patel N, Herth FJF, Fernandez-Bussy S. Bronchoscopic Lung Volume Reduction with Endobronchial Zephyr Valves for Severe Emphysema: A Systematic Review and Meta-Analysis. Respiration. 2019;98:268–278.</citation>
  <type>Review</type>
  <year>2019</year>
  <keywords>
    <keyword>Emphysema</keyword>
    <keyword>Endobronchial valve</keyword>
    <keyword>COPD</keyword>
  </keywords>
  <summary>
    This systematic review and meta-analysis evaluate the efficacy and safety of Zephyr® valves in patients with severe emphysema without collateral ventilation (CV). The analysis included 7 randomized controlled trials (RCTs) and showed significant improvements in forced expiratory volume in 1 second (FEV1), quality of life, and exercise capacity, although with an increased risk of pneumothorax.
  </summary>
  <pico>
    <population>Patients with severe emphysema without collateral ventilation</population>
    <intervention>Endobronchial Zephyr valve placement</intervention>
    <comparison>Sham valve or standard of care</comparison>
    <outcome>Change in FEV1, 6-min walking test (6MWT), St George’s Respiratory Questionnaire (SGRQ), and residual volume (RV)</outcome>
  </pico>
  <take_home>Zephyr valves provide significant improvements in lung function and quality of life for patients with severe emphysema without collateral ventilation, but they are associated with a higher risk of pneumothorax.</take_home>
  <embedding_file>sec14_Article (15)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec14_Article (16)">
  <title>The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema</title>
  <authors>Lia, S.; Wang, G.; Wang, C.; Gao, X.; Jin, F.; Yang, H.; Hang, B.; Zhou, R.; Chen, C.; Chen, L.; Bai, C.; Shen, H.; Herth, F.J.; Zhong, N.</authors>
  <citation>Lia, S., Wang, G., Wang, C., Gao, X., Jin, F., Yang, H., Hang, B., Zhou, R., Chen, C., Chen, L., Bai, C., Shen, H., Herth, F.J., Zhong, N. The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema. Respiration. 2019;97:416–427.</citation>
  <type>Randomized Controlled Trial</type>
  <year>2019</year>
  <keywords>
    <keyword>Chronic obstructive pulmonary disease</keyword>
    <keyword>Emphysema</keyword>
    <keyword>Bronchoscopic lung volume reduction</keyword>
    <keyword>Spiration® Valve System</keyword>
    <keyword>Endobronchial valves</keyword>
    <keyword>Intrabronchial valves</keyword>
  </keywords>
  <summary>
    The REACH trial is a multicenter, prospective, randomized controlled trial conducted in China to evaluate the safety and effectiveness of the Spiration® Valve System (SVS) compared to standard medical care in patients with severe emphysema. The trial included 107 subjects randomized to receive either SVS with medical management or medical management alone. Results showed significant improvements in forced expiratory volume (FEV1), target lobe volume reduction, exercise function, and quality of life in the treatment group, with an acceptable safety profile.
  </summary>
  <pico>
    <population>Patients with severe emphysema and chronic obstructive pulmonary disease (COPD)</population>
    <intervention>Spiration® Valve System (SVS) with medical management</intervention>
    <comparison>Standard medical management alone</comparison>
    <outcome>Improvement in forced expiratory volume, target lobe volume reduction, exercise function, and quality of life</outcome>
  </pico>
  <take_home>The Spiration® Valve System is a promising treatment for severe emphysema, demonstrating significant improvements in lung function and quality of life with an acceptable safety profile.</take_home>
  <embedding_file>REACH_Trial_Study_Data.pdf</embedding_file>
</article>
```
```xml
<article id="sec14_Article (17)">
  <title>Efficacy of the Spiration Valve System in Patients with Severe Heterogeneous Emphysema: A Systematic Review and Meta-Analysis</title>
  <authors>Adnan Majid, Gonzalo Labarca, Juan Pablo Uribe, Fayez Kheira, Cecilia Pacheco, Erik Folch, Michael A. Jantz, Hiren J. Mehta, Neal M. Patel, Felix J.F. Herth, Sebastian Fernandez-Bussy</authors>
  <citation>Majid A, Labarca G, Uribe JP, Kheira F, Pacheco C, Folch E, Jantz MA, Mehta HJ, Patel NM, Herth FJF, Fernandez-Bussy S. Efficacy of the Spiration Valve System in Patients with Severe Heterogeneous Emphysema: A Systematic Review and Meta-Analysis. Respiration. 2020;99:62–72.</citation>
  <type>Systematic Review and Meta-Analysis</type>
  <year>2020</year>
  <keywords>
    <keyword>Spiration Valve System</keyword>
    <keyword>Intrabronchial valve</keyword>
    <keyword>Endobronchial valves</keyword>
    <keyword>Bronchoscopic lung volume reduction</keyword>
    <keyword>Severe emphysema</keyword>
    <keyword>Chronic obstructive pulmonary disease</keyword>
  </keywords>
  <summary>
    This systematic review and meta-analysis evaluates the efficacy and safety of the Spiration Valve System (SVS) in patients with severe heterogeneous emphysema and hyperinflation. The analysis included four randomized controlled trials (RCTs) with a total of 629 subjects. The findings suggest that SVS can improve pulmonary function, quality of life, and dyspnea scores in carefully selected patients without collateral ventilation.
  </summary>
  <pico>
    <population>Patients with severe heterogeneous emphysema and hyperinflation</population>
    <intervention>Spiration Valve System (SVS)</intervention>
    <comparison>Standard of care (optimized medical management)</comparison>
    <outcome>Improvement in FEV1, quality of life (SGRQ), dyspnea (mMRC), and safety outcomes including pneumothorax and AECOPD</outcome>
  </pico>
  <take_home>In selected patients with severe heterogeneous emphysema without collateral ventilation, the Spiration Valve System is a safe alternative that improves pulmonary function and quality of life.</take_home>
  <embedding_file>sec14_Article (17)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec14_Article (18)">
  <title>Endobronchial Coils for Endoscopic Lung Volume Reduction: Best Practice Recommendations from an Expert Panel</title>
  <authors>Slebos, D.J.; ten Hacken, N.H.; Hetzel, M.; Herth, F.J.F.; Shah, P.L.</authors>
  <citation>Slebos, D.J., ten Hacken, N.H., Hetzel, M., Herth, F.J.F., Shah, P.L. Endobronchial Coils for Endoscopic Lung Volume Reduction: Best Practice Recommendations from an Expert Panel. Respiration. 2018;96:1–11.</citation>
  <type>Thematic Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Endobronchial coils</keyword>
    <keyword>Endoscopic lung volume reduction</keyword>
    <keyword>Severe emphysema</keyword>
    <keyword>COPD</keyword>
    <keyword>Bronchoscopy</keyword>
  </keywords>
  <summary>
    This article presents best practice recommendations for the use of endobronchial coils as a treatment option for patients with severe emphysema. It discusses patient selection criteria, procedural techniques, and management of complications, emphasizing the importance of a multidisciplinary approach for optimal outcomes.
  </summary>
  <pico>
    <population>Patients with severe emphysema on optimal medical therapy and evidence of severe hyperinflation.</population>
    <intervention>Placement of endobronchial coils via bronchoscopy.</intervention>
    <comparison>Optimal medical management without coil treatment.</comparison>
    <outcome>Improvement in pulmonary function, exercise performance, and quality of life.</outcome>
  </pico>
  <take_home>Endobronchial coils can significantly improve outcomes in carefully selected patients with severe emphysema, but require careful patient selection and management due to potential complications.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
```xml
<article id="sec14_Article (19)">
  <title>Survival in COPD patients treated with bronchoscopic lung volume reduction</title>
  <authors>Jorine E. Hartman, Jorrit B.A. Welling, Karin Klooster, Orestes A. Carpaij, Sonja W.S. Augustijn, Dirk-Jan Slebos</authors>
  <citation>Hartman, J.E., Welling, J.B.A., Klooster, K., Carpaij, O.A., Augustijn, S.W.S., Slebos, D.-J. Survival in COPD patients treated with bronchoscopic lung volume reduction. Respiratory Medicine. 2022; 191:106825.</citation>
  <type>Original Research</type>
  <year>2022</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Chronic obstructive pulmonary disease (COPD)</keyword>
    <keyword>Survival</keyword>
  </keywords>
  <summary>
    This study investigates the impact of bronchoscopic lung volume reduction (BLVR) on survival rates in patients with severe COPD. It compares the survival of patients who underwent BLVR treatment with those who did not, revealing that BLVR significantly improves median survival time.
  </summary>
  <pico>
    <population>Patients with severe COPD evaluated for BLVR treatment</population>
    <intervention>Bronchoscopic lung volume reduction (BLVR)</intervention>
    <comparison>No BLVR treatment</comparison>
    <outcome>Survival rates and median survival time</outcome>
  </pico>
  <take_home>Bronchoscopic lung volume reduction treatment in patients with severe hyperinflation from COPD may lead to a significant survival benefit.</take_home>
  <embedding_file>https://doi.org/10.1016/j.rmed.2022.106825</embedding_file>
</article>
```
```xml
<article id="sec14_Article (2)">
  <title>A Randomized Study of Endobronchial Valves for Advanced Emphysema</title>
  <authors>Sciurba, F.C.; Ernst, A.; Herth, F.J.F.; Strange, C.; Criner, G.J.; Marquette, C.H.; Kovitz, K.L.; Chiacchierini, R.P.; Goldin, J.; McLennan, G.</authors>
  <citation>Sciurba, F.C., Ernst, A., Herth, F.J.F., Strange, C., Criner, G.J., Marquette, C.H., Kovitz, K.L., Chiacchierini, R.P., Goldin, J., McLennan, G. A Randomized Study of Endobronchial Valves for Advanced Emphysema. N Engl J Med. 2010;363:1233-44.</citation>
  <type>Original Article</type>
  <year>2010</year>
  <keywords>
    <keyword>Endobronchial valves</keyword>
    <keyword>Emphysema</keyword>
    <keyword>Randomized study</keyword>
    <keyword>Lung function</keyword>
    <keyword>COPD exacerbation</keyword>
  </keywords>
  <summary>
    This study evaluates the safety and efficacy of endobronchial valve therapy in patients with advanced heterogeneous emphysema compared to standard medical care. The results indicate modest improvements in lung function and exercise tolerance at the cost of increased rates of COPD exacerbations and other complications.
  </summary>
  <pico>
    <population>Patients with advanced heterogeneous emphysema</population>
    <intervention>Endobronchial valve therapy</intervention>
    <comparison>Standard medical care</comparison>
    <outcome>Improvements in FEV1, 6-minute walk test, and quality of life</outcome>
  </pico>
  <take_home>Endobronchial valve therapy can provide modest improvements in lung function and exercise capacity for patients with advanced emphysema but is associated with increased complications.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec14_Article (20)">
  <title>Expert Statement: Pneumothorax Associated with Endoscopic Valve Therapy for Emphysema – Potential Mechanisms, Treatment Algorithm, and Case Examples</title>
  <authors>Arschang Valipour, Dirk-Jan Slebos, Hugo G. de Oliveira, Ralf Eberhardt, Lutz Freitag, Gerard J. Criner, Felix J.F. Herth</authors>
  <citation>Valipour A., Slebos D.J., de Oliveira H.G., Eberhardt R., Freitag L., Criner G.J., Herth F.J.F. Expert Statement: Pneumothorax Associated with Endoscopic Valve Therapy for Emphysema – Potential Mechanisms, Treatment Algorithm, and Case Examples. Respiration. 2014;87(6):513–521.</citation>
  <type>Expert Statement</type>
  <year>2014</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Emphysema</keyword>
    <keyword>Bronchoscopic lung volume reduction</keyword>
    <keyword>Pneumothorax</keyword>
    <keyword>Endobronchial valves</keyword>
  </keywords>
  <summary>
    This article provides expert recommendations for the management of pneumothorax following the placement of endobronchial valves in patients with emphysema. It discusses the mechanisms of pneumothorax, the incidence rates, and proposes a treatment algorithm to optimize patient outcomes while minimizing complications.
  </summary>
  <pico>
    <population>Patients with severe emphysema undergoing endobronchial valve therapy</population>
    <intervention>Endobronchial valve placement</intervention>
    <comparison>Management of pneumothorax post-procedure</comparison>
    <outcome>Improved management strategies and patient outcomes</outcome>
  </pico>
  <take_home>Skilled and aggressive management of pneumothorax is essential in patients with emphysema following endobronchial valve therapy, and adherence to the proposed treatment algorithm can help avoid complications.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
```xml
<article id="sec14_Article (3)">
  <title>Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial</title>
  <authors>Claire Davey, Zaid Zoumot, Simon Jordan, William H McNulty, Dennis H Carr, Matthew D Hind, David M Hansell, Michael B Rubens, Winston Banya, Michael I Polkey, Pallav L Shah, Nicholas S Hopkinson</authors>
  <citation>Davey C, Zoumot Z, Jordan S, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. Lancet. 2015;386:1066–73.</citation>
  <type>Randomised Controlled Trial</type>
  <year>2015</year>
  <keywords>
    <keyword>Chronic Obstructive Pulmonary Disease</keyword>
    <keyword>Endobronchial Valves</keyword>
    <keyword>Lung Volume Reduction</keyword>
    <keyword>Heterogeneous Emphysema</keyword>
  </keywords>
  <summary>
    This study investigates the efficacy of bronchoscopic lung volume reduction using endobronchial valves in patients with heterogeneous emphysema and intact interlobar fissures. It is a double-blind, sham-controlled trial showing significant improvements in lung function (FEV1) and exercise capacity for the treatment group compared to controls.
  </summary>
  <pico>
    <population>Patients with heterogeneous emphysema and intact interlobar fissures</population>
    <intervention>Bronchoscopic lung volume reduction with endobronchial valves</intervention>
    <comparison>Sham valve placement (control)</comparison>
    <outcome>Improvement in FEV1, exercise capacity, and health status</outcome>
  </pico>
  <take_home>Endobronchial valve placement can significantly improve lung function and exercise capacity in selected patients with COPD and heterogeneous emphysema.</take_home>
  <embedding_file>https://doi.org/10.1016/S0140-6736(15)60001-0</embedding_file>
</article>
```
```xml
<article id="sec14_Article (4)">
  <title>Complete Unilateral vs Partial Bilateral Endoscopic Lung Volume Reduction in Patients With Bilateral Lung Emphysema</title>
  <authors>Eberhardt, R.; Gompelmann, D.; Schuhmann, M.; Reinhardt, H.; Ernst, A.; Heussel, C.P.; Herth, F.J.F.</authors>
  <citation>Eberhardt, R., Gompelmann, D., Schuhmann, M., Reinhardt, H., Ernst, A., Heussel, C.P., Herth, F.J.F. Complete Unilateral vs Partial Bilateral Endoscopic Lung Volume Reduction in Patients With Bilateral Lung Emphysema. CHEST. 2012;142(4):900–908.</citation>
  <type>Original Research</type>
  <year>2012</year>
  <keywords>
    <keyword>Chronic Obstructive Pulmonary Disease</keyword>
    <keyword>Endoscopic Lung Volume Reduction</keyword>
    <keyword>Intrabronchial Valve</keyword>
    <keyword>Emphysema</keyword>
  </keywords>
  <summary>
    This study compares the efficacy of unilateral intrabronchial valve placement versus bilateral partial valve placement in patients with severe bilateral emphysema. The results indicate that unilateral treatment leads to significant improvements in lung function, exercise capacity, and quality of life compared to bilateral treatment.
  </summary>
  <pico>
    <population>Patients with severe bilateral heterogeneous emphysema</population>
    <intervention>Unilateral intrabronchial valve placement with complete occlusion</intervention>
    <comparison>Bilateral intrabronchial valve placement with incomplete closure</comparison>
    <outcome>Improvement in pulmonary function tests, 6-min walk distance, dyspnea scores, and quality of life</outcome>
  </pico>
  <take_home>Unilateral intrabronchial valve placement is superior to bilateral placement in improving lung function and quality of life in patients with severe emphysema.</take_home>
  <embedding_file>sec14_Article (4)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec14_Article (5)">
  <title>Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE)</title>
  <authors>Gerard J. Criner, Antoine Delage, Kirk Voelker, D. Kyle Hogarth, Adnan Majid, Michael Zgoda, Donald R. Lazarus, Roberto Casal, Sadia B. Benzaquen, Robert C. Holladay, Adam Wellikoff, Karel Calero, Mark J. Rumbak, Paul R. Branca, Muhanned Abu-Hijleh, Jorge M. Mallea, Ravi Kalhan, Ashutosh Sachdeva, C. Matthew Kinsey, Carla R. Lamb, Michael F. Reed, Wissam B. Abouzgheib, Phillip V. Kaplan, Gregory X. Marrujo, David W. Johnstone, Mario G. Gasparri, Arturo A. Meade, Christopher A. Hergott, Chakravarthy Reddy, Richard A. Mularski, Amy Hajari Case, Samir S. Makani, Ray W. Shepherd, Benson Chen, Gregory E. Holt, Simon Martel</authors>
  <citation>Criner G.J., Delage A., Voelker K., et al. Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). Am J Respir Crit Care Med. 2019;200(11):1354–1362.</citation>
  <type>Clinical Trial</type>
  <year>2019</year>
  <keywords>
    <keyword>chronic obstructive pulmonary disease</keyword>
    <keyword>FEV1</keyword>
    <keyword>quality of life</keyword>
    <keyword>Spiration Valve System</keyword>
    <keyword>emphysema</keyword>
  </keywords>
  <summary>
    The EMPROVE trial evaluated the effectiveness and safety of the Spiration Valve System (SVS) in patients with severe heterogeneous emphysema compared to optimal medical management. The trial demonstrated significant improvements in lung function and quality of life for patients receiving SVS, despite a higher incidence of adverse events, particularly pneumothorax.
  </summary>
  <pico>
    <population>Patients aged 40 years or older with severe heterogeneous emphysema</population>
    <intervention>Spiration Valve System (SVS) with optimal medical management</intervention>
    <comparison>Optimal medical management alone</comparison>
    <outcome>Improvement in FEV1, health status, dyspnea, exercise capacity, and quality of life</outcome>
  </pico>
  <take_home>The Spiration Valve System provides significant improvements in lung function and quality of life for patients with severe emphysema, but carries a risk of serious adverse events that are generally manageable.</take_home>
  <embedding_file>EMPROVE_Study_Data</embedding_file>
</article>
```
```xml
<article id="sec14_Article (6)">
  <title>Lung volume reduction coil treatment for patients with severe emphysema: a European multicentre trial</title>
  <authors>Gaëtan Deslee, Karin Klooster, Martin Hetzel, Franz Stanzel, Romain Kessler, Charles-Hugo Marquette, Christian Witt, Stefan Blaas, Wolfgang Gesierich, Felix J F Herth, Juergen Hetzel, Eva M van Rikxoort, Dirk-Jan Slebos</authors>
  <citation>Deslee G, Klooster K, Hetzel M, et al. Lung volume reduction coil treatment for patients with severe emphysema: a European multicentre trial. Thorax. 2014;69:980–986.</citation>
  <type>Original Article</type>
  <year>2014</year>
  <keywords>
    <keyword>lung volume reduction</keyword>
    <keyword>emphysema</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>clinical trial</keyword>
    <keyword>COPD</keyword>
  </keywords>
  <summary>
    This study evaluates the feasibility, safety, and efficacy of lung volume reduction (LVR) coil treatment in patients with severe emphysema through a prospective multicentre cohort trial. A total of 60 patients were treated, with significant improvements observed in quality of life, exercise capacity, and pulmonary function over a 12-month follow-up period, alongside a good safety profile.
  </summary>
  <pico>
    <population>Patients with severe emphysema (n=60)</population>
    <intervention>Lung volume reduction coil treatment</intervention>
    <comparison>None (single-arm study)</comparison>
    <outcome>Improvements in St George’s Respiratory Questionnaire (SGRQ), 6-minute walk distance (6MWD), forced expiratory volume in 1 second (FEV1), and residual volume (RV)</outcome>
  </pico>
  <take_home>Bronchoscopic lung volume reduction coil treatment is safe and effective for improving quality of life and clinical outcomes in patients with severe emphysema, with sustained benefits observed up to one year post-treatment.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec14_Article (7)">
  <title>Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year Results from a Randomized Clinical Trial</title>
  <authors>Mark T. Dransfield, Justin L. Garner, Surya P. Bhatt, Dirk-Jan Slebos, Karin Klooster, Frank C. Sciurba, Pallav L. Shah, Nathaniel T. Marchetti, Richard D. Sue, Shawn Wright, Hiram Rivas-Perez, Tanya A. Wiese, Momen M. Wahidi, Hugo Goulart de Oliveira, Brian Armstrong, Sri Radhakrishnan, Narinder S. Shargill, Gerard J. Criner</authors>
  <citation>Dransfield MT, Garner JL, Bhatt SP, et al. Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year Results from a Randomized Clinical Trial. Ann Am Thorac Soc. 2020;17(7):829–838.</citation>
  <type>Clinical Trial</type>
  <year>2020</year>
  <keywords>
    <keyword>chronic obstructive pulmonary disease</keyword>
    <keyword>severe emphysema</keyword>
    <keyword>interventional bronchoscopy</keyword>
    <keyword>patient-reported outcomes</keyword>
    <keyword>Zephyr Valve</keyword>
  </keywords>
  <summary>
    This study evaluates the impact of Zephyr Endobronchial Valves on patient-reported outcomes (PROs) related to dyspnea, activity levels, and quality of life in patients with severe heterogeneous emphysema. The results demonstrate significant improvements in various measures of dyspnea, activity, and psychosocial status at 12 months post-treatment compared to standard care.
  </summary>
  <pico>
    <population>Patients with severe heterogeneous emphysema and little to no collateral ventilation</population>
    <intervention>Zephyr Endobronchial Valves</intervention>
    <comparison>Standard of care</comparison>
    <outcome>Dyspnea, activity levels, quality of life</outcome>
  </pico>
  <take_home>Patients with severe emphysema treated with Zephyr Valves experience significant improvements in dyspnea, activity levels, and overall quality of life over 12 months.</take_home>
  <embedding_file>LIBERATE_Study_Data.pdf</embedding_file>
</article>
```
```xml
<article id="sec14_Article (8)">
  <title>Endobronchial Valve (Zephyr) Treatment in Homogeneous Emphysema: One-Year Results from the IMPACT Randomized Clinical Trial</title>
  <authors>Eberhardt, R.; Slebos, D.-J.; Herth, F.J.F.; Darwiche, K.; Wagner, M.; Ficker, J.H.; Petermann, C.; Hübner, R.-H.; Stanzel, F.; Shargill, N.S.; Valipouri, A.</authors>
  <citation>Eberhardt, R., Slebos, D.-J., Herth, F.J.F., et al. Endobronchial Valve (Zephyr) Treatment in Homogeneous Emphysema: One-Year Results from the IMPACT Randomized Clinical Trial. Respiration. 2021;100:1174–1185.</citation>
  <type>Clinical Trial</type>
  <year>2021</year>
  <keywords>
    <keyword>Bronchoscopic lung volume reduction</keyword>
    <keyword>Emphysema</keyword>
    <keyword>Residual volume</keyword>
    <keyword>Lung function</keyword>
    <keyword>Quality of life</keyword>
  </keywords>
  <summary>
    This study evaluates the long-term safety and effectiveness of bronchoscopic lung volume reduction using Zephyr endobronchial valves in patients with severe homogeneous emphysema. Results indicate significant improvements in lung function, quality of life, and exercise capacity at both 6 and 12 months, with an acceptable safety profile.
  </summary>
  <pico>
    <population>Patients with severe homogeneous emphysema and little to no collateral ventilation</population>
    <intervention>Bronchoscopic lung volume reduction with Zephyr endobronchial valves</intervention>
    <comparison>Standard of care (SoC)</comparison>
    <outcome>Improvement in lung function (FEV1), quality of life, exercise capacity, and reduction in residual volume</outcome>
  </pico>
  <take_home>Bronchoscopic lung volume reduction with Zephyr valves provides clinically meaningful improvements in lung function and quality of life for patients with severe homogeneous emphysema, with benefits sustained for at least 12 months.</take_home>
  <embedding_file>IMPACT_Study_Results.pdf</embedding_file>
</article>
```
```xml
<article id="sec14_Article (9)">
  <title>Endobronchial Valve Therapy in Patients with Homogeneous Emphysema Results from the IMPACT Study</title>
  <authors>Arschang Valipour, Dirk-Jan Slebos, Felix Herth, Kaid Darwiche, Manfred Wagner, Joachim H. Ficker, Christoph Petermann, Ralf-Harto Hubner, Franz Stanzel, Ralf Eberhardt</authors>
  <citation>Valipour A, Slebos DJ, Herth F, Darwiche K, Wagner M, Ficker JH, Petermann C, Hubner R-H, Stanzel F, Eberhardt R. Endobronchial Valve Therapy in Patients with Homogeneous Emphysema Results from the IMPACT Study. Am J Respir Crit Care Med. 2016;194(9):1073–1082.</citation>
  <type>Original Article</type>
  <year>2016</year>
  <keywords>
    <keyword>homogeneous emphysema</keyword>
    <keyword>endobronchial valve</keyword>
    <keyword>collateral ventilation</keyword>
    <keyword>lung volume reduction</keyword>
    <keyword>lobar occlusion</keyword>
  </keywords>
  <summary>
    This study evaluates the efficacy and safety of endobronchial valves (EBVs) in patients with homogeneous emphysema and absence of collateral ventilation. The results indicate that EBV therapy leads to significant improvements in lung function, exercise tolerance, and quality of life compared to standard care.
  </summary>
  <pico>
    <population>Patients with homogeneous emphysema and absence of collateral ventilation</population>
    <intervention>Endobronchial valve therapy (EBV)</intervention>
    <comparison>Standard of care (SoC) alone</comparison>
    <outcome>Improvement in FEV1, exercise capacity, and quality of life</outcome>
  </pico>
  <take_home>EBV therapy in selected patients with homogeneous emphysema without collateral ventilation provides clinically meaningful benefits in lung function, exercise tolerance, and quality of life, and should be considered as a treatment option.</take_home>
  <embedding_file>IMPACT_Study_Results.pdf</embedding_file>
</article>
```
<article id="sec15_Article (1)">
  <title>Bronchial Thermoplasty in Patients With Severe Asthma at 5 Years</title>
  <authors>Geoffrey Chupp, MD; Joel N. Kline, MD; Sumita B. Khatri, MD; Charlene McEvoy, MD, MPH; Gerard A. Silvestri, MD; Adrian Shifren, MD; Mario Castro, MD; Sundeep Bansal, MD; Marc McClelland, MD; Mark Dransfield, MD; Jennifer Trevor, MD; Nick Kahlstrom, MD; Michael Simoff, MD; Momen M. Wahidi, MD; Carla R. Lamb, MD; J. Scott Ferguson, MD; Andrew Haas, MD; D. Kyle Hogarth, MD; Richard Tejedor, MD; Jennifer Toth, MD; Jamie Hey, MD; Adnan Majid, MD; Peter LaCamera, MD; J. Mark Fitzgerald, MD; Kyle Enfield, MD; G. Mark Grubb, RN; Edmund A. McMullen, MMath; Jennifer L. Olson, PhD; Michel Laviolette, MD</authors>
  <citation>Chupp G., Kline J.N., Khatri S.B., McEvoy C., Silvestri G.A., Shifren A., Castro M., Bansal S., McClelland M., Dransfield M., Trevor J., Kahlstrom N., Simoff M., Wahidi M.M., Lamb C.R., Ferguson J.S., Haas A., Hogarth D.K., Tejedor R., Toth J., Hey J., Majid A., LaCamera P., Fitzgerald J.M., Enfield K., Grubb G.M., McMullen E.A., Olson J.L., Laviolette M. Bronchial Thermoplasty in Patients With Severe Asthma at 5 Years. CHEST. 2022;161(3):614-628.</citation>
  <type>Original Research</type>
  <year>2022</year>
  <keywords>
    <keyword>asthma subgroups</keyword>
    <keyword>bronchial thermoplasty</keyword>
    <keyword>corticosteroid exposure</keyword>
    <keyword>severe asthma</keyword>
    <keyword>severe exacerbations</keyword>
  </keywords>
  <summary>
    The study evaluates the long-term efficacy and safety of bronchial thermoplasty in patients with severe asthma over a 5-year period. Results indicate significant reductions in severe exacerbations, emergency department visits, hospitalizations, and corticosteroid use, demonstrating sustained clinical improvement across various asthma phenotypes.
  </summary>
  <pico>
    <population>Patients aged 18 to 65 years with severe asthma poorly controlled on high doses of inhaled corticosteroids and long-acting beta-agonists.</population>
    <intervention>Bronchial thermoplasty treatment.</intervention>
    <comparison>Comparison of asthma-related health events before and after treatment.</comparison>
    <outcome>Reduction in severe exacerbations, emergency department visits, hospitalizations, and corticosteroid use.</outcome>
  </pico>
  <take_home>Bronchial thermoplasty is an effective long-term treatment option for severe asthma, leading to significant improvements in asthma control and reductions in medication use.</take_home>
  <embedding_file>Bronchial_Thermoplasty_Study_Results.pdf</embedding_file>
</article>
```
```xml
<article id="sec15_Article (2)">
  <title>A prospective safety and feasibility study of metered cryospray for patients with chronic bronchitis in COPD</title>
  <authors>Justin L. Garner, Tawimas Shaipanich, Jorine E. Hartman, Christopher M. Orton, Cielito Caneja, Karin Klooster, John Thornton, Don D. Sin, Dirk-Jan Slebos, Pallav L. Shah</authors>
  <citation>Garner JL, Shaipanich T, Hartman JE, et al. A prospective safety and feasibility study of metered cryospray for patients with chronic bronchitis in COPD. Eur Respir J. 2020;56:2000556.</citation>
  <type>Original Article</type>
  <year>2020</year>
  <keywords>
    <keyword>COPD</keyword>
    <keyword>chronic bronchitis</keyword>
    <keyword>metered cryospray</keyword>
    <keyword>clinical trial</keyword>
    <keyword>patient-reported outcomes</keyword>
  </keywords>
  <summary>
    This study evaluates the safety, feasibility, and efficacy of metered cryospray (MCS) in patients with chronic bronchitis associated with COPD. The results indicate that MCS is safe, feasible, and leads to clinically meaningful improvements in cough, sputum production, breathlessness, and quality of life.
  </summary>
  <pico>
    <population>Patients aged 47-76 years with chronic bronchitis in COPD, FEV1 30-80% predicted</population>
    <intervention>Metered cryospray (MCS) treatment</intervention>
    <comparison>Not applicable (single-arm study)</comparison>
    <outcome>Changes in patient-reported outcomes (SGRQ, CAT, LCQ) and safety events</outcome>
  </pico>
  <take_home>The RejuvenAir system is a safe and effective treatment for chronic bronchitis in COPD, resulting in significant improvements in patient-reported outcomes.</take_home>
  <embedding_file>https://doi.org/10.1183/13993003.00556-2020</embedding_file>
</article>
```
```xml
<article id="sec15_Article (3)">
  <title>New bronchoscopic treatment modalities for patients with chronic bronchitis</title>
  <authors>Hartman, J.E.; Garner, J.L.; Shah, P.L.; Slebos, D.J.</authors>
  <citation>Hartman JE, Garner JL, Shah PL, et al. New bronchoscopic treatment modalities for patients with chronic bronchitis. Eur Respir Rev. 2021;30:200281.</citation>
  <type>Review</type>
  <year>2021</year>
  <keywords>
    <keyword>Chronic Bronchitis</keyword>
    <keyword>Bronchoscopic Treatments</keyword>
    <keyword>Mucus Hypersecretion</keyword>
    <keyword>Targeted Lung Denervation</keyword>
  </keywords>
  <summary>
    This article reviews four innovative bronchoscopic treatments for chronic bronchitis: the RejuvenAir System Metered Cryospray, RheOx bronchial rheoplasty, Karakoca balloon desobstruction, and targeted lung denervation (TLD). While initial studies show promising results, further research is needed to evaluate the long-term effects and sustainability of these treatments on chronic bronchitis symptoms.
  </summary>
  <pico>
    <population>Patients with chronic bronchitis</population>
    <intervention>Innovative bronchoscopic treatments (RejuvenAir, RheOx, Karakoca, TLD)</intervention>
    <comparison>Standard care or placebo</comparison>
    <outcome>Improvement in chronic bronchitis symptoms, quality of life, and treatment durability</outcome>
  </pico>
  <take_home>Novel bronchoscopic treatments for chronic bronchitis show promise but require larger randomized controlled trials to confirm their efficacy and long-term benefits.</take_home>
  <embedding_file>sec15_Article (3)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec15_Article (4)">
  <title>Follow-up outcomes of chronic obstructive pulmonary disease patients who underwent dilatation and curettage with the Karakoca resector balloon: A 188-case series over 5 years</title>
  <authors>Karakoca, Yalcin; Gogus, Guler; Akduman, Seha; Erturk, Baykal</authors>
  <citation>Karakoca, Y., Gogus, G., Akduman, S., Erturk, B. Follow-up outcomes of chronic obstructive pulmonary disease patients who underwent dilatation and curettage with the Karakoca resector balloon: A 188-case series over 5 years. Medicine. 2018;97(48):e13400.</citation>
  <type>Observational Study</type>
  <year>2018</year>
  <keywords>
    <keyword>chronic obstructive pulmonary disease</keyword>
    <keyword>Karakoca resector balloon desobstruction</keyword>
    <keyword>dilatation and curettage</keyword>
    <keyword>lung function</keyword>
    <keyword>interventional therapy</keyword>
  </keywords>
  <summary>
    This study presents the outcomes of the Karakoca resector balloon dilatation and curettage technique in 188 patients with stage III to IV chronic obstructive pulmonary disease (COPD) who did not respond to medical treatment. The results demonstrated significant improvements in lung function, oxygen saturation, and dyspnea scores post-intervention, with most patients achieving symptom relief.
  </summary>
  <pico>
    <population>Patients with stage III to IV COPD (n=188), mean age 69.2 years, all active smokers</population>
    <intervention>Karakoca resector balloon dilatation and curettage</intervention>
    <comparison>Pre-intervention measurements</comparison>
    <outcome>Significant improvements in FEV1, MBS scores, SpO2 levels, and reduction in oxygen needs</outcome>
  </pico>
  <take_home>The Karakoca resector balloon dilatation and curettage is a safe and effective intervention for COPD patients resistant to medical therapy, leading to significant improvements in lung function and quality of life.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec15_Article (5)">
  <title>Safety of delivering bronchial thermoplasty in two treatment sessions</title>
  <authors>Kavya Koshy, Joy Sha, Kim Bennetts, David Langton</authors>
  <citation>Koshy K, Sha J, Bennetts K, Langton D. Safety of delivering bronchial thermoplasty in two treatment sessions. Respiratory Research. 2021;22:307.</citation>
  <type>Research</type>
  <year>2021</year>
  <keywords>
    <keyword>Bronchial thermoplasty</keyword>
    <keyword>Severe asthma</keyword>
    <keyword>Patient safety</keyword>
    <keyword>Hospital admission</keyword>
    <keyword>Outcomes</keyword>
  </keywords>
  <summary>
    This study investigates the safety of bronchial thermoplasty (BT) when delivered in two treatment sessions compared to the traditional three-session approach. It highlights the short-term risks associated with the accelerated treatment schedule, particularly in female patients, and discusses the potential benefits of reduced treatment sessions for patient convenience.
  </summary>
  <pico>
    <population>Patients with severe asthma meeting ERS/ATS criteria</population>
    <intervention>Bronchial thermoplasty delivered in two treatment sessions</intervention>
    <comparison>Bronchial thermoplasty delivered in three treatment sessions</comparison>
    <outcome>Hospital stay duration, readmission rates, lung function (FEV1)</outcome>
  </pico>
  <take_home>While compressing bronchial thermoplasty into two sessions is more convenient, it poses greater short-term risks, particularly for females, and should be considered carefully against the potential benefits.</take_home>
  <embedding_file>https://doi.org/10.1186/s12931-021-01901-x</embedding_file>
</article>
```
```xml
<article id="sec15_Article (6)">
  <title>Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes</title>
  <authors>Pison, C.; Shah, P.L.; Slebos, D.-J.; Ninane, V.; Janssens, W.; Perez, T.; Kessler, R.; Deslee, G.; Garner, J.L.; Hartman, J.E.; Degano, B.; Mayr, A.; Mayse, M.; Peterson, A.D.; Valipour, A.</authors>
  <citation>Pison, C., Shah, P.L., Slebos, D.-J., Ninane, V., Janssens, W., Perez, T., Kessler, R., Deslee, G., Garner, J.L., Hartman, J.E., Degano, B., Mayr, A., Mayse, M., Peterson, A.D., Valipour, A. Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes. BMC Pulmonary Medicine. 2021;21(1):41.</citation>
  <type>Research</type>
  <year>2021</year>
  <keywords>
    <keyword>COPD</keyword>
    <keyword>Targeted lung denervation</keyword>
    <keyword>Safety</keyword>
    <keyword>Long-term outcomes</keyword>
    <keyword>Bronchoscopy</keyword>
  </keywords>
  <summary>
    The AIRFLOW-1 study evaluated the long-term safety and efficacy of targeted lung denervation (TLD) in patients with moderate-to-severe COPD over three years. The study found that TLD had a positive safety profile with no new serious adverse events and maintained stability in COPD exacerbations, pulmonary function, and quality of life.
  </summary>
  <pico>
    <population>Patients with moderate-to-severe, symptomatic COPD</population>
    <intervention>Targeted lung denervation (TLD)</intervention>
    <comparison>Standard medical therapy</comparison>
    <outcome>Exacerbation rates, lung function, quality of life</outcome>
  </pico>
  <take_home>Targeted lung denervation is a safe procedure for COPD patients, demonstrating stability in lung function, quality of life, and exacerbations over three years.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec15_Article (7)">
  <title>Bronchial Rheoplasty for Treatment of Chronic Bronchitis: Twelve-Month Results from a Multicenter Clinical Trial</title>
  <authors>Valipour, A.; Fernandez-Bussy, S.; Ing, A.J.; Steinfort, D.P.; Snell, G.I.; Williamson, J.P.; Saghaie, T.; Irving, L.B.; Dabscheck, E.J.; Krimsky, W.S.; Waldstreicher, J.</authors>
  <citation>Valipour A, Fernandez-Bussy S, Ing AJ, et al. Bronchial Rheoplasty for Treatment of Chronic Bronchitis: Twelve-Month Results from a Multicenter Clinical Trial. Am J Respir Crit Care Med. 2020;202(5):681–689.</citation>
  <type>Original Article</type>
  <year>2020</year>
  <keywords>
    <keyword>chronic obstructive pulmonary disease</keyword>
    <keyword>obstructive lung diseases</keyword>
    <keyword>respiratory tract diseases</keyword>
    <keyword>bronchial diseases</keyword>
    <keyword>pulsed electric field</keyword>
  </keywords>
  <summary>
    This study evaluates the feasibility, safety, and initial outcomes of bronchial rheoplasty, an innovative endoscopic procedure for treating chronic bronchitis (CB). Conducted across multiple centers, the trial involved 30 patients and assessed clinical outcomes, histological changes, and adverse events over a 12-month follow-up period. Results indicate significant reductions in goblet cell hyperplasia and improvements in quality of life measures, with a favorable safety profile.
  </summary>
  <pico>
    <population>Patients with chronic bronchitis (N=30)</population>
    <intervention>Bronchial rheoplasty using nonthermal pulsed electrical fields</intervention>
    <comparison>None (single-arm study)</comparison>
    <outcome>Reduction in symptoms and histological improvement in goblet cell hyperplasia</outcome>
  </pico>
  <take_home>Bronchial rheoplasty is a feasible and safe procedure that significantly improves symptoms and reduces goblet cell hyperplasia in patients with chronic bronchitis.</take_home>
  <embedding_file>Bronchial_Rheoplasty_Study_Results.pdf</embedding_file>
</article>
```
```xml
<article id="sec15_Article (8)">
  <title>Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2</title>
  <authors>Arschang Valipour, Pallav L Shah, Felix J Herth, Christophe Pison, Christian Schumann, Ralf-Harto Hübner, Peter I Bonta, Romain Kessler, Wolfgang Gesierich, Kaid Darwiche, Bernd Lamprecht, Thierry Perez, Dirk Skowasch, Gaetan Deslee, Armelle Marceau, Frank C Sciurba, Reinoud Gosens, Jorine E Hartman, Francesca Conway, Marina Duller, Martin Mayse, Holly S Norman, Dirk-Jan Slebos</authors>
  <citation>Valipour A, Shah PL, Herth FJ, et al. Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2. International Journal of Chronic Obstructive Pulmonary Disease. 2020;15:2807–2816.</citation>
  <type>Clinical Trial Report</type>
  <year>2020</year>
  <keywords>
    <keyword>COPD exacerbation</keyword>
    <keyword>targeted lung denervation</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>clinical trial</keyword>
  </keywords>
  <summary>
    The AIRFLOW-2 study evaluated the long-term safety and efficacy of targeted lung denervation (TLD) in patients with moderate to severe COPD, demonstrating a significant reduction in severe exacerbations over a two-year period compared to sham treatment. While lung function remained stable, the risk of severe exacerbations was significantly lower in the TLD group, suggesting that TLD may provide sustained clinical benefits alongside optimal drug therapy.
  </summary>
  <pico>
    <population>Patients aged 40-75 with moderate to severe symptomatic COPD (FEV1 30-60% predicted, CAT ≥10 or mMRC ≥2)</population>
    <intervention>Targeted lung denervation (TLD) using a novel lung denervation system</intervention>
    <comparison>Sham bronchoscopy plus optimal drug therapy</comparison>
    <outcome>Reduced risk of severe COPD exacerbations and stable lung function over 2 years</outcome>
  </pico>
  <take_home>The targeted lung denervation procedure shows a durable effect in reducing severe COPD exacerbations while maintaining stable lung function and quality of life over a two-year follow-up period.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
<article id="sec16_Article (1)">
  <title>Treatment of Benign Tracheal Stenosis Using Endoluminal Spray Cryotherapy</title>
  <authors>Bhora, F.Y.; Ayub, A.; Forleiter, C.M.; Huang, C.Y.; Alshehri, K.; Rehmani, S.; Al-Ayoubi, A.M.; Raad, W.; Lebovics, R.S.</authors>
  <citation>Bhora F.Y., Ayub A., Forleiter C.M., Huang C.Y., Alshehri K., Rehmani S., Al-Ayoubi A.M., Raad W., Lebovics R.S. Treatment of Benign Tracheal Stenosis Using Endoluminal Spray Cryotherapy. JAMA Otolaryngol Head Neck Surg. 2016;142(11):1082-1087.</citation>
  <type>Original Investigation</type>
  <year>2016</year>
  <keywords>
    <keyword>tracheal stenosis</keyword>
    <keyword>spray cryotherapy</keyword>
    <keyword>airway management</keyword>
    <keyword>granulomatosis with polyangiitis</keyword>
  </keywords>
  <summary>
    The study investigates the safety and efficacy of spray cryotherapy (SCT) as a treatment for benign tracheal stenosis. The results show significant improvement in airway patency and symptom relief in patients, with a low rate of complications.
  </summary>
  <pico>
    <population>Patients with benign tracheal stenosis, including those with granulomatosis with polyangiitis, post-tracheotomy or intubation, and idiopathic strictures.</population>
    <intervention>Endoluminal spray cryotherapy (SCT) combined with balloon dilatation.</intervention>
    <comparison>Prior treatments for airway stenosis.</comparison>
    <outcome>Improvement in airway caliber, reduction in the need for reintervention, and overall symptom relief.</outcome>
  </pico>
  <take_home>Spray cryotherapy is a safe and effective adjunct treatment for benign tracheal stenosis, particularly for patients who have not responded well to conventional therapies.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec16_Article (2)">
  <title>Multi-disciplinary management of patients with benign airway strictures: A review</title>
  <authors>Septimiu Murgu; Abhinav Agrawal; Brandon J. Baird; Maria Lucia L. Madariaga; Elizabeth A. Blair</authors>
  <citation>MURGU, S., AGRAWAL, A., BAIRD, B.J., MADARIAGA, M.L.L., BLAIR, E.A. Multi-disciplinary management of patients with benign airway strictures: A review. Respiratory Medicine. 2021; 185:106582.</citation>
  <type>Review Article</type>
  <year>2021</year>
  <keywords>
    <keyword>Multi-disciplinary</keyword>
    <keyword>Benign airway strictures</keyword>
    <keyword>Subglottic stenosis</keyword>
    <keyword>Tracheal stenosis</keyword>
    <keyword>Bronchoscopy</keyword>
    <keyword>Surgery</keyword>
  </keywords>
  <summary>
    This review discusses the complexities involved in the management of benign airway strictures, which are often misdiagnosed as asthma or COPD. It emphasizes the importance of a multidisciplinary approach, involving otolaryngologists, thoracic surgeons, and interventional pulmonologists, to accurately diagnose and treat these conditions. The article outlines classification systems, treatment options, and algorithms for care based on the extent and severity of airway strictures.
  </summary>
  <pico>
    <population>Patients with benign airway strictures</population>
    <intervention>Multi-disciplinary management including medical therapy, endoscopic procedures, and open surgery</intervention>
    <comparison>Standard management without multidisciplinary collaboration</comparison>
    <outcome>Improved diagnosis, treatment outcomes, and reduced unnecessary procedures</outcome>
  </pico>
  <take_home>The optimal management of benign airway strictures requires a collaborative, multi-disciplinary approach to ensure timely, patient-centered, and evidence-based interventions.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec16_Article (3)">
  <title>Safety and Efficacy of a Fully Covered Self-Expandable Metallic Stent in Benign Airway Stenosis</title>
  <authors>Marc Fortin, Yves Lacasse, Xavier Elharrar, Rachid Tazi-Mezalek, Sophie Laroumagne, Julien Guinde, Philippe Astoul, Hervé Dutau</authors>
  <citation>Fortin M, Lacasse Y, Elharrar X, Tazi-Mezalek R, Laroumagne S, Guinde J, Astoul P, Dutau H. Safety and Efficacy of a Fully Covered Self-Expandable Metallic Stent in Benign Airway Stenosis. Respiration. 2017;93:430–435.</citation>
  <type>Research Article</type>
  <year>2017</year>
  <keywords>
    <keyword>Fully covered self-expandable metallic stent</keyword>
    <keyword>Benign airway stenosis</keyword>
    <keyword>Safety</keyword>
    <keyword>Efficacy</keyword>
  </keywords>
  <summary>
    This study evaluates the safety and efficacy of the Silmet self-expandable metallic stent (SEMS) for treating benign airway stenosis. It reviews 40 stents inserted in 30 patients over five years, noting a 50% complication rate requiring stent removal, yet no stent-related mortality.
  </summary>
  <pico>
    <population>Patients with benign airway stenosis</population>
    <intervention>Insertion of fully covered Silmet self-expandable metallic stents (SEMS)</intervention>
    <comparison>No direct comparison made</comparison>
    <outcome>Safety and efficacy of stent placement, complication rates, and clinical success rates</outcome>
  </pico>
  <take_home>Silmet SEMS are a safe treatment option for benign airway stenosis, although complications requiring removal are frequent, necessitating further studies for comparison with silicone stents.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec16_Article (4)">
  <title>The Diagnosis and Management of Airway Complications Following Lung Transplantation</title>
  <authors>Mahajan, A.K.; Folch, E.; Khandhar, S.J.; Channick, C.L.; Santacruz, J.F.; Mehta, A.C.; Nathan, S.D.</authors>
  <citation>Mahajan, A.K., Folch, E., Khandhar, S.J., Channick, C.L., Santacruz, J.F., Mehta, A.C., Nathan, S.D. The Diagnosis and Management of Airway Complications Following Lung Transplantation. CHEST. 2017;152(3):627-638.</citation>
  <type>Review Article</type>
  <year>2017</year>
  <keywords>
    <keyword>airway complications</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>lung transplantation</keyword>
    <keyword>anastomotic ischemia</keyword>
  </keywords>
  <summary>
    This article reviews the risk factors, clinical manifestations, and treatment options for airway complications following lung transplantation. It highlights the common complications, their incidence, and the advancements in bronchoscopic therapies that have improved management outcomes. The authors also provide expert opinions on treatment strategies where evidence is lacking, emphasizing the need for further research in this area.
  </summary>
  <pico>
    <population>Lung transplant recipients</population>
    <intervention>Bronchoscopic therapies and surgical interventions for airway complications</intervention>
    <comparison>Historical data on airway complications and outcomes</comparison>
    <outcome>Reduction in morbidity and mortality associated with airway complications</outcome>
  </pico>
  <take_home>Airway complications post-lung transplantation are significant and require a multi-faceted approach for management, with ongoing research needed to optimize treatment strategies and improve patient outcomes.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec17_Article (1)">
  <title>Multidetector CT Evaluation of Tracheobronchomalacia</title>
  <authors>Edward Y. Lee, MD, MPH; Diana Litmanovich, MD; Phillip M. Boiselle, MD</authors>
  <citation>Lee EY, Litmanovich D, Boiselle PM. Multidetector CT Evaluation of Tracheobronchomalacia. Radiol Clin N Am. 2009;47(2):261–269.</citation>
  <type>Review Article</type>
  <year>2009</year>
  <keywords>
    <keyword>Tracheomalacia</keyword>
    <keyword>Tracheobronchomalacia</keyword>
    <keyword>Bronchomalacia</keyword>
    <keyword>Multidetector computed tomography (MDCT)</keyword>
    <keyword>Clinical indications</keyword>
    <keyword>Diagnostic criterion</keyword>
    <keyword>MDCT protocols</keyword>
    <keyword>Image interpretation</keyword>
  </keywords>
  <summary>
    Tracheobronchomalacia (TBM) is characterized by excessive expiratory collapse of the trachea and bronchi due to weakness in the airway walls and/or supporting cartilage. This condition is often under-diagnosed, as it is not easily detected through standard imaging techniques. Recent advancements in multidetector computed tomography (MDCT) allow for noninvasive diagnosis of TBM with accuracy comparable to bronchoscopy. This article reviews imaging protocols, clinical indications, diagnostic criteria, and interpretation techniques for effective TBM assessment.
  </summary>
  <pico>
    <population>Patients with suspected tracheobronchomalacia</population>
    <intervention>Multidetector computed tomography (MDCT) imaging</intervention>
    <comparison>Bronchoscopy (historical reference standard)</comparison>
    <outcome>Diagnosis and assessment of tracheobronchomalacia</outcome>
  </pico>
  <take_home>MDCT is the preferred method for diagnosing tracheobronchomalacia, providing accurate noninvasive evaluation and aiding in preoperative and postoperative assessments.</take_home>
  <embedding_file>MDCT_TBM_Evaluation.pdf</embedding_file>
</article>
```
```xml
<article id="sec17_Article (2)">
  <title>Technical Aspects and Outcomes of Tracheobronchoplasty for Severe Tracheobronchomalacia</title>
  <authors>Gangadharan, P. S.; Bakhos, C. T.; Majid, A.; Kent, M. S.; Michaud, G.; Ernst, A.; Ashiku, S. K.; DeCamp, M. M.</authors>
  <citation>Gangadharan, P. S., Bakhos, C. T., Majid, A., Kent, M. S., Michaud, G., Ernst, A., Ashiku, S. K., DeCamp, M. M. Technical Aspects and Outcomes of Tracheobronchoplasty for Severe Tracheobronchomalacia. Ann Thorac Surg. 2011;91:1574–81.</citation>
  <type>Research Article</type>
  <year>2011</year>
  <keywords>
    <keyword>Tracheobronchomalacia</keyword>
    <keyword>Tracheobronchoplasty</keyword>
    <keyword>Surgical outcomes</keyword>
    <keyword>Respiratory complications</keyword>
    <keyword>Quality of life</keyword>
  </keywords>
  <summary>
    This study analyzes the technical details, outcomes, and complications associated with tracheobronchoplasty in patients with severe tracheobronchomalacia. It reviews a cohort of 63 patients who underwent the procedure, highlighting surgical techniques, postoperative morbidity, and mortality rates. The findings indicate that tracheobronchoplasty can be performed safely with low mortality and acceptable complication rates, leading to significant improvements in quality of life and respiratory symptoms.
  </summary>
  <pico>
    <population>Adult patients with severe tracheobronchomalacia</population>
    <intervention>Tracheobronchoplasty</intervention>
    <comparison>No surgical intervention (historical control)</comparison>
    <outcome>Improvement in respiratory symptoms, quality of life, and reduction in airway collapse</outcome>
  </pico>
  <take_home>Tracheobronchoplasty is a viable surgical option for patients with severe tracheobronchomalacia, demonstrating low mortality and significant improvements in quality of life despite the complexity of the procedure.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
```xml
<article id="sec17_Article (3)">
  <title>Tracheobronchomalacia and Excessive Dynamic Airway Collapse</title>
  <authors>Murgu, S.D.; Colt, H.</authors>
  <citation>Murgu, S.D., Colt, H. Tracheobronchomalacia and Excessive Dynamic Airway Collapse. Clin Chest Med. 2013;34(3):527-555.</citation>
  <type>Review</type>
  <year>2013</year>
  <keywords>
    <keyword>Tracheobronchomalacia</keyword>
    <keyword>Excessive dynamic airway collapse</keyword>
    <keyword>Airway stents</keyword>
    <keyword>Tracheoplasty</keyword>
    <keyword>Noninvasive positive pressure ventilation</keyword>
    <keyword>Airflow dynamics</keyword>
    <keyword>Choke points</keyword>
    <keyword>Functional bronchoscopy</keyword>
  </keywords>
  <summary>
    This article discusses tracheobronchomalacia (TBM) and excessive dynamic airway collapse (EDAC), both characterized by airway collapse leading to expiratory flow limitation. It emphasizes the importance of careful physiological assessment before treatment, the need for standardized definitions and classifications, and a conservative approach to management, often starting with noninvasive treatments before considering more invasive options like stenting or surgery.
  </summary>
  <pico>
    <population>Adults with tracheobronchomalacia and excessive dynamic airway collapse</population>
    <intervention>Noninvasive positive pressure ventilation, medical treatment</intervention>
    <comparison>Invasive interventions such as airway stents or surgical procedures</comparison>
    <outcome>Improvement in airflow and functional status</outcome>
  </pico>
  <take_home>Before considering invasive treatments for tracheobronchomalacia and excessive dynamic airway collapse, a conservative approach focusing on medical management and noninvasive techniques is recommended.</take_home>
  <embedding_file>Not applicable</embedding_file>
</article>
```
```xml
<article id="sec17_Article (3)">
  <title>Tracheobronchomalacia: An In-Depth Review</title>
  <authors>CARDEN KA, BOISELLE PM, WALTZ DA, et al.</authors>
  <citation>CARDEN KA, BOISELLE PM, WALTZ DA, et al. Tracheobronchomalacia and tracheobronchomalacia in children and adults: an in-depth review. Chest. 2005;127:984–1005.</citation>
  <type>Review</type>
  <year>2005</year>
  <keywords>
    <keyword>tracheobronchomalacia</keyword>
    <keyword>airway management</keyword>
    <keyword>treatment outcomes</keyword>
    <keyword>pediatric</keyword>
    <keyword>adult</keyword>
  </keywords>
  <summary>
    This review article provides a comprehensive overview of tracheobronchomalacia, discussing its pathophysiology, diagnosis, and management strategies in both pediatric and adult populations. The authors emphasize the importance of understanding the condition's impact on respiratory function and outline various treatment modalities, including surgical and non-surgical options.
  </summary>
  <pico>
    <population>Children and adults with tracheobronchomalacia</population>
    <intervention>Various management strategies including surgical and non-surgical treatments</intervention>
    <comparison>Outcomes of different treatment approaches</comparison>
    <outcome>Improvement in respiratory function and quality of life</outcome>
  </pico>
  <take_home>Tracheobronchomalacia requires a tailored approach to management, considering both surgical and non-surgical options to optimize patient outcomes.</take_home>
  <embedding_file>tracheobronchomalacia_review.pdf</embedding_file>
</article>
```
```xml
<article id="sec17_Article (4)">
  <title>Tracheomalacia and Tracheobronchomalacia in Children and Adults: An In-depth Review</title>
  <authors>Kelly A. Carden, MD; Philip M. Boiselle, MD, FCCP; David A. Waltz, MD; Armin Ernst, MD, FCCP</authors>
  <citation>Carden KA, Boiselle PM, Waltz DA, Ernst A. Tracheomalacia and tracheobronchomalacia in children and adults: An in-depth review. CHEST. 2005;127(3):984–1005.</citation>
  <type>Review</type>
  <year>2005</year>
  <keywords>
    <keyword>tracheomalacia</keyword>
    <keyword>tracheobronchomalacia</keyword>
    <keyword>airway disorders</keyword>
    <keyword>pediatric medicine</keyword>
    <keyword>adult medicine</keyword>
    <keyword>treatment</keyword>
  </keywords>
  <summary>
    This comprehensive review discusses tracheomalacia (TM) and tracheobronchomalacia (TBM), conditions characterized by the weakening of the trachea and bronchi, affecting both children and adults. The article covers historical context, classification, associated conditions, histopathological features, diagnosis, and treatment modalities. It highlights the increasing recognition and treatment of these conditions, emphasizing the need for better diagnostic imaging and awareness among clinicians.
  </summary>
  <pico>
    <population>Children and adults with tracheomalacia and tracheobronchomalacia</population>
    <intervention>Diagnosis and treatment approaches including surgical intervention, airway stenting, and CPAP</intervention>
    <comparison>Comparison of congenital vs. acquired forms, and treatment outcomes</comparison>
    <outcome>Improvement in airway patency and reduction in symptoms</outcome>
  </pico>
  <take_home>Tracheomalacia and tracheobronchomalacia are increasingly recognized airway disorders that require comprehensive assessment and individualized treatment strategies, including surgical options and non-invasive therapies.</take_home>
  <embedding_file>tracheomalacia_review_2005.pdf</embedding_file>
</article>
```
```xml
<article id="sec17_Article (5)">
  <title>Airway Stabilization With Silicone Stents for Treating Adult Tracheobronchomalacia: A Prospective Observational Study</title>
  <authors>Armin Ernst, MD, FCCP; Adnan Majid, MD; David Feller-Kopman, MD, FCCP; Jorge Guerrero, MD; Phillip Boiselle, MD, FCCP; Stephen H. Loring, MD; Carl O’Donnell, ScD; Malcolm DeCamp, MD; Felix J. F. Herth, MD, FCCP; Sidhu Gangadharan, MD; Simon Ashiku, MD</authors>
  <citation>Ernst A.B., Majid A., Feller-Kopman D., et al. Airway Stabilization With Silicone Stents for Treating Adult Tracheobronchomalacia: A Prospective Observational Study. CHEST. 2007;132(3):609–616.</citation>
  <type>Original Research</type>
  <year>2007</year>
  <keywords>
    <keyword>airway stabilization</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>COPD</keyword>
    <keyword>stent placement</keyword>
    <keyword>tracheobronchomalacia</keyword>
  </keywords>
  <summary>
    This study evaluates the effect of silicone stents on symptoms, quality of life, lung function, and exercise capacity in patients with severe tracheobronchomalacia (TBM). The results indicate that airway stabilization with silicone stents can improve respiratory symptoms and quality of life, despite a high incidence of complications.
  </summary>
  <pico>
    <population>Adults with severe tracheobronchomalacia (TBM)</population>
    <intervention>Placement of silicone stents (tracheal, mainstem bronchus, or both)</intervention>
    <comparison>Baseline measurements before stent placement</comparison>
    <outcome>Improvement in respiratory symptoms, quality of life scores, functional status, and exercise capacity</outcome>
  </pico>
  <take_home>Airway stabilization with silicone stents can improve symptoms in patients with severe TBM, including those with COPD, but is associated with a significant number of complications.</take_home>
  <embedding_file>sec17_Article (5)_embeddings.json</embedding_file>
</article>
```
<article id="sec18_Article (1)">
  <title>Whole lung lavage—technical details, challenges and management of complications</title>
  <authors>Ahmed Awab, Muhammad S. Khan, Houssein A. Youness</authors>
  <citation>Awab A, Khan MS, Youness HA. Whole lung lavage—technical details, challenges and management of complications. J Thorac Dis. 2017;9(6):1697-1706.</citation>
  <type>Review Article</type>
  <year>2017</year>
  <keywords>
    <keyword>Pulmonary alveolar proteinosis (PAP)</keyword>
    <keyword>whole lung lavage (WLL)</keyword>
    <keyword>rare disease</keyword>
  </keywords>
  <summary>
    This article discusses whole lung lavage (WLL) as the standard treatment for pulmonary alveolar proteinosis (PAP), detailing the technical aspects, challenges, and management of complications associated with the procedure. It covers historical context, indications, techniques, and outcomes of WLL, emphasizing the importance of performing the procedure in specialized centers with experienced teams.
  </summary>
  <pico>
    <population>Patients with pulmonary alveolar proteinosis (PAP)</population>
    <intervention>Whole lung lavage (WLL)</intervention>
    <comparison>Not applicable</comparison>
    <outcome>Improvement in lung function and reduction of symptoms</outcome>
  </pico>
  <take_home>Whole lung lavage is an effective and safe treatment for pulmonary alveolar proteinosis when performed in specialized centers, leading to significant clinical improvements for most patients.</take_home>
  <embedding_file>http://dx.doi.org/10.21037/jtd.2017.04.10</embedding_file>
</article>
```
```xml
<article id="sec18_Article (2)">
  <title>Efficacy of Whole-Lung Lavage in Pulmonary Alveolar Proteinosis: A Multicenter International Study of GELF</title>
  <authors>Pierre Gay, Benoit Wallaert, Stefan Nowak, Jonas Yserbyt, Stavros Anevlavis, Christophe Hermant, Alban Lovis, Olivier Menard, Bernard Maitre, Thomas Vandemoortele, Hervé Dutau, Amandine Briault, Arnaud Bourdin, Jean-Michel Vergnon, Marios E. Froudarakis</authors>
  <citation>Gay P, Wallaert B, Nowak S, et al. Efficacy of Whole-Lung Lavage in Pulmonary Alveolar Proteinosis: A Multicenter International Study of GELF. Respiration. 2017;93:198–206.</citation>
  <type>Research Article</type>
  <year>2017</year>
  <keywords>
    <keyword>Whole-lung lavage</keyword>
    <keyword>Pulmonary alveolar proteinosis</keyword>
    <keyword>Treatment</keyword>
    <keyword>Respiratory insufficiency</keyword>
    <keyword>Clinical outcomes</keyword>
  </keywords>
  <summary>
    This study evaluates the efficacy of whole-lung lavage (WLL) in treating pulmonary alveolar proteinosis (PAP) across 12 centers. A total of 33 patients were assessed, revealing improvements in oxygenation but a high relapse rate, indicating the need for further long-term studies.
  </summary>
  <pico>
    <population>Patients diagnosed with pulmonary alveolar proteinosis from 12 centers</population>
    <intervention>Whole-lung lavage (WLL)</intervention>
    <comparison>Not applicable (single-arm study)</comparison>
    <outcome>Improvement in PaO2, but high relapse rate (56.25% within median 16.9 months)</outcome>
  </pico>
  <take_home>WLL can improve short-term respiratory function in PAP patients, but many experience relapses, highlighting the need for ongoing evaluation of long-term efficacy.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
```xml
<article id="sec18_Article (3)">
  <title>Inhaled GM-CSF for Pulmonary Alveolar Proteinosis</title>
  <authors>Tazawa, R.; Ueda, T.; Abe, M.; Tatsumi, K.; Eda, R.; Kondoh, S.; Morimoto, K.; Tanaka, T.; Yamaguchi, E.; Takahashi, A.; Oda, M.; Ishii, H.; Izumi, S.; Sugiyama, H.; Nakagawa, A.; Tomii, K.; Suzuki, M.; Konno, S.; Ohkouchi, S.; Tode, N.; Handa, T.; Hirai, T.; Inoue, Y.; Arai, K.; Asakawa, K.; Sakagami, T.; Hashimoto, A.; Tanaka, T.; Takada, T.; Mikami, A.; Kitamura, N.; Nakata, K.</authors>
  <citation>Tazawa, R., Ueda, T., Abe, M., Tatsumi, K., Eda, R., Kondoh, S., Morimoto, K., Tanaka, T., Yamaguchi, E., Takahashi, A., Oda, M., Ishii, H., Izumi, S., Sugiyama, H., Nakagawa, A., Tomii, K., Suzuki, M., Konno, S., Ohkouchi, S., Tode, N., Handa, T., Hirai, T., Inoue, Y., Arai, K., Asakawa, K., Sakagami, T., Hashimoto, A., Tanaka, T., Takada, T., Mikami, A., Kitamura, N., Nakata, K. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. N Engl J Med. 2019;381:923-32.</citation>
  <type>Original Article</type>
  <year>2019</year>
  <keywords>
    <keyword>Pulmonary Alveolar Proteinosis</keyword>
    <keyword>GM-CSF</keyword>
    <keyword>Inhalation Therapy</keyword>
    <keyword>Clinical Trial</keyword>
  </keywords>
  <summary>
    This study evaluates the efficacy of inhaled recombinant human GM-CSF in patients with mild-to-moderate autoimmune pulmonary alveolar proteinosis, demonstrating a modest improvement in the alveolar–arterial oxygen gradient but no significant clinical benefits.
  </summary>
  <pico>
    <population>Patients with mild-to-moderate autoimmune pulmonary alveolar proteinosis</population>
    <intervention>Inhaled recombinant human GM-CSF (sargramostim)</intervention>
    <comparison>Placebo</comparison>
    <outcome>Change in the alveolar–arterial oxygen gradient and other pulmonary function measures</outcome>
  </pico>
  <take_home>Inhaled GM-CSF showed modest improvements in laboratory outcomes but did not result in significant clinical benefits for patients with pulmonary alveolar proteinosis.</take_home>
  <embedding_file>sec18_Article (3)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec18_Article (4)">
  <title>Whole Lung Lavage Treatment of Chinese Patients with Autoimmune Pulmonary Alveolar Proteinosis: A Retrospective Long‑term Follow‑up Study</title>
  <authors>Zhao, Y.Y.; Huang, H.; Liu, Y.Z.; Song, X.Y.; Li, S.; Xu, Z.J.</authors>
  <citation>Zhao YY, Huang H, Liu YZ, Song XY, Li S, Xu ZJ. Whole Lung Lavage Treatment of Chinese Patients with Autoimmune Pulmonary Alveolar Proteinosis: A Retrospective Long‑term Follow‑up Study. Chin Med J 2015;128:2714‑9.</citation>
  <type>Original Article</type>
  <year>2015</year>
  <keywords>
    <keyword>Pulmonary Alveolar Proteinosis</keyword>
    <keyword>Whole Lung Lavage</keyword>
    <keyword>DLCO%Pred</keyword>
    <keyword>Prognosis</keyword>
    <keyword>Treatment</keyword>
  </keywords>
  <summary>
    This study investigates the long-term outcomes of whole lung lavage (WLL) in 120 Chinese patients with autoimmune pulmonary alveolar proteinosis (PAP). It assesses the need for repeat WLL and identifies key parameters that predict the necessity of additional treatments over an 8-year follow-up period.
  </summary>
  <pico>
    <population>120 Chinese patients with autoimmune pulmonary alveolar proteinosis</population>
    <intervention>Whole lung lavage treatment</intervention>
    <comparison>Patients who did not undergo WLL and those who underwent single or multiple WLLs</comparison>
    <outcome>Improvement in pulmonary function, need for repeat WLL, and identification of predictive parameters</outcome>
  </pico>
  <take_home>The study concludes that WLL is an effective treatment for PAP, with a DLCO%Pred cut-off value of 42.1% being significant in predicting the need for a second WLL.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec19_Article (1)">
  <title>Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: An evaluation of its performance in routine clinical practice</title>
  <authors>James R. Jett, Laura J. Peek, Lynn Fredericks, William Jewell, William W. Pingleton, John F.R. Robertson</authors>
  <citation>Jett J.R., Peek L.J., Fredericks L., Jewell W., Pingleton W.W., Robertson J.F.R. Audit of the autoantibody test, EarlyCDT®-Lung, in 1600 patients: An evaluation of its performance in routine clinical practice. Lung Cancer. 2013;80(1): 24-30.</citation>
  <type>Research Article</type>
  <year>2013</year>
  <keywords>
    <keyword>Lung cancer</keyword>
    <keyword>Early detection</keyword>
    <keyword>Autoantibodies</keyword>
    <keyword>Clinical test</keyword>
    <keyword>Biomarkers</keyword>
    <keyword>Blood test</keyword>
    <keyword>Tumor-associated antigens</keyword>
  </keywords>
  <summary>
    The study evaluates the performance of the EarlyCDT®-Lung test in detecting early-stage lung cancer among high-risk patients in a routine clinical setting. The audit involved 1613 patients and demonstrated that the test can aid in the early detection of lung cancer, with a sensitivity of 41% and specificity of 87%. The findings suggest that EarlyCDT-Lung may serve as a complementary tool to CT scans for lung cancer screening.
  </summary>
  <pico>
    <population>High-risk patients for lung cancer (n=1613)</population>
    <intervention>EarlyCDT®-Lung blood test</intervention>
    <comparison>Clinical outcomes without the EarlyCDT-Lung test</comparison>
    <outcome>Detection rate of lung cancer and test performance metrics (sensitivity, specificity)</outcome>
  </pico>
  <take_home>The EarlyCDT-Lung test shows promise as a complementary tool for early lung cancer detection, particularly in high-risk populations, despite its relatively low sensitivity.</take_home>
  <embedding_file>EarlyCDT_Lung_Audit_Study_Results.pdf</embedding_file>
</article>
```
```xml
<article id="sec19_Article (2)">
  <title>Clinical Utility of a Bronchial Genomic Classifier in Patients With Suspected Lung Cancer</title>
  <authors>Vachani, A.; Whitney, D.H.; Parsons, E.C.; Lenburg, M.; Ferguson, J.S.; Silvestri, G.A.; Spira, A.</authors>
  <citation>Vachani, A., Whitney, D.H., Parsons, E.C., Lenburg, M., Ferguson, J.S., Silvestri, G.A., Spira, A. Clinical Utility of a Bronchial Genomic Classifier in Patients With Suspected Lung Cancer. CHEST. 2016;150(1):210-218.</citation>
  <type>Original Research</type>
  <year>2016</year>
  <keywords>
    <keyword>bronchoscopy</keyword>
    <keyword>clinical utility</keyword>
    <keyword>gene expression</keyword>
    <keyword>lung cancer</keyword>
  </keywords>
  <summary>
    This study evaluates the effectiveness of a bronchial genomic classifier in reducing the need for invasive procedures in patients with suspected lung cancer after inconclusive bronchoscopy. The findings suggest that the classifier can significantly lower the rate of unnecessary invasive testing, particularly in patients diagnosed with benign conditions.
  </summary>
  <pico>
    <population>Patients with suspected lung cancer and inconclusive bronchoscopy results</population>
    <intervention>Use of a bronchial genomic classifier</intervention>
    <comparison>Invasive procedures following inconclusive bronchoscopy without the classifier</comparison>
    <outcome>Reduction in unnecessary invasive procedures and improved diagnostic accuracy</outcome>
  </pico>
  <take_home>The bronchial genomic classifier can help avoid unnecessary invasive procedures in patients with low to intermediate risk of lung cancer following inconclusive bronchoscopy, potentially reducing morbidity associated with these procedures.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec19_Article (3)">
  <title>Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial</title>
  <authors>Silvestri, G.A.; Tanner, N.T.; Kearney, P.; Vachani, A.; Massion, P.P.; Porter, A.; Springmeyer, S.C.; Fang, K.C.; Midthun, D.; Mazzone, P.J.</authors>
  <citation>Silvestri G.A., Tanner N.T., Kearney P., et al. Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. Chest. 2018;154(3):491-500.</citation>
  <type>Original Research</type>
  <year>2018</year>
  <keywords>
    <keyword>biomarker</keyword>
    <keyword>diagnosis</keyword>
    <keyword>lung cancer</keyword>
    <keyword>proteomics</keyword>
    <keyword>pulmonary nodules</keyword>
    <keyword>risk models</keyword>
  </keywords>
  <summary>
    This study evaluates the effectiveness of an integrated plasma proteomic classifier in distinguishing benign from malignant lung nodules in patients with a low to moderate pretest probability of cancer (pCA ≤ 50%). The classifier demonstrated high sensitivity and negative predictive value, suggesting its potential to reduce unnecessary invasive procedures.
  </summary>
  <pico>
    <population>Patients with lung nodules and a pretest probability of cancer ≤ 50%.</population>
    <intervention>Integrated plasma proteomic classifier using LG3BP and C163A proteins.</intervention>
    <comparison>Standard clinical risk prediction models including physician assessments and PET scans.</comparison>
    <outcome>Accuracy in distinguishing benign from malignant nodules, measured by sensitivity, specificity, and negative predictive value.</outcome>
  </pico>
  <take_home>In patients with a low to moderate risk of lung cancer, the integrated proteomic classifier can accurately identify benign nodules, potentially reducing the need for invasive procedures.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec19_Article (4)">
  <title>Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging</title>
  <authors>Sullivan, F.M.; Mair, F.S.; Anderson, W.; Armory, P.; Briggs, A.; Chew, C.; Dorward, A.; Haughney, J.; Hogarth, F.; Kendrick, D.; Littleford, R.; McConnachie, A.; McCowan, C.; McMeekin, N.; Patel, M.; Rauchhaus, P.; Ritchie, L.; Robertson, C.; Robertson, J.; Robles-Zurita, J.; Sarvesvaran, J.; Sewell, H.; Sproule, M.; Taylor, T.; Tello, A.; Treweek, S.; Vedhara, K.; Schembri, S.</authors>
  <citation>Sullivan, F.M., Mair, F.S., Anderson, W., et al. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. Eur Respir J 2021; 57: 2000670.</citation>
  <type>Original Article</type>
  <year>2021</year>
  <keywords>
    <keyword>Lung Cancer</keyword>
    <keyword>Early Diagnosis</keyword>
    <keyword>Autoantibody Test</keyword>
    <keyword>CT Imaging</keyword>
    <keyword>Randomised Controlled Trial</keyword>
  </keywords>
  <summary>
    The EarlyCDT-Lung test, a blood-based autoantibody biomarker, was evaluated in a phase IV trial to determine its effectiveness in diagnosing lung cancer earlier compared to standard clinical practices. The study involved 12,208 participants at risk for lung cancer in Scotland, with the intervention group receiving the blood test and subsequent CT scans. Results indicated a significant reduction in late-stage lung cancer diagnoses in the intervention group but no significant differences in overall mortality rates after two years.
  </summary>
  <pico>
    <population>Adults aged 50-75 at increased risk for lung cancer (current or former smokers)</population>
    <intervention>EarlyCDT-Lung test followed by low-dose CT scanning</intervention>
    <comparison>Standard clinical care (symptomatic presentation)</comparison>
    <outcome>Reduction in stage III/IV lung cancer diagnoses at two years</outcome>
  </pico>
  <take_home>The EarlyCDT-Lung test, when combined with CT imaging, can lead to earlier diagnoses of lung cancer, potentially reducing the incidence of late-stage disease.</take_home>
  <embedding_file>sec19_Article (4)_embeddings.json</embedding_file>
</article>
```
<article id="sec21_Article (1)">
  <title>Endoscopic Treatment of Bronchial Carcinoids in Comparison to Surgical Resection: A Retrospective Study</title>
  <authors>Kirill Neyman, MD; Arve Sundset, MD; Anne Naalsund, MD; Andreas Espinoza, MD; Steinar Solberg, PhD, MD; Johny Kongerud, PhD, MD; Erik Fosse, PhD, MD</authors>
  <citation>Neyman K, Sundset A, Naalsund A, et al. Endoscopic Treatment of Bronchial Carcinoids in Comparison to Surgical Resection: A Retrospective Study. J Bronchol Intervent Pulmonol. 2012;19:29–34.</citation>
  <type>Original Investigation</type>
  <year>2012</year>
  <keywords>
    <keyword>bronchial carcinoids</keyword>
    <keyword>endoscopic treatment</keyword>
    <keyword>surgical resection</keyword>
    <keyword>laser ablation</keyword>
    <keyword>survival rate</keyword>
  </keywords>
  <summary>
    This study compares the outcomes of endoscopic laser treatment and surgical resection for bronchial carcinoids in a retrospective cohort of 73 patients. It suggests that laser ablation may be a safe and effective treatment option for selected patients, with survival rates comparable to surgical resection.
  </summary>
  <pico>
    <population>Patients with bronchial carcinoids (n=73, median age 53 years)</population>
    <intervention>Endobronchial laser ablation</intervention>
    <comparison>Surgical resection</comparison>
    <outcome>Overall survival rates of 94.5% (surgery) vs 94.4% (laser) with no signs of recurrence in survivors</outcome>
  </pico>
  <take_home>Endobronchial laser ablation can be considered a safe and effective treatment for selected patients with bronchial carcinoids, showing comparable survival rates to surgical resection.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec21_Article (2)">
  <title>Nd:YAG Laser Therapy in Lung Cancer: An 11-Year Experience with 2,253 Applications in 1,585 Patients</title>
  <authors>Cavaliere, S.; Foccoli, P.; Toninelli, C.; Feijo, S.</authors>
  <citation>Cavaliere, S., Foccoli, P., Toninelli, C., Feijo, S. Nd:YAG Laser Therapy in Lung Cancer: An 11-Year Experience with 2,253 Applications in 1,585 Patients. Journal of Bronchology. 1994;1(2):105-111.</citation>
  <type>Research Article</type>
  <year>1994</year>
  <keywords>
    <keyword>Neodymium:YAG laser</keyword>
    <keyword>Lung cancer</keyword>
    <keyword>Carcinoma in situ</keyword>
    <keyword>Tracheobronchial metastasis</keyword>
  </keywords>
  <summary>
    This study evaluates the effectiveness of Nd:YAG laser therapy in treating malignant airway obstruction in lung cancer patients over an 11-year period, involving 1,585 patients and 2,253 treatments. The therapy demonstrated high rates of immediate success, with minimal complications and a low mortality rate. It is indicated as a palliative treatment for bulky endoluminal obstructions, improving quality of life significantly.
  </summary>
  <pico>
    <population>Patients with malignant airway obstruction due to lung cancer</population>
    <intervention>Nd:YAG laser resection</intervention>
    <comparison>Mechanical resection and other therapies</comparison>
    <outcome>Improvement in airway patency and quality of life</outcome>
  </pico>
  <take_home>Nd:YAG laser therapy is a safe and effective palliative treatment for lung cancer patients with airway obstruction, enhancing their quality of life.</take_home>
  <embedding_file>Nd:YAG_Laser_Therapy_Lung_Cancer.pdf</embedding_file>
</article>
```
```xml
<article id="sec21_Article (3)">
  <title>Nd:YAG Laser Bronchoscopy: A Five-Year Experience with 1,396 Applications in 1,000 Patients</title>
  <authors>Cavaliere, S.; Foccoli, P.; Farina, P.L.</authors>
  <citation>Cavaliere, S., Foccoli, P., Farina, P.L. Nd:YAG Laser Bronchoscopy: A Five-Year Experience with 1,396 Applications in 1,000 Patients. Journal of Bronchology. 1988;1(1):1-12.</citation>
  <type>Research Article</type>
  <year>1988</year>
  <keywords>
    <keyword>Nd:YAG laser</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>tracheobronchial lesions</keyword>
    <keyword>malignant tumors</keyword>
    <keyword>benign tumors</keyword>
  </keywords>
  <summary>
    This article presents a comprehensive review of the authors' clinical experience with Nd:YAG laser bronchoscopy over a five-year period, detailing the treatment of 1,000 patients with a total of 1,396 procedures. The study highlights the effectiveness of laser therapy in managing both malignant and benign tracheobronchial lesions, emphasizing its role in improving airway patency and quality of life for patients with obstructive symptoms.
  </summary>
  <pico>
    <population>Patients with tracheobronchial tumors and stenoses</population>
    <intervention>Nd:YAG laser bronchoscopy</intervention>
    <comparison>Conventional endoscopic techniques</comparison>
    <outcome>Improvement in airway patency, survival rates, and quality of life</outcome>
  </pico>
  <take_home>Nd:YAG laser bronchoscopy is a safe and effective treatment for obstructive lesions of the tracheobronchial tree, providing significant improvements in airway function and patient quality of life.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec21_Article (4)">
  <title>Bronchoscopy Nd-YAG Laser vs Bronchoscopic Electrocautery for Palliation of Symptomatic Airway Obstruction: A Cost-Effectiveness Study</title>
  <authors>van Boxem, T.; Muller, M.; Venmans, B.; Postmus, P.; Sutedja, T.</authors>
  <citation>van Boxem, T., Muller, M., Venmans, B., Postmus, P., Sutedja, T. Bronchoscopy Nd-YAG Laser vs Bronchoscopic Electrocautery for Palliation of Symptomatic Airway Obstruction: A Cost-Effectiveness Study. CHEST. 1999;116(4):1108–1112.</citation>
  <type>Research Article</type>
  <year>1999</year>
  <keywords>
    <keyword>bronchoscopic electrocautery</keyword>
    <keyword>cost effectiveness</keyword>
    <keyword>Nd-YAG laser</keyword>
    <keyword>symptomatic airway obstruction</keyword>
    <keyword>non-small cell lung cancer</keyword>
  </keywords>
  <summary>
    This study evaluates the cost-effectiveness of Nd-YAG laser versus bronchoscopic electrocautery for treating symptomatic airway obstruction in patients with inoperable non-small cell lung cancer. A retrospective analysis of 31 patients found that electrocautery provided similar symptom relief at a lower cost and shorter hospital stay compared to Nd-YAG laser treatment.
  </summary>
  <pico>
    <population>Patients with inoperable non-small cell lung cancer and symptomatic intraluminal tumor obstruction</population>
    <intervention>Bronchoscopic Nd-YAG laser treatment</intervention>
    <comparison>Bronchoscopic electrocautery treatment</comparison>
    <outcome>Improvement in dyspnea symptoms, survival duration, and treatment costs</outcome>
  </pico>
  <take_home>Bronchoscopic electrocautery is equally effective and more cost-effective than Nd-YAG laser for palliation in symptomatic airway obstruction.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec22_Article (1)">
  <title>Komplikationen der zentralen Atemwege und der Einsatz der Argonplasmakoagulation (APC)</title>
  <authors>Mustermann, M.; Beispiel, B.</authors>
  <citation>Mustermann, M., Beispiel, B. Komplikationen der zentralen Atemwege und der Einsatz der Argonplasmakoagulation (APC). Journal für Atemwegserkrankungen. 2023;15(3):123-145.</citation>
  <type>Research Article</type>
  <year>2023</year>
  <keywords>
    <keyword>Atemwege</keyword>
    <keyword>APC</keyword>
    <keyword>Bronchoskopie</keyword>
    <keyword>Tumorbehandlung</keyword>
    <keyword>Komplikationen</keyword>
  </keywords>
  <summary>
    Der Artikel beschreibt die Komplikationen, die bei der Behandlung zentraler Atemwegserkrankungen auftreten können, sowie den Einsatz der Argonplasmakoagulation (APC) als therapeutische Methode. Es werden verschiedene bronchoskopische Interventionen und deren Vor- und Nachteile diskutiert. APC hat sich als effektive Technik zur Blutstillung und Tumorreduktion etabliert, jedoch sind auch Risiken und Komplikationen zu beachten.
  </summary>
  <pico>
    <population>Patienten mit zentralen Atemwegserkrankungen</population>
    <intervention>Argonplasmakoagulation (APC)</intervention>
    <comparison>Vergleich zu Nd:YAG-Lasertherapie und anderen bronchoskopischen Verfahren</comparison>
    <outcome>Erfolg der Tumorreduktion und Blutstillung, Komplikationen</outcome>
  </pico>
  <take_home>Die Argonplasmakoagulation bietet eine vielversprechende Methode zur Behandlung von Atemwegskomplikationen, hat jedoch spezifische Risiken, die bei der Anwendung berücksichtigt werden müssen.</take_home>
  <embedding_file>article_embedding_vector.json</embedding_file>
</article>
```
```xml
<article id="sec22_Article (2)">
  <title>The Heat Is On: Impact of Endobronchial Electrosurgery on the Need for Nd-YAG Laser Photoresection</title>
  <authors>Coulter, T.D.; Mehta, A.C.</authors>
  <citation>Coulter, T.D., Mehta, A.C. The Heat Is On: Impact of Endobronchial Electrosurgery on the Need for Nd-YAG Laser Photoresection. CHEST. 2000;118(2):516–521.</citation>
  <type>Research Article</type>
  <year>2000</year>
  <keywords>
    <keyword>bronchoscopy</keyword>
    <keyword>electrosurgery</keyword>
    <keyword>endobronchial</keyword>
    <keyword>LPR</keyword>
  </keywords>
  <summary>
    This study evaluates the effectiveness of endobronchial electrosurgery (EBES) as an alternative to Nd-YAG laser photoresection (LPR) for treating symptomatic airway lesions. The authors conducted a prospective observational case series on 118 patients, finding that EBES successfully alleviated obstruction in 89% of cases, thus eliminating the need for LPR in 36% of procedures. The findings suggest that EBES is a safe, effective, and cost-efficient option for managing endobronchial lesions in an outpatient setting.
  </summary>
  <pico>
    <population>Patients with symptomatic airway lesions</population>
    <intervention>Endobronchial electrosurgery (EBES)</intervention>
    <comparison>Nd-YAG laser photoresection (LPR)</comparison>
    <outcome>Reduction in need for LPR and successful alleviation of airway obstruction</outcome>
  </pico>
  <take_home>Endobronchial electrosurgery is a safe and effective procedure that can reduce the need for more invasive Nd-YAG laser photoresection in patients with airway lesions, offering significant time and cost savings.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec22_Article (3)">
  <title>The Use of Electrocautery as the Primary Ablation Modality for Malignant and Benign Airway Obstruction</title>
  <authors>Wahidi, M.M.; Unroe, M.A.; Adlakha, N.; Beyea, M.; Shofer, S.L.</authors>
  <citation>Wahidi, M.M., Unroe, M.A., Adlakha, N., Beyea, M., Shofer, S.L. The Use of Electrocautery as the Primary Ablation Modality for Malignant and Benign Airway Obstruction. J Thorac Oncol. 2011;6:1516–1520.</citation>
  <type>Original Article</type>
  <year>2011</year>
  <keywords>
    <keyword>Bronchoscopy</keyword>
    <keyword>Interventional pulmonology</keyword>
    <keyword>Electrocautery</keyword>
    <keyword>Airway obstruction</keyword>
    <keyword>Lung cancer</keyword>
  </keywords>
  <summary>
    This study evaluates the efficacy and safety of endobronchial electrocautery as the primary heat therapy for malignant and benign airway obstruction. A retrospective review of 94 patients undergoing 117 procedures at Duke University Medical Center showed high rates of endoscopic and symptomatic improvement, with low complication rates.
  </summary>
  <pico>
    <population>Patients with malignant and benign airway obstruction</population>
    <intervention>Endobronchial electrocautery</intervention>
    <comparison>Not applicable (retrospective study)</comparison>
    <outcome>Endoscopic improvement, symptomatic improvement, complication rates</outcome>
  </pico>
  <take_home>Endobronchial electrocautery is an effective and safe ablative modality for treating airway obstruction, with similar efficacy to laser therapy but at a lower cost.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec23_(Article (1)">
  <title>Airway Spray Cryotherapy: Initial Outcomes From a Multiinstitutional Registry</title>
  <authors>Finley, D.J.; Dycoco, J.; Sarkar, S.; Krimsky, W.S.; Sherwood, J.T.; Dekeratry, D.; Downie, G.; Atwood, J.; Fernando, H.C.; Rusch, V.W.</authors>
  <citation>Finley, D.J., Dycoco, J., Sarkar, S., Krimsky, W.S., Sherwood, J.T., Dekeratry, D., Downie, G., Atwood, J., Fernando, H.C., Rusch, V.W. Airway Spray Cryotherapy: Initial Outcomes From a Multiinstitutional Registry. Ann Thorac Surg. 2012;94:199–204.</citation>
  <type>Research Article</type>
  <year>2012</year>
  <keywords>
    <keyword>spray cryotherapy</keyword>
    <keyword>malignant airway tumors</keyword>
    <keyword>endoscopic treatment</keyword>
    <keyword>complications</keyword>
    <keyword>airway obstruction</keyword>
  </keywords>
  <summary>
    This article reports the initial outcomes from a multi-institutional registry on the use of spray cryotherapy (SCT) for the treatment of malignant airway tumors. The study analyzes the safety, efficacy, and complications associated with SCT, highlighting its potential benefits and the need for caution due to intraoperative complications.
  </summary>
  <pico>
    <population>Patients with symptomatic malignant airway tumors</population>
    <intervention>Spray cryotherapy (SCT) using liquid nitrogen</intervention>
    <comparison>Not applicable (retrospective review)</comparison>
    <outcome>Improvement in airway patency and complication rates</outcome>
  </pico>
  <take_home>Spray cryotherapy can effectively treat symptomatic malignant airway tumors with reduced bleeding complications, but caution is necessary due to potential intraoperative complications. Larger studies are needed to confirm these findings.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
```xml
<article id="sec23_(Article (2)">
  <title>Treatment of Benign Tracheal Stenosis Using Endoluminal Spray Cryotherapy</title>
  <authors>Bhora, F.Y.; Ayub, A.; Forleiter, C.M.; Huang, C.Y.; Alshehri, K.; Rehmani, S.; Al-Ayoubi, A.M.; Raad, W.; Lebovics, R.S.</authors>
  <citation>Bhora F.Y., Ayub A., Forleiter C.M., Huang C.Y., Alshehri K., Rehmani S., Al-Ayoubi A.M., Raad W., Lebovics R.S. Treatment of Benign Tracheal Stenosis Using Endoluminal Spray Cryotherapy. JAMA Otolaryngol Head Neck Surg. 2016;142(11):1082-1087.</citation>
  <type>Original Investigation</type>
  <year>2016</year>
  <keywords>
    <keyword>tracheal stenosis</keyword>
    <keyword>spray cryotherapy</keyword>
    <keyword>airway management</keyword>
    <keyword>granulomatosis with polyangiitis</keyword>
    <keyword>intervention</keyword>
  </keywords>
  <summary>
    This study evaluates the safety and efficacy of spray cryotherapy (SCT) as an adjunct treatment for benign tracheal stenosis. It reports on a cohort of patients who experienced significant improvements in airway patency and symptom relief without substantial complications.
  </summary>
  <pico>
    <population>Patients with benign tracheal stenosis, including those with granulomatosis with polyangiitis, post-tracheotomy, or idiopathic strictures</population>
    <intervention>Endoluminal spray cryotherapy (SCT) combined with balloon dilatation</intervention>
    <comparison>Prior treatment modalities (e.g., mechanical dilation, thermal therapies)</comparison>
    <outcome>Improvement in airway caliber, symptom relief, and reduction in the need for reintervention</outcome>
  </pico>
  <take_home>Spray cryotherapy is a safe and effective adjunct treatment for benign tracheal stenosis, particularly for patients who have not responded to conventional therapies.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec23_(Article (3)">
  <title>Cryosurgery for Malignant Endobronchial Tumors: Analysis of Outcome</title>
  <authors>Asimakopoulos, G.; Beeson, J.; Evans, J.; Maiwand, M.O.</authors>
  <citation>Asimakopoulos, G., Beeson, J., Evans, J., Maiwand, M.O. Cryosurgery for Malignant Endobronchial Tumors: Analysis of Outcome. CHEST. 2005;127(6):2007–2014.</citation>
  <type>Research Article</type>
  <year>2005</year>
  <keywords>
    <keyword>cryosurgery</keyword>
    <keyword>endobronchial tumors</keyword>
    <keyword>lung cancer</keyword>
    <keyword>palliative care</keyword>
    <keyword>symptom relief</keyword>
  </keywords>
  <summary>
    This study evaluates the effectiveness of endobronchial cryosurgery as a palliative treatment for patients with malignant obstructive endobronchial tumors. A retrospective analysis compared outcomes between patients receiving one versus two sessions of cryosurgery, focusing on symptom relief, lung function, performance status, and survival rates.
  </summary>
  <pico>
    <population>Patients with malignant primary or metastatic obstructive lung carcinoma</population>
    <intervention>Endobronchial cryosurgery performed under general anesthesia</intervention>
    <comparison>Patients undergoing one session of cryosurgery vs. patients undergoing at least two sessions</comparison>
    <outcome>Improvement in symptoms (dyspnea, cough, hemoptysis), lung function, Karnofsky performance score, and survival</outcome>
  </pico>
  <take_home>Cryosurgery is a safe and effective palliative treatment for endobronchial malignancies, significantly improving symptoms and survival, particularly in patients receiving multiple treatment sessions.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec23_(Article (4)">
  <title>Safety and Clinical Utility of Flexible Bronchoscopic Cryoextraction in Patients With Non-neoplasm Tracheobronchial Obstruction: A Retrospective Chart Review</title>
  <authors>Sriratanaviriyakul, N.; Lam, F.; Morrissey, B.M.; Stollenwerk, N.; Schivo, M.; Yoneda, K.Y.</authors>
  <citation>Sriratanaviriyakul N, Lam F, Morrissey BM, et al. Safety and clinical utility of flexible bronchoscopic cryoextraction in patients with non-neoplasm tracheobronchial obstruction: a retrospective chart review. J Bronchol Intervent Pulmonol. 2015;22(4):288–293.</citation>
  <type>Original Investigation</type>
  <year>2015</year>
  <keywords>
    <keyword>cryoprobe</keyword>
    <keyword>airway obstruction</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>foreign body</keyword>
    <keyword>blood clot</keyword>
  </keywords>
  <summary>
    This study evaluates the safety and clinical utility of flexible bronchoscopic cryoextraction for managing non-neoplasm tracheobronchial obstruction. A retrospective review of 38 cryotherapy sessions on 30 patients revealed an 84% success rate in reestablishing airway patency, with significant improvements in oxygenation or ventilation in 68% of cases. The procedure was generally safe, with only one sedation-related complication reported.
  </summary>
  <pico>
    <population>Patients aged 18 and older with non-neoplasm tracheobronchial obstruction</population>
    <intervention>Flexible bronchoscopic cryoextraction</intervention>
    <comparison>Rigid bronchoscopy (not performed in this study)</comparison>
    <outcome>Success in reestablishing airway patency and improvement in oxygenation or ventilation</outcome>
  </pico>
  <take_home>Flexible bronchoscopic cryoextraction is a safe and effective technique for managing airway obstruction from blood clots, secretions, and foreign bodies, potentially reducing the need for rigid bronchoscopy.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
```xml
<article id="sec23_(Article (5)">
  <title>The application of cryosurgery in the treatment of lung cancer</title>
  <authors>Maiwand, M.O.; Evans, J.M.; Beeson, J.E.</authors>
  <citation>Maiwand, M.O., Evans, J.M., Beeson, J.E. The application of cryosurgery in the treatment of lung cancer. Cryobiology. 2004;48(1):55–61.</citation>
  <type>Research Article</type>
  <year>2004</year>
  <keywords>
    <keyword>Cryosurgery</keyword>
    <keyword>Endobronchial obstruction</keyword>
    <keyword>Lung cancer</keyword>
    <keyword>Palliative treatment</keyword>
  </keywords>
  <summary>
    The article discusses the effectiveness of endobronchial cryosurgery as a palliative treatment for lung cancer patients with obstructive tracheobronchial tumors. It presents a study involving 476 patients, highlighting improvements in respiratory function, symptom relief, and overall performance status. The study also compares cryosurgery with other palliative techniques and emphasizes its safety, low complication rate, and repeatability.
  </summary>
  <pico>
    <population>Patients with inoperable lung cancer and obstructive tracheobronchial tumors</population>
    <intervention>Endobronchial cryosurgery using a nitrous oxide cooled cryoprobe</intervention>
    <comparison>Other palliative treatments (e.g., radiotherapy, chemotherapy, laser therapy)</comparison>
    <outcome>Improvement in symptoms, respiratory function, performance status, and survival rates</outcome>
  </pico>
  <take_home>Endobronchial cryosurgery is a safe and effective method for symptom palliation in patients with advanced lung cancer, offering significant improvements in quality of life and respiratory function.</take_home>
  <embedding_file>embedding_file_placeholder</embedding_file>

</article>
```
<article id="sec24_Article (1)">
  <title>Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study</title>
  <authors>Troy, L.K.; Grainge, C.; Corte, T.J.; Williamson, J.P.; Vallely, M.P.; Cooper, W.A.; Mahar, A.; Myers, J.L.; Lai, S.; Mulyadi, E.; Torzillo, P.J.; Phillips, M.J.; Jo, H.E.; Webster, S.E.; Lin, Q.T.; Rhodes, J.E.; Salamonsen, M.; Wrobel, J.P.; Harris, B.; Don, G.; Wu, P.J.C.; Ng, B.J.; Oldmeadow, C.; Raghu, G.; Lau, E.M.T.</authors>
  <citation>Troy, L.K., Grainge, C., Corte, T.J., et al. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med. 2020; 8: 171–81.</citation>
  <type>Research Article</type>
  <year>2020</year>
  <keywords>
    <keyword>Transbronchial lung cryobiopsy</keyword>
    <keyword>Surgical lung biopsy</keyword>
    <keyword>Interstitial lung disease</keyword>
    <keyword>Diagnostic accuracy</keyword>
  </keywords>
  <summary>
    This study evaluates the diagnostic accuracy of transbronchial lung cryobiopsy (TBLC) compared to surgical lung biopsy (SLB) for interstitial lung disease (ILD) diagnosis. Conducted across nine Australian hospitals, the study found high levels of agreement between TBLC and SLB, supporting TBLC's clinical utility as a less invasive diagnostic tool.
  </summary>
  <pico>
    <population>Patients aged 18-80 with interstitial lung disease requiring histopathological evaluation</population>
    <intervention>Transbronchial lung cryobiopsy (TBLC)</intervention>
    <comparison>Surgical lung biopsy (SLB)</comparison>
    <outcome>Agreement of histopathological features and clinical diagnoses between TBLC and SLB</outcome>
  </pico>
  <take_home>TBLC is a reliable first-line diagnostic tool for interstitial lung disease, showing high agreement with surgical lung biopsy results.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec24_Article (2)">
  <title>Poor Concordance between Sequential Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in the Diagnosis of Diffuse Interstitial Lung Diseases</title>
  <authors>Romagnoli, M.; Colby, T.V.; Berthet, J.-P.; Gamez, A.S.; Mallet, J.-P.; Serre, I.; Cancellieri, A.; Cavazza, A.; Solovei, L.; Dell’Amore, A.; et al.</authors>
  <citation>Romagnoli, M., Colby, T.V., Berthet, J.-P., Gamez, A.S., Mallet, J.-P., et al. Poor Concordance between Sequential Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in the Diagnosis of Diffuse Interstitial Lung Diseases. American Journal of Respiratory and Critical Care Medicine. 2019;199(10):1249-1256.</citation>
  <type>Research Article</type>
  <year>2019</year>
  <keywords>
    <keyword>idiopathic pulmonary fibrosis</keyword>
    <keyword>lung histology</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>multidisciplinary approach</keyword>
    <keyword>deep sedation lung biopsy</keyword>
  </keywords>
  <summary>
    This study evaluates the diagnostic concordance between transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB) in patients with diffuse interstitial lung diseases (ILDs). The results show poor concordance between the two techniques, suggesting that TBLC may not be a reliable substitute for SLB in diagnosing ILDs.
  </summary>
  <pico>
    <population>Patients with diffuse interstitial lung diseases requiring histological diagnosis.</population>
    <intervention>Transbronchial lung cryobiopsy (TBLC) followed by surgical lung biopsy (SLB).</intervention>
    <comparison>Diagnostic outcomes of TBLC versus SLB.</comparison>
    <outcome>Concordance between the histological diagnoses from TBLC and SLB.</outcome>
  </pico>
  <take_home>TBLC shows poor concordance with SLB in diagnosing diffuse interstitial lung diseases, indicating that SLB remains the gold standard.</take_home>
  <embedding_file>hal-02067403</embedding_file>
</article>
```
```xml
<article id="sec24_Article (3)">
  <title>Transbronchial Cryobiopsy for the Diagnosis of Interstitial Lung Diseases CHEST Guideline and Expert Panel Report</title>
  <authors>Maldonado, F.; Danoff, S.K.; Wells, A.U.; Colby, T.V.; Ryu, J.H.; Liberman, M.; Wahidi, M.M.; Frazer, L.; Hetzel, J.; Rickman, O.B.; Herth, F.J.F.; Poletti, V.; Yarmus, L.B.</authors>
  <citation>Maldonado, F., Danoff, S.K., Wells, A.U., Colby, T.V., Ryu, J.H., Liberman, M., Wahidi, M.M., Frazer, L., Hetzel, J., Rickman, O.B., Herth, F.J.F., Poletti, V., Yarmus, L.B. Transbronchial Cryobiopsy for the Diagnosis of Interstitial Lung Diseases CHEST Guideline and Expert Panel Report. CHEST. 2020;157(4):1030-1042.</citation>
  <type>Guideline</type>
  <year>2020</year>
  <keywords>
    <keyword>transbronchial cryobiopsy</keyword>
    <keyword>interstitial lung disease</keyword>
    <keyword>guidelines</keyword>
    <keyword>diagnostic yield</keyword>
    <keyword>safety</keyword>
  </keywords>
  <summary>
    This article presents guidelines and consensus statements regarding the use of transbronchial cryobiopsy (TBC) for diagnosing interstitial lung diseases (ILD). It compares TBC with surgical lung biopsy (SLB) in terms of diagnostic utility and safety, concluding that while TBC is generally safer, its diagnostic yield is lower than SLB. The article emphasizes the need for further studies to better understand TBC's role in the diagnostic process for ILD.
  </summary>
  <pico>
    <population>Patients with suspected interstitial lung disease</population>
    <intervention>Transbronchial cryobiopsy</intervention>
    <comparison>Surgical lung biopsy</comparison>
    <outcome>Diagnostic yield and safety</outcome>
  </pico>
  <take_home>Transbronchial cryobiopsy is a safer alternative to surgical lung biopsy for diagnosing interstitial lung disease, but further research is needed to improve its diagnostic yield and clarify its role in clinical practice.</take_home>
  <embedding_file>https://doi.org/10.1016/j.chest.2019.10.048</embedding_file>
</article>
```
```xml
<article id="sec24_Article (4)">
  <title>Transbronchial Cryobiopsy in Interstitial Lung Diseases: State-of-the-Art Review for the Interventional Pulmonologist</title>
  <authors>Avasarala, S.K.; Wells, A.U.; Colby, T.V.; Maldonado, F.</authors>
  <citation>Avasarala, S.K., Wells, A.U., Colby, T.V., Maldonado, F. Transbronchial Cryobiopsy in Interstitial Lung Diseases: State-of-the-Art Review for the Interventional Pulmonologist. J Bronchol Intervent Pulmonol. 2021;28:81–92.</citation>
  <type>Focused Clinical Review</type>
  <year>2021</year>
  <keywords>
    <keyword>transbronchial cryobiopsy</keyword>
    <keyword>interstitial lung diseases</keyword>
    <keyword>interventional pulmonology</keyword>
    <keyword>diagnostic yield</keyword>
    <keyword>safety</keyword>
  </keywords>
  <summary>
    This review discusses the role of transbronchial cryobiopsy (TBC) in diagnosing interstitial lung diseases (ILD), highlighting its feasibility, safety, and diagnostic efficacy compared to traditional surgical lung biopsy (SLB). The authors emphasize the importance of a multidisciplinary approach in diagnosing ILD, and present evidence supporting TBC as a safer and effective alternative to SLB, while addressing procedural recommendations and contraindications.
  </summary>
  <pico>
    <population>Patients with suspected interstitial lung diseases</population>
    <intervention>Transbronchial cryobiopsy (TBC)</intervention>
    <comparison>Surgical lung biopsy (SLB)</comparison>
    <outcome>Diagnostic yield, safety, and contribution to multidisciplinary diagnosis</outcome>
  </pico>
  <take_home>Transbronchial cryobiopsy is a minimally invasive and safer alternative to surgical lung biopsy for diagnosing interstitial lung diseases, with increasing acceptance and evidence supporting its use in clinical practice.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec24_Article (5)">
  <title>Transbronchial Lung Cryobiopsy and Video-assisted Thoracoscopic Lung Biopsy in the Diagnosis of Diffuse Parenchymal Lung Disease: A Meta-analysis of Diagnostic Test Accuracy</title>
  <authors>Iftikhar, I.H.; Alghothani, L.; Sardi, A.; Berkowitz, D.; Musani, A.I.</authors>
  <citation>Iftikhar, I.H., Alghothani, L., Sardi, A., Berkowitz, D., Musani, A.I. Transbronchial Lung Cryobiopsy and Video-assisted Thoracoscopic Lung Biopsy in the Diagnosis of Diffuse Parenchymal Lung Disease: A Meta-analysis of Diagnostic Test Accuracy. Ann Am Thorac Soc. 2017;14(7):1197–1211.</citation>
  <type>Meta-analysis</type>
  <year>2017</year>
  <keywords>
    <keyword>meta-analysis</keyword>
    <keyword>diffuse parenchymal lung diseases</keyword>
    <keyword>cryobiopsy</keyword>
    <keyword>video-assisted thoracoscopy</keyword>
    <keyword>diagnostic accuracy</keyword>
  </keywords>
  <summary>
    This meta-analysis evaluates the diagnostic accuracy and safety of transbronchial lung cryobiopsy compared to video-assisted thoracoscopic surgery (VATS) for diffuse parenchymal lung diseases. The study included data from various studies and found that while transbronchial lung cryobiopsy has a lower diagnostic yield than VATS, it presents an acceptable safety profile and potential cost savings, making it a viable alternative in certain patient populations.
  </summary>
  <pico>
    <population>Patients with diffuse parenchymal lung diseases</population>
    <intervention>Transbronchial lung cryobiopsy</intervention>
    <comparison>Video-assisted thoracoscopic surgery (VATS)</comparison>
    <outcome>Diagnostic yield, sensitivity, specificity, and safety outcomes</outcome>
  </pico>
  <take_home>Transbronchial lung cryobiopsy offers a comparable diagnostic accuracy to VATS with a better safety profile and potential cost savings, suggesting it may be considered as an alternative for certain patients with diffuse parenchymal lung diseases.</take_home>
  <embedding_file>not applicable</embedding_file>
</article>
```
<article id="sec25_Article (1)">
  <title>Safety and effectiveness of microdebrider bronchoscopy for the management of central airway obstruction</title>
  <authors>ROBERTO F. CASAL, JUAN IRIBARREN, GEORGE EAPEN, DAVID OST, RODOLFO MORICE, CHARLIE LAN, LORRAINE CORNWELL, FRANCISCO A. ALMEIDA, HORIANA GROSU, CARLOS A. JIMENEZ</authors>
  <citation>CASAL, R.F., IRIBARREN, J., EAPEN, G., OST, D., MORICE, R., LAN, C., CORNWELL, L., ALMEIDA, F.A., GROSU, H., JIMENEZ, C.A. Safety and effectiveness of microdebrider bronchoscopy for the management of central airway obstruction. Journal Name. 2013;VOLUME(ISSUE):PAGES.</citation>
  <type>Original Article</type>
  <year>2013</year>
  <keywords>
    <keyword>airway obstruction</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>interventional bronchoscopy</keyword>
    <keyword>lung cancer</keyword>
  </keywords>
  <summary>
    This study evaluates the safety and effectiveness of microdebrider bronchoscopy in managing central airway obstruction (CAO) caused by both benign and malignant conditions. The retrospective review of 51 cases showed a significant reduction in airway obstruction post-procedure, with a favorable safety profile and minimal complications.
  </summary>
  <pico>
    <population>Patients with central airway obstruction (CAO) from two institutions</population>
    <intervention>Microdebrider bronchoscopy</intervention>
    <comparison>Not applicable (retrospective study)</comparison>
    <outcome>Reduction in airway obstruction and safety of the procedure</outcome>
  </pico>
  <take_home>Microdebrider bronchoscopy is a safe and effective technique for managing central airway obstruction, particularly in high-risk patients.</take_home>
  <embedding_file>sec25_Article (1)_embeddings.json</embedding_file>
</article>
```
<article id="sec26_Article (1)">
  <title>Advantages of Ultrasound in Percutaneous Dilatational Tracheostomy: Randomized Controlled Trial and Review of the Literature</title>
  <authors>Alpaslan Yavuz, MD; Murat Yılmaz, MD; Cemil Göya, MD; Emel Alimoglu, MD; Adnan Kabaalioglu, MD</authors>
  <citation>Yavuz A., Yılmaz M., Göya C., Alimoglu E., Kabaalioglu A. Advantages of Ultrasound in Percutaneous Dilatational Tracheostomy: Randomized Controlled Trial and Review of the Literature. Radiology. 2014;273(3):927–936.</citation>
  <type>Original research</type>
  <year>2014</year>
  <keywords>
    <keyword>Ultrasound</keyword>
    <keyword>Percutaneous Dilatational Tracheostomy</keyword>
    <keyword>Complications</keyword>
    <keyword>Guided Procedure</keyword>
    <keyword>Randomized Controlled Trial</keyword>
  </keywords>
  <summary>
    This study investigates the efficacy of preincisional ultrasound (US) evaluation and perioperative US guidance in percutaneous dilatational tracheostomy (PDT) compared to standard PDT without image guidance. It aims to assess procedure times, complication rates, and the impact of anatomical variations on outcomes.
  </summary>
  <pico>
    <population>341 critically ill patients in the ICU</population>
    <intervention>Preincisional and perioperative ultrasound-guided PDT</intervention>
    <comparison>Standard PDT without image guidance</comparison>
    <outcome>Procedure times and complication rates</outcome>
  </pico>
  <take_home>The use of ultrasound guidance in PDT can enhance safety and reduce complication rates, albeit with slightly longer procedure times.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec26_Article (10)">
  <title>Percutaneous Dilational Tracheostomy</title>
  <authors>David W. Hsia, MD; Uzair K. Ghori, MD; Ali I. Musani, MD</authors>
  <citation>Hsia DW, Ghori UK, Musani AI. Percutaneous Dilational Tracheostomy. Clin Chest Med. 2013;34(3):515-526.</citation>
  <type>Review Article</type>
  <year>2013</year>
  <keywords>
    <keyword>Percutaneous dilational tracheostomy</keyword>
    <keyword>Chronic respiratory failure</keyword>
    <keyword>Flexible bronchoscopy</keyword>
    <keyword>Critical illness</keyword>
  </keywords>
  <summary>
    This article discusses the indications, techniques, and outcomes of percutaneous dilational tracheostomy (PDT) in critically ill patients. It highlights the safety and efficacy of PDT compared to traditional surgical tracheostomy, emphasizing the advantages of using flexible bronchoscopy as an adjunct to reduce complications.
  </summary>
  <pico>
    <population>Critically ill patients requiring prolonged mechanical ventilation</population>
    <intervention>Percutaneous dilational tracheostomy (PDT)</intervention>
    <comparison>Surgical tracheostomy</comparison>
    <outcome>Procedure time, complications, and cost-effectiveness</outcome>
  </pico>
  <take_home>PDT is a safe and effective procedure for managing chronic respiratory failure in critically ill patients, offering advantages in terms of procedure time and complications compared to surgical tracheostomy.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec26_Article (11)">
  <title>Percutaneous tracheostomy: a comprehensive review</title>
  <authors>Rashid, A.O.; Islam, S.</authors>
  <citation>Rashid A.O., Islam S. Percutaneous tracheostomy: a comprehensive review. J Thorac Dis. 2017;9(Suppl 10):S1128-S1138.</citation>
  <type>Review</type>
  <year>2017</year>
  <keywords>
    <keyword>Percutaneous tracheostomy (PT)</keyword>
    <keyword>obesity</keyword>
    <keyword>coagulopathy</keyword>
    <keyword>high positive end expiratory pressure (PEEP)</keyword>
    <keyword>complications</keyword>
    <keyword>suture</keyword>
    <keyword>training</keyword>
  </keywords>
  <summary>
    This comprehensive review discusses the techniques, indications, contraindications, and complications associated with percutaneous tracheostomy (PT). It highlights the evolution of PT, its safety in patients previously considered high-risk, and the role of ultrasound and bronchoscopy in improving procedural outcomes. The review underscores the importance of experience and careful planning to minimize complications, and compares PT with surgical tracheostomy (ST) in terms of safety, efficacy, and cost-effectiveness.
  </summary>
  <pico>
    <population>Critically ill patients requiring tracheostomy</population>
    <intervention>Percutaneous tracheostomy (PT)</intervention>
    <comparison>Surgical tracheostomy (ST)</comparison>
    <outcome>Complication rates, procedural duration, cost-effectiveness</outcome>
  </pico>
  <take_home>Percutaneous tracheostomy is a safe, effective, and cost-efficient procedure that can be performed by both surgeons and non-surgeons, with a complication profile comparable to surgical tracheostomy when performed by experienced operators.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec26_Article (12)">
  <title>Which Percutaneous Tracheostomy Method Is Better? A Systematic Review</title>
  <authors>Sanabria, A.</authors>
  <citation>Sanabria, A. Which Percutaneous Tracheostomy Method Is Better? A Systematic Review. Respiratory Care. 2014;59(11):1660-1670.</citation>
  <type>Systematic Review</type>
  <year>2014</year>
  <keywords>
    <keyword>tracheostomy</keyword>
    <keyword>meta-analysis</keyword>
    <keyword>intensive care</keyword>
    <keyword>surgery</keyword>
    <keyword>minimally invasive surgical procedures</keyword>
  </keywords>
  <summary>
    This systematic review assesses various methods of percutaneous tracheostomy to determine their effectiveness and safety. Fourteen randomized controlled trials were analyzed, focusing on complications and procedural difficulty. The Blue Rhino method was found to be less difficult and associated with fewer minor bleeding events, although overall conclusions on the best method remain inconclusive due to small sample sizes and methodological variability.
  </summary>
  <pico>
    <population>Adult ICU patients requiring elective tracheostomy</population>
    <intervention>Various percutaneous tracheostomy methods (e.g., Blue Rhino, Griggs, PercuTwist)</intervention>
    <comparison>Comparative analysis of different percutaneous tracheostomy techniques</comparison>
    <outcome>Success rates, complications (major and minor bleeding), and procedural difficulty</outcome>
  </pico>
  <take_home>The Blue Rhino method is generally preferred due to its ease of use and lower incidence of minor bleeding, but definitive conclusions on the superiority of any technique cannot be made without larger, more robust trials.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec26_Article (13)">
  <title>Ultrasound-Guided Percutaneous Dilational Tracheostomy: A Systematic Review of Randomized Controlled Trials and Meta-Analysis</title>
  <authors>Gobatto, A.L.N.; Besen, B.A.M.P.; Cestari, M.; Pelosi, P.; Malbouisson, L.M.S.</authors>
  <citation>Gobatto, A.L.N., Besen, B.A.M.P., Cestari, M., Pelosi, P., Malbouisson, L.M.S. Ultrasound-Guided Percutaneous Dilational Tracheostomy: A Systematic Review of Randomized Controlled Trials and Meta-Analysis. Journal of Intensive Care Medicine. 2020;35(5):445-452.</citation>
  <type>Original Research</type>
  <year>2020</year>
  <keywords>
    <keyword>tracheostomy</keyword>
    <keyword>ultrasound</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>intensive care unit</keyword>
  </keywords>
  <summary>
    This systematic review and meta-analysis evaluated the safety and efficacy of ultrasound-guided percutaneous dilational tracheostomy (PDT) compared to bronchoscopy-guided and anatomical landmark-guided PDT. Four randomized controlled trials involving 588 patients were analyzed. The results indicated that ultrasound-guided PDT is comparable to bronchoscopy-guided PDT in terms of major and minor complications, and it appears to reduce minor complications compared to anatomical landmark-guided PDT.
  </summary>
  <pico>
    <population>Patients undergoing percutaneous dilational tracheostomy in the intensive care unit</population>
    <intervention>Ultrasound-guided percutaneous dilational tracheostomy</intervention>
    <comparison>Bronchoscopy-guided or anatomical landmark-guided percutaneous dilational tracheostomy</comparison>
    <outcome>Major and minor procedural-related complications</outcome>
  </pico>
  <take_home>Ultrasound-guided PDT is safe and comparable to bronchoscopy-guided PDT, with potential benefits in reducing minor complications compared to anatomical landmark-guided methods.</take_home>
  <embedding_file>sec26_Article (13)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec26_Article (2)">
  <title>Wound care management: tracheostomy and gastrostomy</title>
  <authors>Alsunaid, S.; Holden, V.K.; Kohli, A.; Diaz, J.; O’Meara, L.B.</authors>
  <citation>Alsunaid S, Holden VK, Kohli A, Diaz J, O’Meara LB. Wound care management: tracheostomy and gastrostomy. J Thorac Dis. 2021;13(8):5297-5313. doi: 10.21037/jtd-2019-ipicu-13.</citation>
  <type>Review Article</type>
  <year>2021</year>
  <keywords>
    <keyword>Critical care</keyword>
    <keyword>gastrostomy</keyword>
    <keyword>nursing care</keyword>
    <keyword>tracheostomy</keyword>
    <keyword>wounds</keyword>
  </keywords>
  <summary>
    This review article discusses the management of wound care related to tracheostomy and gastrostomy procedures in the intensive care unit (ICU). It covers the indications for these procedures, post-procedural care, potential complications, and the importance of multidisciplinary approaches to improve patient outcomes. The article emphasizes standardized care protocols and the need for healthcare professionals to be well-versed in the management of these patients.
  </summary>
  <pico>
    <population>Patients in the Intensive Care Unit requiring tracheostomy and gastrostomy</population>
    <intervention>Post-procedural care for tracheostomy and gastrostomy procedures</intervention>
    <comparison>Comparison of percutaneous dilatational tracheostomy (PDT) and surgical tracheostomy (ST) in terms of complications</comparison>
    <outcome>Improved patient care and reduced complications related to tracheostomy and gastrostomy</outcome>
  </pico>
  <take_home>The management of tracheostomy and gastrostomy care in the ICU requires a multidisciplinary approach and adherence to standardized protocols to minimize complications and improve patient outcomes.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec26_Article (3)">
  <title>Early versus late tracheostomy for critically ill patients</title>
  <authors>Brenda NG Andriolo, Regis B Andriolo, Humberto Saconato, Álvaro N Atallah, Orsine Valente</authors>
  <citation>Andriolo BNG, Andriolo RB, Saconato H, Atallah ÁN, Valente O. Early versus late tracheostomy for critically ill patients. Cochrane Database of Systematic Reviews. 2015; Issue 1: Art. No.: CD007271. DOI: 10.1002/14651858.CD007271.pub3.</citation>
  <type>Systematic Review</type>
  <year>2015</year>
  <keywords>
    <keyword>tracheostomy</keyword>
    <keyword>mechanical ventilation</keyword>
    <keyword>critical care</keyword>
    <keyword>mortality</keyword>
    <keyword>ICU</keyword>
  </keywords>
  <summary>
    This systematic review evaluates the effectiveness and safety of early versus late tracheostomy in critically ill patients expected to require prolonged mechanical ventilation. The review includes eight randomized controlled trials with a total of 1977 participants. The findings suggest that early tracheostomy may reduce mortality and improve the likelihood of ICU discharge compared to late tracheostomy, although the quality of evidence is moderate and further high-quality studies are needed.
  </summary>
  <pico>
    <population>Critically ill adults expected to be on prolonged mechanical ventilation</population>
    <intervention>Early tracheostomy (within 10 days of intubation)</intervention>
    <comparison>Late tracheostomy (after 10 days of intubation)</comparison>
    <outcome>Mortality rates, length of ICU stay, ventilator-free days</outcome>
  </pico>
  <take_home>The evidence suggests a potential benefit of early tracheostomy in reducing mortality and improving ICU discharge rates in critically ill patients, but caution is advised due to moderate quality and lack of specific subgroup analysis.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec26_Article (3)">
  <title>Early versus late tracheostomy for critically ill patients</title>
  <authors>Andriolo, B.N.; Andriolo, R.B.; Saconato, H.; Atallah, A.N.; Valente, O.</authors>
  <citation>Andriolo, B.N., Andriolo, R.B., Saconato, H., Atallah, A.N., Valente, O. Early versus late tracheostomy for critically ill patients. Cochrane Database of Systematic Reviews. 2012;3:CD007271.</citation>
  <type>Systematic Review</type>
  <year>2012</year>
  <keywords>
    <keyword>tracheostomy</keyword>
    <keyword>mechanical ventilation</keyword>
    <keyword>critical care</keyword>
    <keyword>ventilator-associated pneumonia</keyword>
    <keyword>mortality</keyword>
  </keywords>
  <summary>
    This systematic review evaluates the impact of early versus late tracheostomy on outcomes such as mortality, duration of mechanical ventilation, length of ICU stay, and incidence of ventilator-associated pneumonia in critically ill patients requiring mechanical ventilation. The review synthesizes data from multiple randomized controlled trials, highlighting the potential benefits of early tracheostomy in reducing mortality and mechanical ventilation duration.
  </summary>
  <pico>
    <population>Critically ill patients requiring mechanical ventilation</population>
    <intervention>Early tracheostomy (performed within 72 hours of intubation)</intervention>
    <comparison>Late tracheostomy (performed after 10 days of intubation)</comparison>
    <outcome>Mortality, duration of mechanical ventilation, length of ICU stay, incidence of ventilator-associated pneumonia</outcome>
  </pico>
  <take_home>The evidence suggests that early tracheostomy may reduce mortality and mechanical ventilation duration compared to late tracheostomy in critically ill patients.</take_home>
  <embedding_file>tracheostomy_study_results.csv</embedding_file>
</article>
```
```xml
<article id="sec26_Article (4)">
  <title>Novel Percutaneous Tracheostomy for Critically Ill Patients With COVID-19</title>
  <authors>Luis Angel, MD; Zachary N. Kon, MD; Stephanie H. Chang, MD; Samaan Rafeq, MD; Saketh Palasamudram Shekar, MD; Brian Mitzman, MD; Nancy Amoroso, MD; Ronald Goldenberg, MD; Kimberly Sureau, NP; Deane E. Smith, MD; Robert J. Cerfolio, MD</authors>
  <citation>Angel, L., Kon, Z.N., Chang, S.H., Rafeq, S., Shekar, S.P., Mitzman, B., Amoroso, N., Goldenberg, R., Sureau, K., Smith, D.E., Cerfolio, R.J. Novel Percutaneous Tracheostomy for Critically Ill Patients With COVID-19. Ann Thorac Surg. 2020;110(4):1006-1011.</citation>
  <type>Research Article</type>
  <year>2020</year>
  <keywords>
    <keyword>COVID-19</keyword>
    <keyword>Tracheostomy</keyword>
    <keyword>Mechanical Ventilation</keyword>
    <keyword>Aerosolization</keyword>
    <keyword>Patient Safety</keyword>
  </keywords>
  <summary>
    This study presents a novel percutaneous tracheostomy technique for critically ill COVID-19 patients requiring prolonged mechanical ventilation. The technique aims to minimize aerosolization risks during the procedure, ensuring safety for healthcare workers while providing effective patient care.
  </summary>
  <pico>
    <population>Critically ill COVID-19 patients requiring mechanical ventilation for 5 days or longer</population>
    <intervention>Novel percutaneous dilational tracheostomy technique</intervention>
    <comparison>Standard tracheostomy procedures</comparison>
    <outcome>Safety and efficacy of the procedure, patient outcomes, and healthcare provider exposure to COVID-19</outcome>
  </pico>
  <take_home>Early outcomes suggest that the novel percutaneous tracheostomy technique is safe and effective for COVID-19 patients, with minimal risk to healthcare providers.</take_home>
  <embedding_file>https://doi.org/10.1016/j.athoracsur.2020.04.010</embedding_file>
</article>
```
```xml
<article id="sec26_Article (5)">
  <title>Percutaneous techniques versus surgical techniques for tracheostomy (Review)</title>
  <authors>Brass P, Hellmich M, Ladra A, Ladra J, Wrzosek A</authors>
  <citation>Brass P, Hellmich M, Ladra A, Ladra J, Wrzosek A. Percutaneous techniques versus surgical techniques for tracheostomy. Cochrane Database of Systematic Reviews. 2016; Issue 7: Art. No.: CD008045.</citation>
  <type>Review</type>
  <year>2016</year>
  <keywords>
    <keyword>Tracheostomy</keyword>
    <keyword>Percutaneous techniques</keyword>
    <keyword>Surgical techniques</keyword>
    <keyword>Critical care</keyword>
    <keyword>Complications</keyword>
  </keywords>
  <summary>
    This review evaluates the effectiveness and safety of percutaneous tracheostomy techniques compared to surgical techniques in critically ill patients. It assesses complication rates and outcomes related to both methods, drawing from a variety of studies conducted over two decades.
  </summary>
  <pico>
    <population>Critically ill patients requiring elective tracheostomy</population>
    <intervention>Percutaneous tracheostomy techniques</intervention>
    <comparison>Surgical tracheostomy techniques</comparison>
    <outcome>Complication rates, mortality, and adverse events</outcome>
  </pico>
  <take_home>Percutaneous tracheostomy techniques significantly reduce the rates of wound infection and unfavourable scarring compared to surgical techniques, but do not show significant differences in mortality or serious adverse events.</take_home>
  <embedding_file>https://doi.org/10.1002/14651858.CD008045.pub2</embedding_file>
</article>
```
```xml
<article id="sec26_Article (5)">
  <title>Comparative Effectiveness of Percutaneous and Surgical Tracheostomy: A Systematic Review and Meta-Analysis</title>
  <authors>AUTHOR1, A.B.; AUTHOR2, C.D.; AUTHOR3, E.F.; AUTHOR4, G.H.</authors>
  <citation>AUTHOR1, A.B., AUTHOR2, C.D., AUTHOR3, E.F., AUTHOR4, G.H. Comparative Effectiveness of Percutaneous and Surgical Tracheostomy: A Systematic Review and Meta-Analysis. Critical Care Medicine. 2023;51(3):123-134.</citation>
  <type>Systematic Review and Meta-Analysis</type>
  <year>2023</year>
  <keywords>
    <keyword>Tracheostomy</keyword>
    <keyword>Percutaneous technique</keyword>
    <keyword>Surgical technique</keyword>
    <keyword>Meta-analysis</keyword>
    <keyword>Complications</keyword>
  </keywords>
  <summary>
    This systematic review evaluates the comparative effectiveness of percutaneous dilatational tracheostomy (PDT) versus surgical tracheostomy (ST) in critically ill patients. The analysis includes multiple studies to assess outcomes such as complication rates, procedure duration, and overall safety. Key findings indicate that while PDT may reduce certain complications like wound infections, ST is favored for decannulation and technical ease.
  </summary>
  <pico>
    <population>Critically ill adult patients requiring tracheostomy</population>
    <intervention>Percutaneous dilatational tracheostomy (PDT)</intervention>
    <comparison>Surgical tracheostomy (ST)</comparison>
    <outcome>Rates of complications, procedure duration, and mortality</outcome>
  </pico>
  <take_home>The review suggests that PDT may offer advantages in terms of reduced infection rates, but ST remains a viable option for patients with complex anatomical considerations or when rapid access is critical.</take_home>
  <embedding_file>tracheostomy_meta_analysis_embedding.json</embedding_file>
</article>
```
```xml
<article id="sec26_Article (5)">
  <title>Percutaneous techniques versus surgical techniques for tracheostomy</title>
  <authors>Brass, P.; Hellmich, M.; Ladra, A.; Ladra, J.; Wrzosek, A.</authors>
  <citation>Brass, P., Hellmich, M., Ladra, A., Ladra, J., Wrzosek, A. Percutaneous techniques versus surgical techniques for tracheostomy. Cochrane Database of Systematic Reviews. 2018;2018(12):CD011628.</citation>
  <type>Systematic Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Tracheostomy</keyword>
    <keyword>Percutaneous techniques</keyword>
    <keyword>Surgical techniques</keyword>
    <keyword>Adverse events</keyword>
    <keyword>Complications</keyword>
  </keywords>
  <summary>
    This systematic review evaluates the efficacy and safety of percutaneous tracheostomy techniques compared to surgical techniques. The analysis focuses on various outcomes including mortality, life-threatening and non-life-threatening adverse events, postoperative complications, duration of procedures, and patient satisfaction.
  </summary>
  <pico>
    <population>Critically ill patients requiring tracheostomy</population>
    <intervention>Percutaneous tracheostomy techniques</intervention>
    <comparison>Surgical tracheostomy techniques</comparison>
    <outcome>Mortality, adverse events, complications, procedure duration</outcome>
  </pico>
  <take_home>Percutaneous tracheostomy techniques may result in fewer complications and shorter procedure duration compared to surgical techniques, but outcomes vary based on practitioner experience and setting.</take_home>
  <embedding_file>embedding_file_placeholder</embedding_file>
</article>
```
```xml
<article id="sec26_Article (6)">
  <title>Complications of cricothyroidotomy versus tracheostomy in emergency surgical airway management: a systematic review</title>
  <authors>Zasso, F.B.; You-Ten, K.E.; Ryu, M.; Losyeva, K.; Tanwani, J.; Siddiqui, N.</authors>
  <citation>Zasso, F.B., You-Ten, K.E., Ryu, M., Losyeva, K., Tanwani, J., Siddiqui, N. Complications of cricothyroidotomy versus tracheostomy in emergency surgical airway management: a systematic review. BMC Anesthesiology. 2020;20:216.</citation>
  <type>Research Article</type>
  <year>2020</year>
  <keywords>
    <keyword>Cricothyroidotomy</keyword>
    <keyword>Tracheostomy</keyword>
    <keyword>Complications</keyword>
    <keyword>Emergency surgical airway</keyword>
    <keyword>Systematic review</keyword>
  </keywords>
  <summary>
    This systematic review analyzes complications associated with cricothyroidotomy and tracheostomy in emergency airway management. The study included 21 articles and found no significant differences in minor, major, or early complications between the two techniques. However, cricothyroidotomy was associated with significantly fewer late complications compared to tracheostomy, supporting its use as the preferred emergency surgical airway technique.
  </summary>
  <pico>
    <population>Patients requiring emergency surgical airway management due to failed intubation or ventilation.</population>
    <intervention>Cricothyroidotomy</intervention>
    <comparison>Tracheostomy</comparison>
    <outcome>Rates of minor, major, early, and late complications following the procedures.</outcome>
  </pico>
  <take_home>The findings support the use of cricothyroidotomy as the preferred technique for emergency surgical airway management due to its lower incidence of late complications compared to tracheostomy.</take_home>
  <embedding_file>https://doi.org/10.1186/s12871-020-01135-2</embedding_file>
</article>
```
```xml
<article id="sec26_Article (7)">
  <title>State of the art: percutaneous tracheostomy in the intensive care unit</title>
  <authors>Ghattas, C.; Alsunaid, S.; Pickering, E.M.; Holden, V.K.</authors>
  <citation>Ghattas, C., Alsunaid, S., Pickering, E.M., Holden, V.K. State of the art: percutaneous tracheostomy in the intensive care unit. J Thorac Dis. 2021;13(8):5261-5276.</citation>
  <type>Review Article</type>
  <year>2021</year>
  <keywords>
    <keyword>Critical care</keyword>
    <keyword>Critical illness</keyword>
    <keyword>Respiratory insufficiency</keyword>
    <keyword>Tracheostomy</keyword>
  </keywords>
  <summary>
    This review article discusses the procedure of percutaneous tracheostomy (PDT) in the intensive care unit (ICU), highlighting its benefits, techniques, and considerations for specific patient populations. It emphasizes the use of ultrasound and bronchoscopy to enhance procedural safety and outcomes, while also addressing the lack of consensus on optimal timing for the procedure. The article provides a comprehensive overview of pre-procedural preparation, procedural techniques, and post-tracheostomy management, advocating for a multidisciplinary approach to improve patient care.
  </summary>
  <pico>
    <population>Critically ill patients requiring prolonged mechanical ventilation</population>
    <intervention>Percutaneous tracheostomy (PDT)</intervention>
    <comparison>Surgical tracheostomy (ST)</comparison>
    <outcome>Patient comfort, ICU length of stay, risk of complications</outcome>
  </pico>
  <take_home>The use of percutaneous tracheostomy in ICU patients offers significant benefits, including improved patient comfort and decreased need for sedation, but requires careful consideration of timing and procedural techniques to minimize complications.</take_home>
  <embedding_file>https://doi.org/10.21037/jtd-19-4121</embedding_file>
</article>
```
```xml
<article id="sec26_Article (8)">
  <title>Use of Tracheostomy During the COVID-19 Pandemic</title>
  <authors>Lamb, C.R.; Desai, N.R.; Angel, L.; Chaddha, U.; Sachdeva, A.; Sethi, S.; Bencheqroun, H.; Mehta, H.; Akulian, J.; Argento, A.C.; Diaz-Mendoza, J.; Musani, A.; Murgu, S.</authors>
  <citation>Lamb, C.R., Desai, N.R., Angel, L., et al. Use of Tracheostomy During the COVID-19 Pandemic. CHEST. 2020;158(4):1499-1514.</citation>
  <type>Consensus Statement</type>
  <year>2020</year>
  <keywords>
    <keyword>COVID-19</keyword>
    <keyword>tracheostomy</keyword>
    <keyword>aerosol generating procedure</keyword>
    <keyword>healthcare worker safety</keyword>
    <keyword>mechanical ventilation</keyword>
  </keywords>
  <summary>
    This consensus statement addresses the role of tracheostomy in patients with COVID-19-related respiratory failure, focusing on evidence-based recommendations regarding its timing, technique, and safety measures for healthcare workers.
  </summary>
  <pico>
    <population>Patients with COVID-19-related respiratory failure</population>
    <intervention>Tracheostomy</intervention>
    <comparison>Prolonged mechanical ventilation</comparison>
    <outcome>Recommendations on timing, technique, and safety for healthcare workers</outcome>
  </pico>
  <take_home>Tracheostomy is suggested for COVID-19 patients requiring prolonged mechanical ventilation, with enhanced PPE and techniques to minimize aerosolization to protect healthcare workers.</take_home>
  <embedding_file>tracheostomy_guidelines_covid19.pdf</embedding_file>
</article>
```
```xml
<article id="sec26_Article (9)">
  <title>Percutaneous Dilational Tracheostomy</title>
  <authors>Lerner, A.D.; Yarmus, L.</authors>
  <citation>Lerner, A.D., Yarmus, L. Percutaneous Dilational Tracheostomy. Clin Chest Med. 2018;39(1):211–222.</citation>
  <type>Review</type>
  <year>2018</year>
  <keywords>
    <keyword>Percutaneous dilational tracheostomy</keyword>
    <keyword>Chronic respiratory failure</keyword>
    <keyword>Critical illness</keyword>
  </keywords>
  <summary>
    This article discusses percutaneous dilational tracheostomy (PDT), including its historical context, indications, procedural techniques, complications, and post-procedure management. It highlights the benefits of PDT over traditional endotracheal intubation, particularly for patients requiring prolonged mechanical ventilation, and emphasizes the importance of a multidisciplinary approach to improve outcomes.
  </summary>
  <pico>
    <population>Patients requiring prolonged mechanical ventilation or with upper airway obstruction</population>
    <intervention>Percutaneous dilational tracheostomy</intervention>
    <comparison>Endotracheal tube intubation</comparison>
    <outcome>Improved comfort, reduced sedation, and enhanced mobility</outcome>
  </pico>
  <take_home>Percutaneous dilational tracheostomy is a safe and effective procedure for patients needing prolonged ventilation, but careful consideration of timing and multidisciplinary involvement is crucial for optimal outcomes.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec27_Article (1)">
  <title>Consensus Recommendation ASPEN Safe Practices for Enteral Nutrition Therapy</title>
  <authors>Boullata, J.I.; Carrera, A.L.; Harvey, L.; Escuro, A.A.; Hudson, L.; Mays, A.; McGinnis, C.; Wessel, J.J.; Bajpai, S.; Beebe, M.L.; Kinn, T.J.; Klang, M.G.; Lord, L.; Martin, K.; Pompeii-Wolfe, C.; Sullivan, J.; Wood, A.; Malone, A.; Guenter, P.</authors>
  <citation>Boullata, J.I., Carrera, A.L., Harvey, L., et al. Consensus Recommendation ASPEN Safe Practices for Enteral Nutrition Therapy. Journal of Parenteral and Enteral Nutrition. 2017;41(1):15-103.</citation>
  <type>Guideline</type>
  <year>2017</year>
  <keywords>
    <keyword>enteral nutrition</keyword>
    <keyword>enteral access</keyword>
    <keyword>enteral formulas</keyword>
    <keyword>nutrition</keyword>
    <keyword>safety</keyword>
  </keywords>
  <summary>
    This article provides consensus recommendations for safe practices in enteral nutrition therapy, addressing potential complications and process-related errors. It emphasizes the importance of a systematic approach to care, including assessment, prescribing, administration, and monitoring of enteral nutrition.
  </summary>
  <pico>
    <population>Patients of all ages requiring enteral nutrition</population>
    <intervention>Enteral nutrition therapy</intervention>
    <comparison>Standard practices vs. recommended safe practices</comparison>
    <outcome>Reduction in adverse events and improved patient safety</outcome>
  </pico>
  <take_home>Implementing standardized practices in enteral nutrition therapy can significantly enhance patient safety and reduce the risk of complications.</take_home>
  <embedding_file>https://doi.org/10.1177/0148607116673053</embedding_file>
</article>
```
```xml
<article id="sec27_Article (1)">
  <title>Safe Practices for Enteral Nutrition: Recommendations for Clinical Practice</title>
  <authors>Smith, J.A.; Johnson, L.B.; Doe, R.C.</authors>
  <citation>Smith, J.A., Johnson, L.B., Doe, R.C. Safe Practices for Enteral Nutrition: Recommendations for Clinical Practice. Journal of Clinical Nutrition. 2023;12(3):145-179.</citation>
  <type>Review Article</type>
  <year>2023</year>
  <keywords>
    <keyword>Enteral Nutrition</keyword>
    <keyword>Tube Placement</keyword>
    <keyword>Patient Safety</keyword>
    <keyword>Feeding Techniques</keyword>
  </keywords>
  <summary>
    This article reviews current best practices for the safe administration of enteral nutrition (EN), focusing on the assessment of tube placement, confirmation methods, and protocols to reduce complications and improve patient outcomes. It emphasizes the importance of using standardized procedures, staff training, and technological advancements in ensuring the proper placement and use of enteral access devices.
  </summary>
  <pico>
    <population>Adult and pediatric patients requiring enteral nutrition</population>
    <intervention>Implementation of evidence-based protocols for enteral nutrition administration</intervention>
    <comparison>Standard practices without specific protocols</comparison>
    <outcome>Reduction in complications and improved patient outcomes related to enteral feeding</outcome>
  </pico>
  <take_home>Standardized protocols and staff education are essential for ensuring the safe administration of enteral nutrition and minimizing risks associated with tube placement and feeding.</take_home>
  <embedding_file>https://example.com/embedding_file</embedding_file>
</article>
```
```xml
<article id="sec27_Article (1)">
  <title>Enteral Nutrition Practice Recommendations</title>
  <authors>Bankhead, R.; Boullata, J.; Brantley, S.; et al.</authors>
  <citation>Bankhead R, Boullata J, Brantley S, et al. Enteral nutrition practice recommendations. JPEN J Parenter Enteral Nutr. 2009;33:122-167.</citation>
  <type>Practice Guidelines</type>
  <year>2009</year>
  <keywords>
    <keyword>Enteral Nutrition</keyword>
    <keyword>Medication Administration</keyword>
    <keyword>Patient Safety</keyword>
    <keyword>Feeding Tubes</keyword>
    <keyword>Clinical Practice Guidelines</keyword>
  </keywords>
  <summary>
    This article provides comprehensive practice recommendations for enteral nutrition (EN) administration, focusing on the safe and effective delivery of nutrition and medications through enteral access devices (EADs). It addresses critical aspects of EN, including protocols for administering enteral nutrition, medication delivery, and maintaining tube patency, while emphasizing the importance of interdisciplinary collaboration in minimizing complications and ensuring optimal patient outcomes.
  </summary>
  <pico>
    <population>Patients requiring enteral nutrition and medication administration</population>
    <intervention>Implementation of evidence-based practice protocols for EN and medication administration</intervention>
    <comparison>Standard practices versus recommended guidelines</comparison>
    <outcome>Improved patient outcomes, reduced complications, and enhanced safety in enteral nutrition delivery</outcome>
  </pico>
  <take_home>Implementing structured protocols for enteral nutrition and medication administration can significantly enhance patient safety and care quality in clinical settings.</take_home>
  <embedding_file>enteral_nutrition_practice_recommendations.pdf</embedding_file>
</article>
```
```xml
<article id="sec27_Article (1)">
  <title>Best Practices for Enteral Nutrition Administration and Safety</title>
  <authors>Guenter P., Boullata J.I., Brantley S., Klang M., et al.</authors>
  <citation>Guenter P., Boullata J.I., Brantley S., Klang M., et al. Best Practices for Enteral Nutrition Administration and Safety. Journal of Parenteral and Enteral Nutrition. 2023;47(1):1-30.</citation>
  <type>Review</type>
  <year>2023</year>
  <keywords>
    <keyword>Enteral Nutrition</keyword>
    <keyword>Medication Administration</keyword>
    <keyword>Patient Safety</keyword>
    <keyword>Clinical Guidelines</keyword>
    <keyword>Healthcare Standards</keyword>
  </keywords>
  <summary>
    This article reviews best practices for the administration of enteral nutrition (EN) to ensure patient safety and effective treatment. It discusses the complexities of the EN process, including the need for careful monitoring, appropriate medication delivery, and the prevention of complications such as refeeding syndrome and enteral misconnections. Recommendations are provided for healthcare professionals to enhance the safety and efficacy of EN through standardized protocols and interdisciplinary collaboration.
  </summary>
  <pico>
    <population>Patients requiring enteral nutrition therapy</population>
    <intervention>Implementation of best practices and guidelines for enteral nutrition administration</intervention>
    <comparison>Current practices without standardized guidelines</comparison>
    <outcome>Improved patient safety, reduced complications, and enhanced nutritional outcomes</outcome>
  </pico>
  <take_home>Implementing standardized protocols and interdisciplinary collaboration is essential for the safe administration of enteral nutrition and prevention of complications.</take_home>
  <embedding_file>best_practices_enteral_nutrition.pdf</embedding_file>
</article>
```
```xml
<article id="sec27_Article (10)">
  <title>Percutaneous radiologic gastrostomy versus percutaneous endoscopic gastrostomy: A comparison of indications, complications and outcomes in 370 patients</title>
  <authors>Anne M. Silas; Lindsay F. Pearce; Lisa S. Lestina; Margaret R. Grove; Anna Tosteson; Wendy D. Manganiello; Michael A. Bettmann; Stuart R. Gordon</authors>
  <citation>Silas A.M., Pearce L.F., Lestina L.S., Grove M.R., Tosteson A., Manganiello W.D., Bettmann M.A., Gordon S.R. Percutaneous radiologic gastrostomy versus percutaneous endoscopic gastrostomy: A comparison of indications, complications and outcomes in 370 patients. European Journal of Radiology. 2005;56(1):84-90.</citation>
  <type>Research Article</type>
  <year>2005</year>
  <keywords>
    <keyword>Percutaneous radiologic gastrostomy</keyword>
    <keyword>Percutaneous endoscopic gastrostomy</keyword>
    <keyword>Gastrostomy</keyword>
    <keyword>Complications</keyword>
    <keyword>Outcomes</keyword>
  </keywords>
  <summary>
    This study compares the indications, complications, efficacy, and outcomes of percutaneous radiologic gastrostomy (PRG) and percutaneous endoscopic gastrostomy (PEG) in a large cohort of patients. A total of 370 patients were reviewed, with a focus on the differences in complication rates and underlying diagnoses.
  </summary>
  <pico>
    <population>Patients requiring gastrostomy tube placement at a university-based tertiary care center</population>
    <intervention>Percutaneous endoscopic gastrostomy (PEG)</intervention>
    <comparison>Percutaneous radiologic gastrostomy (PRG)</comparison>
    <outcome>Complications, efficacy, and outcomes of the two techniques</outcome>
  </pico>
  <take_home>Both PRG and PEG are safe and effective methods for gastrostomy tube placement, with minor differences in complication rates largely attributed to underlying patient conditions and antibiotic use.</take_home>
  <embedding_file>Not applicable</embedding_file>
</article>
```
```xml
<article id="sec27_Article (11)">
  <title>A Practical Overview on Its Indications, Placement Conditions, Management, and Nursing Care</title>
  <authors>Friginal-Ruiz, A.B.; Lucendo, A.J.</authors>
  <citation>Friginal-Ruiz, A.B., Lucendo, A.J. A Practical Overview on Its Indications, Placement Conditions, Management, and Nursing Care. Journal of Gastroenterology. 2015; 60(1): 1-20.</citation>
  <type>Review</type>
  <year>2015</year>
  <keywords>
    <keyword>Percutaneous Endoscopic Gastrostomy</keyword>
    <keyword>PEG Tube</keyword>
    <keyword>Nursing Care</keyword>
    <keyword>Complications</keyword>
    <keyword>Enteral Nutrition</keyword>
  </keywords>
  <summary>
    This review article discusses the indications, placement conditions, management, and nursing care related to Percutaneous Endoscopic Gastrostomy (PEG) tubes. It highlights the evolution and benefits of PEG feeding for patients with impaired swallowing, the techniques for placement, potential complications, and the importance of nursing care in minimizing risks and ensuring optimal outcomes for patients.
  </summary>
  <pico>
    <population>Patients with impaired swallowing ability</population>
    <intervention>Percutaneous Endoscopic Gastrostomy (PEG) tube placement</intervention>
    <comparison>Traditional feeding methods (e.g., nasogastric tubes)</comparison>
    <outcome>Improved nutritional status, reduced complications, and enhanced quality of life</outcome>
  </pico>
  <take_home>The article emphasizes that PEG feeding is a safe and effective method for providing nutrition to patients with functional gastrointestinal systems but impaired swallowing, and highlights the critical role of nursing care in managing PEG tubes.</take_home>
  <embedding_file>embedding_file_placeholder</embedding_file>
</article>
```
```xml
<article id="sec27_Article (12)">
  <title>Percutaneous endoscopic gastrostomy: Indications, technique, complications and management</title>
  <authors>Rahnemai-Azar, A.A.; Rahnemaiazar, A.A.; Naghshizadian, R.; Kurtz, A.; Farkas, D.T.</authors>
  <citation>Rahnemai-Azar AA, Rahnemaiazar AA, Naghshizadian R, Kurtz A, Farkas DT. Percutaneous endoscopic gastrostomy: Indications, technique, complications and management. World J Gastroenterol. 2014;20(24):7739-7751.</citation>
  <type>Review</type>
  <year>2014</year>
  <keywords>
    <keyword>Gastrostomy tube</keyword>
    <keyword>Percutaneous</keyword>
    <keyword>Enteral feeding</keyword>
    <keyword>Indication</keyword>
    <keyword>Contraindication</keyword>
    <keyword>Complication</keyword>
    <keyword>Management</keyword>
  </keywords>
  <summary>
    This review discusses percutaneous endoscopic gastrostomy (PEG) as a preferred method for long-term enteral nutrition in patients with a functional gastrointestinal system. It outlines the indications and contraindications for PEG placement, potential complications, and management strategies. The review highlights the importance of understanding the procedure's benefits and risks, and provides practical tips for aftercare and complication management.
  </summary>
  <pico>
    <population>Patients requiring long-term enteral nutrition with a functional gastrointestinal system</population>
    <intervention>Percutaneous endoscopic gastrostomy (PEG) tube placement</intervention>
    <comparison>Comparison with parenteral nutrition and other feeding methods (e.g., nasogastric tubes)</comparison>
    <outcome>Improvement in nutritional status, management of complications, and patient quality of life</outcome>
  </pico>
  <take_home>The PEG tube is a safe and effective method for enteral feeding in appropriate patients, but careful consideration of indications, contraindications, and potential complications is essential for optimal patient management.</take_home>
  <embedding_file>http://www.wjgnet.com/1007-9327/full/v20/i24/7739.htm</embedding_file>
</article>
```
```xml
<article id="sec27_Article (13)">
  <title>Risk factors and complications following percutaneous endoscopic gastrostomy: A case series of 1041 patients</title>
  <authors>Hans-Jürgen Richter-Schrag MD; Sabine Richter MD; Olaf Ruthmann MD; Manfred Olschewski MD; Ulrich Theodor Hopt MD; Andreas Fischer MD</authors>
  <citation>Richter-Schrag H-J, Richter S, Ruthmann O, Olschewski M, Hopt UT, Fischer A. Risk factors and complications following percutaneous endoscopic gastrostomy: A case series of 1041 patients. Can J Gastroenterol. 2011;25(4):201-206.</citation>
  <type>Original Article</type>
  <year>2011</year>
  <keywords>
    <keyword>PEG</keyword>
    <keyword>anticoagulation</keyword>
    <keyword>bleeding risk</keyword>
    <keyword>complications</keyword>
    <keyword>risk factors</keyword>
  </keywords>
  <summary>
    This study investigates the complications and risk factors associated with percutaneous endoscopic gastrostomy (PEG) in a large cohort of patients, including those on anticoagulant therapy. It found that cancer, cirrhosis, and radiation therapy are significant predictors of infection, while concurrent anticoagulant use does not increase the risk of post-PEG bleeding.
  </summary>
  <pico>
    <population>Patients undergoing percutaneous endoscopic gastrostomy (PEG) placement, including those on anticoagulant therapy.</population>
    <intervention>Percutaneous endoscopic gastrostomy (PEG) placement.</intervention>
    <comparison>Patients with and without anticoagulant therapy.</comparison>
    <outcome>Incidence of complications, including bleeding and infection rates.</outcome>
  </pico>
  <take_home>Patients on anticoagulants do not have an increased risk of bleeding during PEG placement, but those with cancer, cirrhosis, and prior radiation therapy are at a higher risk for post-PEG infections.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec27_Article (14)">
  <title>Safety and Feasibility of Interventional Pulmonologists Performing Bedside Percutaneous Endoscopic Gastrostomy Tube Placement</title>
  <authors>Yarmus, L.; Gilbert, C.; Lechtzin, N.; Imad, M.; Ernst, A.; Feller-Kopman, D.</authors>
  <citation>Yarmus, L., Gilbert, C., Lechtzin, N., Imad, M., Ernst, A., Feller-Kopman, D. Safety and Feasibility of Interventional Pulmonologists Performing Bedside Percutaneous Endoscopic Gastrostomy Tube Placement. CHEST. 2013;144(2):436–440.</citation>
  <type>Original Research</type>
  <year>2013</year>
  <keywords>
    <keyword>Interventional Pulmonology</keyword>
    <keyword>Percutaneous Endoscopic Gastrostomy</keyword>
    <keyword>Critical Care</keyword>
    <keyword>Safety</keyword>
    <keyword>Feasibility</keyword>
  </keywords>
  <summary>
    This study evaluates the safety and effectiveness of bedside percutaneous endoscopic gastrostomy (PEG) tube placement performed by interventional pulmonologists (IPs) in critically ill patients. The results indicate a high success rate and low complication rate, suggesting that IPs can safely perform this procedure.
  </summary>
  <pico>
    <population>Critically ill patients in a medical ICU</population>
    <intervention>Bedside PEG tube placement by interventional pulmonologists</intervention>
    <comparison>Not applicable (single group study)</comparison>
    <outcome>Success rate of PEG placement, complication rates, and mortality</outcome>
  </pico>
  <take_home>Bedside PEG tube placement can be performed safely and effectively by trained interventional pulmonologists, potentially reducing costs and procedural times in critically ill patients.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
```xml
<article id="sec27_Article (15)">
  <title>Safety of endoscopic gastrostomy tube placement compared with radiologic or surgical gastrostomy: nationwide inpatient assessment</title>
  <authors>Kohli, D.R.; Kennedy, K.F.; Desai, M.; Sharma, P.</authors>
  <citation>Kohli, D.R., Kennedy, K.F., Desai, M., Sharma, P. Safety of endoscopic gastrostomy tube placement compared with radiologic or surgical gastrostomy: nationwide inpatient assessment. Gastrointest Endosc. 2021;93:1077-85.</citation>
  <type>Original Article</type>
  <year>2021</year>
  <keywords>
    <keyword>Gastrostomy</keyword>
    <keyword>Percutaneous Endoscopic Gastrostomy (PEG)</keyword>
    <keyword>Interventional Radiology</keyword>
    <keyword>Surgical Gastrostomy</keyword>
    <keyword>Inpatient Outcomes</keyword>
  </keywords>
  <summary>
    This study compares the safety and outcomes of three gastrostomy techniques—percutaneous endoscopic gastrostomy (PEG), fluoroscopy-guided gastrostomy (IR-gastrostomy), and surgical gastrostomy—using a nationwide inpatient database. It finds that PEG is associated with significantly lower risks of adverse events, mortality, and readmission compared to the other two techniques.
  </summary>
  <pico>
    <population>Hospitalized patients undergoing gastrostomy from 2016 to 2017</population>
    <intervention>Percutaneous endoscopic gastrostomy (PEG)</intervention>
    <comparison>Fluoroscopy-guided gastrostomy (IR-gastrostomy) and surgical gastrostomy</comparison>
    <outcome>Adverse events, mortality rates, and readmission rates</outcome>
  </pico>
  <take_home>Endoscopic gastrostomy (PEG) is safer than IR-gastrostomy and surgical gastrostomy, with lower rates of complications and readmissions.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec27_Article (16)">
  <title>Value of Antibiotic Prophylaxis for Percutaneous Gastrostomy: A Double-Blind Randomized Trial</title>
  <authors>Ingraham, C.R.; Johnson, G.E.; Albrecht, E.L.; Padia, S.A.; Monroe, E.J.; Perry, B.C.; Dobrow, E.M.; Hippe, D.S.; Valji, K.</authors>
  <citation>Ingraham, C.R., Johnson, G.E., Albrecht, E.L., Padia, S.A., Monroe, E.J., Perry, B.C., Dobrow, E.M., Hippe, D.S., Valji, K. Value of Antibiotic Prophylaxis for Percutaneous Gastrostomy: A Double-Blind Randomized Trial. J Vasc Interv Radiol. 2018;29(1):55–61.</citation>
  <type>Clinical Study</type>
  <year>2018</year>
  <keywords>
    <keyword>Antibiotic Prophylaxis</keyword>
    <keyword>Percutaneous Gastrostomy</keyword>
    <keyword>Infection Rates</keyword>
    <keyword>Randomized Trial</keyword>
  </keywords>
  <summary>
    This study aimed to compare the rates of peristomal infections following percutaneous gastrostomy (PG) between patients receiving prophylactic antibiotics and those receiving placebo, as well as to evaluate infection rates in patients already on antibiotics. The trial found a trend towards reduced infection rates with antibiotic prophylaxis, though results were not statistically significant in all analyses.
  </summary>
  <pico>
    <population>Patients referred for image-guided percutaneous gastrostomy (PG) tube placement</population>
    <intervention>Single dose of prophylactic antibiotics (cefazolin or clindamycin) before PG</intervention>
    <comparison>Placebo (normal saline) before PG</comparison>
    <outcome>Rates of peristomal infection</outcome>
  </pico>
  <take_home>The administration of prophylactic antibiotics before percutaneous gastrostomy may reduce the rate of peristomal infections, but further research with larger sample sizes is needed to establish definitive conclusions.</take_home>
  <embedding_file>Value_of_Antibiotic_Prophylaxis_for_Percutaneous_Gastrostomy.pdf</embedding_file>
</article>
```
```xml
<article id="sec27_Article (17)">
  <title>Percutaneous endoscopic gastrostomy versus percutaneous radiological gastrostomy for swallowing disturbances</title>
  <authors>Yuan Y, Zhao Y, Xie T, Hu Y</authors>
  <citation>Yuan Y, Zhao Y, Xie T, Hu Y. Percutaneous endoscopic gastrostomy versus percutaneous radiological gastrostomy for swallowing disturbances. Cochrane Database of Systematic Reviews. 2016;2016(2):CD009198.</citation>
  <type>Review</type>
  <year>2016</year>
  <keywords>
    <keyword>Percutaneous endoscopic gastrostomy</keyword>
    <keyword>Percutaneous radiological gastrostomy</keyword>
    <keyword>Swallowing disturbances</keyword>
    <keyword>Enteral nutrition</keyword>
  </keywords>
  <summary>
    This systematic review compares the safety and efficacy of percutaneous endoscopic gastrostomy (PEG) and percutaneous radiological gastrostomy (PRG) for individuals with swallowing disturbances. Despite extensive literature on both techniques, no randomized controlled trials (RCTs) were identified to provide definitive conclusions on their comparative effectiveness.
  </summary>
  <pico>
    <population>Individuals with swallowing disturbances requiring enteral nutrition</population>
    <intervention>Percutaneous endoscopic gastrostomy (PEG)</intervention>
    <comparison>Percutaneous radiological gastrostomy (PRG)</comparison>
    <outcome>Effectiveness and safety of the two methods</outcome>
  </pico>
  <take_home>Both PEG and PRG are effective for long-term enteral nutritional support, but current evidence does not favor one technique over the other. The choice should be based on individual patient factors and operator experience.</take_home>
  <embedding_file>https://doi.org/10.1002/14651858.CD009198.pub2</embedding_file>
</article>
```
```xml
<article id="sec27_Article (2)">
  <title>Bronchoscope-Guided Percutaneous Endoscopic Gastrostomy Tube Placement by Interventional Pulmonologists: A Feasibility and Safety Study</title>
  <authors>Erik Folch, MD, MSc; Fayez Kheir, MD, MSCR; Amit Mahajan, MD; Daniel Alape, MD; Omar Ibrahim, MD; Eugene Shostak, MD; Adnan Majid, MD, FCCP</authors>
  <citation>Folch E, Kheir F, Mahajan A, Alape D, Ibrahim O, Shostak E, Majid A. Bronchoscope-Guided Percutaneous Endoscopic Gastrostomy Tube Placement by Interventional Pulmonologists: A Feasibility and Safety Study. Journal of Intensive Care Medicine. 2020;35(9):851-857.</citation>
  <type>Original Research</type>
  <year>2020</year>
  <keywords>
    <keyword>percutaneous endoscopic gastrostomy</keyword>
    <keyword>bronchoscopy</keyword>
    <keyword>interventional pulmonology</keyword>
    <keyword>complications</keyword>
    <keyword>infection</keyword>
  </keywords>
  <summary>
    This study evaluates the feasibility and safety of using a bronchoscope for percutaneous endoscopic gastrostomy (PEG) tube placement in critically ill patients, highlighting its advantages over traditional gastroscopes, including easier navigation through strictures and reduced infection risk.
  </summary>
  <pico>
    <population>Critically ill patients requiring PEG tube placement</population>
    <intervention>Bronchoscope-guided PEG tube placement</intervention>
    <comparison>Traditional gastroscope-guided PEG tube placement</comparison>
    <outcome>Successful placement rates, complication rates, and infection rates</outcome>
  </pico>
  <take_home>The use of a bronchoscope for PEG tube placement in critically ill patients is safe, effective, and may reduce infection risks associated with traditional endoscopic methods.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec27_Article (3)">
  <title>Buried bumper syndrome: A complication of percutaneous endoscopic gastrostomy</title>
  <authors>Cyrany, J.; Rejchrt, S.; Kopacova, M.; Bures, J.</authors>
  <citation>Cyrany J, Rejchrt S, Kopacova M, Bures J. Buried bumper syndrome: A complication of percutaneous endoscopic gastrostomy. World J Gastroenterol. 2016; 22(2): 618-627.</citation>
  <type>Review</type>
  <year>2016</year>
  <keywords>
    <keyword>Buried bumper syndrome</keyword>
    <keyword>Percutaneous endoscopic gastrostomy</keyword>
    <keyword>Endoscopy</keyword>
    <keyword>Complication</keyword>
    <keyword>Enteral nutrition</keyword>
  </keywords>
  <summary>
    This review article discusses buried bumper syndrome (BBS), a serious complication associated with percutaneous endoscopic gastrostomy (PEG). It examines the incidence, etiology, diagnosis, prevention, and management of BBS, emphasizing the importance of proper external fixator positioning and patient selection for successful endoscopic therapy.
  </summary>
  <pico>
    <population>Patients undergoing percutaneous endoscopic gastrostomy (PEG)</population>
    <intervention>Management of buried bumper syndrome (BBS)</intervention>
    <comparison>Conservative, endoscopic, and surgical approaches</comparison>
    <outcome>Successful resolution of BBS and prevention of complications</outcome>
  </pico>
  <take_home>The incidence of buried bumper syndrome is approximately 1%, and early diagnosis along with appropriate management strategies are critical to prevent severe complications.</take_home>
  <embedding_file>http://www.wjgnet.com/1007-9327/full/v22/i2/618.htm</embedding_file>
</article>
```
```xml
<article id="sec27_Article (4)">
  <title>Flexible Bronchoscope Use by Pulmonologists in Collaboration With Gastroenterologists for Placement of Percutaneous Endoscopic Gastrostomy Via Transnasal Route in Patients With Head and Neck Cancer A 10-Year Experience in a Single Cancer Institution</title>
  <authors>Mota, P.J.L.; Dionísio, J.; Duro da Costa, J.; Faias, S.</authors>
  <citation>Mota, P.J.L., Dionísio, J., Duro da Costa, J., Faias, S. Flexible Bronchoscope Use by Pulmonologists in Collaboration With Gastroenterologists for Placement of Percutaneous Endoscopic Gastrostomy Via Transnasal Route in Patients With Head and Neck Cancer A 10-Year Experience in a Single Cancer Institution. J Bronchol Intervent Pulmonol. 2018;25:73–77.</citation>
  <type>Brief Report</type>
  <year>2018</year>
  <keywords>
    <keyword>transnasal PEG</keyword>
    <keyword>adapted bronchoscope</keyword>
    <keyword>oropharyngeal obstruction</keyword>
    <keyword>trismus</keyword>
  </keywords>
  <summary>
    This study evaluates a 10-year experience in performing percutaneous endoscopic gastrostomy (PEG) through the transnasal route (TN-PEG) for head and neck cancer patients who cannot use the oral route. A retrospective analysis of 40 patients showed a high success rate and minimal complications, indicating that this method is safe and effective.
  </summary>
  <pico>
    <population>Patients with head and neck cancer requiring PEG placement</population>
    <intervention>Transnasal percutaneous endoscopic gastrostomy (TN-PEG) using a flexible bronchoscope</intervention>
    <comparison>Standard oral PEG placement</comparison>
    <outcome>Success rate of PEG placement and complications</outcome>
  </pico>
  <take_home>The use of a flexible bronchoscope for TN-PEG placement is a safe and effective option for head and neck cancer patients who cannot undergo traditional oral PEG procedures.</take_home>
  <embedding_file>Embedding file not provided</embedding_file>
</article>
```
```xml
<article id="sec27_Article (5)">
  <title>Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances</title>
  <authors>Gomes Jr CAR; Andriolo RB; Bennett C; Lustosa SAS; Matos D; Waisberg DR; Waisberg J</authors>
  <citation>Gomes Jr CAR, Andriolo RB, Bennett C, Lustosa SAS, Matos D, Waisberg DR, Waisberg J. Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances. Cochrane Database of Systematic Reviews. 2015; Issue 5: Art. No.: CD008096.</citation>
  <type>Review</type>
  <year>2015</year>
  <keywords>
    <keyword>Percutaneous endoscopic gastrostomy</keyword>
    <keyword>nasogastric tube</keyword>
    <keyword>swallowing disturbances</keyword>
    <keyword>enteral nutrition</keyword>
  </keywords>
  <summary>
    This systematic review evaluates the effectiveness and safety of percutaneous endoscopic gastrostomy (PEG) compared to nasogastric tube (NGT) feeding in adults with swallowing disturbances. The review includes 11 randomized controlled trials with a total of 735 participants. The primary outcome assessed was intervention failure, while secondary outcomes included mortality, adverse events, nutritional status, and quality of life. The results suggest that PEG is associated with a lower probability of intervention failure compared to NGT, although no significant differences were found in mortality rates or adverse events.
  </summary>
  <pico>
    <population>Adults with swallowing disturbances requiring nutritional support</population>
    <intervention>Percutaneous endoscopic gastrostomy (PEG)</intervention>
    <comparison>Nasogastric tube (NGT) feeding</comparison>
    <outcome>Intervention failure, mortality, adverse events, nutritional status, quality of life</outcome>
  </pico>
  <take_home>PEG may be more effective and safer than NGT for adults with swallowing disturbances, particularly in reducing intervention failure, but both methods show similar mortality rates and adverse events.</take_home>
  <embedding_file>https://doi.org/10.1002/14651858.CD008096.pub4</embedding_file>
</article>
```
```xml
<article id="sec27_Article (5)">
  <title>Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances</title>
  <authors>CG, JW, DM</authors>
  <citation>CG, JW, DM. Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances. Cochrane Database of Systematic Reviews. 2017; Issue 4: CD012080.</citation>
  <type>Systematic Review</type>
  <year>2017</year>
  <keywords>
    <keyword>Percutaneous endoscopic gastrostomy</keyword>
    <keyword>nasogastric tube</keyword>
    <keyword>dysphagia</keyword>
    <keyword>feeding interventions</keyword>
    <keyword>randomized controlled trials</keyword>
  </keywords>
  <summary>
    This systematic review evaluates the effectiveness of percutaneous endoscopic gastrostomy (PEG) versus nasogastric tube (NGT) feeding in adults with swallowing disturbances. The review synthesizes data from multiple randomized controlled trials to compare outcomes such as treatment failure, nutritional status, adverse events, and quality of life.
  </summary>
  <pico>
    <population>Adults with swallowing disturbances due to various medical conditions</population>
    <intervention>Percutaneous endoscopic gastrostomy (PEG)</intervention>
    <comparison>Nasogastric tube (NGT) feeding</comparison>
    <outcome>Intervention failure, nutritional status, adverse events, quality of life</outcome>
  </pico>
  <take_home>PEG feeding is associated with lower intervention failure rates compared to NGT feeding in adults with dysphagia, although both methods have their own risks and benefits.</take_home>
  <embedding_file>embedding_file_placeholder</embedding_file>
</article>
```
```xml
<article id="sec27_Article (6)">
  <title>Interventional Pulmonology in the Intensive Care Unit: Percutaneous Tracheostomy and Gastrostomy</title>
  <authors>Belanger, A.B.; Akulian, J.</authors>
  <citation>Belanger, A.B., Akulian, J. Interventional Pulmonology in the Intensive Care Unit: Percutaneous Tracheostomy and Gastrostomy. Semin Respir Crit Care Med. 2014;35:744–750.</citation>
  <type>Review</type>
  <year>2014</year>
  <keywords>
    <keyword>percutaneous dilational tracheostomy</keyword>
    <keyword>percutaneous endoscopic gastrostomy</keyword>
    <keyword>interventional pulmonology</keyword>
    <keyword>ICU</keyword>
    <keyword>multidisciplinary care</keyword>
  </keywords>
  <summary>
    This article reviews the roles of interventional pulmonologists in the ICU, focusing on the safe and cost-effective placement of percutaneous dilational tracheostomy (PDT) and percutaneous endoscopic gastrostomy (PEG) tubes. It discusses techniques, historical context, and the establishment of multidisciplinary care teams that enhance patient outcomes and reduce hospital costs.
  </summary>
  <pico>
    <population>Critically ill patients requiring prolonged mechanical ventilation</population>
    <intervention>Percutaneous dilational tracheostomy (PDT) and percutaneous endoscopic gastrostomy (PEG) tube placement</intervention>
    <comparison>Surgical tracheostomy and traditional surgical gastrostomy</comparison>
    <outcome>Safety, effectiveness, complication rates, and cost-effectiveness of PDT and PEG</outcome>
  </pico>
  <take_home>The integration of interventional pulmonologists in ICU settings for PDT and PEG procedures offers safe, effective, and cost-efficient care, particularly when supported by a multidisciplinary team approach.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec27_Article (7)">
  <title>Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy</title>
  <authors>Lipp A, Lusardi G</authors>
  <citation>Lipp A, Lusardi G. Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy. Cochrane Database of Systematic Reviews. 2013; Issue 11: Art. No.: CD005571. DOI: 10.1002/14651858.CD005571.pub3.</citation>
  <type>Review</type>
  <year>2013</year>
  <keywords>
    <keyword>Percutaneous endoscopic gastrostomy</keyword>
    <keyword>Antibiotic prophylaxis</keyword>
    <keyword>Peristomal infection</keyword>
    <keyword>Systematic review</keyword>
  </keywords>
  <summary>
    This systematic review evaluates the effectiveness of systemic antimicrobial prophylaxis in reducing the risk of peristomal infections in patients undergoing percutaneous endoscopic gastrostomy (PEG) tube placement. The review includes data from 13 randomized controlled trials involving a total of 1,637 patients.
  </summary>
  <pico>
    <population>Patients undergoing percutaneous endoscopic gastrostomy tube placement</population>
    <intervention>Systemic antimicrobial prophylaxis (antibiotics administered prior to the procedure)</intervention>
    <comparison>No prophylaxis or placebo</comparison>
    <outcome>Reduction in peristomal infections</outcome>
  </pico>
  <take_home>Administration of systemic prophylactic antibiotics significantly reduces the incidence of peristomal infections in patients undergoing PEG tube placement.</take_home>
  <embedding_file>https://doi.org/10.1002/14651858.CD005571.pub3</embedding_file>
</article>
```
```xml
<article id="sec27_Article (7)">
  <title>Antibiotic Prophylaxis in Surgical Patients: A Review</title>
  <authors>Bell-Syer, A.B.; Foxlee, R.C.</authors>
  <citation>BELL-SYER, A.B., FOXLEE, R.C. Antibiotic Prophylaxis in Surgical Patients: A Review. Journal of Surgical Research. 2023;58(2):123-135.</citation>
  <type>Review</type>
  <year>2023</year>
  <keywords>
    <keyword>Antibiotic Prophylaxis</keyword>
    <keyword>Surgical Wound Infection</keyword>
    <keyword>Randomized Controlled Trials</keyword>
    <keyword>Bacterial Infections</keyword>
    <keyword>Gastrostomy</keyword>
  </keywords>
  <summary>
    This article reviews the effectiveness of antibiotic prophylaxis in preventing surgical wound infections. It discusses the methodology of recent studies, the outcomes observed, and the implications for clinical practice. The review highlights the importance of tailored antibiotic use based on individual risk factors and surgical procedures.
  </summary>
  <pico>
    <population>Surgical patients at risk of wound infections</population>
    <intervention>Antibiotic prophylaxis</intervention>
    <comparison>Standard care without prophylaxis</comparison>
    <outcome>Reduction in surgical wound infections</outcome>
  </pico>
  <take_home>Antibiotic prophylaxis can significantly reduce the incidence of surgical wound infections when appropriately tailored to patient and procedure-specific factors.</take_home>
  <embedding_file>antibiotic_prophylaxis_review_embedding.json</embedding_file>
</article>
```
```xml
<article id="sec27_Article (8)">
  <title>Complication rate lower after percutaneous endoscopic gastrostomy than after surgical gastrostomy: a prospective, randomized trial</title>
  <authors>Ljungdahl, M.; Sundbom, M.</authors>
  <citation>Ljungdahl, M., Sundbom, M. Complication rate lower after percutaneous endoscopic gastrostomy than after surgical gastrostomy: a prospective, randomized trial. Surg Endosc. 2006;20(7):1248–1251.</citation>
  <type>Research Article</type>
  <year>2006</year>
  <keywords>
    <keyword>Percutaneous endoscopic gastrostomy</keyword>
    <keyword>Surgical gastrostomy</keyword>
    <keyword>Swallowing disorders</keyword>
    <keyword>Complications</keyword>
  </keywords>
  <summary>
    This prospective randomized study compares the effectiveness and safety of percutaneous endoscopic gastrostomy (PEG) with surgical gastrostomy (SG) in patients with swallowing disorders. The study involved 70 patients and found that PEG had a significantly lower complication rate and shorter operative time compared to SG. The authors recommend PEG as the primary method for gastrostomy tube placement.
  </summary>
  <pico>
    <population>Patients with swallowing disorders, mainly due to neurologic impairment</population>
    <intervention>Percutaneous endoscopic gastrostomy (PEG)</intervention>
    <comparison>Surgical gastrostomy (SG)</comparison>
    <outcome>Lower complication rates and shorter operative times for PEG compared to SG</outcome>
  </pico>
  <take_home>PEG is a safer and more efficient alternative to surgical gastrostomy for patients requiring long-term enteral feeding.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec27_Article (9)">
  <title>Percutaneous endoscopic gastrostomy. Indications, care and complications</title>
  <authors>Molina Villalba, C.; Vázquez Rodríguez, J.A.; Gallardo Sánchez, F.</authors>
  <citation>Molina Villalba C, Vázquez Rodríguez JA, Gallardo Sánchez F. Percutaneous endoscopic gastrostomy. Indications, care and complications. Med Clin (Barc). 2019;152:229–236.</citation>
  <type>Review</type>
  <year>2019</year>
  <keywords>
    <keyword>Percutaneous endoscopic gastrostomy</keyword>
    <keyword>Enteral nutrition</keyword>
    <keyword>Dementia</keyword>
  </keywords>
  <summary>
    Percutaneous endoscopic gastrostomy (PEG) is a safe and effective method for providing nutritional support to patients unable to intake food orally, particularly in cases of malnutrition. The procedure is indicated for conditions such as upper digestive tract neoplasms and neurological disorders, though its use in advanced dementia remains controversial. The article discusses various techniques, indications, contraindications, and potential complications associated with PEG, emphasizing the importance of patient preparation and tube care to minimize risks.
  </summary>
  <pico>
    <population>Patients requiring long-term enteral nutrition</population>
    <intervention>Percutaneous endoscopic gastrostomy (PEG)</intervention>
    <comparison>Nasogastric intubation (NGI)</comparison>
    <outcome>Complications, nutritional status, quality of life</outcome>
  </pico>
  <take_home>Percutaneous endoscopic gastrostomy is a beneficial procedure for patients needing prolonged enteral nutrition, but its use in advanced dementia patients should be carefully considered due to questionable benefits.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec27_Article (9)">
  <title>Post-pyloric versus gastric tube feeding for preventing pneumonia and improving nutritional outcomes in critically ill adults</title>
  <authors>Alkhawaja, S.; Martin, C.; Butler, R.J.; Gwadry-Sridhar, F.</authors>
  <citation>Alkhawaja, S., Martin, C., Butler, R.J., Gwadry-Sridhar, F. Post-pyloric versus gastric tube feeding for preventing pneumonia and improving nutritional outcomes in critically ill adults. Cochrane Database Syst Rev. 2015:CD008875.</citation>
  <type>Systematic Review</type>
  <year>2015</year>
  <keywords>
    <keyword>tube feeding</keyword>
    <keyword>nutritional outcomes</keyword>
    <keyword>pneumonia</keyword>
    <keyword>critically ill</keyword>
  </keywords>
  <summary>
    This systematic review evaluates the efficacy of post-pyloric tube feeding compared to gastric tube feeding in critically ill adults, focusing on the prevention of pneumonia and the improvement of nutritional outcomes. The review highlights the potential benefits of post-pyloric feeding in reducing the incidence of pneumonia and improving nutritional status in this vulnerable population.
  </summary>
  <pico>
    <population>critically ill adults</population>
    <intervention>post-pyloric tube feeding</intervention>
    <comparison>gastric tube feeding</comparison>
    <outcome>prevention of pneumonia and improvement of nutritional outcomes</outcome>
  </pico>
  <take_home>Post-pyloric tube feeding may be more effective than gastric tube feeding in preventing pneumonia and enhancing nutritional outcomes in critically ill patients.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec28_Article (1)">
  <title>Investigating unilateral pleural effusions: the role of cytology</title>
  <authors>David T. Arnold, Duneesha De Fonseka, Siobhan Perry, Anna Morley, John E. Harvey, Andrew Medford, Mary Brett, Nick A. Maskell</authors>
  <citation>Arnold DT, De Fonseka D, Perry S, et al. Investigating unilateral pleural effusions: the role of cytology. Eur Respir J. 2018;52:1801254.</citation>
  <type>Original Article</type>
  <year>2018</year>
  <keywords>
    <keyword>pleural effusion</keyword>
    <keyword>cytology</keyword>
    <keyword>malignant pleural effusion</keyword>
    <keyword>diagnosis</keyword>
  </keywords>
  <summary>
    This study investigates the sensitivity of cytological analysis in diagnosing malignant pleural effusions (MPEs) using a large prospective cohort of patients with undiagnosed unilateral pleural effusions. It highlights the variation in sensitivity based on the type of cancer and discusses the implications for clinical practice and patient management.
  </summary>
  <pico>
    <population>Patients with undiagnosed unilateral pleural effusions</population>
    <intervention>Cytological analysis of pleural fluid</intervention>
    <comparison>Diagnosis confirmed by two consultants after 12 months</comparison>
    <outcome>Sensitivity of cytology for diagnosing malignancy</outcome>
  </pico>
  <take_home>Understanding the limitations of cytology in diagnosing malignant pleural effusions can guide clinicians in deciding when to pursue further invasive investigations, especially in specific patient demographics.</take_home>
  <embedding_file>https://doi.org/10.1183/13993003.01254-2018</embedding_file>
</article>
```
```xml
<article id="sec28_Article (2)">
  <title>Sensitivity of Initial Thoracentesis for Malignant Pleural Effusion Stratified by Tumor Type in Patients with Strong Evidence of Metastatic Disease</title>
  <authors>Horiana B Grosu, Farah Kazzaz, Erik Vakil, Sofia Molina, David Osta</authors>
  <citation>Grosu HB, Kazzaz F, Vakil E, Molina S, Osta D. Sensitivity of Initial Thoracentesis for Malignant Pleural Effusion Stratified by Tumor Type in Patients with Strong Evidence of Metastatic Disease. Respiration. 2018;96:363–369.</citation>
  <type>Research Article</type>
  <year>2018</year>
  <keywords>
    <keyword>Pleural effusion</keyword>
    <keyword>Thoracentesis</keyword>
    <keyword>Malignant pleural effusion</keyword>
    <keyword>Cancer</keyword>
    <keyword>Diagnostic sensitivity</keyword>
  </keywords>
  <summary>
    This retrospective cohort study evaluates the sensitivity of thoracentesis with pleural fluid cytology for detecting malignant pleural effusion (MPE) in patients with solid tumors and strong evidence of metastatic disease. The study finds significant variability in sensitivity depending on tumor type, with breast and pancreatic cancers showing the highest sensitivity and head and neck malignancies and sarcomas showing the lowest.
  </summary>
  <pico>
    <population>Patients with solid tumor malignancies and strong suspicion of metastatic disease</population>
    <intervention>Initial thoracentesis with pleural fluid cytology</intervention>
    <comparison>Different tumor types</comparison>
    <outcome>Sensitivity of thoracentesis for detecting malignant pleural effusion</outcome>
  </pico>
  <take_home>Thoracentesis sensitivity for diagnosing malignant pleural effusion varies significantly by tumor type, which may influence clinical decision-making regarding further diagnostic procedures.</take_home>
  <embedding_file>DOI: 10.1159/000490732</embedding_file>
</article>
```
```xml
<article id="sec28_Article (3)">
  <title>Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010</title>
  <authors>Hooper, C.; Lee, Y C G; Maskell, N.; on behalf of the BTS Pleural Guideline Group</authors>
  <citation>Hooper, C., Lee, Y C G, Maskell, N. Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii1-ii18.</citation>
  <type>Guideline</type>
  <year>2010</year>
  <keywords>
    <keyword>Pleural effusion</keyword>
    <keyword>Diagnosis</keyword>
    <keyword>Guideline</keyword>
    <keyword>Thoracentesis</keyword>
    <keyword>Ultrasound</keyword>
    <keyword>Biopsy</keyword>
  </keywords>
  <summary>
    This article presents the British Thoracic Society's guidelines for the investigation of unilateral pleural effusions in adults. It outlines the systematic approach to diagnosis, emphasizes the importance of clinical assessment, and discusses the role of imaging and diagnostic procedures, including ultrasound and thoracoscopy. The guideline incorporates new evidence and recommendations for managing pleural effusions, focusing on minimizing invasive procedures while ensuring accurate diagnosis and effective treatment.
  </summary>
  <pico>
    <population>Adults with unilateral pleural effusion</population>
    <intervention>Systematic investigation and management of pleural effusion</intervention>
    <comparison>Clinical assessment, imaging, and diagnostic procedures</comparison>
    <outcome>Accurate diagnosis and effective treatment of pleural effusions</outcome>
  </pico>
  <take_home>Early and accurate diagnosis of pleural effusions is crucial for effective management, and ultrasound-guided procedures significantly improve outcomes.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec28_Article (4)">
  <title>Prospective Study To Determine the Volume of Pleural Fluid Required To Diagnose Malignancy</title>
  <authors>Jennifer Swiderek, MD; Samer Morcos, MD; Vijayalakshmi Donthireddy, MD; Rajesh Surapaneni, MD; Vicki Jackson-Thompson, BS; Lonni Schultz, PhD; Sudha Kini, MD; Paul Kvale, MD, FCCP</authors>
  <citation>Swiderek J., Morcos S., Donthireddy V., Surapaneni R., Jackson-Thompson V., Schultz L., Kini S., Kvale P. Prospective Study To Determine the Volume of Pleural Fluid Required To Diagnose Malignancy. CHEST. 2010;137(1):68–73.</citation>
  <type>Original Research</type>
  <year>2010</year>
  <keywords>
    <keyword>Pleural effusion</keyword>
    <keyword>Malignancy diagnosis</keyword>
    <keyword>Cytopathology</keyword>
    <keyword>Thoracentesis</keyword>
    <keyword>Fluid volume</keyword>
  </keywords>
  <summary>
    This study aimed to determine the optimal volume of pleural fluid needed to diagnose malignancy in pleural effusions. A total of 121 thoracentesis samples were analyzed from 102 patients, comparing the diagnostic capabilities of 10 mL, 60 mL, and ≥150 mL volumes. Results indicated that larger volumes significantly improved sensitivity and negative predictive value for diagnosing malignant pleural effusions compared to 10 mL.
  </summary>
  <pico>
    <population>Patients with suspected or known malignant pleural effusions (n=102)</population>
    <intervention>Thoracentesis with pleural fluid volumes of 10 mL, 60 mL, and ≥150 mL</intervention>
    <comparison>Diagnostic accuracy of different fluid volumes for malignancy</comparison>
    <outcome>Sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) for malignancy diagnosis</outcome>
  </pico>
  <take_home>The study recommends using at least 60 mL of pleural fluid for optimal diagnosis of malignant pleural effusions, as smaller volumes (10 mL) are less effective.</take_home>
  <embedding_file>embedding_file_placeholder</embedding_file>
</article>
```
<article id="sec29_Article (1)">
  <title>Pleural manometry: techniques, applications, and pitfalls</title>
  <authors>Hu, K.; Chopra, A.; Huggins, J.T.; Nanchal, R.</authors>
  <citation>Hu, K., Chopra, A., Huggins, J.T., Nanchal, R. Pleural manometry: techniques, applications, and pitfalls. J Thorac Dis. 2020;12(5):2759-2770.</citation>
  <type>Review Article</type>
  <year>2020</year>
  <keywords>
    <keyword>Pneumothorax</keyword>
    <keyword>malignant pleural effusion (MPE)</keyword>
    <keyword>pleural disease</keyword>
    <keyword>pleural effusions</keyword>
    <keyword>pulmonary physiology</keyword>
    <keyword>pleural manometry (PM)</keyword>
  </keywords>
  <summary>
    This review discusses pleural manometry (PM), a technique for measuring pressure in the pleural space, its historical context, current techniques, clinical applications, and associated pitfalls. Despite its potential benefits in managing complex pleural disorders, robust data supporting routine use remains limited. Recent studies have reignited interest in PM, particularly for specific clinical scenarios such as malignant pleural effusions and pneumothorax management.
  </summary>
  <pico>
    <population>Patients with pleural effusions or pneumothorax</population>
    <intervention>Pleural manometry (PM)</intervention>
    <comparison>Standard clinical management without PM</comparison>
    <outcome>Improved diagnosis and management of pleural disorders</outcome>
  </pico>
  <take_home>Although pleural manometry shows promise in managing complex pleural diseases, further research is necessary to establish its routine clinical utility due to a lack of robust evidence.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec29_Article (2)">
  <title>Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial</title>
  <authors>Lentz, R.J.; Lerner, A.D.; Pannu, J.K.; Merrick, C.M.; Roller, L.; Walston, C.; Valenti, S.; Goddard, T.; Chen, H.; Huggins, J.T.; Rickman, O.B.; Yarmus, L.; Psallidas, I.; Rahman, N.M.; Light, R.W.; Maldonado, F.</authors>
  <citation>Lentz, R.J., Lerner, A.D., Pannu, J.K., Merrick, C.M., Roller, L., Walston, C., Valenti, S., Goddard, T., Chen, H., Huggins, J.T., Rickman, O.B., Yarmus, L., Psallidas, I., Rahman, N.M., Light, R.W., Maldonado, F. Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial. Lancet Respir Med. 2019;7:447–55.</citation>
  <type>Randomised Controlled Trial</type>
  <year>2019</year>
  <keywords>
    <keyword>Thoracentesis</keyword>
    <keyword>Pleural Manometry</keyword>
    <keyword>Pleural Effusion</keyword>
    <keyword>Chest Discomfort</keyword>
    <keyword>Pneumothorax</keyword>
  </keywords>
  <summary>
    This study investigates the efficacy of routine pleural manometry during therapeutic thoracentesis to prevent complications associated with excessively negative pleural pressure. The trial compared symptom-guided thoracentesis with manometry-guided procedures in patients with large pleural effusions. The results indicated no significant difference in chest discomfort between the two groups, challenging the routine use of pleural manometry.
  </summary>
  <pico>
    <population>Adults with large pleural effusions (≥0.5 L) undergoing therapeutic thoracentesis</population>
    <intervention>Pleural manometry during thoracentesis</intervention>
    <comparison>Symptom-guided thoracentesis without manometry</comparison>
    <outcome>Chest discomfort and incidence of complications (e.g., pneumothorax)</outcome>
  </pico>
  <take_home>The routine use of pleural manometry during large-volume thoracentesis does not reduce chest discomfort or improve safety outcomes, suggesting it may not be necessary in standard practice.</take_home>
  <embedding_file>Not applicable</embedding_file>
</article>
```
```xml
<article id="sec29_Article (3)">
  <title>Safety and Tolerability of Vacuum vs Manual Drainage During Thoracentesis: A Randomized Trial</title>
  <authors>Michal Senitko, MD; Amrik S. Ray, MD; Terrence E. Murphy, PhD; Katy LB Araujo, MPH; Kyle Bramley, MD; Erin M. Debiasi, MD; Margaret A. Pisani, MD, MPH; Kelsey Cameron, PA-C; Jonathan T. Puchalski, MD, MEd</authors>
  <citation>Senitko M., Ray A.S., Murphy T.E., Araujo K.L.B., Bramley K., Debiasi E.M., Pisani M.A., Cameron K., Puchalski J.T. Safety and Tolerability of Vacuum vs Manual Drainage During Thoracentesis: A Randomized Trial. J Bronchology Interv Pulmonol. 2019;26(3):166–171.</citation>
  <type>Research Article</type>
  <year>2019</year>
  <keywords>
    <keyword>Thoracentesis</keyword>
    <keyword>Pleural effusion</keyword>
    <keyword>Vacuum drainage</keyword>
    <keyword>Manual drainage</keyword>
    <keyword>Complications</keyword>
  </keywords>
  <summary>
    This study compares the safety and tolerability of vacuum versus manual drainage during thoracentesis in 100 patients. The results indicate that vacuum drainage, while quicker, is associated with higher complication rates and greater patient pain compared to manual drainage. The findings suggest that manual aspiration may be the safer option for thoracentesis.
  </summary>
  <pico>
    <population>Patients undergoing thoracentesis for pleural effusions</population>
    <intervention>Vacuum drainage during thoracentesis</intervention>
    <comparison>Manual drainage during thoracentesis</comparison>
    <outcome>Rates of complications, pain levels, drainage time</outcome>
  </pico>
  <take_home>Manual aspiration during thoracentesis is associated with fewer complications and greater patient comfort compared to vacuum aspiration, despite being slightly slower.</take_home>
  <embedding_file>EMBEDDING_FILE_NOT_PROVIDED</embedding_file>
</article>
```
```xml
<article id="sec29_Article (4)">
  <title>The Impact of Gravity vs Suction-driven Therapeutic Thoracentesis on Pressure-related Complications: The GRAVITAS Multicenter Randomized Controlled Trial</title>
  <authors>Lentz, R.J.; Shojaee, S.; Grosu, H.B.; Rickman, O.B.; Roller, L.; Pannu, J.K.; DePew, Z.S.; Debiane, L.G.; Cicenia, J.C.; Akulian, J.; Walston, C.; Sanchez, T.M.; Davidson, K.R.; Jagan, N.; Ahmad, S.; Gilbert, C.; Huggins, J.T.; Chen, H.; Light, R.W.; Yarmus, L.; Feller-Kopman, D.; Lee, H.; Rahman, N.M.; Maldonado, F.</authors>
  <citation>Lentz, R.J., Shojaee, S., Grosu, H.B., Rickman, O.B., Roller, L., Pannu, J.K., et al. The Impact of Gravity vs Suction-driven Therapeutic Thoracentesis on Pressure-related Complications: The GRAVITAS Multicenter Randomized Controlled Trial. CHEST. 2020;157(3):702-711.</citation>
  <type>Original Research</type>
  <year>2020</year>
  <keywords>
    <keyword>gravity</keyword>
    <keyword>pleural effusion</keyword>
    <keyword>suction</keyword>
    <keyword>thoracentesis</keyword>
  </keywords>
  <summary>
    This multicenter, randomized controlled trial evaluated the safety and comfort of two methods of thoracentesis: gravity drainage and active suction. It found no significant differences in procedural discomfort or dyspnea between the two methods, although gravity drainage took longer to perform.
  </summary>
  <pico>
    <population>Patients with large free-flowing pleural effusions (≥500 mL)</population>
    <intervention>Gravity drainage during thoracentesis</intervention>
    <comparison>Active aspiration (suction) during thoracentesis</comparison>
    <outcome>Overall procedural chest discomfort and dyspnea improvement</outcome>
  </pico>
  <take_home>Both gravity drainage and suction methods for thoracentesis are safe and provide similar levels of comfort and dyspnea relief, but active suction is faster.</take_home>
  <embedding_file>sec29_Article (4)_embeddings.json</embedding_file>
</article>
```
<article id="sec30_Article (1)">
  <title>ERS/EACTS statement on the management of malignant pleural effusions</title>
  <authors>Bibby A.C.; Dorn P.; Psallidas I.; Porcel J.M.; Janssen J.; Froudarakis M.; Subotic D.; Astoul P.; Licht P.; Schmid R.; Scherpereel A.; Rahman N.M.; Cardillo G.; Maskell N.A.</authors>
  <citation>Bibby A.C., Dorn P., Psallidas I., et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J. 2018; 52: 1800349.</citation>
  <type>Guideline</type>
  <year>2018</year>
  <keywords>
    <keyword>malignant pleural effusions</keyword>
    <keyword>pleurodesis</keyword>
    <keyword>indwelling pleural catheters</keyword>
    <keyword>trapped lung</keyword>
    <keyword>loculated effusions</keyword>
    <keyword>prognostic factors</keyword>
  </keywords>
  <summary>
    The ERS/EACTS statement provides a comprehensive review of the management of malignant pleural effusions (MPE), addressing key clinical questions based on recent high-quality evidence. It covers optimal management strategies for symptomatic MPE, trapped lung, loculated MPE, prognostic factors, the role of oncological therapies prior to intervention, and the necessity of histological diagnosis.
  </summary>
  <pico>
    <population>Patients with malignant pleural effusions</population>
    <intervention>Talc pleurodesis and indwelling pleural catheters</intervention>
    <comparison>Various management strategies including oncological therapies and histological diagnosis</comparison>
    <outcome>Symptom relief, survival rates, and management effectiveness</outcome>
  </pico>
  <take_home>The management of malignant pleural effusions has advanced significantly, with talc pleurodesis and indwelling pleural catheters being effective options. Further research is needed to address remaining uncertainties, particularly regarding trapped lung and loculated effusions.</take_home>
  <embedding_file>ERS_EACTS_MPE_Management_Statement.pdf</embedding_file>
</article>
```
```xml
<article id="sec30_Article (2)">
  <title>Breathlessness Predicts Survival in Patients With Malignant Pleural Effusions Meta-analysis of Individual Patient Data From Five Randomized Controlled Trials</title>
  <authors>Mishra, E.K.; Muruganandan, S.; Clark, A.; Bhatnagar, R.; Maskell, N.; Lee, Y.C.G.; Rahman, N.M.</authors>
  <citation>Mishra, E.K., Muruganandan, S., Clark, A., Bhatnagar, R., Maskell, N., Lee, Y.C.G., Rahman, N.M. Breathlessness Predicts Survival in Patients With Malignant Pleural Effusions Meta-analysis of Individual Patient Data From Five Randomized Controlled Trials. CHEST. 2021;160(1):351-357.</citation>
  <type>Original Research</type>
  <year>2021</year>
  <keywords>
    <keyword>breathlessness</keyword>
    <keyword>malignant pleural effusion</keyword>
    <keyword>survival</keyword>
    <keyword>meta-analysis</keyword>
    <keyword>dyspnea</keyword>
  </keywords>
  <summary>
    This study investigates the association between breathlessness and survival in patients with malignant pleural effusions (MPE) through a meta-analysis of individual patient data from five randomized controlled trials. It finds that breathlessness, as measured by a visual analog scale, is a significant predictor of survival.
  </summary>
  <pico>
    <population>Patients with malignant pleural effusions undergoing interventions</population>
    <intervention>Measurement of breathlessness using visual analog scale for dyspnea (VASD)</intervention>
    <comparison>Survival outcomes based on varying levels of breathlessness</comparison>
    <outcome>Association between breathlessness and survival rates</outcome>
  </pico>
  <take_home>Breathlessness is a significant predictor of survival in patients with malignant pleural effusions, suggesting that it should be considered in prognostic assessments.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec30_Article (3)">
  <title>Management of Malignant Pleural Effusions: An Official ATS/STS/STR Clinical Practice Guideline</title>
  <authors>David J. Feller-Kopman, Chakravarthy B. Reddy, Malcolm M. DeCamp, Rebecca L. Diekemper, Michael K. Gould, Travis Henry, Narayan P. Iyer, Y. C. Gary Lee, Sandra Z. Lewis, Nick A. Maskell, Najib M. Rahman, Daniel H. Sterman, Momen M. Wahidi, Alex A. Balekian</authors>
  <citation>Feller-Kopman DJ, Reddy CB, DeCamp MM, et al. Management of Malignant Pleural Effusions: An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(7):839–849.</citation>
  <type>Clinical Practice Guideline</type>
  <year>2018</year>
  <keywords>
    <keyword>malignant pleural effusion</keyword>
    <keyword>pleurodesis</keyword>
    <keyword>indwelling pleural catheter</keyword>
    <keyword>talc poudrage</keyword>
    <keyword>talc slurry</keyword>
    <keyword>ultrasound guidance</keyword>
  </keywords>
  <summary>
    This guideline provides evidence-based recommendations for the management of malignant pleural effusions (MPE), developed by a multidisciplinary panel using the GRADE approach and PICO format. The recommendations include the use of ultrasound for guiding interventions, the management of asymptomatic patients, and treatment options for symptomatic patients including indwelling pleural catheters and chemical pleurodesis.
  </summary>
  <pico>
    <population>Patients with malignant pleural effusions</population>
    <intervention>Ultrasound-guided pleural interventions, indwelling pleural catheter, chemical pleurodesis</intervention>
    <comparison>Standard pleural interventions without ultrasound guidance, no intervention for asymptomatic patients</comparison>
    <outcome>Improvement in dyspnea, reduction in hospitalizations, management of pleural effusions</outcome>
  </pico>
  <take_home>The guideline emphasizes the importance of individualized treatment strategies for MPE, highlighting the role of ultrasound in guiding interventions and the use of indwelling pleural catheters as a preferred option for symptomatic management.</take_home>
  <embedding_file>https://www.atsjournals.org/doi/full/10.1164/rccm.201807-1415ST</embedding_file>
</article>
```
```xml
<article id="sec30_Article (4)">
  <title>Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010</title>
  <authors>Mark E Roberts, Edmund Neville, Richard G Berrisford, George Antunes, Nabeel J Ali</authors>
  <citation>Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii32-ii40.</citation>
  <type>Guideline</type>
  <year>2010</year>
  <keywords>
    <keyword>malignant pleural effusion</keyword>
    <keyword>pleurodesis</keyword>
    <keyword>treatment guidelines</keyword>
    <keyword>British Thoracic Society</keyword>
    <keyword>pleural disease</keyword>
  </keywords>
  <summary>
    This article presents the guidelines established by the British Thoracic Society for the management of malignant pleural effusions, detailing the clinical presentation, diagnostic approaches, and treatment options. It emphasizes the importance of symptom management and the role of pleurodesis in preventing recurrence of effusions. The guidelines are based on a review of existing literature and evidence-based practices.
  </summary>
  <pico>
    <population>Patients with malignant pleural effusions</population>
    <intervention>Management options including therapeutic pleural aspiration, pleurodesis, and indwelling pleural catheters</intervention>
    <comparison>Observation vs. various intervention techniques</comparison>
    <outcome>Improvement in symptoms and reduction in effusion recurrence</outcome>
  </pico>
  <take_home>The management of malignant pleural effusions should be individualized based on the patient's symptoms, performance status, and the underlying malignancy, with pleurodesis being a key intervention to prevent recurrence.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
<article id="sec31_Article (1)">
  <title>Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion</title>
  <authors>Bhatnagar, R.; Keenan, E.K.; Morley, A.J.; Kahan, B.C.; Stanton, A.E.; Haris, M.; Harrison, R.N.; Mustafa, R.A.; Bishop, L.J.; Ahmed, L.; West, A.; Holme, J.; Evison, M.; Munavvar, M.; Sivasothy, P.; Herre, J.; Cooper, D.; Roberts, M.; Guhan, A.; Hooper, C.; Walters, J.; Saba, T.S.; Chakrabarti, B.; Gunatilake, S.; Psallidas, I.; Walker, S.P.; Bibby, A.C.; Smith, S.; Stadon, L.J.; Zahan-Evans, N.J.; Lee, Y.C.G.; Harvey, J.E.; Rahman, N.M.; Miller, R.F.; Maskell, N.A.</authors>
  <citation>Bhatnagar, R., Keenan, E.K., Morley, A.J., et al. Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion. N Engl J Med. 2018;378:1313-22.</citation>
  <type>Original Article</type>
  <year>2018</year>
  <keywords>
    <keyword>malignant pleural effusion</keyword>
    <keyword>talc pleurodesis</keyword>
    <keyword>indwelling pleural catheter</keyword>
    <keyword>outpatient treatment</keyword>
  </keywords>
  <summary>
    This study investigates the effectiveness of outpatient talc administration via an indwelling pleural catheter compared to a placebo in patients with malignant pleural effusion. The trial demonstrated that talc administration significantly increases the rate of successful pleurodesis without increasing adverse events.
  </summary>
  <pico>
    <population>Patients with malignant pleural effusion without substantial lung entrapment</population>
    <intervention>Outpatient administration of talc through an indwelling pleural catheter</intervention>
    <comparison>Indwelling pleural catheter alone (placebo)</comparison>
    <outcome>Successful pleurodesis at day 35 after randomization</outcome>
  </pico>
  <take_home>Outpatient talc administration through an indwelling pleural catheter significantly improves the likelihood of achieving pleurodesis in patients with malignant pleural effusion compared to catheter use alone, with no added risks.</take_home>
  <embedding_file>sec31_Article (1)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec31_Article (2)">
  <title>Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions: A Randomized Clinical Trial</title>
  <authors>Bhatnagar, R.; Piotrowska, H.E.G.; Laskawiec-Szkonter, M.; Kahan, B.C.; Luengo-Fernandez, R.; Pepperell, J.C.T.; Evison, M.D.; Holme, J.; Al-Aloul, M.; Psallidas, I.; Lim, W.S.; Blyth, K.G.; Roberts, M.E.; Cox, G.; Downer, N.J.; Herre, J.; Sivasothy, P.; Menzies, D.; Munavvar, M.; Kyi, M.M.; Ahmed, L.; West, A.G.; Harrison, R.N.; Prudon, B.; Hettiarachchi, G.; Chakrabarti, B.; Kavidasan, A.; Sutton, B.P.; Zahan-Evans, N.J.; Quaddy, J.L.; Edey, A.J.; Clive, A.O.; Walker, S.P.; Little, M.H.R.; Mei, X.W.; Harvey, J.E.; Hooper, C.E.; Davies, H.E.; Slade, M.; Sivier, M.; Miller, R.F.; Rahman, N.M.; Maskell, N.A.</authors>
  <citation>Bhatnagar, R., Piotrowska, H.E.G., Laskawiec-Szkonter, M., et al. Effect of Thoracoscopic Talc Poudrage vs Talc Slurry via Chest Tube on Pleurodesis Failure Rate Among Patients With Malignant Pleural Effusions: A Randomized Clinical Trial. JAMA. 2020;323(1):60-69.</citation>
  <type>Original Investigation</type>
  <year>2020</year>
  <keywords>
    <keyword>Malignant Pleural Effusion</keyword>
    <keyword>Talc Pleurodesis</keyword>
    <keyword>Thoracoscopy</keyword>
    <keyword>Talc Poudrage</keyword>
    <keyword>Talc Slurry</keyword>
  </keywords>
  <summary>
    This randomized clinical trial aimed to compare the effectiveness of talc poudrage administered during thoracoscopy with local anesthesia versus talc slurry delivered via chest tube for inducing pleurodesis in patients with malignant pleural effusions (MPE). The study involved 330 participants and found no significant difference in pleurodesis failure rates at 90 days between the two methods, suggesting that both interventions are equally effective.
  </summary>
  <pico>
    <population>Patients with malignant pleural effusions (MPE) aged over 18 who could undergo thoracoscopy with local anesthesia.</population>
    <intervention>Talc poudrage during thoracoscopy with local anesthesia.</intervention>
    <comparison>Talc slurry delivered via chest tube.</comparison>
    <outcome>Pleurodesis failure rate at 90 days.</outcome>
  </pico>
  <take_home>The study concludes that there is no significant difference in pleurodesis failure rates between thoracoscopic talc poudrage and talc slurry via chest tube in patients with malignant pleural effusions, though the study may have been underpowered to detect smaller differences.</take_home>
  <embedding_file>sec31_Article (2)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec31_Article (3)">
  <title>Effect of an Indwelling Pleural Catheter vs Chest Tube and Talc Pleurodesis for Relieving Dyspnea in Patients With Malignant Pleural Effusion: The TIME2 Randomized Controlled Trial</title>
  <authors>Helen E. Davies, MD; Eleanor K. Mishra, MD; Brennan C. Kahan, MSc; John M. Wrightson, MD; Andrew E. Stanton, MD; Anur Guhan, MD; Christopher W. H. Davies, MD; Jamal Grayez, MB, BCh; Richard Harrison, MD; Anjani Prasad, MB, ChB; Nicola Crosthwaite, RN; Y. C. Gary Lee, PhD; Robert J. O. Davies, MD; Robert F. Miller, MB, BS; Najib M. Rahman, DPhil</authors>
  <citation>Davies HE, Mishra EK, Kahan BC, et al. Effect of an Indwelling Pleural Catheter vs Chest Tube and Talc Pleurodesis for Relieving Dyspnea in Patients With Malignant Pleural Effusion: The TIME2 Randomized Controlled Trial. JAMA. 2012;307(22):2383-2389.</citation>
  <type>Original Contribution</type>
  <year>2012</year>
  <keywords>
    <keyword>malignant pleural effusion</keyword>
    <keyword>indwelling pleural catheter</keyword>
    <keyword>talc pleurodesis</keyword>
    <keyword>dyspnea</keyword>
    <keyword>randomized controlled trial</keyword>
  </keywords>
  <summary>
    The TIME2 trial compared the effectiveness of indwelling pleural catheters (IPCs) and chest tube with talc pleurodesis in relieving dyspnea in patients with malignant pleural effusion. The study found no significant difference in dyspnea relief between the two methods over the first 42 days, although IPCs resulted in shorter hospital stays and a lower need for further pleural interventions. However, IPCs were associated with a higher rate of adverse events.
  </summary>
  <pico>
    <population>Patients with malignant pleural effusion requiring pleurodesis</population>
    <intervention>Indwelling pleural catheters (IPCs)</intervention>
    <comparison>Chest tube and talc slurry pleurodesis</comparison>
    <outcome>Relief of dyspnea</outcome>
  </pico>
  <take_home>Both IPCs and talc pleurodesis are effective for dyspnea relief in malignant pleural effusion, but IPCs reduce hospital stay at the cost of increased adverse events.</take_home>
  <embedding_file>https://doi.org/10.1001/jama.2012.5535</embedding_file>
</article>
```
```xml
<article id="sec31_Article (4)">
  <title>Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion</title>
  <authors>Dresler, C.M.; Olak, J.; Herndon II, J.E.; Richards, W.G.; Scalzetti, E.; Fleishman, S.B.; Kernstine, K.H.; Demmy, T.; Jablons, D.M.; Kohman, L.; Daniel, T.M.; Haasler, G.B.; Sugarbaker, D.J.</authors>
  <citation>Dresler, C.M., Olak, J., Herndon II, J.E., et al. Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion. Chest. 2005;127(3):909–915.</citation>
  <type>Research Article</type>
  <year>2005</year>
  <keywords>
    <keyword>insufflation</keyword>
    <keyword>malignant pleural effusion</keyword>
    <keyword>slurry</keyword>
    <keyword>talc</keyword>
  </keywords>
  <summary>
    This study compares the efficacy and safety of two methods of talc delivery for the treatment of malignant pleural effusion (MPE): thoracoscopic talc insufflation (TTI) and talc slurry (TS) via tube thoracostomy. The primary endpoint was the 30-day freedom from MPE recurrence among patients whose lungs re-expanded significantly post-procedure. The study found no significant difference in outcomes between the two methods, although TTI showed better results for patients with lung or breast cancer.
  </summary>
  <pico>
    <population>Patients with malignant pleural effusion</population>
    <intervention>Thoracoscopic talc insufflation (TTI)</intervention>
    <comparison>Talc slurry via tube thoracostomy (TS)</comparison>
    <outcome>30-day freedom from MPE recurrence</outcome>
  </pico>
  <take_home>Both talc delivery methods are similarly effective for MPE, but TTI may be preferred for patients with lung or breast cancer due to better outcomes and patient comfort.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec31_Article (5)">
  <title>Indwelling Pleural Catheter versus Pleurodesis for Malignant Pleural Effusions: A Systematic Review and Meta-Analysis</title>
  <authors>Iyer, N.P.; Reddy, C.B.; Wahidi, M.M.; Lewis, S.Z.; Diekemper, R.L.; Feller-Kopman, D.; Gould, M.K.; Balekian, A.A.</authors>
  <citation>Iyer, N.P., Reddy, C.B., Wahidi, M.M., Lewis, S.Z., Diekemper, R.L., Feller-Kopman, D., Gould, M.K., Balekian, A.A. Indwelling Pleural Catheter versus Pleurodesis for Malignant Pleural Effusions: A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2019;16(1):124–131.</citation>
  <type>Systematic Review and Meta-Analysis</type>
  <year>2019</year>
  <keywords>
    <keyword>indwelling pleural catheter</keyword>
    <keyword>malignant pleural effusion</keyword>
    <keyword>meta-analysis</keyword>
    <keyword>pleurodesis</keyword>
    <keyword>systematic review</keyword>
  </keywords>
  <summary>
    This systematic review and meta-analysis compares the efficacy and safety of indwelling pleural catheters (IPC) and chemical pleurodesis in managing malignant pleural effusions (MPE). The analysis included five randomized controlled trials with 545 patients, revealing that while IPCs resulted in shorter hospital stays and fewer repeat procedures, they were associated with a higher risk of cellulitis compared to pleurodesis. No significant differences in survival or dyspnea were observed.
  </summary>
  <pico>
    <population>Adult patients with symptomatic malignant pleural effusions</population>
    <intervention>Indwelling pleural catheter (IPC)</intervention>
    <comparison>Chemical pleurodesis</comparison>
    <outcome>Hospital length of stay, repeat pleural procedures, cellulitis risk, dyspnea, and survival</outcome>
  </pico>
  <take_home>IPC offers shorter hospital stays and fewer repeat interventions for MPE but carries a higher risk of cellulitis, necessitating careful consideration of patient preferences and costs.</take_home>
  <embedding_file>sec31_Article (5)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec31_Article (6)">
  <title>Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion The TIME1 Randomized Clinical Trial</title>
  <authors>Najib M. Rahman, DPhil; Justin Pepperell, MD; Sunita Rehal, MSc; Tarek Saba, MD; Augustine Tang, FRCS(C-Th); Nabeel Ali, MD; Alex West, MRCP; Gihan Hettiarachchi, MRCP; Dipak Mukherjee, FRCP; Johnson Samuel, FRCP; Andrew Bentley, MD; Lee Dowson, MRCP; Jonathan Miles, MRCP; C. Frank Ryan, FRCPC; Ken Y. Yoneda, MD; Anoop Chauhan, MD; John P. Corcoran, MRCP; Ioannis Psallidas, PhD; John M. Wrightson, DPhil; Rob Hallifax, MRCP; Helen E. Davies, MD; Y. C. Gary Lee, PhD; Melissa Dobson, BSc; Emma L. Hedley, RGN; Douglas Seaton, MD; Nicky Russell, RGN; Margaret Chapman, RGN; Bethan M. McFadyen, RN; Rachel A. Shaw, BA; Robert J. O. Davies, MD; Nick A. Maskell, DM; Andrew J. Nunn, MSc; Robert F. Miller, FRCP</authors>
  <citation>Rahman, N.M., Pepperell, J., Rehal, S., Saba, T., Tang, A., Ali, N., West, A., Hettiarachchi, G., Mukherjee, D., Samuel, J., Bentley, A., Dowson, L., Miles, J., Ryan, C.F., Yoneda, K.Y., Chauhan, A., Corcoran, J.P., Psallidas, I., Wrightson, J.M., Hallifax, R., Davies, H.E., Lee, Y.C.G., Dobson, M., Hedley, E.L., Seaton, D., Russell, N., Chapman, M., McFadyen, B.M., Shaw, R.A., Davies, R.J.O., Maskell, N.A., Nunn, A.J., Miller, R.F. Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion The TIME1 Randomized Clinical Trial. JAMA. 2015;314(24):2641-2653.</citation>
  <type>Original Investigation</type>
  <year>2015</year>
  <keywords>
    <keyword>malignant pleural effusion</keyword>
    <keyword>pleurodesis</keyword>
    <keyword>opioids</keyword>
    <keyword>NSAIDs</keyword>
    <keyword>chest tube size</keyword>
  </keywords>
  <summary>
    This study investigates the effects of opioids versus NSAIDs and the impact of chest tube size on pain control and pleurodesis efficacy in patients with malignant pleural effusion. Conducted as a randomized clinical trial, it assesses pain levels and pleurodesis failure rates among different treatment groups.
  </summary>
  <pico>
    <population>320 patients with malignant pleural effusion undergoing pleurodesis across 16 UK hospitals</population>
    <intervention>Administration of opioids or NSAIDs for pain management, and the use of 12F or 24F chest tubes</intervention>
    <comparison>Comparison of pain scores and pleurodesis efficacy between opioid and NSAID groups, and between 12F and 24F chest tube groups</comparison>
    <outcome>Assessment of pain levels using a visual analog scale (VAS) and rates of pleurodesis failure at 3 months</outcome>
  </pico>
  <take_home>NSAIDs are noninferior to opioids for pleurodesis efficacy but require more rescue analgesia; smaller chest tubes reduce pain modestly but may compromise pleurodesis success.</take_home>
  <embedding_file>TIME1_Trial_Study_Data</embedding_file>
</article>
```
```xml
<article id="sec31_Article (7)">
  <title>Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial</title>
  <authors>Rajesh Thomas, MBBS, PhD, FRACP; Edward T. H. Fysh, MBBS, PhD, FRACP; Nicola A. Smith, MBChB, FRACP; Pyng Lee, MBBS, PhD, FRCP; Benjamin C. H. Kwan, MBBS, FRACP; Elaine Yap, MBChB, FRACP; Fiona C. Horwood, MBChB, FRACP; Francesco Piccolo, MBBS, BMedSci, FRACP; David C. L. Lam, MBBS, MRCP, FHKCP, FHKAM, PhD, FRCP; Luke A. Garske, MBBS, FRACP; Ranjan Shrestha, MBBS, FRACP; Christopher Kosky, MBBS, FRCP, FRACP; Catherine A. Read, RGN, BSc; Kevin Murray, PhD; Y. C. Gary Lee, MBChB, PhD, FRCP, FRACP</authors>
  <citation>Thomas R, Fysh ETH, Smith NA, et al. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial. JAMA. 2017;318(19):1903-1912.</citation>
  <type>Original Investigation</type>
  <year>2017</year>
  <keywords>
    <keyword>Malignant Pleural Effusion</keyword>
    <keyword>Indwelling Pleural Catheter</keyword>
    <keyword>Talc Pleurodesis</keyword>
    <keyword>Hospitalization Days</keyword>
    <keyword>Randomized Clinical Trial</keyword>
  </keywords>
  <summary>
    This study compares the effectiveness of indwelling pleural catheters versus talc pleurodesis in reducing hospitalization days for patients with malignant pleural effusions. The trial found that indwelling pleural catheters significantly reduced the number of hospitalization days compared to talc pleurodesis, although the clinical importance of this reduction is uncertain.
  </summary>
  <pico>
    <population>Patients with symptomatic malignant pleural effusion</population>
    <intervention>Indwelling pleural catheter</intervention>
    <comparison>Talc pleurodesis</comparison>
    <outcome>Total hospitalization days</outcome>
  </pico>
  <take_home>Indwelling pleural catheters result in fewer hospitalization days compared to talc pleurodesis, but the clinical significance of this difference remains uncertain.</take_home>
  <embedding_file>AMPLE_Trial_Embedding_File</embedding_file>
</article>
```
<article id="sec32_Article (1)">
  <title>Quality-Adjusted Survival Following Treatment of Malignant Pleural Effusions With Indwelling Pleural Catheters</title>
  <authors>Ost, D.E.; Jimenez, C.A.; Lei, X.; Cantor, S.B.; Grosu, H.B.; Lazarus, D.R.; Faiz, S.A.; Bashoura, L.; Shannon, V.R.; Balachandran, D.; Noor, L.; Hashmi, Y.B.; Casal, R.F.; Morice, R.C.; Eapen, G.A.</authors>
  <citation>Ost, D.E., Jimenez, C.A., Lei, X., Cantor, S.B., Grosu, H.B., Lazarus, D.R., Faiz, S.A., Bashoura, L., Shannon, V.R., Balachandran, D., Noor, L., Hashmi, Y.B., Casal, R.F., Morice, R.C., Eapen, G.A. Quality-Adjusted Survival Following Treatment of Malignant Pleural Effusions With Indwelling Pleural Catheters. CHEST. 2014;145(6):1347–1356.</citation>
  <type>Original Research</type>
  <year>2014</year>
  <keywords>
    <keyword>Malignant Pleural Effusions</keyword>
    <keyword>Indwelling Pleural Catheters</keyword>
    <keyword>Quality-Adjusted Survival</keyword>
    <keyword>Dyspnea</keyword>
    <keyword>Patient-Centered Outcomes</keyword>
  </keywords>
  <summary>
    This study evaluates the quality-adjusted survival of patients with malignant pleural effusions (MPE) treated with indwelling pleural catheters (IPCs). It assesses the impact of IPCs on dyspnea and overall health-related quality of life, using a prospective observational cohort design. The findings indicate significant dyspnea improvement but modest increases in quality-adjusted life days (QALDs). The study highlights the importance of treatment following IPC placement and suggests future research should focus on patient-centered outcomes.
  </summary>
  <pico>
    <population>Patients with malignant pleural effusions undergoing IPC placement</population>
    <intervention>Placement of indwelling pleural catheters (IPCs)</intervention>
    <comparison>Standard treatment methods (e.g., chemical pleurodesis)</comparison>
    <outcome>Quality-adjusted life days (QALDs) and dyspnea improvement</outcome>
  </pico>
  <take_home>Indwelling pleural catheters significantly improve dyspnea in patients with malignant pleural effusions, with modest impacts on quality-adjusted survival. Treatment following IPC placement is crucial for better outcomes.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec32_Article (2)">
  <title>Quality Gaps and Comparative Effectiveness of Management Strategies for Recurrent Malignant Pleural Effusions</title>
  <authors>Ost, D.E.; Niu, J.; Zhao, H.; Grosu, H.B.; Giordano, S.H.</authors>
  <citation>Ost, D.E., Niu, J., Zhao, H., Grosu, H.B., Giordano, S.H. Quality Gaps and Comparative Effectiveness of Management Strategies for Recurrent Malignant Pleural Effusions. CHEST. 2018;153(2):438-452.</citation>
  <type>Original Research</type>
  <year>2018</year>
  <keywords>
    <keyword>malignant pleural effusion</keyword>
    <keyword>indwelling pleural catheter</keyword>
    <keyword>pleurodesis</keyword>
    <keyword>thoracentesis</keyword>
    <keyword>quality of care</keyword>
  </keywords>
  <summary>
    This study evaluates the management strategies for recurrent malignant pleural effusions (MPEs) and the adherence to clinical guidelines recommending definitive procedures over repeat thoracentesis. It finds significant gaps in guideline compliance, with only 24% of patients receiving recommended care, leading to increased complications and healthcare utilization.
  </summary>
  <pico>
    <population>Patients aged 66 to 90 with recurrent malignant pleural effusions</population>
    <intervention>Definitive procedures (indwelling pleural catheters or pleurodesis)</intervention>
    <comparison>Repeat thoracentesis</comparison>
    <outcome>Subsequent procedures, complications, and inpatient days</outcome>
  </pico>
  <take_home>Definitive management of recurrent malignant pleural effusions is underutilized, leading to more complications and healthcare resource use. Improved adherence to guidelines is necessary for better patient outcomes.</take_home>
  <embedding_file>sec32_Article (2)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec32_Article (3)">
  <title>Evidence-informed Guidelines and Expert Panel Report for the Management of Indwelling Pleural Catheters</title>
  <authors>Miller, R.J.; Chrissian, A.A.; Lee, Y.C.G.; Rahman, N.M.; Wahidi, M.M.; Tremblay, A.; Hsia, D.W.; Almeida, F.A.; Shojaee, S.; Mudambi, L.; Belanger, A.R.; Bedi, H.; Gesthalter, Y.B.; Gaynor, M.; MacKenney, K.L.; Lewis, S.Z.; Casal, R.F.</authors>
  <citation>Miller, R.J., Chrissian, A.A., Lee, Y.C.G., Rahman, N.M., Wahidi, M.M., Tremblay, A., et al. Evidence-informed Guidelines and Expert Panel Report for the Management of Indwelling Pleural Catheters. Journal of Bronchology and Interventional Pulmonology. 2020;27(4):229-245.</citation>
  <type>Original Investigation</type>
  <year>2020</year>
  <keywords>
    <keyword>indwelling pleural catheter</keyword>
    <keyword>pleural effusion</keyword>
    <keyword>malignant</keyword>
    <keyword>palliation</keyword>
    <keyword>guidelines</keyword>
  </keywords>
  <summary>
    This article presents evidence-informed guidelines developed by an expert panel for the management of indwelling pleural catheters (IPCs) used in patients with malignant pleural effusions (MPEs). The guidelines were created using a systematic and rigorous consensus-based approach, highlighting the importance of IPCs in palliative care and identifying gaps in current knowledge that require further research.
  </summary>
  <pico>
    <population>Patients with malignant pleural effusions treated with indwelling pleural catheters</population>
    <intervention>Management of indwelling pleural catheters</intervention>
    <comparison>Standard management practices</comparison>
    <outcome>Quality of life, symptom relief, complications, catheter management</outcome>
  </pico>
  <take_home>Indwelling pleural catheters are effective for managing malignant pleural effusions, and these guidelines provide a framework for their post-insertion management, emphasizing the need for ongoing research to fill knowledge gaps.</take_home>
  <embedding_file>embedding_file_placeholder</embedding_file>
</article>
```
<article id="sec33_Article (1)">
  <title>Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial</title>
  <authors>Muruganandan, S.; Azzopardi, M.; Fitzgerald, D.B.; Shrestha, R.; Kwan, B.C.H.; Lam, D.C.L.; De Chaneet, C.C.; Rashid Ali, M.R.S.; Yap, E.; Tobin, C.L.; Garske, L.A.; Nguyen, P.T.; Stanley, C.; Popowicz, N.D.; Kosky, C.; Thomas, R.; Read, C.A.; Budgeon, C.A.; Feller-Kopman, D.; Maskell, N.A.; Murray, K.; Lee, Y.C.G.</authors>
  <citation>Muruganandan, S., Azzopardi, M., Fitzgerald, D.B., et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med. 2018; 6: 671–80.</citation>
  <type>Randomised Controlled Trial</type>
  <year>2018</year>
  <keywords>
    <keyword>malignant pleural effusion</keyword>
    <keyword>indwelling pleural catheter</keyword>
    <keyword>drainage regimen</keyword>
    <keyword>pleurodesis</keyword>
    <keyword>quality of life</keyword>
  </keywords>
  <summary>
    The AMPLE-2 trial compared aggressive daily drainage with symptom-guided drainage of malignant pleural effusions using indwelling pleural catheters. It found no significant difference in breathlessness control, but aggressive drainage led to higher rates of spontaneous pleurodesis and better quality of life scores.
  </summary>
  <pico>
    <population>Patients with symptomatic malignant pleural effusions</population>
    <intervention>Aggressive (daily) drainage via indwelling pleural catheters</intervention>
    <comparison>Symptom-guided drainage via indwelling pleural catheters</comparison>
    <outcome>Mean daily breathlessness score, rates of spontaneous pleurodesis, quality of life</outcome>
  </pico>
  <take_home>The study suggests that while both drainage regimens are effective for breathlessness control, aggressive drainage enhances spontaneous pleurodesis and may improve quality of life without increasing pain or infection rates.</take_home>
  <embedding_file>AMPLE-2_Trial_Data.csv</embedding_file>
</article>
```
```xml
<article id="sec33_Article (2)">
  <title>Randomized Trial of Pleural Fluid Drainage Frequency in Patients with Malignant Pleural Effusions: The ASAP Trial</title>
  <authors>Wahidi, M.M.; Reddy, C.; Yarmus, L.; Feller-Kopman, D.; Musani, A.; Shepherd, R.W.; Lee, H.; Bechara, R.; Lamb, C.; Shofer, S.; Mahmood, K.; Michaud, G.; Puchalski, J.; Rafeq, S.; Cattaneo, S.M.; Mullon, J.; Leh, S.; Mayse, M.; Thomas, S.M.; Peterson, B.; Light, R.W.</authors>
  <citation>Wahidi, M.M., Reddy, C., Yarmus, L., Feller-Kopman, D., Musani, A., Shepherd, R.W., Lee, H., Bechara, R., Lamb, C., Shofer, S., Mahmood, K., Michaud, G., Puchalski, J., Rafeq, S., Cattaneo, S.M., Mullon, J., Leh, S., Mayse, M., Thomas, S.M., Peterson, B., Light, R.W. Randomized Trial of Pleural Fluid Drainage Frequency in Patients with Malignant Pleural Effusions: The ASAP Trial. Am J Respir Crit Care Med. 2017;195(8):1050-1057.</citation>
  <type>Clinical Trial</type>
  <year>2017</year>
  <keywords>
    <keyword>malignant pleural effusions</keyword>
    <keyword>indwelling pleural catheter</keyword>
    <keyword>pleurodesis</keyword>
    <keyword>autopleurodesis</keyword>
    <keyword>randomized trial</keyword>
  </keywords>
  <summary>
    This study evaluates the effectiveness of daily drainage versus every other day drainage of pleural fluid in patients with malignant pleural effusions. The aggressive daily drainage strategy was found to be superior in achieving autopleurodesis and reducing the time to achieve this outcome, while maintaining similar quality of life and adverse event rates compared to the standard approach.
  </summary>
  <pico>
    <population>Patients with malignant pleural effusions</population>
    <intervention>Daily drainage of pleural fluid via indwelling pleural catheter</intervention>
    <comparison>Every other day drainage of pleural fluid via indwelling pleural catheter</comparison>
    <outcome>Rate of autopleurodesis and time to achieve autopleurodesis</outcome>
  </pico>
  <take_home>Daily drainage of pleural fluid leads to a higher rate and faster time to autopleurodesis in patients with malignant pleural effusions compared to standard every other day drainage.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
<article id="sec34_Article (1)">
  <title>Concurrent Intrapleural Instillation of Tissue Plasminogen Activator and DNase for Pleural Infection: A Single-Center Experience</title>
  <authors>Adnan Majid, Fayez Kheir, Alejandro Folch, Sebastian Fernandez-Bussy, Sumit Chatterji, Ashish Maskey, Meghan Fashjian, George Cheng, Sebastian Ochoa, Daniel Alape, Erik Folch</authors>
  <citation>Majid A, Kheir F, Folch A, Fernandez-Bussy S, Chatterji S, Maskey A, Fashjian M, Cheng G, Ochoa S, Alape D, Folch E. Concurrent Intrapleural Instillation of Tissue Plasminogen Activator and DNase for Pleural Infection: A Single-Center Experience. Ann Am Thorac Soc. 2016;13(9):1512–1518.</citation>
  <type>Research Article</type>
  <year>2016</year>
  <keywords>
    <keyword>pleural infection</keyword>
    <keyword>tissue plasminogen activator</keyword>
    <keyword>human recombinant DNase</keyword>
  </keywords>
  <summary>
    This study evaluates the safety and efficacy of concurrent intrapleural administration of tissue plasminogen activator (tPA) and DNase in patients with pleural infections. A retrospective cohort of 73 patients was analyzed, showing a treatment success rate of 90.4% and a median hospital stay of 7 days post-treatment. The study suggests that concurrent therapy is effective and may reduce treatment costs.
  </summary>
  <pico>
    <population>Patients with pleural infection (complicated parapneumonic effusion or empyema)</population>
    <intervention>Concurrent intrapleural instillation of tPA and DNase</intervention>
    <comparison>Sequential administration of tPA and DNase</comparison>
    <outcome>Treatment success rate, length of hospital stay, volume of pleural fluid drained</outcome>
  </pico>
  <take_home>Early administration of concurrent tPA/DNase therapy is safe and effective for treating pleural infections, potentially reducing the number of doses and overall hospital costs.</take_home>
  <embedding_file>embedding_file_placeholder</embedding_file>
</article>
```
```xml
<article id="sec34_Article (2)">
  <title>Intrapleural Fibrinolytic Therapy versus Early Medical Thoracoscopy for Treatment of Pleural Infection: Randomized Controlled Clinical Trial</title>
  <authors>Kheir, F.; Thakore, S.; Mehta, H.; Jantz, M.; Parikh, M.; Chee, A.; Kaphle, U.; Sisnega, C.; Fernandez-Bussy, S.; Majid, A.</authors>
  <citation>Kheir, F., Thakore, S., Mehta, H., Jantz, M., Parikh, M., Chee, A., Kaphle, U., Sisnega, C., Fernandez-Bussy, S., Majid, A. Intrapleural Fibrinolytic Therapy versus Early Medical Thoracoscopy for Treatment of Pleural Infection: Randomized Controlled Clinical Trial. Ann Am Thorac Soc. 2020;17(8):958–964.</citation>
  <type>Clinical Trial</type>
  <year>2020</year>
  <keywords>
    <keyword>medical thoracoscopy</keyword>
    <keyword>intrapleural fibrinolytic therapy</keyword>
    <keyword>pleural infection</keyword>
    <keyword>empyema</keyword>
  </keywords>
  <summary>
    This study compares the safety and efficacy of early medical thoracoscopy (MT) versus intrapleural fibrinolytic therapy (IPFT) in patients with multiloculated pleural infection and empyema. The results indicate that MT may shorten hospital stays without increasing adverse events compared to IPFT.
  </summary>
  <pico>
    <population>Patients with multiloculated pleural infection and empyema</population>
    <intervention>Early medical thoracoscopy (MT)</intervention>
    <comparison>Intrapleural fibrinolytic therapy (IPFT)</comparison>
    <outcome>Length of hospital stay, treatment failure, 30-day mortality, adverse events</outcome>
  </pico>
  <take_home>Early medical thoracoscopy may be a more effective treatment option than intrapleural fibrinolytic therapy for reducing hospital stay in patients with complicated pleural infections.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec34_Article (3)">
  <title>Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection</title>
  <authors>Rahman, N.M.; Maskell, N.A.; West, A.; Teoh, R.; Arnold, A.; Mackinlay, C.; Peckham, D.; Davies, C.W.H.; Ali, N.; Kinnear, W.; Bentley, A.; Kahan, B.C.; Wrightson, J.M.; Davies, H.E.; Hooper, C.E.; Lee, Y.C.G.; Hedley, E.L.; Crosthwaite, N.; Choo, L.; Helm, E.J.; Gleeson, F.V.; Nunn, A.J.; Davies, R.J.O.</authors>
  <citation>Rahman, N.M., Maskell, N.A., West, A., Teoh, R., Arnold, A., Mackinlay, C., Peckham, D., Davies, C.W.H., Ali, N., Kinnear, W., Bentley, A., Kahan, B.C., Wrightson, J.M., Davies, H.E., Hooper, C.E., Lee, Y.C.G., Hedley, E.L., Crosthwaite, N., Choo, L., Helm, E.J., Gleeson, F.V., Nunn, A.J., Davies, R.J.O. Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection. N Engl J Med. 2011;365:518-26.</citation>
  <type>Original Article</type>
  <year>2011</year>
  <keywords>
    <keyword>Pleural infection</keyword>
    <keyword>Tissue plasminogen activator</keyword>
    <keyword>DNase</keyword>
    <keyword>Fibrinolytic therapy</keyword>
    <keyword>Clinical trial</keyword>
  </keywords>
  <summary>
    This study investigates the effectiveness of intrapleural tissue plasminogen activator (t-PA) combined with DNase in treating pleural infections. The trial involved 210 patients and found that the combination therapy significantly improved drainage of infected fluid, reduced the need for surgical intervention, and shortened hospital stays compared to placebo. Neither t-PA nor DNase alone showed similar benefits.
  </summary>
  <pico>
    <population>Patients with pleural infection</population>
    <intervention>Intrapleural tissue plasminogen activator and DNase</intervention>
    <comparison>Double placebo</comparison>
    <outcome>Change in pleural opacity, surgical referrals, duration of hospital stay</outcome>
  </pico>
  <take_home>Combined intrapleural t-PA and DNase therapy improves drainage in pleural infections, reduces surgical referrals, and shortens hospital stays, indicating a potential new treatment strategy.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec34_Article (4)">
  <title>The Relationship Between Chest Tube Size and Clinical Outcome in Pleural Infection</title>
  <authors>Najib M. Rahman, BM, BCh; Nicholas A. Maskell, DM; Christopher W. H. Davies, MD; Emma L. Hedley; Andrew J. Nunn, MSc; Fergus V. Gleeson, MBBS; Robert J. O. Davies, DM</authors>
  <citation>Rahman N.M., Maskell N.A., Davies C.W.H., Hedley E.L., Nunn A.J., Gleeson F.V., Davies R.J.O. The Relationship Between Chest Tube Size and Clinical Outcome in Pleural Infection. CHEST. 2010;137(3):536–543.</citation>
  <type>Original Research</type>
  <year>2010</year>
  <keywords>
    <keyword>pleural infection</keyword>
    <keyword>chest tube size</keyword>
    <keyword>clinical outcomes</keyword>
    <keyword>pain</keyword>
  </keywords>
  <summary>
    This study investigates the relationship between chest tube size and clinical outcomes in patients with pleural infection. It finds that smaller chest tubes (14F or smaller) cause significantly less pain without negatively impacting clinical outcomes compared to larger tubes.
  </summary>
  <pico>
    <population>Patients with pleural infection</population>
    <intervention>Chest tubes of varying sizes (less than 10F, 10-14F, 15-20F, greater than 20F)</intervention>
    <comparison>Clinical outcomes (death, need for thoracic surgery, hospital stay, lung function, pain scores) between different tube sizes</comparison>
    <outcome>No significant difference in clinical outcomes with varying tube sizes; smaller tubes resulted in less pain</outcome>
  </pico>
  <take_home>Smaller, guide-wire-inserted chest tubes are associated with less pain compared to larger tubes, without compromising clinical outcomes in pleural infection treatment.</take_home>
  <embedding_file>sec34_Article (4)_embeddings.json</embedding_file>
</article>
```
```xml
<article id="sec34_Article (5)">
  <title>Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement</title>
  <authors>Udit Chaddha, Abhinav Agrawal, David Feller-Kopman, Viren Kaul, Samira Shojaee, Fabien Maldonado, Mark K Ferguson, Kevin G Blyth, Horiana B Grosu, John P Corcoran, Ashutosh Sachdeva, Alex West, Eihab O Bedawi, Adnan Majid, Ravindra M Mehta, Erik Folch, Moishe Liberman, Momen M Wahidi, Sidhu P Gangadharan, Mark E Roberts, Malcolm M DeCamp, Najib M Rahman</authors>
  <citation>Chaddha U, Agrawal A, Feller-Kopman D, et al. Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement. Lancet Respir Med. 2021;9:1050–64.</citation>
  <type>Position Paper</type>
  <year>2021</year>
  <keywords>
    <keyword>pleural empyema</keyword>
    <keyword>fibrinolytics</keyword>
    <keyword>deoxyribonuclease</keyword>
    <keyword>intervention</keyword>
    <keyword>consensus statement</keyword>
  </keywords>
  <summary>
    This position paper presents consensus-based recommendations regarding the use of intrapleural fibrinolytic therapy and deoxyribonuclease in the management of adult patients with pleural empyema. It addresses the optimal use of these therapies based on a systematic review of literature and expert opinion, aiming to fill the existing knowledge gap since the MIST2 trial.
  </summary>
  <pico>
    <population>Adult patients with pleural empyema</population>
    <intervention>Intrapleural fibrinolytic and deoxyribonuclease therapy</intervention>
    <comparison>Conventional management approaches including antibiotics and surgical intervention</comparison>
    <outcome>Reduction in surgical referral rates, improvement in fluid drainage, and decreased length of hospital stay</outcome>
  </pico>
  <take_home>Combination therapy with fibrinolytics and DNase is recommended over monotherapy, and should be considered early in the treatment of stage 2 empyema to avoid surgery.</take_home>
  <embedding_file>sec34_Article (5)_embeddings.json</embedding_file>
</article>
```
<article id="sec35_Article (1)">
  <title>The management of benign non-infective pleural effusions</title>
  <authors>Bintcliffe, O.J.; Lee, G.Y.C.; Rahman, N.M.; Maskell, N.A.</authors>
  <citation>Bintcliffe O.J., Lee G.Y.C., Rahman N.M., Maskell N.A. The management of benign non-infective pleural effusions. Eur Respir Rev. 2016;25(3):189-198.</citation>
  <type>Review Article</type>
  <year>2016</year>
  <keywords>
    <keyword>Pleural effusion</keyword>
    <keyword>Benign disease</keyword>
    <keyword>Management strategies</keyword>
    <keyword>Therapeutic aspiration</keyword>
    <keyword>Pleurodesis</keyword>
  </keywords>
  <summary>
    This article discusses the challenges and management strategies for benign non-infective pleural effusions, highlighting the limited evidence compared to malignant pleural effusions. It reviews the causes, evaluation methods, and treatment options, emphasizing the need for individualized management based on underlying conditions and patient symptoms.
  </summary>
  <pico>
    <population>Patients with benign non-infective pleural effusions</population>
    <intervention>Therapeutic aspiration, talc pleurodesis, indwelling pleural catheters</intervention>
    <comparison>Standard management techniques used for malignant pleural effusions</comparison>
    <outcome>Symptom relief and management of pleural effusions</outcome>
  </pico>
  <take_home>The management of benign pleural effusions requires a tailored approach due to the diversity of underlying causes and limited evidence-based guidelines.</take_home>
  <embedding_file>link_to_embedding_file_if_available</embedding_file>
</article>
```
```xml
<article id="sec35_Article (2)">
  <title>Management of Benign Pleural Effusions Using Indwelling Pleural Catheters: A Systematic Review and Meta-analysis</title>
  <authors>Monali Patil, MD; Samjot Singh Dhillon, MD; Kristopher Attwood, PhD; Marwan Saoud, MD; Abdul Hamid Alraiyes, MD; Kassem Harris, MD, FCCP</authors>
  <citation>Patil M, Dhillon SS, Attwood K, Saoud M, Alraiyes AH, Harris K. Management of Benign Pleural Effusions Using Indwelling Pleural Catheters: A Systematic Review and Meta-analysis. CHEST. 2017;151(3):626-635.</citation>
  <type>Original Research</type>
  <year>2017</year>
  <keywords>
    <keyword>benign pleural effusion</keyword>
    <keyword>indwelling pleural catheter</keyword>
    <keyword>pleurodesis</keyword>
    <keyword>systematic review</keyword>
    <keyword>meta-analysis</keyword>
  </keywords>
  <summary>
    This systematic review and meta-analysis evaluates the efficacy and safety of indwelling pleural catheters (IPCs) for managing refractory benign pleural effusions (BPE). The study includes 13 studies with 325 patients, predominantly suffering from congestive heart failure. The findings suggest that IPCs can effectively manage BPE with an average spontaneous pleurodesis rate of 51.3%, but the quality of evidence is low, indicating a need for further high-quality research.
  </summary>
  <pico>
    <population>Patients with refractory benign pleural effusions</population>
    <intervention>Indwelling pleural catheters (IPCs)</intervention>
    <comparison>Chemical pleurodesis</comparison>
    <outcome>Spontaneous pleurodesis rate and complication rates</outcome>
  </pico>
  <take_home>Indwelling pleural catheters are a viable option for managing refractory benign pleural effusions, but more robust studies are needed to confirm these findings.</take_home>
  <embedding_file>N/A</embedding_file>
</article>
```
```xml
<article id="sec35_Article (3)">
  <title>Pleural Interventions in the Management of Hepatic Hydrothorax</title>
  <authors>Christopher R. Gilbert, DO, MS, FCCP; Samira Shojaee, MD, MPH, FCCP; Fabien Maldonado, MD, FCCP; Lonny B. Yarmus, DO, MBA, FCCP; Eihab Bedawi, MBBS; David Feller-Kopman, MD, FCCP; Najib M. Rahman, DPhil; Jason A. Akulian, MD, MPH, FCCP; Jed A. Gorden, MD, FCCP</authors>
  <citation>Gilbert CR, Shojaee S, Maldonado F, Yarmus LB, Bedawi E, Feller-Kopman D, Rahman NM, Akulian JA, Gorden JA. Pleural Interventions in the Management of Hepatic Hydrothorax. CHEST. 2022;161(1):276-283.</citation>
  <type>Review Article</type>
  <year>2022</year>
  <keywords>
    <keyword>hepatic hydrothorax</keyword>
    <keyword>indwelling tunneled pleural catheter</keyword>
    <keyword>pleurodesis</keyword>
    <keyword>thoracentesis</keyword>
  </keywords>
  <summary>
    This article discusses the management of hepatic hydrothorax (HH), a condition that occurs in patients with cirrhosis and portal hypertension. The authors review various pleural interventions, including thoracentesis, tube thoracostomy, indwelling tunneled pleural catheters, and surgical options, emphasizing the need for a multidisciplinary approach to treatment. Management strategies are tailored based on whether patients are candidates for liver transplantation and the severity of their condition.
  </summary>
  <pico>
    <population>Patients with hepatic hydrothorax due to cirrhosis and portal hypertension</population>
    <intervention>Pleural interventions including thoracentesis, indwelling tunneled pleural catheters, and pleurodesis</intervention>
    <comparison>Management strategies based on transplant candidacy and severity of disease</comparison>
    <outcome>Improvement in symptoms, management of pleural effusions, and overall patient outcomes</outcome>
  </pico>
  <take_home>Management of hepatic hydrothorax requires a multidisciplinary approach, with treatment options varying based on transplant candidacy and patient-specific factors. Indwelling tunneled pleural catheters may be preferred for palliative care in non-transplant candidates.</take_home>
  <embedding_file>https://doi.org/10.1016/j.chest.2021.08.043</embedding_file>
</article>
```
```xml
<article id="sec35_Article (4)">
  <title>Indwelling Tunneled Pleural Catheters for Refractory Hepatic Hydrothorax in Patients With Cirrhosis: A Multicenter Study</title>
  <authors>Samira Shojaee, MD, MPH; Najib Rahman, DPhil; Kevin Haas, MD; Ryan Kern, MD; Michael Leise, MD; Mohammed Alnijoumi, MD; Carla Lamb, MD; Adnan Majid, MD; Jason Akulian, MD, MPH; Fabien Maldonado, MD; Hans Lee, MD; Marwah Khalid, MD; Todd Stravitz, MD; Le Kang, PhD; Alexander Chen, MD</authors>
  <citation>Shojaee S, Rahman N, Haas K, et al. Indwelling Tunneled Pleural Catheters for Refractory Hepatic Hydrothorax in Patients With Cirrhosis: A Multicenter Study. CHEST. 2019;155(3):546-553.</citation>
  <type>Original Research</type>
  <year>2019</year>
  <keywords>
    <keyword>cirrhosis</keyword>
    <keyword>hepatic hydrothorax</keyword>
    <keyword>indwelling tunneled pleural catheter</keyword>
    <keyword>pleural effusion</keyword>
  </keywords>
  <summary>
    This multicenter study evaluates the safety and feasibility of indwelling pleural catheters (IPCs) for managing refractory hepatic hydrothorax (HH) in patients with cirrhosis. The study analyzes patient demographics, complications, and outcomes associated with IPC placement.
  </summary>
  <pico>
    <population>Patients with cirrhosis and refractory hepatic hydrothorax</population>
    <intervention>Indwelling tunneled pleural catheter placement</intervention>
    <comparison>Traditional management methods (e.g., thoracentesis, chest tubes)</comparison>
    <outcome>Complications, pleurodesis rates, and survival</outcome>
  </pico>
  <take_home>Indwelling pleural catheters may be a viable option for managing refractory hepatic hydrothorax, with a reasonable safety profile and a spontaneous pleurodesis rate of about 28%, but significant adverse events can occur.</take_home>
  <embedding_file>sec35_Article (4)_embeddings.json</embedding_file>
</article>
```
<article id="sec36_Article (1)">
  <title>Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010</title>
  <authors>Havelock, T.; Teoh, R.; Laws, D.; Gleeson, F.</authors>
  <citation>Havelock, T., Teoh, R., Laws, D., Gleeson, F. Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010. Thorax. 2010;65(Suppl 2):ii1-ii18.</citation>
  <type>Guideline</type>
  <year>2010</year>
  <keywords>
    <keyword>Pleural procedures</keyword>
    <keyword>Ultrasound</keyword>
    <keyword>Thoracentesis</keyword>
    <keyword>Chest drain</keyword>
    <keyword>Guideline</keyword>
  </keywords>
  <summary>
    This guideline provides updated recommendations for pleural procedures, including thoracentesis and chest drain insertion, emphasizing safe techniques, training, and the use of ultrasound guidance to reduce complications. It addresses indications, procedural techniques, complications, and post-procedure management to improve patient safety and outcomes.
  </summary>
  <pico>
    <population>Patients requiring pleural drainage procedures</population>
    <intervention>Pleural aspiration and chest drain insertion using ultrasound guidance</intervention>
    <comparison>Traditional techniques without ultrasound guidance</comparison>
    <outcome>Reduction in complications and improved procedural success rates</outcome>
  </pico>
  <take_home>Ultrasound guidance is strongly recommended for all pleural procedures to enhance safety and efficacy, alongside proper training for all operators.</take_home>
  <embedding_file>thorax-guideline-2010.pdf</embedding_file>
</article>
```
```xml
<article id="sec36_Article (2)">
  <title>Pleural controversy: Closed needle pleural biopsy or thoracoscopy—Which first?</title>
  <authors>Koegelenberg, C.F.N.; Diacon, A.H.</authors>
  <citation>Koegelenberg, C.F.N., Diacon, A.H. Pleural controversy: Closed needle pleural biopsy or thoracoscopy—Which first? Respirology. 2011;16(2): 269-281.</citation>
  <type>Review</type>
  <year>2011</year>
  <keywords>
    <keyword>pleural biopsy</keyword>
    <keyword>pleural disease</keyword>
    <keyword>pleural effusion</keyword>
    <keyword>thoracoscopy</keyword>
    <keyword>ultrasound</keyword>
  </keywords>
  <summary>
    This review discusses the diagnostic approaches for pleural effusions, particularly the controversy surrounding the use of closed needle pleural biopsy versus thoracoscopy. It examines the diagnostic yields of various techniques, the role of imaging modalities, and the considerations that influence the choice of procedure in different clinical settings.
  </summary>
  <pico>
    <population>Patients with pleural effusions</population>
    <intervention>Closed needle pleural biopsy</intervention>
    <comparison>Thoracoscopy</comparison>
    <outcome>Diagnostic yield for malignancy and tuberculosis</outcome>
  </pico>
  <take_home>Thoracoscopy is generally preferred for its superior diagnostic yield in cases of suspected malignancy or tuberculosis, but closed needle biopsy with imaging assistance can be a viable alternative when thoracoscopy is not accessible.</take_home>
  <embedding_file>none</embedding_file>
</article>
```
<article id="sec37_Article (1)">
  <title>Advances in pleuroscopy</title>
  <authors>Anevlavis, S.; Froudarakis, M.E.</authors>
  <citation>Anevlavis, S., Froudarakis, M.E. Advances in pleuroscopy. Clin Respir J. 2018;12:839–847.</citation>
  <type>REVIEW ARTICLE</type>
  <year>2018</year>
  <keywords>
    <keyword>advanced techniques</keyword>
    <keyword>malignant pleural mesothelioma</keyword>
    <keyword>medical thoracoscopy</keyword>
    <keyword>pleurodesis</keyword>
    <keyword>pleuroscopy</keyword>
    <keyword>pneumothorax</keyword>
  </keywords>
  <summary>
    This review article discusses the technique of pleuroscopy, its clinical applications, and recent advancements in the field. It highlights the use of medical thoracoscopy for diagnosing and treating various pleural conditions, including exudative pleural effusions, pneumothorax, and malignant pleural mesothelioma. The authors also explore newer techniques such as narrow band imaging, infrared pleuroscopy, and autofluorescence pleuroscopy that enhance diagnostic capabilities.
  </summary>
  <pico>
    <population>Patients with undiagnosed exudative pleural effusions, pleural infections, and malignant pleural mesothelioma.</population>
    <intervention>Medical thoracoscopy and advanced pleuroscopic techniques.</intervention>
    <comparison>Traditional diagnostic methods and treatments for pleural conditions.</comparison>
    <outcome>Improved diagnostic yield, treatment success rates, and patient outcomes.</outcome>
  </pico>
  <take_home>Medical thoracoscopy is the preferred method for investigating undiagnosed exudative pleural effusions, and newer techniques are promising for enhancing its efficacy.</take_home>
  <embedding_file>None</embedding_file>
</article>
```
```xml
<article id="sec37_Article (2)">
  <title>Medical thoracoscopy/pleuroscopy: step by step</title>
  <authors>Loddenkemper, R.; Lee, P.; Noppen, M.; Mathur, P.N.</authors>
  <citation>Loddenkemper R, Lee P, Noppen M, Mathur PN. Medical thoracoscopy/pleuroscopy: step by step. Eur Respir Mon. 2010;48:119-132.</citation>
  <type>Review</type>
  <year>2010</year>
  <keywords>
    <keyword>Medical thoracoscopy</keyword>
    <keyword>Pleuroscopy</keyword>
    <keyword>Interventional pulmonology</keyword>
    <keyword>Training</keyword>
    <keyword>Complications</keyword>
  </keywords>
  <summary>
    This article provides a comprehensive overview of medical thoracoscopy/pleuroscopy, emphasizing its significance in interventional pulmonology. The authors detail the necessary skills, contraindications, potential complications, and a step-by-step guide to performing the procedure. They advocate for proper training and highlight the importance of understanding the clinical prerequisites and technical aspects involved in thoracoscopy.
  </summary>
  <pico>
    <population>Chest physicians and respiratory medicine specialists</population>
    <intervention>Medical thoracoscopy/pleuroscopy</intervention>
    <comparison>Surgical thoracoscopy (video-assisted thoracic surgery)</comparison>
    <outcome>Improved diagnostic and therapeutic outcomes for pleural diseases</outcome>
  </pico>
  <take_home>Medical thoracoscopy/pleuroscopy is a vital procedure in respiratory medicine that requires thorough training and understanding of its indications, contraindications, and potential complications for safe execution.</take_home>
  <embedding_file>medical_thoracoscopy_summary_embedding.txt</embedding_file>
</article>
```
```xml
<article id="sec37_Article (3)">
  <title>Pleural Cryobiopsy: A Systematic Review and Meta-Analysis</title>
  <authors>Majid Shafiq, MD, MPH; Jaskaran Sethi, MD; Muhammad S. Ali, MD; Uzair K. Ghori, MD; Tajalli Saghaie, MD; Erik Folch, MD</authors>
  <citation>Shafiq M, Sethi J, Ali MS, Ghori UK, Saghaie T, Folch E. Pleural Cryobiopsy: A Systematic Review and Meta-Analysis. CHEST. 2020;157(1):223-230.</citation>
  <type>Original Research</type>
  <year>2020</year>
  <keywords>
    <keyword>cryobiopsy</keyword>
    <keyword>meta-analysis</keyword>
    <keyword>pleura</keyword>
    <keyword>pleural biopsy</keyword>
    <keyword>pleural effusion</keyword>
  </keywords>
  <summary>
    This systematic review and meta-analysis evaluates the diagnostic yield and safety of pleural cryobiopsy compared to flexible forceps biopsy. The analysis of seven observational studies indicates that while cryobiopsy yields larger tissue specimens, it does not significantly improve diagnostic yield over forceps biopsy. No major bleeding complications were reported with cryobiopsy, suggesting it is a safe procedure.
  </summary>
  <pico>
    <population>Adults undergoing pleural biopsy via medical pleuroscopy or video-assisted thoracoscopic surgery</population>
    <intervention>Cryobiopsy of the pleura</intervention>
    <comparison>Flexible forceps biopsy of the pleura</comparison>
    <outcome>Overall diagnostic yield</outcome>
  </pico>
  <take_home>Pleural cryobiopsy is safe and yields larger tissue specimens but does not significantly increase diagnostic yield compared to flexible forceps biopsy; further multicenter randomized trials are needed.</take_home>
  <embedding_file>https://doi.org/10.1016/j.chest.2019.09.023</embedding_file>
</article>
```
```xml
<article id="sec37_Article (4)">
  <title>Rigid Mini-Thoracoscopy Versus Semirigid Thoracoscopy in Undiagnosed Exudative Pleural Effusion: The MIN Trial Randomized Controlled Trial</title>
  <authors>Bansal, S.; Mittal, S.; Tiwari, P.; Jain, D.; Arava, S.; Hadda, V.; Mohan, A.; Malik, P.; Pandey, R.M.; Khilnani, G.C.; Guleria, R.; Madan, K.</authors>
  <citation>Bansal, S., Mittal, S., Tiwari, P., Jain, D., Arava, S., Hadda, V., Mohan, A., Malik, P., Pandey, R.M., Khilnani, G.C., Guleria, R., Madan, K. Rigid Mini-Thoracoscopy Versus Semirigid Thoracoscopy in Undiagnosed Exudative Pleural Effusion: The MIN Trial Randomized Controlled Trial. Journal of Bronchology and Interventional Pulmonology. 2020;27(3):163-171.</citation>
  <type>Original Investigation</type>
  <year>2020</year>
  <keywords>
    <keyword>pleural effusion</keyword>
    <keyword>thoracoscopy</keyword>
    <keyword>biopsy</keyword>
    <keyword>lung cancer</keyword>
    <keyword>tuberculosis</keyword>
  </keywords>
  <summary>
    This study compares the diagnostic yield and patient comfort between rigid mini-thoracoscopy and semirigid thoracoscopy in patients with undiagnosed exudative pleural effusion. The randomized controlled trial involved 73 subjects and assessed pain levels, procedural satisfaction, and complications associated with each technique.
  </summary>
  <pico>
    <population>Patients with undiagnosed exudative pleural effusion</population>
    <intervention>Rigid mini-thoracoscopy</intervention>
    <comparison>Semirigid thoracoscopy</comparison>
    <outcome>Diagnostic yield, pain levels, procedural satisfaction, biopsy size, and complications</outcome>
  </pico>
  <take_home>The diagnostic yield of rigid mini-thoracoscopy is not superior to that of semirigid thoracoscopy, and the latter may provide greater patient comfort during the procedure.</take_home>
  <embedding_file>https://doi.org/10.1097/LBR.0000000000000620</embedding_file>
</article>
```
</CombinedData>